<html lang="en" class="js"><head><link rel="preload" href="/static/fonts/HardingText-Regular-Web-cecd90984f.woff2" as="font" type="font/woff2" crossorigin=""><script async="" src="https://scripts.webcontentassessor.com/scripts/93dabb8d80079a87fec7bb6f67b807fce90e1688f8957ad7ad152bfd58ea01c2"></script><script type="text/javascript" async="" src="https://pagead2.googlesyndication.com/tag/js/gpt.js"></script><script async="" src="https://www.googletagmanager.com/gtm.js?id=GTM-MRVXSHQ"></script><script type="text/javascript" src="https://www.nature.com/F4sb1TbK05l7-GL9XIgT-26L_zpyLz9W5jJMoOGCIk8Pbg-APPVCT1uPgV4JYNo8UBaS82nWffCqOFFzyKIltw=="></script><script src="https://cmp.nature.com/production_live/en/consent-bundle-8-85.js" onload="initGTM(window,document,'script','dataLayer','GTM-MRVXSHQ')"></script>
    <title>CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial | Nature Medicine</title>
    
        
<link rel="alternate" type="application/rss+xml" href="https://www.nature.com/nm.rss">


    
        

        <script id="save-data-connection-testing">
            function hasConnection() {
                return navigator.connection || navigator.mozConnection || navigator.webkitConnection || navigator.msConnection;
            }

            function createLink(src) {
                var preloadLink = document.createElement("link");
                preloadLink.rel = "preload";
                preloadLink.href = src;
                preloadLink.as = "font";
                preloadLink.type = "font/woff2";
                preloadLink.crossOrigin = "";
                document.head.insertBefore(preloadLink, document.head.firstChild);
            }

            var connectionDetail = {
                saveDataEnabled: false,
                slowConnection: false
            };

            var connection = hasConnection();
            if (connection) {
                connectionDetail.saveDataEnabled = connection.saveData;
                if (/\slow-2g|2g/.test(connection.effectiveType)) {
                    connectionDetail.slowConnection = true;
                }
            }

            if (!(connectionDetail.saveDataEnabled || connectionDetail.slowConnection)) {
                createLink("/static/fonts/HardingText-Regular-Web-cecd90984f.woff2");
            } else {
                document.documentElement.classList.add('save-data');
            }
        </script>
    

<link rel="preconnect" href="https://cmp.nature.com" crossorigin="">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="applicable-device" content="pc,mobile">
<meta name="viewport" content="width=device-width,initial-scale=1.0,maximum-scale=5,user-scalable=yes">
<meta name="360-site-verification" content="5a2dc4ab3fcb9b0393241ffbbb490480">

<script data-test="dataLayer">
    window.dataLayer = [{"content":{"category":{"contentType":"article","legacy":{"webtrendsPrimaryArticleType":"research","webtrendsSubjectTerms":"acute-lymphocytic-leukaemia;cancer-immunotherapy;lymphoma;phase-i-trials","webtrendsContentCategory":null,"webtrendsContentCollection":null,"webtrendsContentGroup":"Nature Medicine","webtrendsContentGroupType":null,"webtrendsContentSubGroup":"Article","status":null}},"article":{"doi":"10.1038/s41591-021-01436-0"},"attributes":{"cms":null,"deliveryPlatform":"oscar","copyright":{"open":true,"legacy":{"webtrendsLicenceType":"http://creativecommons.org/licenses/by/4.0/"}}},"contentInfo":{"authors":["Jay Y. Spiegel","Shabnum Patel","Lori Muffly","Nasheed M. Hossain","Jean Oak","John H. Baird","Matthew J. Frank","Parveen Shiraz","Bita Sahaf","Juliana Craig","Maria Iglesias","Sheren Younes","Yasodha Natkunam","Michael G. Ozawa","Eric Yang","John Tamaresis","Harshini Chinnasamy","Zach Ehlinger","Warren Reynolds","Rachel Lynn","Maria Caterina Rotiroti","Nikolaos Gkitsas","Sally Arai","Laura Johnston","Robert Lowsky","Robbie G. Majzner","Everett Meyer","Robert S. Negrin","Andrew R. Rezvani","Surbhi Sidana","Judith Shizuru","Wen-Kai Weng","Chelsea Mullins","Allison Jacob","Ilan Kirsch","Magali Bazzano","Jing Zhou","Sean Mackay","Scott J. Bornheimer","Liora Schultz","Sneha Ramakrishna","Kara L. Davis","Katherine A. Kong","Nirali N. Shah","Haiying Qin","Terry Fry","Steven Feldman","Crystal L. Mackall","David B. Miklos"],"publishedAt":1627257600,"publishedAtString":"2021-07-26","title":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial","legacy":null,"publishedAtTime":null,"documentType":"aplusplus","subjects":"Acute lymphocytic leukaemia,Cancer immunotherapy,Lymphoma,Phase I trials"},"journal":{"pcode":"nm","title":"nature medicine","volume":"27","issue":"8","id":41591,"publishingModel":"Hybrid Access"},"authorization":{"status":true},"features":[{"name":"furtherReadingSection","present":true}],"collection":null},"page":{"category":{"pageType":"article"},"attributes":{"template":"mosaic","featureFlags":[{"name":"nature-onwards-journey","active":false}],"testGroup":null},"search":null},"privacy":{},"version":"1.0.0","product":null,"session":null,"user":null,"backHalfContent":true,"country":"BR","hasBody":true,"uneditedManuscript":false,"twitterId":["o3xnx","o43y9","o3ef7"],"baiduId":"d38bce82bcb44717ccc29a90c4b781ea","japan":false}];
    window.dataLayer.push({
        ga4MeasurementId: 'G-ERRNTNZ807',
        ga360TrackingId: 'UA-71668177-1',
        twitterId: ['3xnx', 'o43y9', 'o3ef7'],
        baiduId: 'd38bce82bcb44717ccc29a90c4b781ea',
        ga4ServerUrl: 'https://collect.nature.com',
        imprint: 'nature'
    });
</script>

<script>
    (function(w, d) {
        w.config = w.config || {};
        w.config.mustardcut = false;

        
        if (w.matchMedia && w.matchMedia('only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)').matches) {
            w.config.mustardcut = true;
            d.classList.add('js');
            d.classList.remove('grade-c');
            d.classList.remove('no-js');
        }
    })(window, document.documentElement);
</script>
 



     
    
    
        
    
    <style>@media only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark) {  .c-article-editorial-summary__container .c-article-editorial-summary__article-title,.c-card--major .c-card__title,.c-card__title,.u-h2,.u-h3,h2,h3{font-weight:700;-webkit-font-smoothing:antialiased;font-family:Harding,Palatino,serif;letter-spacing:-.0117156rem}.c-article-editorial-summary__container .c-article-editorial-summary__article-title,.c-card__title,.u-h3,h3{font-size:1.25rem;line-height:1.4rem}.c-reading-companion__figure-title,.u-h4,h4{font-weight:700;-webkit-font-smoothing:antialiased;line-height:1.4rem}html{line-height:1.15;text-size-adjust:100%;box-sizing:border-box;font-size:100%;height:100%;overflow-y:scroll}body{background:#eee;color:#222;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1.125rem;line-height:1.76;margin:0;min-height:100%}details,main{display:block}h1{font-size:2em;margin:.67em 0}a,sup{vertical-align:baseline}a{background-color:transparent;color:#069;overflow-wrap:break-word;text-decoration:underline;text-decoration-skip-ink:auto;word-break:break-word}b{font-weight:bolder}sup{font-size:75%;line-height:0;position:relative;top:-.5em}img{border:0;height:auto;max-width:100%;vertical-align:middle}button,input,select{font-family:inherit;font-size:100%;line-height:1.15;margin:0}button,input{overflow:visible}button,select{text-transform:none}[type=submit],button{-webkit-appearance:button}[type=checkbox]{box-sizing:border-box;padding:0}summary{display:list-item}[hidden]{display:none}button{border-radius:0;cursor:pointer;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif}h1{font-weight:700;-webkit-font-smoothing:antialiased;font-family:Harding,Palatino,serif;font-size:2rem;letter-spacing:-.0390625rem;line-height:2.25rem}.c-card--major .c-card__title,.u-h2,.u-h3,h2{font-family:Harding,Palatino,serif;letter-spacing:-.0117156rem}.c-card--major .c-card__title,.u-h2,h2{font-weight:700;-webkit-font-smoothing:antialiased;font-size:1.5rem;line-height:1.6rem}.u-h3{font-size:1.25rem}.c-card__title,.c-reading-companion__figure-title,.u-h3,.u-h4,h4,h5,h6{font-weight:700;-webkit-font-smoothing:antialiased;line-height:1.4rem}.c-article-editorial-summary__container .c-article-editorial-summary__article-title,.c-card__title,h3{font-family:Harding,Palatino,serif;font-size:1.25rem}.c-article-editorial-summary__container .c-article-editorial-summary__article-title,h3{font-weight:700;-webkit-font-smoothing:antialiased;letter-spacing:-.0117156rem;line-height:1.4rem}.c-reading-companion__figure-title,.u-h4,h4{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1.125rem;letter-spacing:-.0117156rem}input+label{padding-left:.5em}nav ol,nav ul{list-style:none none}p:empty{display:none}.sans-serif{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif}.article-page{background:#fff}.c-article-header{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;margin-bottom:40px}.c-article-identifiers{color:#6f6f6f;display:flex;flex-wrap:wrap;font-size:1rem;line-height:1.3;list-style:none;margin:0 0 8px;padding:0}.c-article-identifiers__item{border-right:1px solid #6f6f6f;list-style:none;margin-right:8px;padding-right:8px}.c-article-identifiers__item:last-child{border-right:0;margin-right:0;padding-right:0}.c-article-title{font-size:1.5rem;line-height:1.25;margin:0 0 16px}@media only screen and (min-width:768px){.c-article-title{font-size:1.875rem;line-height:1.2}}.c-article-author-list{display:inline;font-size:1rem;list-style:none;margin:0 8px 0 0;padding:0;width:100%}.c-article-author-list__item{display:inline;padding-right:0}.c-article-author-list svg{margin-left:4px}.c-article-author-list__show-more{display:none;margin-right:4px}.c-article-author-list__button,.js .c-article-author-list__item--hide,.js .c-article-author-list__show-more{display:none}.js .c-article-author-list--long .c-article-author-list__show-more,.js .c-article-author-list--long+.c-article-author-list__button{display:inline}@media only screen and (max-width:539px){.js .c-article-author-list__item--hide-small-screen{display:none}.js .c-article-author-list--short .c-article-author-list__show-more,.js .c-article-author-list--short+.c-article-author-list__button{display:inline}}#uptodate-client,.js .c-article-author-list--expanded .c-article-author-list__show-more{display:none!important}.js .c-article-author-list--expanded .c-article-author-list__item--hide-small-screen{display:inline!important}.c-article-author-list__button,.c-button-author-list{background:#ebf1f5;border:4px solid #ebf1f5;border-radius:20px;color:#666;font-size:.875rem;line-height:1.4;padding:2px 11px 2px 8px;text-decoration:none}.c-article-author-list__button svg,.c-button-author-list svg{margin:1px 4px 0 0}.c-article-author-list__button:hover,.c-button-author-list:hover{background:#069;border-color:transparent;color:#fff}.c-article-info-details{font-size:1rem;margin-bottom:8px;margin-top:16px}.c-article-info-details__cite-as{border-left:1px solid #6f6f6f;margin-left:8px;padding-left:8px}.c-article-metrics-bar{display:flex;flex-wrap:wrap;font-size:1rem;line-height:1.3}.c-article-metrics-bar__wrapper{margin:16px 0}.c-article-metrics-bar__item{align-items:baseline;border-right:1px solid #6f6f6f;margin-right:8px}.c-article-metrics-bar__item:last-child{border-right:0}.c-article-metrics-bar__count{font-weight:700;margin:0}.c-article-metrics-bar__label{color:#626262;font-style:normal;font-weight:400;margin:0 10px 0 5px}.c-article-metrics-bar__details{margin:0}.c-article-main-column{font-family:Harding,Palatino,serif;margin-right:8.6%;width:60.2%}@media only screen and (max-width:1023px){.c-article-main-column{margin-right:0;width:100%}}.c-article-extras{float:left;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;width:31.2%}@media only screen and (max-width:1023px){.c-article-extras{display:none}}.c-article-associated-content__container .c-article-associated-content__title,.c-article-section__title{border-bottom:2px solid #d5d5d5;font-size:1.25rem;margin:0;padding-bottom:8px}@media only screen and (min-width:768px){.c-article-associated-content__container .c-article-associated-content__title,.c-article-section__title{font-size:1.5rem;line-height:1.24}}.c-article-associated-content__container .c-article-associated-content__title{margin-bottom:8px}.c-article-body p{margin-bottom:24px;margin-top:0}.c-article-section{clear:both}.c-article-section__content{margin-bottom:40px;padding-top:8px}@media only screen and (max-width:1023px){.c-article-section__content{padding-left:0}}.c-article-authors-search{margin-bottom:24px;margin-top:0}.c-article-authors-search__item,.c-article-authors-search__title{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif}.c-article-authors-search__title{color:#626262;font-size:1.05rem;font-weight:700;margin:0;padding:0}.c-article-authors-search__item{font-size:1rem}.c-article-authors-search__text{margin:0}.c-code-block{border:1px solid #eee;font-family:monospace;margin:0 0 24px;padding:20px}.c-code-block__heading{font-weight:400;margin-bottom:16px}.c-code-block__line{display:block;overflow-wrap:break-word;white-space:pre-wrap}.c-article-share-box__no-sharelink-info{font-size:.813rem;font-weight:700;margin-bottom:24px;padding-top:4px}.c-article-share-box__only-read-input{border:1px solid #d5d5d5;box-sizing:content-box;display:inline-block;font-size:.875rem;font-weight:700;height:24px;margin-bottom:8px;padding:8px 10px}.c-article-share-box__button--link-like{background-color:transparent;border:0;color:#069;cursor:pointer;font-size:.875rem;margin-bottom:8px;margin-left:10px}.c-article-editorial-summary__container{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem}.c-article-editorial-summary__container .c-article-editorial-summary__content p:last-child{margin-bottom:0}.c-article-editorial-summary__container .c-article-editorial-summary__content--less{max-height:9.5rem;overflow:hidden}.c-article-editorial-summary__container .c-article-editorial-summary__button{background-color:#fff;border:0;color:#069;font-size:.875rem;margin-bottom:16px}.c-article-editorial-summary__container .c-article-editorial-summary__button.active,.c-article-editorial-summary__container .c-article-editorial-summary__button.hover,.c-article-editorial-summary__container .c-article-editorial-summary__button:active,.c-article-editorial-summary__container .c-article-editorial-summary__button:hover{text-decoration:underline;text-decoration-skip-ink:auto}.c-article-associated-content__container .c-article-associated-content__collection-label{font-size:.875rem;line-height:1.4}.c-article-associated-content__container .c-article-associated-content__collection-title{line-height:1.3}.c-context-bar{box-shadow:0 0 10px 0 rgba(51,51,51,.2);position:relative;width:100%}.c-context-bar__title{display:none}.c-reading-companion{clear:both;min-height:389px}.c-reading-companion__sticky{max-width:389px}.c-reading-companion__scroll-pane{margin:0;min-height:200px;overflow:hidden auto}.c-reading-companion__tabs{display:flex;flex-flow:row nowrap;font-size:1rem;list-style:none;margin:0 0 8px;padding:0}.c-reading-companion__tabs>li{flex-grow:1}.c-reading-companion__tab{background-color:#eee;border:1px solid #d5d5d5;border-image:initial;border-left-width:0;color:#069;font-size:1rem;padding:8px 8px 8px 15px;text-align:left;width:100%}.c-reading-companion__tabs li:first-child .c-reading-companion__tab{border-left-width:1px}.c-reading-companion__tab--active{background-color:#fff;border-bottom:1px solid #fff;color:#222;font-weight:700}.c-reading-companion__sections-list{list-style:none;padding:0}.c-reading-companion__figures-list,.c-reading-companion__references-list{list-style:none;min-height:389px;padding:0}.c-reading-companion__references-list--numeric{list-style:decimal inside}.c-reading-companion__sections-list{margin:0 0 8px;min-height:50px}.c-reading-companion__section-item{font-size:1rem;padding:0}.c-reading-companion__section-item a{display:block;line-height:1.5;overflow:hidden;padding:8px 0 8px 16px;text-overflow:ellipsis;white-space:nowrap}.c-reading-companion__figure-item{border-top:1px solid #d5d5d5;font-size:1rem;padding:16px 8px 16px 0}.c-reading-companion__figure-item:first-child{border-top:none;padding-top:8px}.c-reading-companion__reference-item{border-top:1px solid #d5d5d5;font-size:1rem;padding:8px 8px 8px 16px}.c-reading-companion__reference-item:first-child{border-top:none}.c-reading-companion__reference-item a{word-break:break-word}.c-reading-companion__reference-citation{display:inline}.c-reading-companion__reference-links{font-size:.813rem;font-weight:700;list-style:none;margin:8px 0 0;padding:0;text-align:right}.c-reading-companion__reference-links>a{display:inline-block;padding-left:8px}.c-reading-companion__reference-links>a:first-child{display:inline-block;padding-left:0}.c-reading-companion__figure-title{display:block;margin:0 0 8px}.c-reading-companion__figure-links{display:flex;justify-content:space-between;margin:8px 0 0}.c-reading-companion__figure-links>a{align-items:center;display:flex}.c-reading-companion__figure-full-link svg{height:.8em;margin-left:2px}.c-reading-companion__panel{border-top:none;display:none;margin-top:0;padding-top:0}.c-cod,.c-reading-companion__panel--active{display:block}.c-cod{font-size:1rem;width:100%}.c-cod__form{background:#ebf0f3}.c-cod__prompt{font-size:1.125rem;line-height:1.3;margin:0 0 24px}.c-cod__label{display:block;margin:0 0 4px}.c-cod__row{display:flex;margin:0 0 16px}.c-cod__row:last-child{margin:0}.c-cod__input{border:1px solid #d5d5d5;border-radius:2px;flex-basis:75%;flex-shrink:0;margin:0;padding:13px}.c-cod__input--submit{background-color:#069;border:1px solid #069;color:#fff;flex-shrink:1;margin-left:8px;transition:background-color .2s ease-out 0s,color .2s ease-out 0s}.c-cod__input--submit-single{flex-basis:100%;flex-shrink:0;margin:0}.c-cod__input--submit:focus,.c-cod__input--submit:hover{background-color:#fff;color:#069}.c-pdf-download__link .u-icon{padding-top:2px}.c-pdf-download{display:flex;margin-bottom:16px;max-height:48px}@media only screen and (min-width:540px){.c-pdf-download{max-height:none}}@media only screen and (min-width:1024px){.c-pdf-download{max-height:48px}}.c-pdf-download__link{display:flex;flex:1 1 0%}.c-pdf-download__link:hover{text-decoration:none}.c-pdf-download__text{padding-right:4px}@media only screen and (max-width:539px){.c-pdf-download__text{text-transform:capitalize}}@media only screen and (min-width:540px){.c-pdf-download__text{padding-right:8px}}.c-context-bar--sticky .c-pdf-download{display:block;margin-bottom:0;white-space:nowrap}@media only screen and (max-width:539px){.c-pdf-download .u-sticky-visually-hidden{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}}.c-pdf-container{display:flex;justify-content:flex-end}@media only screen and (max-width:539px){.c-pdf-container .c-pdf-download{display:flex;flex-basis:100%}}.c-pdf-container .c-pdf-download+.c-pdf-download{margin-left:16px}.c-article-extras .c-pdf-container .c-pdf-download{width:100%}.c-article-extras .c-pdf-container .c-pdf-download+.c-pdf-download{margin-left:0}@media only screen and (min-width:540px){.c-context-bar--sticky .c-pdf-download__link{align-items:center;flex:1 1 183px}}@media only screen and (max-width:320px){.c-context-bar--sticky .c-pdf-download__link{padding:16px}}.article-page--commercial .c-article-main-column .c-pdf-button__container .c-pdf-download{display:none}@media only screen and (max-width:1023px){.article-page--commercial .c-article-main-column .c-pdf-button__container .c-pdf-download{display:block}}.c-recommendations-column-switch .c-meta{margin-top:auto}.c-article-recommendations-card__meta-type,.c-meta .c-meta__item:first-child{font-weight:700}.c-article-metrics__heading a,.c-article-metrics__posts .c-card__title a{color:inherit}.c-article-metrics__posts .c-card__title{font-size:1.05rem}.c-article-metrics__posts .c-card__title+span{color:#6f6f6f;font-size:1rem}p{overflow-wrap:break-word;word-break:break-word}.c-ad{text-align:center}@media only screen and (min-width:320px){.c-ad{padding:8px}}.c-ad--728x90{background-color:#ccc;display:none}.c-ad--728x90 .c-ad__inner{min-height:calc(1.5em + 94px)}@media only screen and (min-width:768px){.js .c-ad--728x90{display:none}.js .u-show-following-ad+.c-ad--728x90{display:block}}.c-ad__label{color:#333;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:.875rem;font-weight:400;line-height:1.5;margin-bottom:4px}.app-author-list{color:#6f6f6f;font-family:inherit;font-size:1rem;line-height:inherit;list-style:none;margin:0;padding:0}.app-author-list>li,.c-breadcrumbs>li,.c-footer__links>li,.js .app-author-list,.u-list-comma-separated>li,.u-list-inline>li{display:inline}.app-author-list>li:not(:first-child):not(:last-child):before{content:", "}.app-author-list>li:not(:only-child):last-child:before{content:" & "}.app-author-list--compact{font-size:.875rem;line-height:1.4}.app-author-list--truncated>li:not(:only-child):last-child:before{content:" ... "}.js .app-author-list__hide{display:none;visibility:hidden}.js .app-author-list__hide:first-child+*{margin-block-start:0}.c-meta{color:inherit;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:.875rem;line-height:1.4;list-style:none;margin:0;padding:0}.c-meta--large{font-size:1rem}.c-meta--large .c-meta__item{margin-bottom:8px}.c-meta__item{display:inline-block;margin-bottom:4px}.c-meta__item:not(:last-child){border-right:1px solid #d5d5d5;margin-right:4px;padding-right:4px}@media only screen and (max-width:539px){.c-meta__item--block-sm-max{display:block}.c-meta__item--block-sm-max:not(:last-child){border-right:none;margin-right:0;padding-right:0}}@media only screen and (min-width:1024px){.c-meta__item--block-at-lg{display:block}.c-meta__item--block-at-lg:not(:last-child){border-right:none;margin-right:0;padding-right:0}}.c-meta__type{font-weight:700;text-transform:none}.c-skip-link{background:#069;bottom:auto;color:#fff;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:.875rem;padding:8px;position:absolute;text-align:center;transform:translateY(-100%);z-index:9999}@media (prefers-reduced-motion:reduce){.c-skip-link{transition:top .3s ease-in-out 0s}}@media print{.c-skip-link{display:none}}.c-skip-link:link{color:#fff}.c-status-message{align-items:center;box-sizing:border-box;display:flex;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem;position:relative;width:100%}.c-card__summary>p:last-child,.c-status-message :last-child{margin-bottom:0}.c-status-message--boxed{background-color:#fff;border:1px solid #eee;border-radius:2px;line-height:1.4;padding:16px}.c-status-message__heading{font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem;font-weight:700}.c-status-message__icon{fill:currentcolor;display:inline-block;flex:0 0 auto;height:1.5em;margin-right:8px;transform:translate(0);vertical-align:text-top;width:1.5em}.c-status-message__icon--top{align-self:flex-start}.c-status-message--info .c-status-message__icon{color:#003f8d}.c-status-message--boxed.c-status-message--info{border-bottom:4px solid #003f8d}.c-status-message--error .c-status-message__icon{color:#c40606}.c-status-message--boxed.c-status-message--error{border-bottom:4px solid #c40606}.c-status-message--success .c-status-message__icon{color:#00b8b0}.c-status-message--boxed.c-status-message--success{border-bottom:4px solid #00b8b0}.c-status-message--warning .c-status-message__icon{color:#edbc53}.c-status-message--boxed.c-status-message--warning{border-bottom:4px solid #edbc53}.c-breadcrumbs{color:#000;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1rem;list-style:none;margin:0;padding:0}.c-breadcrumbs__link{color:#666}svg.c-breadcrumbs__chevron{margin:4px 4px 0;fill:#888;height:10px;width:10px}@media only screen and (max-width:539px){.c-breadcrumbs .c-breadcrumbs__item{display:none}.c-breadcrumbs .c-breadcrumbs__item:last-child,.c-breadcrumbs .c-breadcrumbs__item:nth-last-child(2){display:inline}}.c-card{background-color:transparent;border:0;box-shadow:none;display:flex;flex-direction:column;font-size:14px;min-width:0;overflow:hidden;padding:0;position:relative}.c-card--no-shape{background:0 0;border:0;box-shadow:none}.c-card__image{display:flex;justify-content:center;overflow:hidden;padding-bottom:56.25%;position:relative}@supports (aspect-ratio:1/1){.c-card__image{padding-bottom:0}}.c-card__image img{left:0;min-height:100%;min-width:100%;position:absolute}@supports ((-o-object-fit:cover) or (object-fit:cover)){.c-card__image img{height:100%;object-fit:cover;width:100%}}.c-card__body{flex:1 1 auto;padding:16px}.c-card--no-shape .c-card__body{padding:0}.c-card--no-shape .c-card__body:not(:first-child){padding-top:16px}.c-card__title{letter-spacing:-.01875rem;margin-bottom:8px;margin-top:0}[lang=de] .c-card__title{hyphens:auto}.c-card__summary{line-height:1.4}.c-card__summary>p{margin-bottom:5px}.c-card__summary a{text-decoration:underline}.c-card__link:not(.c-card__link--no-block-link):before{bottom:0;content:"";left:0;position:absolute;right:0;top:0}.c-card--flush .c-card__body{padding:0}.c-card--major{font-size:1rem}.c-card--dark{background-color:#29303c;border-width:0;color:#e3e4e5}.c-card--dark .c-card__title{color:#fff}.c-card--dark .c-card__link,.c-card--dark .c-card__summary a{color:inherit}.c-header{background-color:#fff;border-bottom:5px solid #000;font-size:1rem;line-height:1.4;margin-bottom:16px}.c-header__row{padding:0;position:relative}.c-header__row:not(:last-child){border-bottom:1px solid #eee}.c-header__split{align-items:center;display:flex;justify-content:space-between}.c-header__logo-container{flex:1 1 0px;line-height:0;margin:8px 24px 8px 0}.c-header__logo{transform:translateZ(0)}.c-header__logo img{max-height:32px}.c-header__container{margin:0 auto;max-width:1280px}.c-header__menu{align-items:center;display:flex;flex:0 1 auto;flex-wrap:wrap;font-weight:700;gap:8px 8px;line-height:1.4;list-style:none;margin:0 -8px;padding:0}@media print{.c-header__menu{display:none}}@media only screen and (max-width:1023px){.c-header__menu--hide-lg-max{display:none;visibility:hidden}}.c-header__menu--global{font-weight:400;justify-content:flex-end}.c-header__menu--global svg{display:none;visibility:hidden}.c-header__menu--global svg:first-child+*{margin-block-start:0}@media only screen and (min-width:540px){.c-header__menu--global svg{display:block;visibility:visible}}.c-header__menu--journal{font-size:.875rem;margin:8px 0 8px -8px}@media only screen and (min-width:540px){.c-header__menu--journal{flex-wrap:nowrap;font-size:1rem}}.c-header__item{padding-bottom:0;padding-top:0;position:static}.c-header__item--pipe{border-left:2px solid #eee;padding-left:8px}.c-header__item--padding{padding-bottom:8px;padding-top:8px}@media only screen and (min-width:540px){.c-header__item--dropdown-menu{position:relative}}@media only screen and (min-width:1024px){.c-header__item--hide-lg{display:none;visibility:hidden}}@media only screen and (max-width:767px){.c-header__item--hide-md-max{display:none;visibility:hidden}.c-header__item--hide-md-max:first-child+*{margin-block-start:0}}.c-header__link{align-items:center;color:inherit;display:inline-flex;gap:4px 4px;padding:8px;white-space:nowrap}.c-header__link svg{transition-duration:.2s}.c-header__show-text{display:none;visibility:hidden}.has-tethered .c-header__heading--js-hide:first-child+*{margin-block-start:0}@media only screen and (min-width:540px){.c-header__show-text{display:inline;visibility:visible}}.c-header__dropdown{background-color:#000;border-bottom:1px solid #2f2f2f;color:#eee;font-size:.875rem;line-height:1.2;padding:16px 0}@media print{.c-header__dropdown{display:none}}.c-header__heading{display:inline-block;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:1.25rem;font-weight:400;line-height:1.4;margin-bottom:8px}.c-header__heading--keyline{border-top:1px solid;border-color:#2f2f2f;margin-top:16px;padding-top:16px;width:100%}.c-header__list{display:flex;flex-wrap:wrap;gap:0 16px;list-style:none;margin:0 -8px}.c-header__flush{margin:0 -8px}.c-header__visually-hidden{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}.c-header__search-form{margin-bottom:8px}.c-header__search-layout{display:flex;flex-wrap:wrap;gap:16px 16px}.c-header__search-layout>:first-child{flex:999 1 auto}.c-header__search-layout>*{flex:1 1 auto}.c-header__search-layout--max-width{max-width:720px}.c-header__search-button{align-items:center;background-color:transparent;background-image:none;border:1px solid #fff;border-radius:2px;color:#fff;cursor:pointer;display:flex;font-family:sans-serif;font-size:1rem;justify-content:center;line-height:1.15;margin:0;padding:8px 16px;position:relative;text-decoration:none;transition:all .25s ease 0s,color .25s ease 0s,border-color .25s ease 0s;width:100%}.u-button svg,.u-button--primary svg{fill:currentcolor}.c-header__input,.c-header__select{border:1px solid;border-radius:3px;box-sizing:border-box;font-size:1rem;padding:8px 16px;width:100%}.c-header__select{-webkit-appearance:none;background-image:url("data:image/svg+xml,%3Csvg height='16' viewBox='0 0 16 16' width='16' xmlns='http://www.w3.org/2000/svg'%3E%3Cpath d='m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z' fill='%23333' fill-rule='evenodd' transform='matrix(0 1 -1 0 11 3)'/%3E%3C/svg%3E");background-position:right .7em top 50%;background-repeat:no-repeat;background-size:1em;box-shadow:0 1px 0 1px rgba(0,0,0,.04);display:block;margin:0;max-width:100%;min-width:150px}@media only screen and (min-width:540px){.c-header__menu--journal .c-header__item--dropdown-menu:last-child .c-header__dropdown.has-tethered{left:auto;right:0}}@media only screen and (min-width:768px){.c-header__menu--journal .c-header__item--dropdown-menu:last-child .c-header__dropdown.has-tethered{left:0;right:auto}}.c-header__dropdown.has-tethered{border-bottom:0;border-radius:0 0 2px 2px;left:0;position:absolute;top:100%;transform:translateY(5px);width:100%;z-index:1}@media only screen and (min-width:540px){.c-header__dropdown.has-tethered{transform:translateY(8px);width:auto}}@media only screen and (min-width:768px){.c-header__dropdown.has-tethered{min-width:225px}}.c-header__dropdown--full-width.has-tethered{padding:32px 0 24px;transform:none;width:100%}.has-tethered .c-header__heading--js-hide{display:none;visibility:hidden}.has-tethered .c-header__list--js-stack{flex-direction:column}.has-tethered .c-header__item--keyline,.has-tethered .c-header__list~.c-header__list .c-header__item:first-child{border-top:1px solid #d5d5d5;margin-top:8px;padding-top:8px}.c-header__item--snid-account-widget{display:flex}.c-header__container{padding:0 4px}.c-header__list{padding:0 12px}.c-header__menu .c-header__link{font-size:14px}.c-header__item--snid-account-widget .c-header__link{padding:8px}.c-header__menu--journal{margin-left:0}@media only screen and (min-width:540px){.c-header__container{padding:0 16px}.c-header__menu--journal{margin-left:-8px}.c-header__menu .c-header__link{font-size:16px}.c-header__link--search{gap:13px 13px}}.u-button{align-items:center;background-color:transparent;background-image:none;border:1px solid #069;border-radius:2px;color:#069;cursor:pointer;display:inline-flex;font-family:sans-serif;font-size:1rem;justify-content:center;line-height:1.3;margin:0;padding:8px;position:relative;text-decoration:none;transition:all .25s ease 0s,color .25s ease 0s,border-color .25s ease 0s;width:auto}.u-button--primary{background-color:#069;background-image:none;border:1px solid #069;color:#fff}.u-button--full-width{display:flex;width:100%}.u-display-none{display:none}.js .u-js-hide,.u-hide{display:none;visibility:hidden}.u-hide:first-child+*{margin-block-start:0}.u-visually-hidden{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}@media print{.u-hide-print{display:none}}@media only screen and (min-width:1024px){.u-hide-at-lg{display:none;visibility:hidden}.u-hide-at-lg:first-child+*{margin-block-start:0}}.u-clearfix:after,.u-clearfix:before{content:"";display:table}.u-clearfix:after{clear:both}.u-color-open-access{color:#b74616}.u-float-left{float:left}.u-icon{fill:currentcolor;display:inline-block;height:1em;transform:translate(0);vertical-align:text-top;width:1em}.u-full-height{height:100%}.u-list-reset{list-style:none;margin:0;padding:0}.u-container{margin:0 auto;max-width:1280px;padding:0 16px}.u-justify-content-space-between{justify-content:space-between}.u-mt-32{margin-top:32px}.u-mb-8{margin-bottom:8px}.u-mb-16{margin-bottom:16px}.u-mb-24{margin-bottom:24px}.u-mb-32{margin-bottom:32px}.c-nature-box svg+.c-article__button-text,.u-ml-8{margin-left:8px}.u-pa-16{padding:16px}html *,html :after,html :before{box-sizing:inherit}.c-article-section__title,.c-article-title{font-weight:700}.c-card__title{line-height:1.4em}.c-article__button{background-color:#069;border:1px solid #069;border-radius:2px;color:#fff;display:flex;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif;font-size:.875rem;line-height:1.4;margin-bottom:16px;padding:13px;transition:background-color .2s ease-out 0s,color .2s ease-out 0s}.c-article__button,.c-article__button:hover{text-decoration:none}.c-article__button--inverted,.c-article__button:hover{background-color:#fff;color:#069}.c-article__button--inverted:hover{background-color:#069;color:#fff}.c-header__link{text-decoration:inherit}.grade-c-hide{display:block}.c-nature-box{background-color:#fff;border:1px solid #d5d5d5;border-radius:2px;box-shadow:0 0 5px 0 rgba(51,51,51,.1);line-height:1.3;margin-bottom:24px;padding:16px 16px 3px}.c-nature-box__text{font-size:1rem;margin-bottom:16px}.c-nature-box--access-to-pdf{display:none}@media only screen and (min-width:1024px){.c-nature-box--mobile{display:none}}.c-nature-box .c-pdf-download{margin-bottom:16px!important}.c-nature-box--version{background-color:#eee}.c-nature-box__wrapper{transform:translateZ(0)}.c-nature-box__wrapper--placeholder{min-height:165px}.c-pdf-download__link{padding:13px 24px} } </style>




    
        <link data-test="critical-css-handler" data-inline-css-source="critical-css" rel="stylesheet" href="/static/css/enhanced-article-nature-branded-1dd982e2cc.css" media="only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)" onload="this.media='only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)';this.onload=null">
    
    <noscript>
        <link rel="stylesheet" type="text/css" href="/static/css/enhanced-article-nature-branded-1dd982e2cc.css" media="only print, only all and (prefers-color-scheme: no-preference), only all and (prefers-color-scheme: light), only all and (prefers-color-scheme: dark)">
    </noscript>

<link rel="stylesheet" type="text/css" href="/static/css/article-print-c9121fecab.css" media="print">
    



<link rel="apple-touch-icon" sizes="180x180" href="/static/images/favicons/nature/apple-touch-icon-f39cb19454.png">
<link rel="icon" type="image/png" sizes="48x48" href="/static/images/favicons/nature/favicon-48x48-b52890008c.png">
<link rel="icon" type="image/png" sizes="32x32" href="/static/images/favicons/nature/favicon-32x32-3fe59ece92.png">
<link rel="icon" type="image/png" sizes="16x16" href="/static/images/favicons/nature/favicon-16x16-951651ab72.png">
<link rel="manifest" href="/static/manifest.json" crossorigin="use-credentials">
<link rel="mask-icon" href="/static/images/favicons/nature/safari-pinned-tab-69bff48fe6.svg" color="#000000">
<link rel="shortcut icon" href="/static/images/favicons/nature/favicon.ico">
<meta name="msapplication-TileColor" content="#000000">
<meta name="msapplication-config" content="/static/browserconfig.xml">
<meta name="theme-color" content="#000000">
<meta name="application-name" content="Nature">


<script>
    (function () {
        if ( typeof window.CustomEvent === "function" ) return false;
        function CustomEvent ( event, params ) {
            params = params || { bubbles: false, cancelable: false, detail: null };
            var evt = document.createEvent( 'CustomEvent' );
            evt.initCustomEvent( event, params.bubbles, params.cancelable, params.detail );
            return evt;
        }

        CustomEvent.prototype = window.Event.prototype;

        window.CustomEvent = CustomEvent;
    })();
</script>



<!-- Google Tag Manager -->
<script data-test="gtm-head">
    window.initGTM = function() {
        if (window.config.mustardcut) {
            (function (w, d, s, l, i) {
                w[l] = w[l] || [];
                w[l].push({'gtm.start': new Date().getTime(), event: 'gtm.js'});
                var f = d.getElementsByTagName(s)[0],
                        j = d.createElement(s),
                        dl = l != 'dataLayer' ? '&l=' + l : '';
                j.async = true;
                j.src = 'https://www.googletagmanager.com/gtm.js?id=' + i + dl;
                f.parentNode.insertBefore(j, f);
            })(window, document, 'script', 'dataLayer', 'GTM-MRVXSHQ');
        }
    }
</script>
<!-- End Google Tag Manager -->

    <script>
    (function(w,d,t) {
        function cc() {
            var h = w.location.hostname;
            if (h.indexOf('preview-www.nature.com') > -1) return;

            var e = d.createElement(t),
                    s = d.getElementsByTagName(t)[0];

            if (h.indexOf('nature.com') > -1) {
                if (h.indexOf('test-www.nature.com') > -1) {
                    e.src = 'https://cmp.nature.com/production_live/en/consent-bundle-8-85.js';
                    e.setAttribute('onload', "initGTM(window,document,'script','dataLayer','GTM-MRVXSHQ')");
                } else {
                    e.src = 'https://cmp.nature.com/production_live/en/consent-bundle-8-85.js';
                    e.setAttribute('onload', "initGTM(window,document,'script','dataLayer','GTM-MRVXSHQ')");
                }
            } else {
                e.src = '/static/js/cookie-consent-es5-bundle-cb57c2c98a.js';
                e.setAttribute('data-consent', h);
            }
            s.insertAdjacentElement('afterend', e);
        }

        cc();
    })(window,document,'script');
</script>


<script id="js-position0">
    (function(w, d) {
        w.idpVerifyPrefix = 'https://verify.nature.com';
        w.ra21Host = 'https://wayf.springernature.com';
        var moduleSupport = (function() {
            return 'noModule' in d.createElement('script');
        })();

        if (w.config.mustardcut === true) {
            w.loader = {
                index: 0,
                registered: [],
                scripts: [
                    
                        {src: '/static/js/global-article-es6-bundle-c8a573ca90.js', test: 'global-article-js', module: true},
                        {src: '/static/js/global-article-es5-bundle-d17603b9e9.js', test: 'global-article-js', nomodule: true},
                        {src: '/static/js/shared-es6-bundle-e9d2061c95.js', test: 'shared-js', module: true},
                        {src: '/static/js/shared-es5-bundle-1cbf3a8b56.js', test: 'shared-js', nomodule: true},
                        {src: '/static/js/header-150-es6-bundle-5bb959eaa1.js', test: 'header-150-js', module: true},
                        {src: '/static/js/header-150-es5-bundle-994fde5b1d.js', test: 'header-150-js', nomodule: true}
                    
                ].filter(function (s) {
                    if (s.src === null) return false;
                    if (moduleSupport && s.nomodule) return false;
                    return !(!moduleSupport && s.module);
                }),

                register: function (value) {
                    this.registered.push(value);
                },

                ready: function () {
                    if (this.registered.length === this.scripts.length) {
                        this.registered.forEach(function (fn) {
                            if (typeof fn === 'function') {
                                setTimeout(fn, 0); 
                            }
                        });
                        this.ready = function () {};
                    }
                },

                insert: function (s) {
                    var t = d.getElementById('js-position' + this.index);
                    if (t && t.insertAdjacentElement) {
                        t.insertAdjacentElement('afterend', s);
                    } else {
                        d.head.appendChild(s);
                    }
                    ++this.index;
                },

                createScript: function (script, beforeLoad) {
                    var s = d.createElement('script');
                    s.id = 'js-position' + (this.index + 1);
                    s.setAttribute('data-test', script.test);
                    if (beforeLoad) {
                        s.defer = 'defer';
                        s.onload = function () {
                            if (script.noinit) {
                                loader.register(true);
                            }
                            if (d.readyState === 'interactive' || d.readyState === 'complete') {
                                loader.ready();
                            }
                        };
                    } else {
                        s.async = 'async';
                    }
                    s.src = script.src;
                    return s;
                },

                init: function () {
                    this.scripts.forEach(function (s) {
                        loader.insert(loader.createScript(s, true));
                    });

                    d.addEventListener('DOMContentLoaded', function () {
                        loader.ready();
                        var conditionalScripts;
                        
                            conditionalScripts = [
                                {match: 'div[data-pan-container]', src: '/static/js/pan-zoom-es6-bundle-464a2af269.js', test: 'pan-zoom-js',  module: true },
                                {match: 'div[data-pan-container]', src: '/static/js/pan-zoom-es5-bundle-98fb9b653b.js', test: 'pan-zoom-js',  nomodule: true },
                                {match: 'math,span.mathjax-tex', src: '/static/js/math-es6-bundle-23597ae350.js', test: 'math-js', module: true},
                                {match: 'math,span.mathjax-tex', src: '/static/js/math-es5-bundle-6532c6f78b.js', test: 'math-js', nomodule: true}
                            ];
                        

                        if (conditionalScripts) {
                            conditionalScripts.filter(function (script) {
                                return !!document.querySelector(script.match) && !((moduleSupport && script.nomodule) || (!moduleSupport && script.module));
                            }).forEach(function (script) {
                                loader.insert(loader.createScript(script));
                            });
                        }
                    }, false);
                }
            };
            loader.init();
        }
    })(window, document);
</script><script id="js-position1" data-test="global-article-js" defer="" src="/static/js/global-article-es6-bundle-c8a573ca90.js"></script><script id="js-position2" data-test="shared-js" defer="" src="/static/js/shared-es6-bundle-e9d2061c95.js"></script><script id="js-position3" data-test="header-150-js" defer="" src="/static/js/header-150-es6-bundle-5bb959eaa1.js"></script>










<meta name="robots" content="noarchive">
<meta name="access" content="Yes">


<link rel="search" href="https://www.nature.com/search">
<link rel="search" href="https://www.nature.com/opensearch/opensearch.xml" type="application/opensearchdescription+xml" title="nature.com">
<link rel="search" href="https://www.nature.com/opensearch/request" type="application/sru+xml" title="nature.com">





    
    <script type="application/ld+json">{"mainEntity":{"headline":"CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial","description":"Despite impressive progress, more than 50% of patients treated with CD19-targeting chimeric antigen receptor T cells (CAR19) experience progressive disease. Ten of 16 patients with large B cell lymphoma (LBCL) with progressive disease after CAR19 treatment had absent or low CD19. Lower surface CD19 density pretreatment was associated with progressive disease. To prevent relapse with CD19− or CD19lo disease, we tested a bispecific CAR targeting CD19 and/or CD22 (CD19-22.BB.z-CAR) in a phase I clinical trial (\n                NCT03233854\n                \n              ) of adults with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL) and LBCL. The primary end points were manufacturing feasibility and safety with a secondary efficacy end point. Primary end points were met; 97% of products met protocol-specified dose and no dose-limiting toxicities occurred during dose escalation. In B-ALL (n = 17), 100% of patients responded with 88% minimal residual disease-negative complete remission (CR); in LBCL (n = 21), 62% of patients responded with 29% CR. Relapses were CD19−/lo in 50% (5 out of 10) of patients with B-ALL and 29% (4 out of 14) of patients with LBCL but were not associated with CD22−/lo disease. CD19/22-CAR products demonstrated reduced cytokine production when stimulated with CD22 versus CD19. Our results further implicate antigen loss as a major cause of CAR T cell resistance, highlight the challenge of engineering multi-specific CAR T cells with equivalent potency across targets and identify cytokine production as an important quality indicator for CAR T cell potency. Bispecific CAR T cells targeting CD19 and CD22 exhibit clinical activity and low toxicity in patients with large B cell lymphoma and B cell acute lymphoblastic leukemia, with relapses associated with loss of CD19 but not CD22.","datePublished":"2021-07-26T00:00:00Z","dateModified":"2021-07-26T00:00:00Z","pageStart":"1419","pageEnd":"1431","license":"http://creativecommons.org/licenses/by/4.0/","sameAs":"https://doi.org/10.1038/s41591-021-01436-0","keywords":["Acute lymphocytic leukaemia","Cancer immunotherapy","Lymphoma","Phase I trials","Biomedicine","general","Cancer Research","Metabolic Diseases","Infectious Diseases","Molecular Medicine","Neurosciences"],"image":["https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_Fig1_HTML.png","https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_Fig2_HTML.png","https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_Fig3_HTML.png","https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_Fig4_HTML.png"],"isPartOf":{"name":"Nature Medicine","issn":["1546-170X","1078-8956"],"volumeNumber":"27","@type":["Periodical","PublicationVolume"]},"publisher":{"name":"Nature Publishing Group US","logo":{"url":"https://www.springernature.com/app-sn/public/images/logo-springernature.png","@type":"ImageObject"},"@type":"Organization"},"author":[{"name":"Jay Y. Spiegel","url":"http://orcid.org/0000-0001-6491-0044","affiliation":[{"name":"Stanford University School of Medicine","address":{"name":"Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Shabnum Patel","url":"http://orcid.org/0000-0002-4782-9540","affiliation":[{"name":"Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine","address":{"name":"Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Lori Muffly","url":"http://orcid.org/0000-0002-9887-6136","affiliation":[{"name":"Stanford University School of Medicine","address":{"name":"Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine","address":{"name":"Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Nasheed M. Hossain","url":"http://orcid.org/0000-0002-3278-655X","affiliation":[{"name":"Loyola University Medical Center","address":{"name":"Division of Hematology/Oncology, Loyola University Medical Center, Chicago, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Jean Oak","affiliation":[{"name":"Stanford University School of Medicine","address":{"name":"Department of Clinical Pathology, Stanford University School of Medicine, Stanford, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"John H. Baird","url":"http://orcid.org/0000-0001-8291-6546","affiliation":[{"name":"Stanford University School of Medicine","address":{"name":"Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Matthew J. Frank","affiliation":[{"name":"Stanford University School of Medicine","address":{"name":"Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Parveen Shiraz","affiliation":[{"name":"Stanford University School of Medicine","address":{"name":"Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Bita Sahaf","affiliation":[{"name":"Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine","address":{"name":"Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Juliana Craig","url":"http://orcid.org/0000-0002-5644-2292","affiliation":[{"name":"Stanford University School of Medicine","address":{"name":"Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Maria Iglesias","affiliation":[{"name":"Stanford University School of Medicine","address":{"name":"Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Sheren Younes","affiliation":[{"name":"Stanford University School of Medicine","address":{"name":"Department of Clinical Pathology, Stanford University School of Medicine, Stanford, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Yasodha Natkunam","url":"http://orcid.org/0000-0002-9816-1018","affiliation":[{"name":"Stanford University School of Medicine","address":{"name":"Department of Clinical Pathology, Stanford University School of Medicine, Stanford, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Michael G. Ozawa","affiliation":[{"name":"Stanford University School of Medicine","address":{"name":"Department of Clinical Pathology, Stanford University School of Medicine, Stanford, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Eric Yang","affiliation":[{"name":"Stanford University School of Medicine","address":{"name":"Department of Clinical Pathology, Stanford University School of Medicine, Stanford, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"John Tamaresis","affiliation":[{"name":"Stanford University School of Medicine","address":{"name":"Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Harshini Chinnasamy","affiliation":[{"name":"Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine","address":{"name":"Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Zach Ehlinger","affiliation":[{"name":"Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine","address":{"name":"Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Warren Reynolds","affiliation":[{"name":"Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine","address":{"name":"Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Rachel Lynn","affiliation":[{"name":"Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine","address":{"name":"Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Lyell Immunopharma","address":{"name":"Lyell Immunopharma, San Francisco, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Maria Caterina Rotiroti","affiliation":[{"name":"Stanford University School of Medicine","address":{"name":"Department of Pediatrics–Hematology/Oncology, Stanford University School of Medicine, Stanford, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Nikolaos Gkitsas","affiliation":[{"name":"Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine","address":{"name":"Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Sally Arai","affiliation":[{"name":"Stanford University School of Medicine","address":{"name":"Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Laura Johnston","affiliation":[{"name":"Stanford University School of Medicine","address":{"name":"Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Robert Lowsky","affiliation":[{"name":"Stanford University School of Medicine","address":{"name":"Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Robbie G. Majzner","url":"http://orcid.org/0000-0001-6969-8011","affiliation":[{"name":"Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine","address":{"name":"Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Stanford University School of Medicine","address":{"name":"Department of Pediatrics–Hematology/Oncology, Stanford University School of Medicine, Stanford, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Everett Meyer","affiliation":[{"name":"Stanford University School of Medicine","address":{"name":"Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Robert S. Negrin","affiliation":[{"name":"Stanford University School of Medicine","address":{"name":"Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Andrew R. Rezvani","affiliation":[{"name":"Stanford University School of Medicine","address":{"name":"Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Surbhi Sidana","url":"http://orcid.org/0000-0003-3288-7614","affiliation":[{"name":"Stanford University School of Medicine","address":{"name":"Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Judith Shizuru","url":"http://orcid.org/0000-0003-3246-4726","affiliation":[{"name":"Stanford University School of Medicine","address":{"name":"Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Wen-Kai Weng","affiliation":[{"name":"Stanford University School of Medicine","address":{"name":"Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Chelsea Mullins","affiliation":[{"name":"Adaptive Biotechnologies","address":{"name":"Adaptive Biotechnologies, Seattle, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Allison Jacob","affiliation":[{"name":"Adaptive Biotechnologies","address":{"name":"Adaptive Biotechnologies, Seattle, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Ilan Kirsch","affiliation":[{"name":"Adaptive Biotechnologies","address":{"name":"Adaptive Biotechnologies, Seattle, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Magali Bazzano","affiliation":[{"name":"IsoPlexis","address":{"name":"IsoPlexis, Brantford, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Jing Zhou","affiliation":[{"name":"IsoPlexis","address":{"name":"IsoPlexis, Brantford, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Sean Mackay","affiliation":[{"name":"IsoPlexis","address":{"name":"IsoPlexis, Brantford, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Scott J. Bornheimer","affiliation":[{"name":"BD Biosciences","address":{"name":"BD Biosciences, San Jose, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Liora Schultz","affiliation":[{"name":"Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine","address":{"name":"Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Stanford University School of Medicine","address":{"name":"Department of Pediatrics–Hematology/Oncology, Stanford University School of Medicine, Stanford, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"National Institutes of Health","address":{"name":"Pediatric Oncology Branch Center for Cancer Research, National Institutes of Health, Bethesda, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Sneha Ramakrishna","url":"http://orcid.org/0000-0001-7445-3190","affiliation":[{"name":"Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine","address":{"name":"Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Stanford University School of Medicine","address":{"name":"Department of Pediatrics–Hematology/Oncology, Stanford University School of Medicine, Stanford, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Kara L. Davis","url":"http://orcid.org/0000-0002-7182-2592","affiliation":[{"name":"Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine","address":{"name":"Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Stanford University School of Medicine","address":{"name":"Department of Pediatrics–Hematology/Oncology, Stanford University School of Medicine, Stanford, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Katherine A. Kong","affiliation":[{"name":"Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine","address":{"name":"Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Nirali N. Shah","url":"http://orcid.org/0000-0002-8474-9080","affiliation":[{"name":"National Institutes of Health","address":{"name":"Pediatric Oncology Branch Center for Cancer Research, National Institutes of Health, Bethesda, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Haiying Qin","url":"http://orcid.org/0000-0001-5966-8812","affiliation":[{"name":"National Institutes of Health","address":{"name":"Pediatric Oncology Branch Center for Cancer Research, National Institutes of Health, Bethesda, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Terry Fry","url":"http://orcid.org/0000-0001-8044-5226","affiliation":[{"name":"National Institutes of Health","address":{"name":"Pediatric Oncology Branch Center for Cancer Research, National Institutes of Health, Bethesda, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"University of Colorado Anschutz and Children’s Hospital Colorado","address":{"name":"Department of Pediatrics–Hematology/Oncology, University of Colorado Anschutz and Children’s Hospital Colorado, Denver, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Steven Feldman","affiliation":[{"name":"Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine","address":{"name":"Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, USA","@type":"PostalAddress"},"@type":"Organization"}],"@type":"Person"},{"name":"Crystal L. Mackall","url":"http://orcid.org/0000-0001-6323-4304","affiliation":[{"name":"Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine","address":{"name":"Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Stanford University School of Medicine","address":{"name":"Department of Pediatrics–Hematology/Oncology, Stanford University School of Medicine, Stanford, USA","@type":"PostalAddress"},"@type":"Organization"}],"email":"cmackall@stanford.edu","@type":"Person"},{"name":"David B. Miklos","url":"http://orcid.org/0000-0003-0717-4305","affiliation":[{"name":"Stanford University School of Medicine","address":{"name":"Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, USA","@type":"PostalAddress"},"@type":"Organization"},{"name":"Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine","address":{"name":"Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, USA","@type":"PostalAddress"},"@type":"Organization"}],"email":"dmiklos@stanford.edu","@type":"Person"}],"isAccessibleForFree":true,"@type":"ScholarlyArticle"},"@context":"https://schema.org","@type":"WebPage"}</script>




    
    
    


    
    <link rel="canonical" href="https://www.nature.com/articles/s41591-021-01436-0">
    
    
    <meta name="journal_id" content="41591">
    <meta name="dc.title" content="CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial">
    <meta name="dc.source" content="Nature Medicine 2021 27:8">
    <meta name="dc.format" content="text/html">
    <meta name="dc.publisher" content="Nature Publishing Group">
    <meta name="dc.date" content="2021-07-26">
    <meta name="dc.type" content="OriginalPaper">
    <meta name="dc.language" content="En">
    <meta name="dc.copyright" content="2021 The Author(s)">
    <meta name="dc.rights" content="2021 The Author(s)">
    <meta name="dc.rightsAgent" content="journalpermissions@springernature.com">
    <meta name="dc.description" content="Despite impressive progress, more than 50% of patients treated with CD19-targeting chimeric antigen receptor T cells (CAR19) experience progressive disease. Ten of 16 patients with large B cell lymphoma (LBCL) with progressive disease after CAR19 treatment had absent or low CD19. Lower surface CD19 density pretreatment was associated with progressive disease. To prevent relapse with CD19− or CD19lo disease, we tested a bispecific CAR targeting CD19 and/or CD22 (CD19-22.BB.z-CAR) in a phase I clinical trial ( NCT03233854 ) of adults with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL) and LBCL. The primary end points were manufacturing feasibility and safety with a secondary efficacy end point. Primary end points were met; 97% of products met protocol-specified dose and no dose-limiting toxicities occurred during dose escalation. In B-ALL (n = 17), 100% of patients responded with 88% minimal residual disease-negative complete remission (CR); in LBCL (n = 21), 62% of patients responded with 29% CR. Relapses were CD19−/lo in 50% (5 out of 10) of patients with B-ALL and 29% (4 out of 14) of patients with LBCL but were not associated with CD22−/lo disease. CD19/22-CAR products demonstrated reduced cytokine production when stimulated with CD22 versus CD19. Our results further implicate antigen loss as a major cause of CAR T cell resistance, highlight the challenge of engineering multi-specific CAR T cells with equivalent potency across targets and identify cytokine production as an important quality indicator for CAR T cell potency. Bispecific CAR T cells targeting CD19 and CD22 exhibit clinical activity and low toxicity in patients with large B cell lymphoma and B cell acute lymphoblastic leukemia, with relapses associated with loss of CD19 but not CD22.">
    <meta name="prism.issn" content="1546-170X">
    <meta name="prism.publicationName" content="Nature Medicine">
    <meta name="prism.publicationDate" content="2021-07-26">
    <meta name="prism.volume" content="27">
    <meta name="prism.number" content="8">
    <meta name="prism.section" content="OriginalPaper">
    <meta name="prism.startingPage" content="1419">
    <meta name="prism.endingPage" content="1431">
    <meta name="prism.copyright" content="2021 The Author(s)">
    <meta name="prism.rightsAgent" content="journalpermissions@springernature.com">
    <meta name="prism.url" content="https://www.nature.com/articles/s41591-021-01436-0">
    <meta name="prism.doi" content="doi:10.1038/s41591-021-01436-0">
    <meta name="citation_pdf_url" content="https://www.nature.com/articles/s41591-021-01436-0.pdf">
    <meta name="citation_fulltext_html_url" content="https://www.nature.com/articles/s41591-021-01436-0">
    <meta name="citation_journal_title" content="Nature Medicine">
    <meta name="citation_journal_abbrev" content="Nat Med">
    <meta name="citation_publisher" content="Nature Publishing Group">
    <meta name="citation_issn" content="1546-170X">
    <meta name="citation_title" content="CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial">
    <meta name="citation_volume" content="27">
    <meta name="citation_issue" content="8">
    <meta name="citation_publication_date" content="2021/08">
    <meta name="citation_online_date" content="2021/07/26">
    <meta name="citation_firstpage" content="1419">
    <meta name="citation_lastpage" content="1431">
    <meta name="citation_article_type" content="Article">
    <meta name="citation_fulltext_world_readable" content="">
    <meta name="citation_language" content="en">
    <meta name="dc.identifier" content="doi:10.1038/s41591-021-01436-0">
    <meta name="DOI" content="10.1038/s41591-021-01436-0">
    <meta name="size" content="338349">
    <meta name="citation_doi" content="10.1038/s41591-021-01436-0">
    <meta name="citation_springer_api_url" content="http://api.springer.com/xmldata/jats?q=doi:10.1038/s41591-021-01436-0&amp;api_key=">
    <meta name="description" content="Despite impressive progress, more than 50% of patients treated with CD19-targeting chimeric antigen receptor T cells (CAR19) experience progressive disease. Ten of 16 patients with large B cell lymphoma (LBCL) with progressive disease after CAR19 treatment had absent or low CD19. Lower surface CD19 density pretreatment was associated with progressive disease. To prevent relapse with CD19− or CD19lo disease, we tested a bispecific CAR targeting CD19 and/or CD22 (CD19-22.BB.z-CAR) in a phase I clinical trial ( NCT03233854 ) of adults with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL) and LBCL. The primary end points were manufacturing feasibility and safety with a secondary efficacy end point. Primary end points were met; 97% of products met protocol-specified dose and no dose-limiting toxicities occurred during dose escalation. In B-ALL (n = 17), 100% of patients responded with 88% minimal residual disease-negative complete remission (CR); in LBCL (n = 21), 62% of patients responded with 29% CR. Relapses were CD19−/lo in 50% (5 out of 10) of patients with B-ALL and 29% (4 out of 14) of patients with LBCL but were not associated with CD22−/lo disease. CD19/22-CAR products demonstrated reduced cytokine production when stimulated with CD22 versus CD19. Our results further implicate antigen loss as a major cause of CAR T cell resistance, highlight the challenge of engineering multi-specific CAR T cells with equivalent potency across targets and identify cytokine production as an important quality indicator for CAR T cell potency. Bispecific CAR T cells targeting CD19 and CD22 exhibit clinical activity and low toxicity in patients with large B cell lymphoma and B cell acute lymphoblastic leukemia, with relapses associated with loss of CD19 but not CD22.">
    <meta name="dc.creator" content="Spiegel, Jay Y.">
    <meta name="dc.creator" content="Patel, Shabnum">
    <meta name="dc.creator" content="Muffly, Lori">
    <meta name="dc.creator" content="Hossain, Nasheed M.">
    <meta name="dc.creator" content="Oak, Jean">
    <meta name="dc.creator" content="Baird, John H.">
    <meta name="dc.creator" content="Frank, Matthew J.">
    <meta name="dc.creator" content="Shiraz, Parveen">
    <meta name="dc.creator" content="Sahaf, Bita">
    <meta name="dc.creator" content="Craig, Juliana">
    <meta name="dc.creator" content="Iglesias, Maria">
    <meta name="dc.creator" content="Younes, Sheren">
    <meta name="dc.creator" content="Natkunam, Yasodha">
    <meta name="dc.creator" content="Ozawa, Michael G.">
    <meta name="dc.creator" content="Yang, Eric">
    <meta name="dc.creator" content="Tamaresis, John">
    <meta name="dc.creator" content="Chinnasamy, Harshini">
    <meta name="dc.creator" content="Ehlinger, Zach">
    <meta name="dc.creator" content="Reynolds, Warren">
    <meta name="dc.creator" content="Lynn, Rachel">
    <meta name="dc.creator" content="Rotiroti, Maria Caterina">
    <meta name="dc.creator" content="Gkitsas, Nikolaos">
    <meta name="dc.creator" content="Arai, Sally">
    <meta name="dc.creator" content="Johnston, Laura">
    <meta name="dc.creator" content="Lowsky, Robert">
    <meta name="dc.creator" content="Majzner, Robbie G.">
    <meta name="dc.creator" content="Meyer, Everett">
    <meta name="dc.creator" content="Negrin, Robert S.">
    <meta name="dc.creator" content="Rezvani, Andrew R.">
    <meta name="dc.creator" content="Sidana, Surbhi">
    <meta name="dc.creator" content="Shizuru, Judith">
    <meta name="dc.creator" content="Weng, Wen-Kai">
    <meta name="dc.creator" content="Mullins, Chelsea">
    <meta name="dc.creator" content="Jacob, Allison">
    <meta name="dc.creator" content="Kirsch, Ilan">
    <meta name="dc.creator" content="Bazzano, Magali">
    <meta name="dc.creator" content="Zhou, Jing">
    <meta name="dc.creator" content="Mackay, Sean">
    <meta name="dc.creator" content="Bornheimer, Scott J.">
    <meta name="dc.creator" content="Schultz, Liora">
    <meta name="dc.creator" content="Ramakrishna, Sneha">
    <meta name="dc.creator" content="Davis, Kara L.">
    <meta name="dc.creator" content="Kong, Katherine A.">
    <meta name="dc.creator" content="Shah, Nirali N.">
    <meta name="dc.creator" content="Qin, Haiying">
    <meta name="dc.creator" content="Fry, Terry">
    <meta name="dc.creator" content="Feldman, Steven">
    <meta name="dc.creator" content="Mackall, Crystal L.">
    <meta name="dc.creator" content="Miklos, David B.">
    <meta name="dc.subject" content="Acute lymphocytic leukaemia">
    <meta name="dc.subject" content="Cancer immunotherapy">
    <meta name="dc.subject" content="Lymphoma">
    <meta name="dc.subject" content="Phase I trials">
    <meta name="citation_reference" content="citation_journal_title=J. Clin. Invest.; citation_title=CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients; citation_author=CJ Turtle; citation_volume=126; citation_publication_date=2016; citation_pages=2123-2138; citation_doi=10.1172/JCI85309; citation_id=CR1">
    <meta name="citation_reference" content="citation_journal_title=Lancet Oncol.; citation_title=Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial; citation_author=FL Locke; citation_volume=20; citation_publication_date=2019; citation_pages=31-42; citation_doi=10.1016/S1470-2045(18)30864-7; citation_id=CR2">
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma; citation_author=SS Neelapu; citation_volume=377; citation_publication_date=2017; citation_pages=2531-2544; citation_doi=10.1056/NEJMoa1707447; citation_id=CR3">
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma; citation_author=SJ Schuster; citation_volume=380; citation_publication_date=2019; citation_pages=45-56; citation_doi=10.1056/NEJMoa1804980; citation_id=CR4">
    <meta name="citation_reference" content="citation_journal_title=Blood; citation_title=Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy; citation_author=KA Hay; citation_volume=133; citation_publication_date=2019; citation_pages=1652-1663; citation_doi=10.1182/blood-2018-11-883710; citation_id=CR5">
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia; citation_author=SL Maude; citation_volume=378; citation_publication_date=2018; citation_pages=439-448; citation_doi=10.1056/NEJMoa1709866; citation_id=CR6">
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia; citation_author=JH Park; citation_volume=378; citation_publication_date=2018; citation_pages=449-459; citation_doi=10.1056/NEJMoa1709919; citation_id=CR7">
    <meta name="citation_reference" content="citation_journal_title=J. Clin. Oncol.; citation_title=Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium; citation_author=LJ Nastoupil; citation_volume=38; citation_publication_date=2020; citation_pages=3119-3128; citation_doi=10.1200/JCO.19.02104; citation_id=CR8">
    <meta name="citation_reference" content="citation_journal_title=Blood; citation_title=Pivotal safety and efficacy results from Transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed/refractory (R/R) large B cell lymphomas; citation_author=JS Abramson; citation_volume=134; citation_publication_date=2019; citation_pages=241; citation_doi=10.1182/blood-2019-127508; citation_id=CR9">
    <meta name="citation_reference" content="citation_journal_title=Lancet; citation_title=T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial; citation_author=DW Lee; citation_volume=385; citation_publication_date=2015; citation_pages=517-528; citation_doi=10.1016/S0140-6736(14)61403-3; citation_id=CR10">
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors; citation_author=E Liu; citation_volume=382; citation_publication_date=2020; citation_pages=545-553; citation_doi=10.1056/NEJMoa1910607; citation_id=CR11">
    <meta name="citation_reference" content="citation_journal_title=Cancer Discov.; citation_title=Tumor antigen escape from CAR T-cell therapy; citation_author=RG Majzner, CL Mackall; citation_volume=8; citation_publication_date=2018; citation_pages=1219-1226; citation_doi=10.1158/2159-8290.CD-18-0442; citation_id=CR12">
    <meta name="citation_reference" content="citation_journal_title=Mol. Cell. Biol.; citation_title=CD19 alterations emerging after CD19-directed immunotherapy cause retention of the misfolded protein in the endoplasmic reticulum; citation_author=A Bagashev; citation_volume=38; citation_publication_date=2018; citation_pages=e00383-18; citation_doi=10.1128/MCB.00383-18; citation_id=CR13">
    <meta name="citation_reference" content="citation_journal_title=Leukemia; citation_title=Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19; citation_author=M Asnani; citation_volume=34; citation_publication_date=2020; citation_pages=1202-1207; citation_doi=10.1038/s41375-019-0580-z; citation_id=CR14">
    <meta name="citation_reference" content="citation_journal_title=Nat. Med.; citation_title=Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia; citation_author=EJ Orlando; citation_volume=24; citation_publication_date=2018; citation_pages=1504-1506; citation_doi=10.1038/s41591-018-0146-z; citation_id=CR15">
    <meta name="citation_reference" content="citation_journal_title=Cancer Discov.; citation_title=Convergence of acquired mutations and alternative splicing of CD19 enables Resistance to CART-19 Immunotherapy; citation_author=E Sotillo; citation_volume=5; citation_publication_date=2015; citation_pages=1282-1295; citation_doi=10.1158/2159-8290.CD-15-1020; citation_id=CR16">
    <meta name="citation_reference" content="citation_journal_title=Clin. Cancer Res.; citation_title=CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors; citation_author=RG Majzner; citation_volume=25; citation_publication_date=2019; citation_pages=2560-2574; citation_doi=10.1158/1078-0432.CCR-18-0432; citation_id=CR17">
    <meta name="citation_reference" content="citation_journal_title=J. Immunol.; citation_title=Target antigen density governs the efficacy of anti-CD20-CD28-CD3 ζ chimeric antigen receptor-modified effector CD8+ T cells; citation_author=K Watanabe; citation_volume=194; citation_publication_date=2015; citation_pages=911-920; citation_doi=10.4049/jimmunol.1402346; citation_id=CR18">
    <meta name="citation_reference" content="citation_journal_title=Mol. Ther.; citation_title=Superior therapeutic index in lymphoma therapy: CD30+ CD34+ hematopoietic stem cells resist a chimeric antigen receptor T-cell attack; citation_author=AA Hombach; citation_volume=24; citation_publication_date=2016; citation_pages=1423-1434; citation_doi=10.1038/mt.2016.82; citation_id=CR19">
    <meta name="citation_reference" content="citation_journal_title=Mol. Ther.; citation_title=Tumor antigen and receptor densities regulate efficacy of a chimeric antigen receptor targeting anaplastic lymphoma kinase; citation_author=AJ Walker; citation_volume=25; citation_publication_date=2017; citation_pages=2189-2201; citation_doi=10.1016/j.ymthe.2017.06.008; citation_id=CR20">
    <meta name="citation_reference" content="citation_journal_title=Cancer Discov.; citation_title=Tuning the antigen density requirement for CAR T-cell activity; citation_author=RG Majzner; citation_volume=10; citation_publication_date=2020; citation_pages=702-723; citation_doi=10.1158/2159-8290.CD-19-0945; citation_id=CR21">
    <meta name="citation_reference" content="citation_journal_title=Nat. Med.; citation_title=CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy; citation_author=TJ Fry; citation_volume=24; citation_publication_date=2018; citation_pages=20-28; citation_doi=10.1038/nm.4441; citation_id=CR22">
    <meta name="citation_reference" content="citation_journal_title=J. Clin. Invest.; citation_title=B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma; citation_author=AD Cohen; citation_volume=129; citation_publication_date=2019; citation_pages=2210-2221; citation_doi=10.1172/JCI126397; citation_id=CR23">
    <meta name="citation_reference" content="citation_journal_title=Blood; citation_title=Target antigen downregulation and other mechanisms of failure after axicabtagene ciloleucel (CAR19) therapy; citation_author=J Oak; citation_volume=132; citation_publication_date=2018; citation_pages=4656; citation_doi=10.1182/blood-2018-99-120206; citation_id=CR24">
    <meta name="citation_reference" content="citation_journal_title=Blood; citation_title=CD19-loss with preservation of other B cell lineage features in patients with large B cell lymphoma who relapsed post-axi-cel; citation_author=SS Neelapu; citation_volume=134; citation_publication_date=2019; citation_pages=203; citation_doi=10.1182/blood-2019-126218; citation_id=CR25">
    <meta name="citation_reference" content="citation_journal_title=Pediatr. Blood Cancer; citation_title=Characterization of CD22 expression in acute lymphoblastic leukemia; citation_author=NN Shah; citation_volume=62; citation_publication_date=2015; citation_pages=964-969; citation_doi=10.1002/pbc.25410; citation_id=CR26">
    <meta name="citation_reference" content="citation_journal_title=Blood; citation_title=Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia; citation_author=W Haso; citation_volume=121; citation_publication_date=2013; citation_pages=1165-1174; citation_doi=10.1182/blood-2012-06-438002; citation_id=CR27">
    <meta name="citation_reference" content="citation_journal_title=Adv. Immunol.; citation_title=CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction; citation_author=TF Tedder, JC Poe, KM Haas; citation_volume=88; citation_publication_date=2005; citation_pages=1-50; citation_doi=10.1016/S0065-2776(05)88001-0; citation_id=CR28">
    <meta name="citation_reference" content="citation_journal_title=Leuk. Lymphoma; citation_title=Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases; citation_author=S Raponi; citation_volume=52; citation_publication_date=2011; citation_pages=1098-1107; citation_doi=10.3109/10428194.2011.559668; citation_id=CR29">
    <meta name="citation_reference" content="citation_journal_title=Immunol. Invest.; citation_title=A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry; citation_author=SH Olejniczak, CC Stewart, K Donohue, MS Czuczman; citation_volume=35; citation_publication_date=2006; citation_pages=93-114; citation_doi=10.1080/08820130500496878; citation_id=CR30">
    <meta name="citation_reference" content="citation_journal_title=J. Clin. Oncol.; citation_title=CD4/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial; citation_author=NN Shah; citation_volume=38; citation_publication_date=2020; citation_pages=1938-1950; citation_doi=10.1200/JCO.19.03279; citation_id=CR31">
    <meta name="citation_reference" content="citation_journal_title=Mol. Ther. Oncolytics; citation_title=Preclinical development of bivalent chimeric antigen receptors targeting both CD19 and CD22; citation_author=H Qin; citation_volume=11; citation_publication_date=2018; citation_pages=127-137; citation_doi=10.1016/j.omto.2018.10.006; citation_id=CR32">
    <meta name="citation_reference" content="Frank, M. J. et al. Optimizing circulating tumor DNA based assessments in patients with large B-cell lymphoma undergoing axicabtagene ciloleucel. J. Clin. Oncol. 
                  https://doi.org/10.1200/JCO.21.00377
                  
                 (2021).">
    <meta name="citation_reference" content="citation_journal_title=Science; citation_title=Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling; citation_author=EW Weber; citation_volume=372; citation_publication_date=2021; citation_pages=eaba1786; citation_doi=10.1126/science.aba1786; citation_id=CR34">
    <meta name="citation_reference" content="citation_journal_title=Am. J. Hematol.; citation_title=Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma; citation_author=H Yu; citation_volume=92; citation_publication_date=2017; citation_pages=E11-E13; citation_doi=10.1002/ajh.24594; citation_id=CR35">
    <meta name="citation_reference" content="citation_journal_title=Blood; citation_title=CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR-refractory large B-cell lymphoma; citation_author=JH Baird; citation_volume=137; citation_publication_date=2021; citation_pages=2321-2325; citation_doi=10.1182/blood.2020009432; citation_id=CR36">
    <meta name="citation_reference" content="citation_journal_title=Blood; citation_title=Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy; citation_author=R Gardner; citation_volume=127; citation_publication_date=2016; citation_pages=2406-2410; citation_doi=10.1182/blood-2015-08-665547; citation_id=CR37">
    <meta name="citation_reference" content="citation_journal_title=Nat. Commun.; citation_title=CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity; citation_author=E Jacoby; citation_volume=7; citation_publication_date=2016; citation_doi=10.1038/ncomms12320; citation_id=CR38">
    <meta name="citation_reference" content="citation_journal_title=N. Engl. J. Med.; citation_title=Chimeric antigen receptor T cells in refractory B-cell lymphomas; citation_author=SJ Schuster; citation_volume=377; citation_publication_date=2017; citation_pages=2545-2554; citation_doi=10.1056/NEJMoa1708566; citation_id=CR39">
    <meta name="citation_reference" content="citation_journal_title=Haematologica; citation_title=Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma; citation_author=H Shalabi; citation_volume=103; citation_publication_date=2018; citation_pages=e215-e218; citation_doi=10.3324/haematol.2017.183459; citation_id=CR40">
    <meta name="citation_reference" content="citation_journal_title=Blood; citation_title=T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma; citation_author=SA Ali; citation_volume=128; citation_publication_date=2016; citation_pages=1688-1700; citation_doi=10.1182/blood-2016-04-711903; citation_id=CR41">
    <meta name="citation_reference" content="citation_journal_title=J. Clin. Invest.; citation_title=Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape; citation_author=M Hegde; citation_volume=126; citation_publication_date=2016; citation_pages=3036-3052; citation_doi=10.1172/JCI83416; citation_id=CR42">
    <meta name="citation_reference" content="citation_journal_title=Neuro Oncol.; citation_title=Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma; citation_author=K Bielamowicz; citation_volume=20; citation_publication_date=2018; citation_pages=506-518; citation_doi=10.1093/neuonc/nox182; citation_id=CR43">
    <meta name="citation_reference" content="citation_journal_title=Nat. Commun.; citation_title=Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma; citation_author=E Zah; citation_volume=11; citation_publication_date=2020; citation_pages=2283; citation_doi=10.1038/s41467-020-16160-5; citation_id=CR44">
    <meta name="citation_reference" content="citation_journal_title=Blood; citation_title=Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia; citation_author=X He; citation_volume=135; citation_publication_date=2020; citation_pages=713-723; citation_doi=10.1182/blood.2019002779; citation_id=CR45">
    <meta name="citation_reference" content="citation_journal_title=Blood Adv.; citation_title=Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma; citation_author=A Schmidts; citation_volume=3; citation_publication_date=2019; citation_pages=3248-3260; citation_doi=10.1182/bloodadvances.2019000703; citation_id=CR46">
    <meta name="citation_reference" content="citation_journal_title=Nat. Med.; citation_title=Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial; citation_author=NN Shah; citation_volume=26; citation_publication_date=2020; citation_pages=1569-1575; citation_doi=10.1038/s41591-020-1081-3; citation_id=CR47">
    <meta name="citation_reference" content="citation_journal_title=Blood; citation_title=Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma; citation_author=C Tong; citation_volume=136; citation_publication_date=2020; citation_pages=1632-1644; citation_id=CR48">
    <meta name="citation_reference" content="citation_journal_title=J. Clin. Oncol.; citation_title=Efficacy of SCRI-CAR19x22 T cell product in B-ALL and persistence of anti-CD22 activity; citation_author=RA Gardner; citation_volume=38; citation_publication_date=2020; citation_pages=3035; citation_doi=10.1200/JCO.2020.38.15_suppl.3035; citation_id=CR49">
    <meta name="citation_reference" content="citation_journal_title=Leukemia; citation_title=CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression; citation_author=K Fousek; citation_volume=35; citation_publication_date=2021; citation_pages=75-89; citation_doi=10.1038/s41375-020-0792-2; citation_id=CR50">
    <meta name="citation_reference" content="citation_journal_title=J. Hematol. Oncol.; citation_title=Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia; citation_author=H Dai; citation_volume=13; citation_publication_date=2020; citation_pages=30; citation_doi=10.1186/s13045-020-00856-8; citation_id=CR51">
    <meta name="citation_reference" content="citation_journal_title=Blood; citation_title=Phase I study of AUTO3, a bicistronic chimeric antigen receptor (CAR) T-cell therapy targeting CD19 and CD22, in pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL): Amelia study; citation_author=PJ Amrolia; citation_volume=134; citation_publication_date=2019; citation_pages=2620; citation_doi=10.1182/blood-2019-123424; citation_id=CR52">
    <meta name="citation_reference" content="citation_journal_title=Nature; citation_title=c-Jun overexpression in CAR T cells induces exhaustion resistance; citation_author=RC Lynn; citation_volume=576; citation_publication_date=2019; citation_pages=293-300; citation_doi=10.1038/s41586-019-1805-z; citation_id=CR53">
    <meta name="citation_reference" content="citation_journal_title=J. Immunother.; citation_title=The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens; citation_author=RD Guest; citation_volume=28; citation_publication_date=2005; citation_pages=203-211; citation_doi=10.1097/01.cji.0000161397.96582.59; citation_id=CR54">
    <meta name="citation_reference" content="citation_journal_title=Clin. Cancer Res.; citation_title=Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells; citation_author=M Hudecek; citation_volume=19; citation_publication_date=2013; citation_pages=3153-3164; citation_doi=10.1158/1078-0432.CCR-13-0330; citation_id=CR55">
    <meta name="citation_reference" content="citation_journal_title=Oncoimmunology; citation_title=Lessons learned from a highly-active CD22-specific chimeric antigen receptor; citation_author=AH Long, WM Haso, RJ Orentas; citation_volume=2; citation_publication_date=2013; citation_pages=e23621; citation_doi=10.4161/onci.23621; citation_id=CR56">
    <meta name="citation_reference" content="citation_journal_title=Gastroenterology; citation_title=Persistent polyfunctional chimeric antigen receptor T cells that target glypican 3 eliminate orthotopic hepatocellular carcinomas in mice; citation_author=D Li; citation_volume=158; citation_publication_date=2020; citation_pages=2250-2265.e20; citation_doi=10.1053/j.gastro.2020.02.011; citation_id=CR57">
    <meta name="citation_reference" content="citation_journal_title=Blood; citation_title=Single chain variable fragment linker length regulates CAR biology and T cell efficacy; citation_author=N Singh; citation_volume=134; citation_publication_date=2019; citation_pages=247; citation_doi=10.1182/blood-2019-131024; citation_id=CR58">
    <meta name="citation_reference" content="citation_journal_title=Mol. Ther. Nucleic Acids; citation_title=TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy; citation_author=Z Grada; citation_volume=2; citation_publication_date=2013; citation_pages=e105; citation_doi=10.1038/mtna.2013.32; citation_id=CR59">
    <meta name="citation_reference" content="citation_journal_title=Cancer Immunol. Res.; citation_title=T cells expressing CD19/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells; citation_author=E Zah, M-Y Lin, A Silva-Benedict, MC Jensen, YY Chen; citation_volume=4; citation_publication_date=2016; citation_pages=498-508; citation_doi=10.1158/2326-6066.CIR-15-0231; citation_id=CR60">
    <meta name="citation_reference" content="citation_journal_title=Blood; citation_title=Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy; citation_author=JY Spiegel; citation_volume=137; citation_publication_date=2021; citation_pages=1832-1835; citation_id=CR61">
    <meta name="citation_reference" content="citation_journal_title=Cancer Immunol. Immunother.; citation_title=Induction of a central memory and stem cell memory phenotype in functionally active CD4+ and CD8+ CAR T cells produced in an automated good manufacturing practice system for the treatment of CD19+ acute lymphoblastic leukemia; citation_author=F Blaeschke; citation_volume=67; citation_publication_date=2018; citation_pages=1053-1066; citation_doi=10.1007/s00262-018-2155-7; citation_id=CR62">
    <meta name="citation_reference" content="citation_journal_title=Blood; citation_title=Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15; citation_author=Y Xu; citation_volume=123; citation_publication_date=2014; citation_pages=3750-3759; citation_doi=10.1182/blood-2014-01-552174; citation_id=CR63">
    <meta name="citation_reference" content="citation_journal_title=Blood Adv.; citation_title=Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma; citation_author=MC Pasquini; citation_volume=4; citation_publication_date=2020; citation_pages=5414-5424; citation_doi=10.1182/bloodadvances.2020003092; citation_id=CR64">
    <meta name="citation_reference" content="citation_journal_title=J. Clin. Oncol.; citation_title=Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification; citation_author=BD Cheson; citation_volume=32; citation_publication_date=2014; citation_pages=3059-3067; citation_doi=10.1200/JCO.2013.54.8800; citation_id=CR65">
    <meta name="citation_reference" content="citation_journal_title=Blood; citation_title=Current concepts in the diagnosis and management of cytokine release syndrome; citation_author=DW Lee; citation_volume=124; citation_publication_date=2014; citation_pages=188-195; citation_doi=10.1182/blood-2014-05-552729; citation_id=CR66">
    <meta name="citation_reference" content="citation_journal_title=Biol. Blood Marrow Transplant.; citation_title=ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells; citation_author=DW Lee; citation_volume=25; citation_publication_date=2019; citation_pages=625-638; citation_doi=10.1016/j.bbmt.2018.12.758; citation_id=CR67">
    <meta name="citation_reference" content="citation_journal_title=Nucleic Acids Res.; citation_title=The Stanford Tissue Microarray Database; citation_author=RJ Marinelli; citation_volume=36; citation_publication_date=2008; citation_pages=D871-D877; citation_doi=10.1093/nar/gkm861; citation_id=CR68">
    <meta name="citation_reference" content="citation_journal_title=PLoS ONE; citation_title=Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials; citation_author=B Jena; citation_volume=8; citation_publication_date=2013; citation_pages=e57838; citation_doi=10.1371/journal.pone.0057838; citation_id=CR69">
    <meta name="citation_reference" content="citation_journal_title=BMC Cancer; citation_title=Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma; citation_author=T Ching; citation_volume=20; citation_publication_date=2020; citation_doi=10.1186/s12885-020-07077-9; citation_id=CR70">
    <meta name="citation_author" content="Spiegel, Jay Y.">
    <meta name="citation_author_institution" content="Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, USA">
    <meta name="citation_author" content="Patel, Shabnum">
    <meta name="citation_author_institution" content="Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, USA">
    <meta name="citation_author" content="Muffly, Lori">
    <meta name="citation_author_institution" content="Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, USA">
    <meta name="citation_author_institution" content="Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, USA">
    <meta name="citation_author" content="Hossain, Nasheed M.">
    <meta name="citation_author_institution" content="Division of Hematology/Oncology, Loyola University Medical Center, Chicago, USA">
    <meta name="citation_author" content="Oak, Jean">
    <meta name="citation_author_institution" content="Department of Clinical Pathology, Stanford University School of Medicine, Stanford, USA">
    <meta name="citation_author" content="Baird, John H.">
    <meta name="citation_author_institution" content="Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, USA">
    <meta name="citation_author" content="Frank, Matthew J.">
    <meta name="citation_author_institution" content="Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, USA">
    <meta name="citation_author" content="Shiraz, Parveen">
    <meta name="citation_author_institution" content="Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, USA">
    <meta name="citation_author" content="Sahaf, Bita">
    <meta name="citation_author_institution" content="Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, USA">
    <meta name="citation_author" content="Craig, Juliana">
    <meta name="citation_author_institution" content="Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, USA">
    <meta name="citation_author" content="Iglesias, Maria">
    <meta name="citation_author_institution" content="Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, USA">
    <meta name="citation_author" content="Younes, Sheren">
    <meta name="citation_author_institution" content="Department of Clinical Pathology, Stanford University School of Medicine, Stanford, USA">
    <meta name="citation_author" content="Natkunam, Yasodha">
    <meta name="citation_author_institution" content="Department of Clinical Pathology, Stanford University School of Medicine, Stanford, USA">
    <meta name="citation_author" content="Ozawa, Michael G.">
    <meta name="citation_author_institution" content="Department of Clinical Pathology, Stanford University School of Medicine, Stanford, USA">
    <meta name="citation_author" content="Yang, Eric">
    <meta name="citation_author_institution" content="Department of Clinical Pathology, Stanford University School of Medicine, Stanford, USA">
    <meta name="citation_author" content="Tamaresis, John">
    <meta name="citation_author_institution" content="Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, USA">
    <meta name="citation_author" content="Chinnasamy, Harshini">
    <meta name="citation_author_institution" content="Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, USA">
    <meta name="citation_author" content="Ehlinger, Zach">
    <meta name="citation_author_institution" content="Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, USA">
    <meta name="citation_author" content="Reynolds, Warren">
    <meta name="citation_author_institution" content="Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, USA">
    <meta name="citation_author" content="Lynn, Rachel">
    <meta name="citation_author_institution" content="Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, USA">
    <meta name="citation_author_institution" content="Lyell Immunopharma, San Francisco, USA">
    <meta name="citation_author" content="Rotiroti, Maria Caterina">
    <meta name="citation_author_institution" content="Department of Pediatrics–Hematology/Oncology, Stanford University School of Medicine, Stanford, USA">
    <meta name="citation_author" content="Gkitsas, Nikolaos">
    <meta name="citation_author_institution" content="Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, USA">
    <meta name="citation_author" content="Arai, Sally">
    <meta name="citation_author_institution" content="Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, USA">
    <meta name="citation_author" content="Johnston, Laura">
    <meta name="citation_author_institution" content="Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, USA">
    <meta name="citation_author" content="Lowsky, Robert">
    <meta name="citation_author_institution" content="Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, USA">
    <meta name="citation_author" content="Majzner, Robbie G.">
    <meta name="citation_author_institution" content="Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, USA">
    <meta name="citation_author_institution" content="Department of Pediatrics–Hematology/Oncology, Stanford University School of Medicine, Stanford, USA">
    <meta name="citation_author" content="Meyer, Everett">
    <meta name="citation_author_institution" content="Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, USA">
    <meta name="citation_author" content="Negrin, Robert S.">
    <meta name="citation_author_institution" content="Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, USA">
    <meta name="citation_author" content="Rezvani, Andrew R.">
    <meta name="citation_author_institution" content="Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, USA">
    <meta name="citation_author" content="Sidana, Surbhi">
    <meta name="citation_author_institution" content="Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, USA">
    <meta name="citation_author" content="Shizuru, Judith">
    <meta name="citation_author_institution" content="Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, USA">
    <meta name="citation_author" content="Weng, Wen-Kai">
    <meta name="citation_author_institution" content="Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, USA">
    <meta name="citation_author" content="Mullins, Chelsea">
    <meta name="citation_author_institution" content="Adaptive Biotechnologies, Seattle, USA">
    <meta name="citation_author" content="Jacob, Allison">
    <meta name="citation_author_institution" content="Adaptive Biotechnologies, Seattle, USA">
    <meta name="citation_author" content="Kirsch, Ilan">
    <meta name="citation_author_institution" content="Adaptive Biotechnologies, Seattle, USA">
    <meta name="citation_author" content="Bazzano, Magali">
    <meta name="citation_author_institution" content="IsoPlexis, Brantford, USA">
    <meta name="citation_author" content="Zhou, Jing">
    <meta name="citation_author_institution" content="IsoPlexis, Brantford, USA">
    <meta name="citation_author" content="Mackay, Sean">
    <meta name="citation_author_institution" content="IsoPlexis, Brantford, USA">
    <meta name="citation_author" content="Bornheimer, Scott J.">
    <meta name="citation_author_institution" content="BD Biosciences, San Jose, USA">
    <meta name="citation_author" content="Schultz, Liora">
    <meta name="citation_author_institution" content="Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, USA">
    <meta name="citation_author_institution" content="Department of Pediatrics–Hematology/Oncology, Stanford University School of Medicine, Stanford, USA">
    <meta name="citation_author_institution" content="Pediatric Oncology Branch Center for Cancer Research, National Institutes of Health, Bethesda, USA">
    <meta name="citation_author" content="Ramakrishna, Sneha">
    <meta name="citation_author_institution" content="Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, USA">
    <meta name="citation_author_institution" content="Department of Pediatrics–Hematology/Oncology, Stanford University School of Medicine, Stanford, USA">
    <meta name="citation_author" content="Davis, Kara L.">
    <meta name="citation_author_institution" content="Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, USA">
    <meta name="citation_author_institution" content="Department of Pediatrics–Hematology/Oncology, Stanford University School of Medicine, Stanford, USA">
    <meta name="citation_author" content="Kong, Katherine A.">
    <meta name="citation_author_institution" content="Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, USA">
    <meta name="citation_author" content="Shah, Nirali N.">
    <meta name="citation_author_institution" content="Pediatric Oncology Branch Center for Cancer Research, National Institutes of Health, Bethesda, USA">
    <meta name="citation_author" content="Qin, Haiying">
    <meta name="citation_author_institution" content="Pediatric Oncology Branch Center for Cancer Research, National Institutes of Health, Bethesda, USA">
    <meta name="citation_author" content="Fry, Terry">
    <meta name="citation_author_institution" content="Pediatric Oncology Branch Center for Cancer Research, National Institutes of Health, Bethesda, USA">
    <meta name="citation_author_institution" content="Department of Pediatrics–Hematology/Oncology, University of Colorado Anschutz and Children’s Hospital Colorado, Denver, USA">
    <meta name="citation_author" content="Feldman, Steven">
    <meta name="citation_author_institution" content="Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, USA">
    <meta name="citation_author" content="Mackall, Crystal L.">
    <meta name="citation_author_institution" content="Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, USA">
    <meta name="citation_author_institution" content="Department of Pediatrics–Hematology/Oncology, Stanford University School of Medicine, Stanford, USA">
    <meta name="citation_author" content="Miklos, David B.">
    <meta name="citation_author_institution" content="Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, USA">
    <meta name="citation_author_institution" content="Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, USA">
    <meta name="access_endpoint" content="https://www.nature.com/platform/readcube-access">
    <meta name="twitter:site" content="@naturemedicine">
    <meta name="twitter:card" content="summary_large_image">
    <meta name="twitter:image:alt" content="Content cover image">
    <meta name="twitter:title" content="CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial">
    <meta name="twitter:description" content="Nature Medicine - Bispecific CAR T cells targeting CD19 and CD22 exhibit clinical activity and low toxicity in patients with large B cell lymphoma and B cell acute lymphoblastic leukemia, with...">
    <meta name="twitter:image" content="https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_Fig1_HTML.png">
    

    
    
    <meta property="og:url" content="https://www.nature.com/articles/s41591-021-01436-0">
    <meta property="og:type" content="article">
    <meta property="og:site_name" content="Nature">
    <meta property="og:title" content="CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial - Nature Medicine">
    <meta property="og:description" content="Bispecific CAR T cells targeting CD19 and CD22 exhibit clinical activity and low toxicity in patients with large B cell lymphoma and B cell acute lymphoblastic leukemia, with relapses associated with loss of CD19 but not CD22.">
    <meta property="og:image" content="https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_Fig1_HTML.png">
    

    <script>
        window.eligibleForRa21 = 'false'; 
    </script>
<style type="text/css">.cc-banner{background-color:#01324b;border:none!important;bottom:0;box-sizing:border-box;color:#fff!important;left:0;line-height:1.3;margin:auto 0 0;max-width:100%;outline:0;overflow:visible;padding:0;position:fixed;right:0;width:100%;z-index:99999}.cc-banner::backdrop{background-color:#0000004d}.cc-banner *{color:inherit!important}.cc-banner:focus{box-shadow:none;outline:0}.cc-banner a{color:#fff!important;text-decoration:underline}.cc-banner a:active,.cc-banner a:focus,.cc-banner a:hover{color:inherit;text-decoration:none}.cc-banner a:focus{outline:3px solid #08c!important}.cc-banner h2,.cc-banner h3,.cc-banner h4,.cc-banner h5,.cc-banner h6{font-family:sans-serif;font-style:normal;font-weight:700;margin:0 0 .5em}.cc-banner .cc-h2,.cc-banner h2{font-size:18px}.cc-banner .cc-h3,.cc-banner h3{font-size:16px}.cc-banner .cc-h4,.cc-banner .cc-h5,.cc-banner .cc-h6,.cc-banner h4,.cc-banner h5,.cc-banner h6{font-size:14px}.cc-banner .cc-button{font-size:16px}.cc-banner__content{background-color:#01324b;display:flex;flex-direction:column;margin:0 auto;max-height:90vh;max-width:100%;padding:16px;position:relative}.cc-banner__content:focus{outline:0}@media (min-width:680px){.cc-banner__content{padding:12px}}@media (min-width:980px){.cc-banner__content{max-height:60vh;padding-bottom:20px;padding-top:20px}}@media (min-width:1320px){.cc-banner__content{padding-bottom:40px;padding-top:40px}}.cc-banner__container{display:flex;flex-direction:column;margin:auto;max-width:1320px;overflow:auto}.cc-banner__title{background:none!important;border:0;flex-shrink:0;font-size:18px!important;font-size:22px!important;font-weight:700!important;letter-spacing:normal;margin:0 0 12px!important;padding:0}@media (min-width:680px){.cc-banner__title{font-size:24px!important;margin:0 0 16px!important}}@media (min-width:1320px){.cc-banner__title{font-size:26px!important;margin:0 0 24px!important}}.cc-banner__body{display:flex;flex-direction:column;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif!important;overflow-x:hidden;overflow-y:auto;padding:3px 3px 16px}@media (min-width:980px){.cc-banner__body{flex-direction:row}}.cc-banner__policy p{font-size:16px!important;margin:0;max-width:none;padding:0}.cc-banner__policy p:not(:last-child){margin:0 0 16px}@media (min-width:980px){.cc-banner__policy p:not(:last-child){margin:0 0 24px}}.cc-banner__policy p a{font-size:16px!important;font-weight:700}.cc-banner__footer{box-shadow:none;flex-shrink:0;font-family:-apple-system,BlinkMacSystemFont,Segoe UI,Roboto,Oxygen-Sans,Ubuntu,Cantarell,Helvetica Neue,sans-serif !important!important;margin:0;padding:12px 0 3px 3px;position:relative}@media (min-width:380px){.cc-banner__footer{align-items:stretch;display:flex;flex-wrap:wrap}}@media (min-width:680px){.cc-banner__footer{box-shadow:none;flex-wrap:nowrap;width:40%}}.cc-banner__footer .cc-banner__button{flex:1 1 auto;font-weight:700;overflow:hidden;padding:.5em 1em;width:100%}@media (min-width:680px){.cc-banner__footer .cc-banner__button{max-width:275px}}.cc-banner__footer .cc-banner__button:not(:last-child){margin-bottom:12px}@media (min-width:680px){.cc-banner__footer .cc-banner__button:not(:last-child){margin-bottom:0;margin-right:16px}}@media (min-width:980px){.cc-banner__footer .cc-banner__button:not(:last-child){margin-right:24px}}@media (min-width:680px){html[dir=rtl] .cc-banner__footer .cc-banner__button:not(:last-child){margin-left:16px!important;margin-right:0!important}}@media (min-width:980px){html[dir=rtl] .cc-banner__footer .cc-banner__button:not(:last-child){margin-left:24px!important;margin-right:0!important}}.cc-banner__button-preferences{padding-left:0;padding-right:0}@media (min-width:380px){.cc-banner__button-preferences{flex:0 0 auto;margin:auto}}@media (min-width:680px){.cc-banner__button-preferences{margin:0}}@media (min-width:380px) and (max-width:680px){.cc-banner__button-break{display:block}}@media (min-width:680px){.cc-banner--is-tcf .cc-banner__footer{width:auto}}@media (min-width:980px){.cc-banner--is-tcf .cc-banner__footer{padding-right:48px;width:66%}}.cc-banner--is-tcf .cc-banner__stacks-intro{font-size:16px!important}.cc-banner--is-tcf .cc-banner__stacks{margin:16px 0 0}@media (min-width:980px){.cc-banner--is-tcf .cc-banner__stacks{display:flex;flex:0 0 33%;flex-direction:column;margin:0 0 0 48px;overflow:auto}}.cc-banner--is-tcf .cc-banner__stacks-intro{font-size:16px;margin:0 0 12px}.cc-banner--is-tcf .cc-banner__stacks-details{padding:0 3px}.cc-banner--is-tcf .cc-banner .cc-details{border-color:#fff3!important}.cc-box{border-radius:10px;padding:12px}.cc-box--info{background-color:#eff6fb}.cc-box--light{background-color:#faf9f6}.cc-button{border:2px solid #0000;border-radius:32px!important;color:inherit;cursor:pointer;font-size:14px;font-weight:700!important;left:auto;line-height:1.2;margin:0;padding:.5em 1em;right:auto;text-transform:none!important;transition:all .2s}@media (min-width:680px){.cc-button{font-size:14px;padding:.75em 1em}}.cc-button--sm{font-size:12px;padding:2px 8px!important}.cc-button--primary{background-color:#025e8d!important;border-color:#025e8d!important;color:#fff!important}.cc-button--primary:focus{outline:3px solid #08c}.cc-button--primary:focus,.cc-button--primary:hover,.cc-button--secondary{background-color:#fff!important;border-color:#025e8d!important;color:#025e8d!important}.cc-button--secondary:focus{background-color:#025e8d!important;border-color:#fff!important;color:#fff!important;outline:3px solid #08c!important}.cc-button--secondary:hover{background-color:#025e8d!important;border-color:#025e8d!important;color:#fff!important}.cc-button--secondary:active{border:2px solid #01324b!important}.cc-button--secondary.cc-button--contrast{border-color:#fff!important}.cc-button--secondary.cc-button--contrast:hover{background-color:initial!important;color:#fff!important}.cc-button--tertiary{background-color:#f0f7fc!important;background-image:none;border:2px solid #f0f7fc;color:#025e8d!important;text-decoration:underline!important;text-underline-offset:.25em}.cc-button--tertiary:focus{outline:3px solid #08c!important}.cc-button--tertiary:hover{text-decoration-thickness:.25em}.cc-button--tertiary:active{color:#013c5b}.cc-button--link{background-color:initial!important;border-color:#0000!important;border-radius:0!important;color:inherit!important;padding:0!important;text-decoration:underline!important;width:inherit!important}.cc-button--link:focus{outline:3px solid #08c}.cc-button--link:hover{background-color:initial!important;box-shadow:none;text-decoration:none}.cc-button--text{border-radius:0;padding:0}.cc-button--details{padding-right:24px!important;position:relative;width:auto}.cc-button--details:after,.cc-button--details:before{background-color:currentColor;content:"";position:absolute;transition:transform .25s ease-out}.cc-button--details:before{height:10px;margin-top:-5px;right:12px;top:50%;width:2px}.cc-button--details:after{height:2px;margin-top:-1px;right:8px;top:50%;width:10px}.cc-button--details.cc-active:before{transform:rotate(90deg);transform-origin:center}.cc-button--details.cc-active:after{display:none}.cc-details{border-bottom:1px solid #0000001a;padding:12px 0;position:relative;width:100%}.cc-details__summary{align-items:center;display:flex;font-size:14px;font-weight:700;list-style-type:none}.cc-details__summary:focus,.cc-details__summary:focus-visible{outline:3px solid #08c!important;will-change:auto}.cc-details__title{align-items:baseline;display:flex}.cc-details__title h2,.cc-details__title h3,.cc-details__title h4,.cc-details__title h5{line-height:1.4;margin:0!important;padding:0!important}.cc-details__title svg{flex-shrink:0;height:auto;margin-right:8px;position:relative;top:-1px;transition:all .2s;width:auto}.cc-details[open] .cc-details__title svg{top:2px;transform:rotate(90deg)}.cc-details__switch{margin-left:auto}.cc-details__section{padding:16px 0 0 18px}.cc-details__section p{margin:0}.cc-details__section p:not(:last-child){margin-bottom:12px}details summary::-webkit-details-marker{display:none}.cc-radio{align-items:center;display:flex;position:relative}.cc-radio *{cursor:pointer}.cc-radio__input{height:22px;left:0;position:absolute;top:0;width:22px}.cc-radio__input:focus{outline:none}.cc-radio__label{color:inherit;font-size:14px;font-weight:700;line-height:23px;margin:0;padding-left:28px}.cc-radio__label:after,.cc-radio__label:before{background-color:#fff;content:"";display:block;position:absolute;transition:transform .25s ease-out}.cc-radio__label:before{border:1px solid #777;border-radius:50%;height:22px;left:0;top:0;width:22px}.cc-radio__label:after{border:7px solid #025e8d;border-radius:50%;height:0;left:4px;opacity:0;top:4px;width:0}.cc-radio__input:focus+.cc-radio__label:before{box-shadow:0 0 0 2px #08c;outline:none}.cc-radio__label--hidden{display:none}.cc-radio__input:checked+.cc-radio__label:after{opacity:1}.cc-radio__input:disabled{cursor:default}.cc-radio__input:disabled+.cc-radio__label{cursor:default;opacity:.5}.cc-switch *{cursor:pointer}.cc-switch{align-items:center;display:flex;line-height:1}.cc-switch__label{cursor:pointer;display:inline-block;font-size:14px;font-weight:700;margin:0;-webkit-user-select:none;user-select:none}.cc-switch__input[type=checkbox]{-webkit-appearance:none;appearance:none;background-color:#fff!important;background-image:url("data:image/svg+xml;charset=utf-8,%3Csvg xmlns='http://www.w3.org/2000/svg' viewBox='-4 -4 8 8'%3E%3Ccircle r='3' fill='rgba(0, 0, 0, 0.25)'/%3E%3C/svg%3E")!important;background-position:0!important;background-repeat:no-repeat!important;border:1px solid #777!important;border-radius:16px!important;height:18px!important;margin:0 8px 0 0!important;transition:background-position .2s ease-in-out!important;width:32px!important}.cc-switch__input[type=checkbox]:focus{background-image:url("data:image/svg+xml;charset=utf-8,%3Csvg xmlns='http://www.w3.org/2000/svg' viewBox='-4 -4 8 8'%3E%3Ccircle r='3' fill='%2380b3cc'/%3E%3C/svg%3E")!important}.cc-switch__input[type=checkbox]:checked{background-color:#025e8d!important;background-image:url("data:image/svg+xml;charset=utf-8,%3Csvg xmlns='http://www.w3.org/2000/svg' viewBox='-4 -4 8 8'%3E%3Ccircle r='3' fill='%23fff'/%3E%3C/svg%3E")!important;background-position:100%!important}.cc-switch__input[type=checkbox]:checked~.cc-switch__label>.cc-switch__text-off,.cc-switch__input[type=checkbox]:not(:checked)~.cc-switch__label>.cc-switch__text-on{display:none}.cc-switch__input[type=checkbox]:hover{cursor:pointer;outline:none}.cc-switch__input[type=checkbox]:focus-visible{cursor:pointer;outline:3px solid #fc0}.cc-switch__input[type=checkbox]:checked:before{background-color:none!important;color:#0000!important}html[dir=rtl] .cc-switch__input[type=checkbox]{margin-left:8px!important;margin-right:0!important}.cc-list>ul,ul.cc-list{list-style-type:disc;margin-left:0;padding-left:0}.cc-list>ul>li,ul.cc-list>li{margin-left:1em}.cc-list>ul>li:not(:last-child),ul.cc-list>li:not(:last-child){margin-bottom:4px}.cc-list__title{margin-bottom:8px!important}.cc-list--inline>ul,ul.cc-list--inline{display:flex;flex-wrap:wrap;list-style-type:none}.cc-list--inline>ul>li,ul.cc-list--inline>li{margin:0 .5em .5em 0}.cc-overlay{background-color:#0000004d;z-index:99998}.cc-overlay,.cc-preferences{bottom:0;left:0;position:fixed;right:0;top:0}.cc-preferences{background-color:#050a14f2!important;border:0;box-sizing:border-box;color:#111;font-family:sans-serif!important;line-height:1.4;margin:auto;max-height:100vh;overflow:auto;padding:0;z-index:100000}.cc-preferences:focus{outline:none}.cc-preferences *,.cc-preferences :after,.cc-preferences :before{box-sizing:inherit!important}.cc-preferences h2,.cc-preferences h3,.cc-preferences h4,.cc-preferences h5,.cc-preferences h6{font-family:sans-serif;font-style:normal;font-weight:700;margin:0 0 .5em}.cc-preferences .cc-h2,.cc-preferences h2{font-size:18px}.cc-preferences .cc-h3,.cc-preferences h3{font-size:16px}.cc-preferences .cc-h4,.cc-preferences .cc-h5,.cc-preferences .cc-h6,.cc-preferences h4,.cc-preferences h5,.cc-preferences h6{font-size:14px}.cc-preferences a{color:#025e8d;text-decoration:underline}.cc-preferences a:hover{color:inherit;text-decoration:none}.cc-preferences h3{background:none;color:#111;padding:0;text-transform:none}dialog.cc-preferences{background-color:initial}dialog.cc-preferences::backdrop{background-color:#000000e6}.cc-preferences__dialog{display:flex;flex-direction:column;margin:auto;max-height:100vh;max-width:860px;padding:12px;position:relative}.cc-preferences__dialog>:last-child{border-bottom-left-radius:10px;border-bottom-right-radius:10px}@media (min-width:980px){.cc-preferences__dialog{padding:16px}}.cc-preferences__close{background:#0000!important;border:1px solid #ececec;border-radius:50%;color:#111!important;cursor:pointer;font-family:Times New Roman,serif;font-size:40px;height:40px;left:auto;line-height:1;margin-top:-20px;padding:0!important;position:absolute;right:20px;top:50%;width:40px}.cc-preferences__close:focus{outline:3px solid #08c}.cc-preferences__close-label{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}.cc-preferences__header{background:#fff!important;border-bottom:1px solid #0000001a;border-top-left-radius:10px;border-top-right-radius:10px;padding:16px;position:relative;text-align:center}.cc-preferences__title{background:none!important;color:#111!important;font-family:sans-serif!important;font-size:18px!important;font-weight:700!important;margin:0!important;padding:0 16px 0 0!important}@media (min-width:480px){.cc-preferences__title{padding-right:0!important}}@media (min-width:980px){.cc-preferences__title{font-size:22px!important}}.cc-preferences__body{background:#fff!important;flex:1 1 auto;min-height:200px;overflow-x:hidden;overflow-y:auto;padding:16px}.cc-preferences__footer{background:#fff!important;border-top:1px solid #d0d0d0;box-shadow:0 0 5px 0 #0003;margin-bottom:0;padding:12px;position:relative}@media (min-width:480px){.cc-preferences__footer{align-items:stretch;display:flex}}.cc-preferences__footer>.cc-button{display:block;width:100%}@media (min-width:480px){.cc-preferences__footer>.cc-button{flex:1 1 auto}}@media (min-width:980px){.cc-preferences__footer>.cc-button{flex-basis:auto}}@media (min-width:480px){.cc-preferences__footer>.cc-button:not(:first-child){margin-left:12px}}.cc-preferences__footer>.cc-button:not(:last-child){margin-bottom:8px}@media (min-width:480px){.cc-preferences__footer>.cc-button:not(:last-child){margin-bottom:0}}.cc-preferences__categories{list-style:none;margin:0;padding:0}.cc-preferences__category:not(:last-child){border-bottom:1px solid #0000001a;margin-bottom:12px;padding-bottom:12px}.cc-preferences__category-description{font-size:14px;margin:0 0 8px;padding:0}.cc-preferences__category-footer{align-items:center;display:flex;justify-content:space-between}.cc-preferences__status{border:0;clip:rect(0,0,0,0);height:1px;margin:-100%;overflow:hidden;padding:0;position:absolute!important;width:1px}.cc-preferences__controls{display:flex;margin:0}.cc-preferences__controls>:not(:last-child){margin-right:12px}.cc-preferences__always-on{font-size:14px;font-weight:700;padding-left:26px;position:relative}.cc-preferences__always-on:before{background:#0000!important;border:solid;border-top-color:#0000;border-width:0 0 4px 4px;content:"";display:block;height:10px;left:0;position:absolute;top:2px;transform:rotate(-45deg);width:18px}.cc-preferences__details{background-color:#eff6fb!important;border-radius:10px;font-size:14px;margin:12px 0 0;padding:12px}.cc-preferences__cookie-list,.cc-preferences__provider-list{list-style:none;margin:0;padding:0}.cc-preferences__provider-list{columns:170px}.cc-preferences__cookie-title{font-size:1em;font-style:normal;font-weight:400;margin:0}.cc-preferences__cookie-description{font-size:1em;margin:0 0 8px}.cc-preferences__cookie-domain,.cc-preferences__cookie-lifespan{border-left:1px solid #999;color:#666;margin-left:8px;padding-left:4px}body.cc-has-preferences-open{overflow:hidden;position:relative}.cc-table{border-collapse:collapse;width:100%}.cc-table tbody tr{border-top:1px solid #0000001a}.cc-table td,.cc-table th{font-size:14px;padding:4px 8px;vertical-align:top}.cc-table+.cc-table{margin-top:8px}.cc-table--purposes td:first-child,.cc-table--purposes th:first-child{width:70%}@media (min-width:680px){.cc-table--purposes td:first-child,.cc-table--purposes th:first-child{width:80%}}.cc-table--purposes td:last-child,.cc-table--purposes th:last-child{padding-left:8px;width:40%}@media (min-width:680px){.cc-table--purposes td:last-child,.cc-table--purposes th:last-child{width:30%}}.cc-tabs,.cc-tabs>ul{background-color:#faf9f6;display:flex;list-style:none;margin:0;padding:0}.cc-tabs__panel{border-top:1px solid #ececec;margin-top:-1px}.cc-tabs__button{background-color:initial;border:0;border-left:1px solid #0000;border-right:1px solid #0000;color:#111;font-size:16px;font-weight:700;margin:0;padding:15px 16px 12px;position:relative}.cc-tabs__button:before{background-color:initial;content:"";display:block;height:3px;left:0;position:absolute;top:0;width:100%}.cc-tabs__button.cc-active{background-color:#fff;border-color:#025e8d #ececec #ececec;color:#111}.cc-tabs__button.cc-active:before{background-color:#025e8d}.cc-tabs__content{background-color:#fff;display:none;font-size:14px;padding:16px}.cc-tabs__section:not(:first-child){padding-top:24px}.cc-tcf{font-size:14px;margin-top:16px}.cc-tcf__list{list-style:none;margin:0;padding:0}.cc-vendor-count{color:#666;font-size:16px;margin:0 0 8px}.cc-hide{display:none!important}.cc-show{display:block!important}.cc-external-link{background-color:#ececec;background-image:url("data:image/svg+xml;base64,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");background-position:right 8px center;background-repeat:no-repeat;background-size:10px auto;border-radius:3px;box-shadow:0 1px 0 #0003;color:#111!important;display:inline-block;font-size:12px;padding:4px 26px 4px 8px;text-decoration:none!important}.cc-external-link:hover{text-decoration:underline!important}.cc-m-0{margin:0!important}.cc-grey{color:#666}</style><script async="" type="text/javascript" src="https://injections.readcube.com/nature/inject.fa744f3f.js"></script></head>
<body class="article-page"><dialog class="cc-banner" data-cc-banner="" data-nosnippet="" aria-labelledby="cc-banner-label" open="">
		<div class="cc-banner__content" autofocus="" tabindex="-1">
			<div class="cc-banner__container">
				<div class="cc-banner__header">
					<h2 class="cc-banner__title" id="cc-banner-label">Your privacy, your choice</h2>
				</div>
				<div class="cc-banner__body">
					<div class="cc-banner__policy">
						<p>We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.</p><p>By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.</p><p>See our <a href="https://www.nature.com/info/privacy" data-cc-action="privacy">privacy policy</a> for more information on the use of your personal data.</p><p><button type="button" data-cc-action="preferences" class="cc-button cc-button--link cc-button--text">Manage preferences</button> for further information and to change your choices.</p>
					</div>
					
				</div>
				<div class="cc-banner__footer">
					
			<button data-cc-action="accept" class="cc-button cc-button--secondary cc-button--contrast cc-banner__button cc-banner__button-accept">Accept all cookies</button>
			
		
				</div>
			</div>
		</div>
	</dialog>

<noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-MRVXSHQ"
                  height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>



<div class="position-relative cleared z-index-50 background-white" data-test="top-containers">
    <a class="c-skip-link" href="#content">Skip to main content</a>



<div class="c-grade-c-banner u-hide">
    <div class="c-grade-c-banner__container">
        
        <p>Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
            the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
            Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
            and JavaScript.</p>

    </div>
</div>

    

    

    
    
        <div class="u-hide u-show-following-ad"></div>

    <aside class="c-ad c-ad--728x90" style="display: none !important;">
        <div class="c-ad__inner" data-container-type="banner-advert">
            <p class="c-ad__label">Advertisement</p>
            
        
            
    <div id="div-gpt-ad-top-1" class="div-gpt-ad advert leaderboard js-ad text-center hide-print grade-c-hide" data-ad-type="top" data-test="top-ad" data-pa11y-ignore="" data-gpt="" data-gpt-unitpath="/285/medicine.nature.com/article" data-gpt-sizes="728x90" data-gpt-targeting="type=article;pos=top;artid=s41591-021-01436-0;doi=10.1038/s41591-021-01436-0;subjmeta=1059,109,1541,1940,1990,2125,2325,2779,283,291,308,631,67,692,699;kwrd=Acute+lymphocytic+leukaemia,Cancer+immunotherapy,Lymphoma,Phase+I+trials">
        <noscript>
            <a href="//pubads.g.doubleclick.net/gampad/jump?iu=/285/medicine.nature.com/article&amp;sz=728x90&amp;c=944587101&amp;t=pos%3Dtop%26type%3Darticle%26artid%3Ds41591-021-01436-0%26doi%3D10.1038/s41591-021-01436-0%26subjmeta%3D1059,109,1541,1940,1990,2125,2325,2779,283,291,308,631,67,692,699%26kwrd%3DAcute+lymphocytic+leukaemia,Cancer+immunotherapy,Lymphoma,Phase+I+trials">
                <img data-test="gpt-advert-fallback-img"
                     src="//pubads.g.doubleclick.net/gampad/ad?iu=/285/medicine.nature.com/article&amp;sz=728x90&amp;c=944587101&amp;t=pos%3Dtop%26type%3Darticle%26artid%3Ds41591-021-01436-0%26doi%3D10.1038/s41591-021-01436-0%26subjmeta%3D1059,109,1541,1940,1990,2125,2325,2779,283,291,308,631,67,692,699%26kwrd%3DAcute+lymphocytic+leukaemia,Cancer+immunotherapy,Lymphoma,Phase+I+trials"
                     alt="Advertisement"
                     width="728"
                     height="90"></a>
        </noscript>
    </div>

        
    
        </div>
    </aside>


    <header class="c-header" id="header" data-header="" data-track-component="nature-150-split-header" style="border-color:#e40428">
        <div class="c-header__row">
            <div class="c-header__container">
                <div class="c-header__split">
                    
                    
                    <div class="c-header__logo-container">
                        
                        <a href="/nm" data-track="click" data-track-action="home" data-track-label="image">
                            <picture class="c-header__logo">
                                <source srcset="https://media.springernature.com/full/nature-cms/uploads/product/nm/header-95e59e63930e5d6009bad2c23a42ab2d.svg" media="(min-width: 875px)">
                                <img src="https://media.springernature.com/full/nature-cms/uploads/product/nm/header-95e59e63930e5d6009bad2c23a42ab2d.svg" height="32" alt="Nature Medicine">
                            </picture>
                        </a>
                    
                    </div>
                    
                    <ul class="c-header__menu c-header__menu--global">
                        <li class="c-header__item c-header__item--padding c-header__item--hide-md-max">
                            <a class="c-header__link" href="https://www.nature.com/siteindex" data-test="siteindex-link" data-track="click" data-track-action="open nature research index" data-track-label="link">
                                <span>View all journals</span>
                            </a>
                        </li>
                        <li class="c-header__item c-header__item--padding c-header__item--pipe">
                            <a class="c-header__link c-header__link--search" href="javascript:;" data-header-expander="" data-test="search-link" data-track="click" data-track-action="open search tray" data-track-label="button" role="button" aria-haspopup="true" aria-expanded="false">
                                <svg role="img" aria-hidden="true" focusable="false" height="22" width="22" viewBox="0 0 18 18" xmlns="http://www.w3.org/2000/svg"><path d="M16.48 15.455c.283.282.29.749.007 1.032a.738.738 0 01-1.032-.007l-3.045-3.044a7 7 0 111.026-1.026zM8 14A6 6 0 108 2a6 6 0 000 12z"></path></svg><span>Search</span>
                            </a><div id="search-menu" class="c-header__dropdown c-header__dropdown--full-width has-tethered u-js-hide" data-track-component="nature-150-split-header" hidden="">
    <div class="c-header__container">
        <h2 class="c-header__visually-hidden">Search</h2>
        <form class="c-header__search-form" action="/search" method="get" role="search" autocomplete="off" data-test="inline-search">
            <label class="c-header__heading" for="keywords">Search articles by subject, keyword or author</label>
            <div class="c-header__search-layout c-header__search-layout--max-width">
                <div>
                    <input type="text" required="" class="c-header__input" id="keywords" name="q" value="">
                </div>
                <div class="c-header__search-layout">
                    <div>
                        <label for="results-from" class="c-header__visually-hidden">Show results from</label>
                        <select id="results-from" name="journal" class="c-header__select">
                            
                                
                                    <option value="" selected="">All journals</option>
                                    <option value="nm">This journal</option>
                                
                            
                        </select>
                    </div>
                    <div>
                        <button type="submit" class="c-header__search-button">Search</button>
                    </div>
                </div>

            </div>
        </form>

        <div class="c-header__flush">
            <a class="c-header__link" href="/search/advanced" data-track="click" data-track-action="advanced search" data-track-label="link">
                Advanced search
            </a>
        </div>

        <h3 class="c-header__heading c-header__heading--keyline">Quick links</h3>
        <ul class="c-header__list">
            <li><a class="c-header__link" href="/subjects" data-track="click" data-track-action="explore articles by subject" data-track-label="link">Explore articles by subject</a></li>
            <li><a class="c-header__link" href="/naturecareers" data-track="click" data-track-action="find a job" data-track-label="link">Find a job</a></li>
            <li><a class="c-header__link" href="/authors/index.html" data-track="click" data-track-action="guide to authors" data-track-label="link">Guide to authors</a></li>
            <li><a class="c-header__link" href="/authors/editorial_policies/" data-track="click" data-track-action="editorial policies" data-track-label="link">Editorial policies</a></li>
        </ul>
    </div>
</div>
                        </li>
                        <li class="c-header__item c-header__item--padding c-header__item--snid-account-widget c-header__item--pipe">
                            
                                <a class="c-header__link eds-c-header__link" id="identity-account-widget" data-track="click_login" data-track-context="header" href="https://idp.nature.com/auth/personal/springernature?redirect_uri=https://www.nature.com/articles/s41591-021-01436-0"><span class="eds-c-header__widget-fragment-title">Log in</span></a>
                            
                        </li>
                    </ul>
                </div>
            </div>
        </div>
        
            <div class="c-header__row">
                <div class="c-header__container" data-test="navigation-row">
                    <div class="c-header__split">
                        <ul class="c-header__menu c-header__menu--journal">
                            
                                <li class="c-header__item c-header__item--dropdown-menu" data-test="explore-content-button">
                                    <a href="javascript:;" class="c-header__link" data-header-expander="" data-test="menu-button--explore" data-track="click" data-track-action="open explore expander" data-track-label="button" role="button" aria-haspopup="true" aria-expanded="false">
                                        <span><span class="c-header__show-text">Explore</span> content</span><svg role="img" aria-hidden="true" focusable="false" height="16" viewBox="0 0 16 16" width="16" xmlns="http://www.w3.org/2000/svg"><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" transform="matrix(0 1 -1 0 11 3)"></path></svg>
                                    </a><nav class="c-header__dropdown has-tethered u-js-hide" aria-labelledby="Explore-content" data-test="Explore-content" id="explore" data-track-component="nature-150-split-header" hidden="">
            <div class="c-header__container">
                <h2 id="Explore-content" class="c-header__heading c-header__heading--js-hide">Explore content</h2>
                <ul class="c-header__list c-header__list--js-stack">
                    
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/research-articles" data-track="click" data-track-action="research articles" data-track-label="link" data-test="explore-nav-item">
                                    Research articles
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/reviews-and-analysis" data-track="click" data-track-action="reviews &amp; analysis" data-track-label="link" data-test="explore-nav-item">
                                    Reviews &amp; Analysis
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/news-and-comment" data-track="click" data-track-action="news &amp; comment" data-track-label="link" data-test="explore-nav-item">
                                    News &amp; Comment
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/podcast" data-track="click" data-track-action="podcasts" data-track-label="link" data-test="explore-nav-item">
                                    Podcasts
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/current-issue" data-track="click" data-track-action="current issue" data-track-label="link" data-test="explore-nav-item">
                                    Current issue
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/collections" data-track="click" data-track-action="collections" data-track-label="link" data-test="explore-nav-item">
                                    Collections
                                </a>
                            </li>
                        
                    
                </ul>
                <ul class="c-header__list c-header__list--js-stack">
                    
                        <li class="c-header__item">
                            <a class="c-header__link" href="https://www.facebook.com/Nature-Medicine-193691346949/" data-track="click" data-track-action="facebook" data-track-label="link">Follow us on Facebook
                            </a>
                        </li>
                    
                    
                        <li class="c-header__item">
                            <a class="c-header__link" href="https://twitter.com/naturemedicine" data-track="click" data-track-action="twitter" data-track-label="link">Follow us on Twitter
                            </a>
                        </li>
                    
                    
                    
                        <li class="c-header__item c-header__item--hide-lg">
                            <a class="c-header__link" href="https://www.nature.com/my-account/alerts/subscribe-journal?list-id=5" rel="nofollow" data-track="nav_sign_up_for_alerts" data-track-action="Sign up for alerts" data-track-external="" data-track-label="link (mobile dropdown)">Sign up for alerts<svg role="img" aria-hidden="true" focusable="false" height="18" viewBox="0 0 18 18" width="18" xmlns="http://www.w3.org/2000/svg"><path d="m4 10h2.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-3.08578644l-1.12132034 1.1213203c-.18753638.1875364-.29289322.4418903-.29289322.7071068v.1715729h14v-.1715729c0-.2652165-.1053568-.5195704-.2928932-.7071068l-1.7071068-1.7071067v-3.4142136c0-2.76142375-2.2385763-5-5-5-2.76142375 0-5 2.23857625-5 5zm3 4c0 1.1045695.8954305 2 2 2s2-.8954305 2-2zm-5 0c-.55228475 0-1-.4477153-1-1v-.1715729c0-.530433.21071368-1.0391408.58578644-1.4142135l1.41421356-1.4142136v-3c0-3.3137085 2.6862915-6 6-6s6 2.6862915 6 6v3l1.4142136 1.4142136c.3750727.3750727.5857864.8837805.5857864 1.4142135v.1715729c0 .5522847-.4477153 1-1 1h-4c0 1.6568542-1.3431458 3-3 3-1.65685425 0-3-1.3431458-3-3z" fill="#fff"></path></svg>
                            </a>
                        </li>
                    
                    
                        <li class="c-header__item c-header__item--hide-lg">
                            <a class="c-header__link" href="https://www.nature.com/nm.rss" data-track="click" data-track-action="rss feed" data-track-label="link">
                                <span>RSS feed</span>
                            </a>
                        </li>
                    
                </ul>
            </div>
        </nav>
                                </li>
                            
                            
                                <li class="c-header__item c-header__item--dropdown-menu">
                                    <a href="javascript:;" class="c-header__link" data-header-expander="" data-test="menu-button--about-the-journal" data-track="click" data-track-action="open about the journal expander" data-track-label="button" role="button" aria-haspopup="true" aria-expanded="false">
                                        <span>About <span class="c-header__show-text">the journal</span></span><svg role="img" aria-hidden="true" focusable="false" height="16" viewBox="0 0 16 16" width="16" xmlns="http://www.w3.org/2000/svg"><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" transform="matrix(0 1 -1 0 11 3)"></path></svg>
                                    </a><nav class="c-header__dropdown has-tethered u-js-hide" aria-labelledby="About-the-journal" id="about-the-journal" data-test="about-the-journal" data-track-component="nature-150-split-header" hidden="">
                <div class="c-header__container">
                    <h2 id="About-the-journal" class="c-header__heading c-header__heading--js-hide">About the journal</h2>
                    <ul class="c-header__list c-header__list--js-stack">
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/aims" data-track="click" data-track-action="aims &amp; scope" data-track-label="link">
                                    Aims &amp; Scope
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/journal-information" data-track="click" data-track-action="journal information" data-track-label="link">
                                    Journal Information
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/journal-impact" data-track="click" data-track-action="journal metrics" data-track-label="link">
                                    Journal Metrics
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/editors" data-track="click" data-track-action="about the editors" data-track-label="link">
                                    About the Editors
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/research-cross-journal-editorial-team" data-track="click" data-track-action="research cross-journal editorial team" data-track-label="link">
                                    Research Cross-Journal Editorial Team
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/reviews-cross-journal-editorial-team" data-track="click" data-track-action="reviews cross-journal editorial team" data-track-label="link">
                                    Reviews Cross-Journal Editorial Team
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/statistics-advisory-panel" data-track="click" data-track-action="statistical advisory panel" data-track-label="link">
                                    Statistical Advisory Panel
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/our-publishing-models" data-track="click" data-track-action="our publishing models" data-track-label="link">
                                    Our publishing models
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/editorial-values-statement" data-track="click" data-track-action="editorial values statement" data-track-label="link">
                                    Editorial Values Statement
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/editorial-policies" data-track="click" data-track-action="editorial policies" data-track-label="link">
                                    Editorial Policies
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/content" data-track="click" data-track-action="content types" data-track-label="link">
                                    Content Types
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/web-feeds" data-track="click" data-track-action="web feeds" data-track-label="link">
                                    Web Feeds
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/contact" data-track="click" data-track-action="contact" data-track-label="link">
                                    Contact
                                </a>
                            </li>
                        
                    </ul>
                </div>
            </nav>
                                </li>
                                
                                    <li class="c-header__item c-header__item--dropdown-menu" data-test="publish-with-us-button">
                                        <a href="javascript:;" class="c-header__link c-header__link--dropdown-menu" data-header-expander="" data-test="menu-button--publish" data-track="click" data-track-action="open publish with us expander" data-track-label="button" role="button" aria-haspopup="true" aria-expanded="false">
                                            <span>Publish <span class="c-header__show-text">with us</span></span><svg role="img" aria-hidden="true" focusable="false" height="16" viewBox="0 0 16 16" width="16" xmlns="http://www.w3.org/2000/svg"><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" transform="matrix(0 1 -1 0 11 3)"></path></svg>
                                        </a><nav class="c-header__dropdown has-tethered u-js-hide" aria-labelledby="Publish-with-us-label" id="publish-with-us" data-test="publish-with-us" data-track-component="nature-150-split-header" hidden="">
                <div class="c-header__container">
                    <h2 id="Publish-with-us-label" class="c-header__heading c-header__heading--js-hide">Publish with us</h2>
                    <ul class="c-header__list c-header__list--js-stack">
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/submission-guidelines" data-track="click" data-track-action="submission guidelines" data-track-label="link">
                                    Submission Guidelines
                                </a>
                            </li>
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/for-reviewers" data-track="click" data-track-action="for reviewers" data-track-label="link">
                                    For Reviewers
                                </a>
                            </li>
                        
                        
                            <li class="c-header__item">
                                <a class="c-header__link" data-test="nature-author-services" data-track="nav_language_services" data-track-context="header publish with us dropdown menu" data-track-action="manuscript author services" data-track-label="link manuscript author services" href="https://authorservices.springernature.com/go/sn/?utm_source=For+Authors&amp;utm_medium=Website_Nature&amp;utm_campaign=Platform+Experimentation+2022&amp;utm_id=PE2022">
                                    Language editing services
                                </a>
                            </li>
                        
                        
                            <li class="c-header__item">
                                <a class="c-header__link" href="/nm/open-access-funding" data-test="funding-eligibility-link" data-track="click_explore_funding" data-track-context="header publish with us" data-track-action="funding eligibility">Open access funding</a>
                            </li>
                        
                        
                            <li class="c-header__item c-header__item--keyline">
                                <a class="c-header__link" href="https://mts-nmed.nature.com/cgi-bin/main.plex" data-track="click_submit_manuscript" data-track-context="submit link in Nature header dropdown menu" data-track-action="submit manuscript" data-track-label="link (publish with us dropdown menu)" data-track-external="" data-gtm-criteo="submit-manuscript">Submit manuscript<svg role="img" aria-hidden="true" focusable="false" height="18" viewBox="0 0 18 18" width="18" xmlns="http://www.w3.org/2000/svg"><path d="m15 0c1.1045695 0 2 .8954305 2 2v5.5c0 .27614237-.2238576.5-.5.5s-.5-.22385763-.5-.5v-5.5c0-.51283584-.3860402-.93550716-.8833789-.99327227l-.1166211-.00672773h-9v3c0 1.1045695-.8954305 2-2 2h-3v10c0 .5128358.38604019.9355072.88337887.9932723l.11662113.0067277h7.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-7.5c-1.1045695 0-2-.8954305-2-2v-10.17157288c0-.53043297.21071368-1.0391408.58578644-1.41421356l3.82842712-3.82842712c.37507276-.37507276.88378059-.58578644 1.41421356-.58578644zm-.5442863 8.18867991 3.3545404 3.35454039c.2508994.2508994.2538696.6596433.0035959.909917-.2429543.2429542-.6561449.2462671-.9065387-.0089489l-2.2609825-2.3045251.0010427 7.2231989c0 .3569916-.2898381.6371378-.6473715.6371378-.3470771 0-.6473715-.2852563-.6473715-.6371378l-.0010428-7.2231995-2.2611222 2.3046654c-.2531661.2580415-.6562868.2592444-.9065605.0089707-.24295423-.2429542-.24865597-.6576651.0036132-.9099343l3.3546673-3.35466731c.2509089-.25090888.6612706-.25227691.9135302-.00001728zm-.9557137-3.18867991c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-6c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm-8.5-3.587-3.587 3.587h2.587c.55228475 0 1-.44771525 1-1zm8.5 1.587c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-6c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill="#fff"></path></svg>
                                </a>
                            </li>
                        
                    </ul>
                </div>
            </nav>
                                    </li>
                                
                            
                            
                        </ul>
                        <ul class="c-header__menu c-header__menu--hide-lg-max">
                            
                                <li class="c-header__item" data-test="alert-link">
                                    <a class="c-header__link" href="https://journal-alerts.springernature.com/subscribe?journal_id=41591" rel="nofollow" data-track="nav_sign_up_for_alerts" data-track-action="Sign up for alerts" data-track-label="link (desktop site header)" data-track-external="">
                                        <span>Sign up for alerts</span><svg role="img" aria-hidden="true" focusable="false" height="18" viewBox="0 0 18 18" width="18" xmlns="http://www.w3.org/2000/svg"><path d="m4 10h2.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-3.08578644l-1.12132034 1.1213203c-.18753638.1875364-.29289322.4418903-.29289322.7071068v.1715729h14v-.1715729c0-.2652165-.1053568-.5195704-.2928932-.7071068l-1.7071068-1.7071067v-3.4142136c0-2.76142375-2.2385763-5-5-5-2.76142375 0-5 2.23857625-5 5zm3 4c0 1.1045695.8954305 2 2 2s2-.8954305 2-2zm-5 0c-.55228475 0-1-.4477153-1-1v-.1715729c0-.530433.21071368-1.0391408.58578644-1.4142135l1.41421356-1.4142136v-3c0-3.3137085 2.6862915-6 6-6s6 2.6862915 6 6v3l1.4142136 1.4142136c.3750727.3750727.5857864.8837805.5857864 1.4142135v.1715729c0 .5522847-.4477153 1-1 1h-4c0 1.6568542-1.3431458 3-3 3-1.65685425 0-3-1.3431458-3-3z" fill="#222"></path></svg>
                                    </a>
                                </li>
                            
                            
                                <li class="c-header__item c-header__item--pipe">
                                    <a class="c-header__link" href="https://www.nature.com/nm.rss" data-track="click" data-track-action="rss feed" data-track-label="link">
                                            <span>RSS feed</span>
                                    </a>
                                </li>
                            
                        </ul>
                    </div>
                </div>
            </div>
        
    </header>


    
    
        <nav class="u-mb-16" aria-label="breadcrumbs">
            <div class="u-container">
                <ol class="c-breadcrumbs" itemscope="" itemtype="https://schema.org/BreadcrumbList">
                    <li class="c-breadcrumbs__item" id="breadcrumb0" itemprop="itemListElement" itemscope="" itemtype="https://schema.org/ListItem"><a class="c-breadcrumbs__link" href="/" itemprop="item" data-track="click" data-track-action="breadcrumb" data-track-category="header" data-track-label="link:nature"><span itemprop="name">nature</span></a><meta itemprop="position" content="1">
                                    <svg class="c-breadcrumbs__chevron" role="img" aria-hidden="true" focusable="false" height="10" viewBox="0 0 10 10" width="10" xmlns="http://www.w3.org/2000/svg">
                                        <path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill="#666" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path>
                                    </svg>
                                </li><li class="c-breadcrumbs__item" id="breadcrumb1" itemprop="itemListElement" itemscope="" itemtype="https://schema.org/ListItem"><a class="c-breadcrumbs__link" href="/nm" itemprop="item" data-track="click" data-track-action="breadcrumb" data-track-category="header" data-track-label="link:nature medicine"><span itemprop="name">nature medicine</span></a><meta itemprop="position" content="2">
                                    <svg class="c-breadcrumbs__chevron" role="img" aria-hidden="true" focusable="false" height="10" viewBox="0 0 10 10" width="10" xmlns="http://www.w3.org/2000/svg">
                                        <path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill="#666" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path>
                                    </svg>
                                </li><li class="c-breadcrumbs__item" id="breadcrumb2" itemprop="itemListElement" itemscope="" itemtype="https://schema.org/ListItem"><a class="c-breadcrumbs__link" href="/nm/articles?type=article" itemprop="item" data-track="click" data-track-action="breadcrumb" data-track-category="header" data-track-label="link:articles"><span itemprop="name">articles</span></a><meta itemprop="position" content="3">
                                    <svg class="c-breadcrumbs__chevron" role="img" aria-hidden="true" focusable="false" height="10" viewBox="0 0 10 10" width="10" xmlns="http://www.w3.org/2000/svg">
                                        <path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill="#666" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path>
                                    </svg>
                                </li><li class="c-breadcrumbs__item" id="breadcrumb3" itemprop="itemListElement" itemscope="" itemtype="https://schema.org/ListItem">
                                    <span itemprop="name">article</span><meta itemprop="position" content="4"></li>
                </ol>
            </div>
        </nav>
    



    

</div>


<div class="u-container u-mt-32 u-mb-32 u-clearfix" id="content" data-component="article-container" data-container-type="article">
    <main class="c-article-main-column u-float-left js-main-column" data-track-component="article body">
        
            
                <div class="c-context-bar u-hide" id="js-enable-context-bar" data-test="context-bar" data-context-bar="" aria-hidden="true">
                    <div class="c-context-bar__container u-container" data-track-context="sticky banner">
                        <div class="c-context-bar__title">
                            CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial
                        </div>
                        
    
        <div class="c-pdf-download u-clear-both js-pdf-download">
            <a href="/articles/s41591-021-01436-0.pdf" class="u-button u-button--full-width u-button--primary u-justify-content-space-between c-pdf-download__link" data-article-pdf="true" data-readcube-pdf-url="true" data-test="download-pdf" data-draft-ignore="true" data-track="content_download" data-track-type="article pdf download" data-track-action="download pdf" data-track-label="link" data-track-external="" download="">
                <span class="c-pdf-download__text">Download PDF</span>
                <svg aria-hidden="true" focusable="false" width="16" height="16" class="u-icon"><use xlink:href="#icon-download"></use></svg>
            </a>
        </div>
    

                    </div>
                </div>
            
        
        <article lang="en">
            
                <div class="c-pdf-button__container u-mb-16 u-hide-at-lg js-context-bar-sticky-point-mobile">
                    <div class="c-pdf-container" data-track-context="article body">
                        
                            
                                
    
        <div class="c-pdf-download u-clear-both js-pdf-download">
            <a href="/articles/s41591-021-01436-0.pdf" class="u-button u-button--full-width u-button--primary u-justify-content-space-between c-pdf-download__link" data-article-pdf="true" data-readcube-pdf-url="true" data-test="download-pdf" data-draft-ignore="true" data-track="content_download" data-track-type="article pdf download" data-track-action="download pdf" data-track-label="link" data-track-external="" download="">
                <span class="c-pdf-download__text">Download PDF</span>
                <svg aria-hidden="true" focusable="false" width="16" height="16" class="u-icon"><use xlink:href="#icon-download"></use></svg>
            </a>
        </div>
    

                            
                        
                    </div>
                </div>
            
            <div class="c-article-header">
                <header>
                    <ul class="c-article-identifiers" data-test="article-identifier">
                        
        <li class="c-article-identifiers__item" data-test="article-category">Article</li>
    
        <li class="c-article-identifiers__item">
            <a href="https://www.springernature.com/gp/open-research/about/the-fundamentals-of-open-access-and-open-research" data-track="click" data-track-action="open access" data-track-label="link" class="u-color-open-access" data-test="open-access">Open access</a>
        </li>
    
    

                        <li class="c-article-identifiers__item">Published: <time datetime="2021-07-26">26 July 2021</time></li>
                    </ul>

                    <h1 class="c-article-title" data-test="article-title" data-article-title="">CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial</h1>
                    <ul class="c-article-author-list c-article-author-list--long js-no-scroll" data-test="authors-list" data-component-authors-activator="authors-list"><li class="c-article-author-list__item"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Jay_Y_-Spiegel-Aff1" data-author-popup="auth-Jay_Y_-Spiegel-Aff1" data-author-search="Spiegel, Jay Y." data-track-context="researcher popup with no profile" data-track-index="1_49">Jay Y. Spiegel</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0001-6491-0044"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0001-6491-0044</a></span><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup><sup class="u-js-hide">&nbsp;<a href="#na1" tabindex="-1">na1</a></sup>, </li><li class="c-article-author-list__item"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Shabnum-Patel-Aff2" data-author-popup="auth-Shabnum-Patel-Aff2" data-author-search="Patel, Shabnum" data-track-context="researcher popup with no profile" data-track-index="2_49">Shabnum Patel</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0002-4782-9540"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0002-4782-9540</a></span><sup class="u-js-hide"><a href="#Aff2" tabindex="-1">2</a></sup><sup class="u-js-hide">&nbsp;<a href="#na1" tabindex="-1">na1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Lori-Muffly-Aff1-Aff2" data-author-popup="auth-Lori-Muffly-Aff1-Aff2" data-author-search="Muffly, Lori" data-track-context="researcher popup with no profile" data-track-index="3_49">Lori Muffly</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0002-9887-6136"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0002-9887-6136</a></span><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a>,<a href="#Aff2" tabindex="-1">2</a></sup><sup class="u-js-hide">&nbsp;<a href="#na1" tabindex="-1">na1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Nasheed_M_-Hossain-Aff3" data-author-popup="auth-Nasheed_M_-Hossain-Aff3" data-author-search="Hossain, Nasheed M." data-track-context="researcher popup with no profile" data-track-index="4_49">Nasheed M. Hossain</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0002-3278-655X"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0002-3278-655X</a></span><sup class="u-js-hide"><a href="#Aff3" tabindex="-1">3</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Jean-Oak-Aff4" data-author-popup="auth-Jean-Oak-Aff4" data-author-search="Oak, Jean" data-track-context="researcher popup with no profile" data-track-index="5_49">Jean Oak</a><sup class="u-js-hide"><a href="#Aff4" tabindex="-1">4</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-John_H_-Baird-Aff1" data-author-popup="auth-John_H_-Baird-Aff1" data-author-search="Baird, John H." data-track-context="researcher popup with no profile" data-track-index="6_49">John H. Baird</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0001-8291-6546"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0001-8291-6546</a></span><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Matthew_J_-Frank-Aff1" data-author-popup="auth-Matthew_J_-Frank-Aff1" data-author-search="Frank, Matthew J." data-track-context="researcher popup with no profile" data-track-index="7_49">Matthew J. Frank</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Parveen-Shiraz-Aff1" data-author-popup="auth-Parveen-Shiraz-Aff1" data-author-search="Shiraz, Parveen" data-track-context="researcher popup with no profile" data-track-index="8_49">Parveen Shiraz</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Bita-Sahaf-Aff2" data-author-popup="auth-Bita-Sahaf-Aff2" data-author-search="Sahaf, Bita" data-track-context="researcher popup with no profile" data-track-index="9_49">Bita Sahaf</a><sup class="u-js-hide"><a href="#Aff2" tabindex="-1">2</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Juliana-Craig-Aff1" data-author-popup="auth-Juliana-Craig-Aff1" data-author-search="Craig, Juliana" data-track-context="researcher popup with no profile" data-track-index="10_49">Juliana Craig</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0002-5644-2292"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0002-5644-2292</a></span><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Maria-Iglesias-Aff1" data-author-popup="auth-Maria-Iglesias-Aff1" data-author-search="Iglesias, Maria" data-track-context="researcher popup with no profile" data-track-index="11_49">Maria Iglesias</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Sheren-Younes-Aff4" data-author-popup="auth-Sheren-Younes-Aff4" data-author-search="Younes, Sheren" data-track-context="researcher popup with no profile" data-track-index="12_49">Sheren Younes</a><sup class="u-js-hide"><a href="#Aff4" tabindex="-1">4</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Yasodha-Natkunam-Aff4" data-author-popup="auth-Yasodha-Natkunam-Aff4" data-author-search="Natkunam, Yasodha" data-track-context="researcher popup with no profile" data-track-index="13_49">Yasodha Natkunam</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0002-9816-1018"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0002-9816-1018</a></span><sup class="u-js-hide"><a href="#Aff4" tabindex="-1">4</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Michael_G_-Ozawa-Aff4" data-author-popup="auth-Michael_G_-Ozawa-Aff4" data-author-search="Ozawa, Michael G." data-track-context="researcher popup with no profile" data-track-index="14_49">Michael G. Ozawa</a><sup class="u-js-hide"><a href="#Aff4" tabindex="-1">4</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Eric-Yang-Aff4" data-author-popup="auth-Eric-Yang-Aff4" data-author-search="Yang, Eric" data-track-context="researcher popup with no profile" data-track-index="15_49">Eric Yang</a><sup class="u-js-hide"><a href="#Aff4" tabindex="-1">4</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-John-Tamaresis-Aff5" data-author-popup="auth-John-Tamaresis-Aff5" data-author-search="Tamaresis, John" data-track-context="researcher popup with no profile" data-track-index="16_49">John Tamaresis</a><sup class="u-js-hide"><a href="#Aff5" tabindex="-1">5</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Harshini-Chinnasamy-Aff2" data-author-popup="auth-Harshini-Chinnasamy-Aff2" data-author-search="Chinnasamy, Harshini" data-track-context="researcher popup with no profile" data-track-index="17_49">Harshini Chinnasamy</a><sup class="u-js-hide"><a href="#Aff2" tabindex="-1">2</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Zach-Ehlinger-Aff2" data-author-popup="auth-Zach-Ehlinger-Aff2" data-author-search="Ehlinger, Zach" data-track-context="researcher popup with no profile" data-track-index="18_49">Zach Ehlinger</a><sup class="u-js-hide"><a href="#Aff2" tabindex="-1">2</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Warren-Reynolds-Aff2" data-author-popup="auth-Warren-Reynolds-Aff2" data-author-search="Reynolds, Warren" data-track-context="researcher popup with no profile" data-track-index="19_49">Warren Reynolds</a><sup class="u-js-hide"><a href="#Aff2" tabindex="-1">2</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Rachel-Lynn-Aff2-Aff12" data-author-popup="auth-Rachel-Lynn-Aff2-Aff12" data-author-search="Lynn, Rachel" data-track-context="researcher popup with no profile" data-track-index="20_49">Rachel Lynn</a><sup class="u-js-hide"><a href="#Aff2" tabindex="-1">2</a></sup><sup class="u-js-hide">&nbsp;<a href="#nAff12" tabindex="-1">nAff12</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Maria_Caterina-Rotiroti-Aff6" data-author-popup="auth-Maria_Caterina-Rotiroti-Aff6" data-author-search="Rotiroti, Maria Caterina" data-track-context="researcher popup with no profile" data-track-index="21_49">Maria Caterina Rotiroti</a><sup class="u-js-hide"><a href="#Aff6" tabindex="-1">6</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Nikolaos-Gkitsas-Aff2" data-author-popup="auth-Nikolaos-Gkitsas-Aff2" data-author-search="Gkitsas, Nikolaos" data-track-context="researcher popup with no profile" data-track-index="22_49">Nikolaos Gkitsas</a><sup class="u-js-hide"><a href="#Aff2" tabindex="-1">2</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Sally-Arai-Aff1" data-author-popup="auth-Sally-Arai-Aff1" data-author-search="Arai, Sally" data-track-context="researcher popup with no profile" data-track-index="23_49">Sally Arai</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Laura-Johnston-Aff1" data-author-popup="auth-Laura-Johnston-Aff1" data-author-search="Johnston, Laura" data-track-context="researcher popup with no profile" data-track-index="24_49">Laura Johnston</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Robert-Lowsky-Aff1" data-author-popup="auth-Robert-Lowsky-Aff1" data-author-search="Lowsky, Robert" data-track-context="researcher popup with no profile" data-track-index="25_49">Robert Lowsky</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Robbie_G_-Majzner-Aff2-Aff6" data-author-popup="auth-Robbie_G_-Majzner-Aff2-Aff6" data-author-search="Majzner, Robbie G." data-track-context="researcher popup with no profile" data-track-index="26_49">Robbie G. Majzner</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0001-6969-8011"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0001-6969-8011</a></span><sup class="u-js-hide"><a href="#Aff2" tabindex="-1">2</a>,<a href="#Aff6" tabindex="-1">6</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Everett-Meyer-Aff1" data-author-popup="auth-Everett-Meyer-Aff1" data-author-search="Meyer, Everett" data-track-context="researcher popup with no profile" data-track-index="27_49">Everett Meyer</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Robert_S_-Negrin-Aff1" data-author-popup="auth-Robert_S_-Negrin-Aff1" data-author-search="Negrin, Robert S." data-track-context="researcher popup with no profile" data-track-index="28_49">Robert S. Negrin</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Andrew_R_-Rezvani-Aff1" data-author-popup="auth-Andrew_R_-Rezvani-Aff1" data-author-search="Rezvani, Andrew R." data-track-context="researcher popup with no profile" data-track-index="29_49">Andrew R. Rezvani</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Surbhi-Sidana-Aff1" data-author-popup="auth-Surbhi-Sidana-Aff1" data-author-search="Sidana, Surbhi" data-track-context="researcher popup with no profile" data-track-index="30_49">Surbhi Sidana</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0003-3288-7614"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0003-3288-7614</a></span><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Judith-Shizuru-Aff1" data-author-popup="auth-Judith-Shizuru-Aff1" data-author-search="Shizuru, Judith" data-track-context="researcher popup with no profile" data-track-index="31_49">Judith Shizuru</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0003-3246-4726"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0003-3246-4726</a></span><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Wen_Kai-Weng-Aff1" data-author-popup="auth-Wen_Kai-Weng-Aff1" data-author-search="Weng, Wen-Kai" data-track-context="researcher popup with no profile" data-track-index="32_49">Wen-Kai Weng</a><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Chelsea-Mullins-Aff7" data-author-popup="auth-Chelsea-Mullins-Aff7" data-author-search="Mullins, Chelsea" data-track-context="researcher popup with no profile" data-track-index="33_49">Chelsea Mullins</a><sup class="u-js-hide"><a href="#Aff7" tabindex="-1">7</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Allison-Jacob-Aff7" data-author-popup="auth-Allison-Jacob-Aff7" data-author-search="Jacob, Allison" data-track-context="researcher popup with no profile" data-track-index="34_49">Allison Jacob</a><sup class="u-js-hide"><a href="#Aff7" tabindex="-1">7</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Ilan-Kirsch-Aff7" data-author-popup="auth-Ilan-Kirsch-Aff7" data-author-search="Kirsch, Ilan" data-track-context="researcher popup with no profile" data-track-index="35_49">Ilan Kirsch</a><sup class="u-js-hide"><a href="#Aff7" tabindex="-1">7</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Magali-Bazzano-Aff8" data-author-popup="auth-Magali-Bazzano-Aff8" data-author-search="Bazzano, Magali" data-track-context="researcher popup with no profile" data-track-index="36_49">Magali Bazzano</a><sup class="u-js-hide"><a href="#Aff8" tabindex="-1">8</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Jing-Zhou-Aff8" data-author-popup="auth-Jing-Zhou-Aff8" data-author-search="Zhou, Jing" data-track-context="researcher popup with no profile" data-track-index="37_49">Jing Zhou</a><sup class="u-js-hide"><a href="#Aff8" tabindex="-1">8</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Sean-Mackay-Aff8" data-author-popup="auth-Sean-Mackay-Aff8" data-author-search="Mackay, Sean" data-track-context="researcher popup with no profile" data-track-index="38_49">Sean Mackay</a><sup class="u-js-hide"><a href="#Aff8" tabindex="-1">8</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Scott_J_-Bornheimer-Aff9" data-author-popup="auth-Scott_J_-Bornheimer-Aff9" data-author-search="Bornheimer, Scott J." data-track-context="researcher popup with no profile" data-track-index="39_49">Scott J. Bornheimer</a><sup class="u-js-hide"><a href="#Aff9" tabindex="-1">9</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Liora-Schultz-Aff2-Aff6-Aff10" data-author-popup="auth-Liora-Schultz-Aff2-Aff6-Aff10" data-author-search="Schultz, Liora" data-track-context="researcher popup with no profile" data-track-index="40_49">Liora Schultz</a><sup class="u-js-hide"><a href="#Aff2" tabindex="-1">2</a>,<a href="#Aff6" tabindex="-1">6</a>,<a href="#Aff10" tabindex="-1">10</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Sneha-Ramakrishna-Aff2-Aff6" data-author-popup="auth-Sneha-Ramakrishna-Aff2-Aff6" data-author-search="Ramakrishna, Sneha" data-track-context="researcher popup with no profile" data-track-index="41_49">Sneha Ramakrishna</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0001-7445-3190"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0001-7445-3190</a></span><sup class="u-js-hide"><a href="#Aff2" tabindex="-1">2</a>,<a href="#Aff6" tabindex="-1">6</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Kara_L_-Davis-Aff2-Aff6" data-author-popup="auth-Kara_L_-Davis-Aff2-Aff6" data-author-search="Davis, Kara L." data-track-context="researcher popup with no profile" data-track-index="42_49">Kara L. Davis</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0002-7182-2592"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0002-7182-2592</a></span><sup class="u-js-hide"><a href="#Aff2" tabindex="-1">2</a>,<a href="#Aff6" tabindex="-1">6</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Katherine_A_-Kong-Aff2" data-author-popup="auth-Katherine_A_-Kong-Aff2" data-author-search="Kong, Katherine A." data-track-context="researcher popup with no profile" data-track-index="43_49">Katherine A. Kong</a><sup class="u-js-hide"><a href="#Aff2" tabindex="-1">2</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Nirali_N_-Shah-Aff10" data-author-popup="auth-Nirali_N_-Shah-Aff10" data-author-search="Shah, Nirali N." data-track-context="researcher popup with no profile" data-track-index="44_49">Nirali N. Shah</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0002-8474-9080"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0002-8474-9080</a></span><sup class="u-js-hide"><a href="#Aff10" tabindex="-1">10</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Haiying-Qin-Aff10" data-author-popup="auth-Haiying-Qin-Aff10" data-author-search="Qin, Haiying" data-track-context="researcher popup with no profile" data-track-index="45_49">Haiying Qin</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0001-5966-8812"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0001-5966-8812</a></span><sup class="u-js-hide"><a href="#Aff10" tabindex="-1">10</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Terry-Fry-Aff10-Aff11" data-author-popup="auth-Terry-Fry-Aff10-Aff11" data-author-search="Fry, Terry" data-track-context="researcher popup with no profile" data-track-index="46_49">Terry Fry</a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0001-8044-5226"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0001-8044-5226</a></span><sup class="u-js-hide"><a href="#Aff10" tabindex="-1">10</a>,<a href="#Aff11" tabindex="-1">11</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Steven-Feldman-Aff2" data-author-popup="auth-Steven-Feldman-Aff2" data-author-search="Feldman, Steven" data-track-context="researcher popup with no profile" data-track-index="47_49">Steven Feldman</a><sup class="u-js-hide"><a href="#Aff2" tabindex="-1">2</a></sup><sup class="u-js-hide">&nbsp;<a href="#na2" tabindex="-1">na2</a></sup>, </li><li class="c-article-author-list__item c-article-author-list__item--hide c-article-author-list__item--hide-small-screen"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-Crystal_L_-Mackall-Aff2-Aff6" data-author-popup="auth-Crystal_L_-Mackall-Aff2-Aff6" data-author-search="Mackall, Crystal L." data-corresp-id="c1" data-track-context="researcher popup with no profile" data-track-index="48_49">Crystal L. Mackall<svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-mail-medium"></use></svg></a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0001-6323-4304"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0001-6323-4304</a></span><sup class="u-js-hide"><a href="#Aff2" tabindex="-1">2</a>,<a href="#Aff6" tabindex="-1">6</a></sup><sup class="u-js-hide">&nbsp;<a href="#na2" tabindex="-1">na2</a></sup> &amp; </li><li class="c-article-author-list__show-more" aria-label="Show all 49 authors for this article" title="Show all 49 authors for this article">…</li><li class="c-article-author-list__item"><a data-test="author-name" data-track="click" data-track-action="open author" data-track-label="link" href="#auth-David_B_-Miklos-Aff1-Aff2" data-author-popup="auth-David_B_-Miklos-Aff1-Aff2" data-author-search="Miklos, David B." data-corresp-id="c2" data-track-context="researcher popup with no profile" data-track-index="49_49">David B. Miklos<svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-mail-medium"></use></svg></a><span class="u-js-hide">&nbsp;
            <a class="js-orcid" href="http://orcid.org/0000-0003-0717-4305"><span class="u-visually-hidden">ORCID: </span>orcid.org/0000-0003-0717-4305</a></span><sup class="u-js-hide"><a href="#Aff1" tabindex="-1">1</a>,<a href="#Aff2" tabindex="-1">2</a></sup><sup class="u-js-hide">&nbsp;<a href="#na2" tabindex="-1">na2</a></sup>&nbsp;</li></ul><button aria-expanded="false" class="c-article-author-list__button"><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-down-medium"></use></svg><span>Show authors</span></button>

                    

                    <p class="c-article-info-details" data-container-section="info">
                        
    <a data-test="journal-link" href="/nm" data-track="click" data-track-action="journal homepage" data-track-category="article body" data-track-label="link"><i data-test="journal-title">Nature Medicine</i></a>

                        <b data-test="journal-volume"><span class="u-visually-hidden">volume</span>&nbsp;27</b>,&nbsp;<span class="u-visually-hidden">pages </span>1419–1431 (<span data-test="article-publication-year">2021</span>)<a href="#citeas" class="c-article-info-details__cite-as u-hide-print" data-track="click" data-track-action="cite this article" data-track-label="link">Cite this article</a>
                    </p>
                    
        <div class="c-article-metrics-bar__wrapper u-clear-both">
            <ul class="c-article-metrics-bar u-list-reset">
                
                    <li class=" c-article-metrics-bar__item" data-test="access-count">
                        <p class="c-article-metrics-bar__count">77k <span class="c-article-metrics-bar__label">Accesses</span></p>
                    </li>
                
                
                    <li class="c-article-metrics-bar__item" data-test="citation-count">
                        <p class="c-article-metrics-bar__count">386 <span class="c-article-metrics-bar__label">Citations</span></p>
                    </li>
                
                
                    
                        <li class="c-article-metrics-bar__item" data-test="altmetric-score">
                            <p class="c-article-metrics-bar__count">454 <span class="c-article-metrics-bar__label">Altmetric</span></p>
                        </li>
                    
                
                <li class="c-article-metrics-bar__item">
                    <p class="c-article-metrics-bar__details"><a href="/articles/s41591-021-01436-0/metrics" data-track="click" data-track-action="view metrics" data-track-label="link" rel="nofollow">Metrics <span class="u-visually-hidden">details</span></a></p>
                </li>
            </ul>
        </div>
    
                    
                </header>

                
    

                
    
    

    
    

                
            </div>

        <div class="c-article-body">
            <section aria-labelledby="Abs1" data-title="Abstract" lang="en"><div class="c-article-section" id="Abs1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Abs1">Abstract</h2><div class="c-article-section__content" id="Abs1-content"><p>Despite impressive progress, more than 50% of patients treated with CD19-targeting chimeric antigen receptor T cells (CAR19) experience progressive disease. Ten of 16 patients with large B cell lymphoma (LBCL) with progressive disease after CAR19 treatment had absent or low CD19. Lower surface CD19 density pretreatment was associated with progressive disease. To prevent relapse with CD19<sup>−</sup> or CD19<sup>lo</sup> disease, we tested a bispecific CAR targeting CD19 and/or CD22 (CD19-22.BB.z-CAR) in a phase I clinical trial (<a href="https://clinicaltrials.gov/ct2/show/NCT03233854">NCT03233854</a>) of adults with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL) and LBCL. The primary end points were manufacturing feasibility and safety with a secondary efficacy end point. Primary end points were met; 97% of products met protocol-specified dose and no dose-limiting toxicities occurred during dose escalation. In B-ALL (<i>n</i> = 17), 100% of patients responded with 88% minimal residual disease-negative complete remission (CR); in LBCL (<i>n</i> = 21), 62% of patients responded with 29% CR. Relapses were CD19<sup>−/lo</sup> in 50% (5 out of 10) of patients with B-ALL and 29% (4 out of 14) of patients with LBCL but were not associated with CD22<sup>−/lo</sup> disease. CD19/22-CAR products demonstrated reduced cytokine production when stimulated with CD22 versus CD19. Our results further implicate antigen loss as a major cause of CAR T cell resistance, highlight the challenge of engineering multi-specific CAR T cells with equivalent potency across targets and identify cytokine production as an important quality indicator for CAR T cell potency.</p></div></div></section>

            
                
            

            
                
                    
        
            <section aria-labelledby="inline-recommendations" data-title="Inline Recommendations" class="c-article-recommendations" data-track-component="inline-recommendations">
                <h3 class="c-article-recommendations-title" id="inline-recommendations">Similar content being viewed by others</h3>
                <div class="c-article-recommendations-list">
                    
                        <div class="c-article-recommendations-list__item">
                            <article class="c-article-recommendations-card" itemscope="" itemtype="http://schema.org/ScholarlyArticle">
                                
                                    <div class="c-article-recommendations-card__img"><img src="https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41591-020-1081-3/MediaObjects/41591_2020_1081_Fig1_HTML.png" loading="lazy" alt=""></div>
                                
                                <div class="c-article-recommendations-card__main">
                                    <h3 class="c-article-recommendations-card__heading" itemprop="name headline">
                                        <a class="c-article-recommendations-card__link" itemprop="url" href="https://www.nature.com/articles/s41591-020-1081-3?fromPaywallRec=false" data-track="select_recommendations_1" data-track-context="inline recommendations" data-track-action="click recommendations inline - 1" data-track-label="10.1038/s41591-020-1081-3">Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial
                                        </a>
                                    </h3>
                                    <div class="c-article-meta-recommendations" data-test="recommendation-info">
                                        <span class="c-article-meta-recommendations__item-type">Article</span>
                                        
                                         <span class="c-article-meta-recommendations__date">05 October 2020</span>
                                    </div>
                                </div>
                            </article>
                        </div>
                    
                        <div class="c-article-recommendations-list__item">
                            <article class="c-article-recommendations-card" itemscope="" itemtype="http://schema.org/ScholarlyArticle">
                                
                                    <div class="c-article-recommendations-card__img"><img src="https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41591-021-01497-1/MediaObjects/41591_2021_1497_Fig1_HTML.png" loading="lazy" alt=""></div>
                                
                                <div class="c-article-recommendations-card__main">
                                    <h3 class="c-article-recommendations-card__heading" itemprop="name headline">
                                        <a class="c-article-recommendations-card__link" itemprop="url" href="https://www.nature.com/articles/s41591-021-01497-1?fromPaywallRec=false" data-track="select_recommendations_2" data-track-context="inline recommendations" data-track-action="click recommendations inline - 2" data-track-label="10.1038/s41591-021-01497-1">CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial
                                        </a>
                                    </h3>
                                    <div class="c-article-meta-recommendations" data-test="recommendation-info">
                                        <span class="c-article-meta-recommendations__item-type">Article</span>
                                         <span class="c-article-meta-recommendations__access-type">Open access</span>
                                         <span class="c-article-meta-recommendations__date">12 October 2021</span>
                                    </div>
                                </div>
                            </article>
                        </div>
                    
                        <div class="c-article-recommendations-list__item">
                            <article class="c-article-recommendations-card" itemscope="" itemtype="http://schema.org/ScholarlyArticle">
                                
                                    <div class="c-article-recommendations-card__img"><img src="https://media.springernature.com/w215h120/springer-static/image/art%3A10.1038%2Fs41375-024-02392-7/MediaObjects/41375_2024_2392_Fig1_HTML.png" loading="lazy" alt=""></div>
                                
                                <div class="c-article-recommendations-card__main">
                                    <h3 class="c-article-recommendations-card__heading" itemprop="name headline">
                                        <a class="c-article-recommendations-card__link" itemprop="url" href="https://www.nature.com/articles/s41375-024-02392-7?fromPaywallRec=false" data-track="select_recommendations_3" data-track-context="inline recommendations" data-track-action="click recommendations inline - 3" data-track-label="10.1038/s41375-024-02392-7">Third-generation anti-CD19 CAR T cells for relapsed/refractory chronic lymphocytic leukemia: a phase 1/2 study
                                        </a>
                                    </h3>
                                    <div class="c-article-meta-recommendations" data-test="recommendation-info">
                                        <span class="c-article-meta-recommendations__item-type">Article</span>
                                         <span class="c-article-meta-recommendations__access-type">Open access</span>
                                         <span class="c-article-meta-recommendations__date">27 August 2024</span>
                                    </div>
                                </div>
                            </article>
                        </div>
                    
                </div>
            </section>
        
            <script>
                window.dataLayer = window.dataLayer || [];
                window.dataLayer.push({
                    recommendations: {
                        recommender: 'semantic',
                        model: 'specter',
                        policy_id: 'NA',
                        timestamp: 1749519894,
                        embedded_user: 'null'
                    }
                });
            </script>
        
    
                
                
                <div class="main-content">
                    
                        <section data-title="Main"><div class="c-article-section" id="Sec1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec1">Main</h2><div class="c-article-section__content" id="Sec1-content"><p>Impressive antitumor effects of chimeric antigen receptor-modified T cells<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Turtle, C. J. et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J. Clin. Invest. 126, 2123–2138 (2016)." href="#ref-CR1" id="ref-link-section-d45070288e1157">1</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Locke, F. L. et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol. 20, 31–42 (2019)." href="#ref-CR2" id="ref-link-section-d45070288e1157_1">2</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531–2544 (2017)." href="#ref-CR3" id="ref-link-section-d45070288e1157_2">3</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Schuster, S. J. et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 380, 45–56 (2019)." href="#ref-CR4" id="ref-link-section-d45070288e1157_3">4</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Hay, K. A. et al. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood 133, 1652–1663 (2019)." href="#ref-CR5" id="ref-link-section-d45070288e1157_4">5</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439–448 (2018)." href="#ref-CR6" id="ref-link-section-d45070288e1157_5">6</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Park, J. H. et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N. Engl. J. Med. 378, 449–459 (2018)." href="#ref-CR7" id="ref-link-section-d45070288e1157_6">7</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Nastoupil, L. J. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium. J. Clin. Oncol. 38, 3119–3128 (2020)." href="#ref-CR8" id="ref-link-section-d45070288e1157_7">8</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Abramson, J. S. et al. Pivotal safety and efficacy results from Transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed/refractory (R/R) large B cell lymphomas. Blood 134, 241 (2019)." href="#ref-CR9" id="ref-link-section-d45070288e1157_8">9</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 10" title="Lee, D. W. et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385, 517–528 (2015)." href="/articles/s41591-021-01436-0#ref-CR10" id="ref-link-section-d45070288e1160">10</a></sup> and natural killer (NK) cells<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 11" title="Liu, E. et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N. Engl. J. Med. 382, 545–553 (2020)." href="/articles/s41591-021-01436-0#ref-CR11" id="ref-link-section-d45070288e1164">11</a></sup> targeting CD19 (CAR19) have driven a paradigm shift in the treatment of relapsed or chemotherapy-refractory (relapsed/refractory) B cell malignancies. However, most patients treated with CAR19 experience disease progression. Clinical factors such as preCAR disease burden and serum lactate dehydrogenase (LDH)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 5" title="Hay, K. A. et al. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood 133, 1652–1663 (2019)." href="/articles/s41591-021-01436-0#ref-CR5" id="ref-link-section-d45070288e1168">5</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 8" title="Nastoupil, L. J. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium. J. Clin. Oncol. 38, 3119–3128 (2020)." href="/articles/s41591-021-01436-0#ref-CR8" id="ref-link-section-d45070288e1171">8</a></sup> have been linked to response to CAR19 therapies. Disease progression associated with loss of cell surface CD19 has been reported in 30–95% of relapses after CAR19 therapy in B-ALL<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 12" title="Majzner, R. G. &amp; Mackall, C. L. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 8, 1219–1226 (2018)." href="/articles/s41591-021-01436-0#ref-CR12" id="ref-link-section-d45070288e1175">12</a></sup>, through a variety of mechanisms including splice mutations and retained intracellular CD19<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Majzner, R. G. &amp; Mackall, C. L. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 8, 1219–1226 (2018)." href="#ref-CR12" id="ref-link-section-d45070288e1179">12</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Bagashev, A. et al. CD19 alterations emerging after CD19-directed immunotherapy cause retention of the misfolded protein in the endoplasmic reticulum. Mol. Cell. Biol. 38, e00383-18 (2018)." href="#ref-CR13" id="ref-link-section-d45070288e1179_1">13</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Asnani, M. et al. Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19. Leukemia 34, 1202–1207 (2020)." href="#ref-CR14" id="ref-link-section-d45070288e1179_2">14</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Orlando, E. J. et al. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat. Med. 24, 1504–1506 (2018)." href="#ref-CR15" id="ref-link-section-d45070288e1179_3">15</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 16" title="Sotillo, E. et al. Convergence of acquired mutations and alternative splicing of CD19 enables Resistance to CART-19 Immunotherapy. Cancer Discov. 5, 1282–1295 (2015)." href="/articles/s41591-021-01436-0#ref-CR16" id="ref-link-section-d45070288e1182">16</a></sup>. Several reports have also demonstrated that effective CAR T cell responses require high target antigen expression density<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Majzner, R. G. et al. CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors. Clin. Cancer Res. 25, 2560–2574 (2019)." href="#ref-CR17" id="ref-link-section-d45070288e1187">17</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Watanabe, K. et al. Target antigen density governs the efficacy of anti-CD20-CD28-CD3 ζ chimeric antigen receptor-modified effector CD8+ T cells. J. Immunol. 194, 911–920 (2015)." href="#ref-CR18" id="ref-link-section-d45070288e1187_1">18</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Hombach, A. A. et al. Superior therapeutic index in lymphoma therapy: CD30+ CD34+ hematopoietic stem cells resist a chimeric antigen receptor T-cell attack. Mol. Ther. 24, 1423–1434 (2016)." href="#ref-CR19" id="ref-link-section-d45070288e1187_2">19</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Walker, A. J. et al. Tumor antigen and receptor densities regulate efficacy of a chimeric antigen receptor targeting anaplastic lymphoma kinase. Mol. Ther. 25, 2189–2201 (2017)." href="#ref-CR20" id="ref-link-section-d45070288e1187_3">20</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 21" title="Majzner, R. G. et al. Tuning the antigen density requirement for CAR T-cell activity. Cancer Discov. 10, 702–723 (2020)." href="/articles/s41591-021-01436-0#ref-CR21" id="ref-link-section-d45070288e1190">21</a></sup>; resistance associated with diminished antigen density has been shown after treatment with a monospecific CD22-CAR<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 22" title="Fry, T. J. et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat. Med. 24, 20–28 (2018)." href="/articles/s41591-021-01436-0#ref-CR22" id="ref-link-section-d45070288e1194">22</a></sup> and B cell maturation antigen CARs<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 23" title="Cohen, A. D. et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J. Clin. Invest. 129, 2210–2221 (2019)." href="/articles/s41591-021-01436-0#ref-CR23" id="ref-link-section-d45070288e1198">23</a></sup>. While CD19 is expressed at variable levels in LBCL<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 21" title="Majzner, R. G. et al. Tuning the antigen density requirement for CAR T-cell activity. Cancer Discov. 10, 702–723 (2020)." href="/articles/s41591-021-01436-0#ref-CR21" id="ref-link-section-d45070288e1202">21</a></sup>, the role of emergence of CD19<sup>−/lo</sup> LBCL in CAR19 resistance has not been well studied<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 24" title="Oak, J. et al. Target antigen downregulation and other mechanisms of failure after axicabtagene ciloleucel (CAR19) therapy. Blood 132, 4656 (2018)." href="/articles/s41591-021-01436-0#ref-CR24" id="ref-link-section-d45070288e1208">24</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 25" title="Neelapu, S. S. et al. CD19-loss with preservation of other B cell lineage features in patients with large B cell lymphoma who relapsed post-axi-cel. Blood 134, 203 (2019)." href="/articles/s41591-021-01436-0#ref-CR25" id="ref-link-section-d45070288e1211">25</a></sup>. Engineering next-generation therapeutics to overcome newly defined mechanisms of resistance is an important unmet goal.</p><p>CD22 is a sialic acid-binding adhesion molecule largely restricted to the B cell lineage and expressed on most B-lineage malignancies<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Shah, N. N. et al. Characterization of CD22 expression in acute lymphoblastic leukemia. Pediatr. Blood Cancer 62, 964–969 (2015)." href="#ref-CR26" id="ref-link-section-d45070288e1218">26</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Haso, W. et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood 121, 1165–1174 (2013)." href="#ref-CR27" id="ref-link-section-d45070288e1218_1">27</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Tedder, T. F., Poe, J. C. &amp; Haas, K. M. CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction. Adv. Immunol. 88, 1–50 (2005)." href="#ref-CR28" id="ref-link-section-d45070288e1218_2">28</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Raponi, S. et al. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk. Lymphoma 52, 1098–1107 (2011)." href="#ref-CR29" id="ref-link-section-d45070288e1218_3">29</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 30" title="Olejniczak, S. H., Stewart, C. C., Donohue, K. &amp; Czuczman, M. S. A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry. Immunol. Invest. 35, 93–114 (2006)." href="/articles/s41591-021-01436-0#ref-CR30" id="ref-link-section-d45070288e1221">30</a></sup>. In a study of children and young adults with B-ALL enriched for patients with progressive disease after CD19-directed therapy, CD22 CAR T cells induced a 73% CR rate with equal effectiveness in CD19<sup>+</sup> and CD19<sup>−</sup> B-ALL<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 22" title="Fry, T. J. et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat. Med. 24, 20–28 (2018)." href="/articles/s41591-021-01436-0#ref-CR22" id="ref-link-section-d45070288e1229">22</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 31" title="Shah, N. N. et al. CD4/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial. J. Clin. Oncol. 38, 1938–1950 (2020)." href="/articles/s41591-021-01436-0#ref-CR31" id="ref-link-section-d45070288e1232">31</a></sup>. However, relapse was associated with the emergence of CD22<sup>lo</sup> B-ALL, illustrating the limitation of sequential targeting in B-ALL. In a phase I trial of adults with relapsed/refractory LBCL and B-ALL, we tested a bispecific CAR T targeting CD19 and/or CD22 (CD19-22.BB.z)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 22" title="Fry, T. J. et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat. Med. 24, 20–28 (2018)." href="/articles/s41591-021-01436-0#ref-CR22" id="ref-link-section-d45070288e1239">22</a></sup> and demonstrated the feasibility of manufacturing in a closed system, safety of bispecific CAR T cells and clinical activity in both B-ALL and LBCL. The observed relapses with CD19<sup>−/lo</sup> and maintained CD22 expression could be due to reduced potency of the bispecific receptor toward CD22 versus CD19.</p></div></div></section><section data-title="Results"><div class="c-article-section" id="Sec2-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec2">Results</h2><div class="c-article-section__content" id="Sec2-content"><h3 class="c-article__sub-heading" id="Sec3">Axicabtagene ciloleucel resistance is associated with CD19<sup>−</sup> and CD19<sup>lo</sup> LBCL</h3><p>To assess whether resistance to CAR19 therapy in LBCL is associated with CD19<sup>−/lo</sup> relapse, we used the semiquantitative immunohistochemistry (IHC) H-score to measure CD19 expression at baseline and at disease progression in patients treated with axicabtagene ciloleucel (axi-cel) at our institution. Our cohort comprised 44 consecutive patients treated with axi-cel with available pretreatment tissue biopsies for IHC. With a median follow-up of 21 months (95% confidence interval (CI) 11–24), median progression-free survival (PFS) was 6.1 months (95% CI 3.1–not estimable); 23 patients (52%) experienced progression. Sixteen of 23 patients with progression had postprogression biopsies available. Before axi-cel, the median CD19 H-score was 285 (interquartile range (IQR) = 240–285) (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig1">1a</a> and Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01436-0#MOESM1">1</a>). Using an H-score cutoff of 150 to indicate CD19 positivity, 39 (89%) patients were CD19<sup>+</sup> pretherapy. CD19 positivity was not associated with durable response (Fisher’s exact test <i>P</i> = 1). In contrast, only 6 of 16 samples studied (37.5%) were CD19<sup>+</sup> at disease progression. Among patients with paired pre- and posttherapy H-scores, 9 of 15 (60%) converted from CD19<sup>+</sup> pretherapy to CD19<sup>−</sup> at relapse (McNemar test <i>P</i> = 0.003) (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig1">1b</a>). Some postprogression biopsies showed complete loss of CD19, while others demonstrated diminished CD19 expression (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig1">1c</a>). Additionally, treating the pretreatment H-score as a continuous variable also demonstrated no difference between patients with durable disease control versus those who experienced disease progression (<i>t</i>-test <i>P</i> = 0.32). These data demonstrate that progression after axi-cel therapy for LBCL is associated with emergent CD19<sup>−/lo</sup> disease in a high percentage of patients, but pretreatment semiquantitative IHC measurement of CD19 expression does not identify patients at risk of relapse.</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-1" data-title="IHC demonstrates CD19−/lo disease postaxi-cel and quantitative flow cytometry of LBCL preaxi-cel therapy is associated with disease progression."><figure><figcaption><b id="Fig1" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 1: IHC demonstrates CD19<sup>−/lo</sup> disease postaxi-cel and quantitative flow cytometry of LBCL preaxi-cel therapy is associated with disease progression.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41591-021-01436-0/figures/1" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_Fig1_HTML.png?as=webp"><img aria-describedby="Fig1" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_Fig1_HTML.png" alt="figure 1" loading="lazy" width="685" height="889"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-1-desc"><p><b>a</b>, Preaxi-cel H-scores did not distinguish long-term responders and those with progression postaxi-cel (<i>P</i> = 0.32 by <i>t</i>-test, <i>P</i> = 1 Fisher’s exact test). Waterfall plot of CD19 IHC H-scores preaxi-cel therapy (<i>n</i> = 44 patients). The H-score was calculated by the percentage of positive tumor cells (0–100) × stain intensity (1–3). The dashed line denotes the H-score of 150, which was used to define antigen positivity. ND, not detectable. <b>b</b>, Paired CD19 H-scores preaxi-cel and at progression show significant differences (<i>P</i> = 0.003 by Wilcoxon signed-rank test). Using an H-score cutoff of 150, and the observed rate of CD19<sup>−/lo</sup> progression (10 out of 16 patients), the estimated 95% binomial CI (Wilson score) for CD19<sup>−/lo</sup> progression was 38–82%. N/A, no data point. <b>c</b>, Representative patients with IHC demonstrating decreased CD19 expression at the time of progression (A75, relapse H-score = 160; A62 relapse H-score = 120; A30, relapse H-score = 100; A53, relapse H-score = 0) <b>d</b>, Preaxi-cel site density by quantitative flow cytometry in a patient with ongoing response (A116) compared with a patient who experienced progression (A140) <b>e</b>, Preaxi-cel median CD19 site density by quantitative flow cytometry organized from highest (dark blue) to lowest (white) in 15 patients. Patients with lower site density were more likely to experience disease progression after axi-cel (<i>P</i> = 0.03 by Firth logistic regression). Based on the fit model, 3,000 molecules per cell was defined as the cutoff for CD19 positivity. <b>f</b>, Median site density at the time of axi-cel progression (<i>n</i> = 8). Four patients had a site density &lt;3,000 molecules per cell. <b>g</b>, The preaxi-cel H-score did not correlate with antigen site density by quantitative flow cytometry (<i>n</i> = 12) (Spearman <i>r</i> = 0.28, <i>P</i> = 0.38).</p><p><a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01436-0#MOESM3">Source data</a></p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41591-021-01436-0/figures/1" data-track-dest="link:Figure1 Full size image" aria-label="Full size image figure 1" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><p>To evaluate whether quantitative assessment of CD19 cell surface density might predict outcomes after axi-cel and attempt to define a threshold level of antigen expression associated with relapse, we used quantitative flow cytometry to measure CD19 site density on viable single-cell suspensions obtained by fine needle aspiration. Preaxi-cel LBCL demonstrated substantial intra- and interpatient variability in median CD19 site density as illustrated in Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig1">1d</a>, which shows LBCLs from two representative patients, both of whom were CD19<sup>+</sup> by IHC H-score. Patient A116 had a median CD19 site density of 6,538 molecules per cell and experienced durable disease control; in contrast, patient A140 had a median CD19 site density of 952 molecules per cell and experienced disease progression at 3 months after initial CR. Median preaxi-cel CD19 site density (<i>n</i> = 15) using quantitative flow cytometry was 6,396 molecules per cell (IQR = 3647–8540) with a range of 952–46,805 molecules per cell (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig1">1e</a>). Using a penalized logistic regression model, patients with lower pretherapy median CD19 site density had significantly increased risk of progression after axi-cel (<i>P</i> = 0.03), with a 50% risk of progression for patients with 2,934 CD19 molecules per cell. Therefore, we selected 3,000 molecules per cell as a cutoff to define CD19 positivity (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig5">1</a>). In our cohort, 3 of 4 patients with LBCL expressing ≤3,000 CD19 molecules per cell experienced progression while 1 of 11 patients with LBCL expressing &gt;3,000 molecules per cell had disease progression. Of 8 patients studied after axi-cel progression, 4 demonstrated a CD19 site density ≤3,000 molecules per cell (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig1">1f</a> and Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig6">2</a>). The H-score did not correlate well with antigen site density (Spearman <i>r</i> = 0.28, <i>P</i> = 0.38; Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig1">1g</a> and Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig6">2</a>). These data corroborate the emergence of CD19<sup>−/lo</sup> LBCL as a major cause of resistance to CAR19 therapy, suggesting that the risk of relapse increases in LBCLs expressing a median of ≤3,000 molecules per cell before therapy, raising the prospect that quantitative flow cytometry, but not IHC, may identify LBCL patients a priori at risk of CD19<sup>−/lo</sup> relapse after CAR19.</p><h3 class="c-article__sub-heading" id="Sec4">CAR construct and clinical trial design</h3><p>Previous data demonstrated that CD19 loss is an important mechanism of CAR19 failure in B-ALL. The data presented in this study similarly implicate absent or decreased cell surface CD19 as a mechanism of resistance after CAR19 in LBCL, providing a rationale for dual antigen targeting in B-ALL and LBCL. As reported previously<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 22" title="Fry, T. J. et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat. Med. 24, 20–28 (2018)." href="/articles/s41591-021-01436-0#ref-CR22" id="ref-link-section-d45070288e1436">22</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 32" title="Qin, H. et al. Preclinical development of bivalent chimeric antigen receptors targeting both CD19 and CD22. Mol. Ther. Oncolytics 11, 127–137 (2018)." href="/articles/s41591-021-01436-0#ref-CR32" id="ref-link-section-d45070288e1439">32</a></sup>, we generated a CD19-22.BB.z-CAR comprising a single cistron encoding the anti-CD19 murine FMC63 single-chain variable fragment (scFv) and fully human anti-CD22 m971 scFv (ɑCD19 vH-ɑCD22 vL-linker-ɑCD22 vH-ɑCD19 vL), followed by human CD8 hinge and transmembrane domains, 4-1BB costimulation and CD3ζ activation domains. The CD19-22.BB.z-CAR was encoded by a self-inactivating lentiviral vector under control of an murine stem cell virus internal promoter (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig2">2a</a> and Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01436-0#MOESM1">2</a>). We conducted a phase I clinical trial of CD19-22.BB.z-CAR in patients with relapsed/refractory B-ALL and LBCL, evaluating the feasibility of manufacture and safety of CD19-22.BB.z-CAR as the primary end points. Eligible patients had disease relapsed or refractory after two or more lines of therapy and had measurable disease that expressed CD19. Patients received conditioning chemotherapy followed by CAR T cell infusion at 2 dose levels: 1 × 10<sup>6</sup> CAR<sup>+</sup> cells kg<sup>−1</sup> (DL1) and 3 × 10<sup>6</sup> CAR<sup>+</sup> cells kg<sup>−1</sup> (DL2) using a 3 + 3 dose escalation phase that enrolled LBCL and B-ALL in one cohort. While a maximal tolerated dose was not identified, a third dose level at 1 × 10<sup>7</sup> cells kg<sup>−1</sup> was not pursued due to the efficacy seen at DL2 and concern regarding the possible toxicity of cell doses higher than 3 × 10<sup>6</sup> cells kg<sup>−1</sup> seen in other clinical trials. Therefore, the two disease-specific expansion cohorts received the recommended phase 2 dose of 3 × 10<sup>6</sup> CAR T cells kg<sup>−1</sup> (DL2).</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-2" data-title="Characterization of CAR products throughout the manufacturing process reveals compositional and phenotypic changes."><figure><figcaption><b id="Fig2" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 2: Characterization of CAR products throughout the manufacturing process reveals compositional and phenotypic changes.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41591-021-01436-0/figures/2" rel="nofollow"><picture><img aria-describedby="Fig2" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_Fig2_HTML.png" alt="figure 2" loading="lazy" width="685" height="874"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-2-desc"><p><b>a</b>, CD19-22-CD8.BB.z-CAR contained the CD19 FMC63 and CD22 M971 scFvs, CD8α hinge and transmembrane domains, a 4-1BB costimulatory domain and a CD3ζ domain. The unique bispecific structure shows FMC63 heavy chain proximal, followed by M971 light chain, M971 heavy chain and FMC63 light chain distal. <b>b</b>, CAR T manufacturing and clinical trial schema. The manufacturing schema shows the TransAct process change from old to new matrix. The clinical trial schema shows the screening, lymphodepletion, CAR T cell infusion and disease evaluation time points. LP, lumbar puncture. <b>c</b>, Improved culture expansion resulting from the new matrix manufacturing process compared to the old matrix (<i>P</i> &lt; 0.0001, two-tailed <i>t</i>-test). <b>d</b>, Significant reduction in doubling time with the new matrix process compared to the old matrix (<i>P</i> = 0.0411, two-tailed <i>t</i>-test). <b>e</b>, No significant difference in transduction efficiency between old and new matrix (<i>P</i> = not significant (NS), two-tailed <i>t</i>-test). Overall average transduction efficiency was 60.1% (<i>n</i> = 39 individual products). <b>f</b>, Composition of apheresis, CD4/8-enriched and CD19-22.BB.z product over time, looking at T cell (CD3<sup>+</sup>CD56<sup>−</sup>), B cell or leukemic cell (CD20<sup>+</sup>), CD4<sup>+</sup>, CD8<sup>+</sup>, NKT-like (CD3<sup>+</sup>CD56<sup>+</sup>CD16<sup>+</sup>), NK, monocyte and neutrophil subsets. <b>g</b>, Phenotyping of CAR T cell product reveals a skewing toward CD4<sup>+</sup> cells (<i>n</i> = 39 individual products). <b>h</b>, Comparing the fold increase from apheresis to enrichment to final product reveals the skewing toward CD4<sup>+</sup> cells that occurred during culture between enrichment and final product (<i>P</i> &lt; 0.0001, two-tailed <i>t</i>-test). <b>i</b>, Phenotyping of T cell memory subsets revealed an enrichment in T<sub>SCM</sub> (<i>P</i> &lt; 0.0001, two-tailed <i>t</i>-test) and T<sub>CM</sub> (<i>P</i> &lt; 0.0001, two-tailed <i>t</i>-test) cell subsets and a depletion of the T<sub>EMRA</sub> (<i>P</i> &lt; 0.0001, two-tailed <i>t</i>-test) subset. There was no significant change in T<sub>N</sub> or T<sub>EM</sub> cell subsets between enrichment and CD19-22.BB.z product.</p><p><a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01436-0#MOESM4">Source data</a></p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41591-021-01436-0/figures/2" data-track-dest="link:Figure2 Full size image" aria-label="Full size image figure 2" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><h3 class="c-article__sub-heading" id="Sec5">Patient characteristics</h3><p>Thirty-nine patients were enrolled in two cohorts (B-ALL, <i>n</i> = 17, LBCL, <i>n</i> = 22); 38 patients received the CD19-22.BB.z-CAR infusion while one patient with LBCL died during lymphodepletion due to progressive disease and sepsis (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig7">3</a>). The median age for the cohort with LBCL who received the infusion was 69 years (range 25–78) (Table <a data-track="click" data-track-label="link" data-track-action="table anchor" href="/articles/s41591-021-01436-0#Tab1">1</a>); 15 had double expressor (expression of c-MYC and BCL2) LBCL, 3 had high-grade B cell lymphoma with translocation of c-MYC and BCL2 and/or BCL6 (double-hit) and 4 had previous autologous stem cell transplant. All patients with LBCL were CAR-naive. In the cohort with B-ALL, median age was 47 years (range 26–68); 71% had progressed after allogeneic hematopoietic cell transplantation (HCT), 65% had previous CD19-directed therapy (including 1 patient receiving previous CAR T) and 29% had previous CD22-directed therapy (Table <a data-track="click" data-track-label="link" data-track-action="table anchor" href="/articles/s41591-021-01436-0#Tab2">2</a>). Sixty-three percent had previous central nervous system (CNS) involvement and 12% had active CNS disease at the time of enrollment.</p><div class="c-article-table" data-test="inline-table" data-container-section="table" id="table-1"><figure><figcaption class="c-article-table__figcaption"><b id="Tab1" data-test="table-caption">Table 1 Patient characteristics, responses and outcomes for enrolled patients with LBCL</b></figcaption><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="table-link" data-track="click" data-track-action="view table" data-track-label="button" rel="nofollow" href="/articles/s41591-021-01436-0/tables/1" aria-label="Full size table 1"><span>Full size table</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><div class="c-article-table" data-test="inline-table" data-container-section="table" id="table-2"><figure><figcaption class="c-article-table__figcaption"><b id="Tab2" data-test="table-caption">Table 2 Patient characteristics, responses and outcomes for enrolled patients with B-ALL</b></figcaption><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="table-link" data-track="click" data-track-action="view table" data-track-label="button" rel="nofollow" href="/articles/s41591-021-01436-0/tables/2" aria-label="Full size table 2"><span>Full size table</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><h3 class="c-article__sub-heading" id="Sec6">Feasibility of closed-system manufacturing</h3><p>A primary objective of this clinical trial was to assess the feasibility of cell production using closed-system manufacturing in the CliniMACS Prodigy (Miltenyi Biotec), defined as &gt;80% of cell products meeting the protocol-specified cell dose. The manufacturing schema is illustrated in Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig2">2b</a> and Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig8">4a</a>. Initially, a 7–9 d manufacturing process (old matrix) utilized washout of the T cell activator (TransAct) on day 5. At DL1, 57% (4 out of 7) of products met the prescribed cell dose within 7 d and 43% (3 out of 7) of products within 9 d. To reduce manufacturing time while increasing dose level, we incorporated a process change to remove the TransAct on day 3 (new matrix), significantly shortening the culture time required to meet the dose, which is reflected by the increased total cell count by day 7 (<i>P</i> &lt; 0.0001; Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig2">2c</a>) and decreased product doubling time (<i>P</i> = 0.04; Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig2">2d</a>). Among 39 patients who underwent apheresis, CAR T products meeting predefined release criteria were successfully manufactured in 100%. Ninety-seven percent of products met the protocol-specified dose; 82% (32 out of 39) met the protocol-specified dose in 7 d (4 old matrix, 28 new matrix) (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig8">4b–d</a>). Mean transduction efficiency was 60.1% (range 34.6–75.2%; Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig2">2e</a>), with an average vector copy number of 2.23 (range 1.31–4.0; Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig8">4e</a>).</p><h3 class="c-article__sub-heading" id="Sec7">Characterization of CD19-22.BB.z-CAR T infusion products</h3><p>Samples were obtained from apheresis, postCD4/CD8 T cell enrichment and final CAR T product collection for cell subset analysis and to confirm enrichment in T cell populations and removal of leukemic cells. Compared to apheresis products, manufactured products demonstrated increased T cell and CD4<sup>+</sup> populations, no change in CD8<sup>+</sup> and natural killer T (NKT)-like subsets and depletion of B or leukemic cells (defined by CD20<sup>+</sup>), NK cells, monocytes and neutrophils (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig2">2f</a>).</p><p>CD19-22.BB.z products showed a CD4<sup>+</sup> predominance (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig2">2g</a>). To determine whether this was due to T cell enrichment postapheresis or the manufacturing process, we assessed the fold increase in CD4<sup>+</sup> and CD8<sup>+</sup> populations over the manufacturing process (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig2">2h</a>). While there was no difference in fold increase from apheresis to enrichment, there was a significant difference in fold increase between CD4<sup>+</sup> and CD8<sup>+</sup> T cell subsets from enrichment to final product (<i>P</i> &lt; 0.0001), implicating the manufacturing process in enriching the proportion of CD4<sup>+</sup> cells in the manufactured product. Compared to enriched apheresis samples, products demonstrated enrichment in stem cell memory T (T<sub>SCM</sub>) (<i>P</i> &lt; 0.0001) and central memory T (T<sub>CM</sub>) (<i>P</i> &lt; 0.0001) cell subsets, no change in naive T (T<sub>N</sub>) and effector memory T (T<sub>EM</sub>) cell populations and a decrease in terminally differentiated effector memory (T<sub>EMRA</sub>) cell subsets (<i>P</i> &lt; 0.0001; Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig2">2i</a>).</p><h3 class="c-article__sub-heading" id="Sec8">Toxicity</h3><p>No dose-limiting toxicity (DLT) occurred during dose escalation and one DLT total occurred during the clinical trial. Cytokine release syndrome (CRS) of any grade occurred in 29 patients (76%) with median onset 1 d after infusion (range 0–8) and lasted a median of 4 d (range 1–12) (Tables <a data-track="click" data-track-label="link" data-track-action="table anchor" href="/articles/s41591-021-01436-0#Tab1">1</a> and <a data-track="click" data-track-label="link" data-track-action="table anchor" href="/articles/s41591-021-01436-0#Tab2">2</a> and Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig9">5</a>). Grade ≥3 CRS occurred in 2 patients (5%). Neurological toxicity occurred in 14 patients (37%; 9 with LBCL and 5 with B-ALL); 4 experienced ≥grade 3 neurotoxicity. Onset of neurotoxicity occurred a median of 5 d after infusion (range 3–9) and lasted a median of 4 d (range 1–11). Both CRS and neurotoxicity were treated according to institutional guidelines, with 15 patients (39%) receiving ≥1 dose of tocilizumab (range 1–3) and 45% of patients receiving corticosteroids. All episodes of CRS and neurotoxicity resolved. Two patients had laboratory evidence of macrophage activation syndrome with hyperferritinemia and hypofibrinogenemia concurrent with grade ≥3 neurotoxicity and received high-dose corticosteroids and anakinra<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 31" title="Shah, N. N. et al. CD4/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial. J. Clin. Oncol. 38, 1938–1950 (2020)." href="/articles/s41591-021-01436-0#ref-CR31" id="ref-link-section-d45070288e5229">31</a></sup>.</p><h3 class="c-article__sub-heading" id="Sec9">Response</h3><p>The primary response assessment for LBCL was undertaken at three months after infusion. For patients with LBCL treated at the recommended phase II dose (<i>n</i> = 15), the overall response rate (ORR) and CR rate at 3 months were 40% (95% CI 16–68%) and 33% (95% CI 12–62%), respectively. For the entire patient cohort with LBCL (<i>n</i> = 21), the best ORR at any time point was 62% (95% CI 38–82%) and the CR rate was 29% (95% CI 11–52%). Five of 13 responders had improvement in response from month 1 to month 3 after infusion (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig3">3a–c</a>). With a median follow-up of 10 months (95% CI 8.7–21.5), median overall survival was 22.5 months (95% CI 8.3–not estimable; Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig3">3d</a>), which could change with a longer follow-up. Median PFS was 3.2 months (95% CI 1.2–5.5; Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig3">3e</a>). To understand the kinetics of response in patients with LBCL treated with CD19-22.BB.z, we assessed change in lymphoma burden over time by cell-free circulating tumor DNA (ctDNA) in 16 patients with available diagnostic tumor samples (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig10">6</a>)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 33" title="Frank, M. J. et al. Optimizing circulating tumor DNA based assessments in patients with large B-cell lymphoma undergoing axicabtagene ciloleucel. J. Clin. Oncol. 
                  https://doi.org/10.1200/JCO.21.00377
                  
                 (2021)." href="/articles/s41591-021-01436-0#ref-CR33" id="ref-link-section-d45070288e5260">33</a></sup>. Four patients with ongoing clinical response had no detectable ctDNA at the time of the last assessment. Among 12 patients with disease progression, we observed an initial reduction in ctDNA that nadired 14–21 d postinfusion, with 9 patients demonstrating a rise in ctDNA at or before clinical progression. These findings suggest that progressive disease after CD19-22.BB.z-CAR in LBCL is associated with a robust early response followed by early acquired resistance.</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-3" data-title="CD19-22.BB.z-CAR is active in both LBCL and B-ALL."><figure><figcaption><b id="Fig3" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 3: CD19-22.BB.z-CAR is active in both LBCL and B-ALL.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41591-021-01436-0/figures/3" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_Fig3_HTML.png?as=webp"><img aria-describedby="Fig3" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_Fig3_HTML.png" alt="figure 3" loading="lazy" width="685" height="855"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-3-desc"><p><b>a</b>, Swimmer plot showing the duration of remission and ongoing responses in patients with lymphoma (<i>n</i> = 21). Five patients had an increasing depth of response from 1 to 3 months postinfusion <b>b</b>, PET scans for patient S2 showing partial remission at 1 month postinfusion with subsequent progression 6 months after infusion. <b>c</b>, Lymphoma disease monitoring using ctDNA. After infusion of CD19-22.BB.z for patient SL02, disease burden continued to decrease; this was coincident with prolonged persistence of CD19-22.BBZ<b>. d</b>, Overall survival for 21 infused patients with LBCL. <b>e</b>, PFS for the cohort with lymphoma. <b>f</b>, Swimmer plot for the cohort with B-ALL (<i>n</i> = 17). Two patients received a consolidative allogeneic stem cell transplant (white star) <b>g</b>, PET scans for patient SA8, with large bulk disease preinfusion that improved to a CR 6 months postinfusion. <b>h</b>, Disease monitoring of patient SA8 using cellular-based NGS with sensitivity of 10<sup>−6</sup> demonstrates increasing disease control over time coinciding with improving PET response and ongoing persistence of CD19-22.BB.z. <b>i</b>, Overall survival of 17 infused patients with B-ALL. <b>j</b>, PFS for the cohort with B-ALL. <b>k</b>, Absolute number of circulating CD4 and CD8 CD19-22.BB.z CAR T cells after infusion as measured by flow cytometry (<i>n</i> = 38 autologous infused products). <b>l</b>, Number of circulating CD19-22.BB.z copies per 50 ng of genomic DNA as measured by qPCR (<i>n</i> = 33 autologous infused products) showing initial expansion and persistence of CD19-22.BB.z as measured at 1 and 2 months (days 35–75 postinfusion), 3 months (days 76–120) and 6 months after infusion (days 120–200).</p><p><a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01436-0#MOESM5">Source data</a></p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41591-021-01436-0/figures/3" data-track-dest="link:Figure3 Full size image" aria-label="Full size image figure 3" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><p>Primary response for B-ALL was evaluated at 28 days postinfusion. All (<i>n</i> = 17) patients with B-ALL achieved response; 14 with CR (82%) and 3 with partial remission (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig3">3f</a>). One patient’s response (SA8) improved to CR 6 months after infusion (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig3">3g,h</a>), leading to an overall CR rate of 88%, all of whom were negative for minimal residual disease (MRD) at 10<sup>−4</sup> bone marrow sensitivity (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig11">7</a>) or by positron emission tomography (PET)/computed tomography (CT) for patients with extramedullary disease. After a median follow-up of 9.3 months (95% CI 7.2–NE), median overall survival was 11.8 months (95% CI 5.5–NE) (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig3">3i</a>) and PFS was 5.8 months (95% CI 2.6–NE) (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig3">3j</a>). Two patients proceeded to allogeneic stem cell transplant in CR and are in ongoing remission. Serial MRD analyses by next-generation sequencing (NGS) of immunoglobulin receptors from bone marrow revealed that 100% (5 out of 5) of patients with ongoing CR achieved persistent MRD-negative response, while 70% (7 out of 10) of progressors had persistence or rise in MRD before or at the time of morphological relapse (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig11">7</a>).</p><h3 class="c-article__sub-heading" id="Sec10">In vivo quantification of CD19-22.BB.z CAR T cells</h3><p>CD19-22.BB.z-CAR cells were detected in the blood by both flow cytometry and quantitative PCR (qPCR) and peaked between days 10–14 postinfusion (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig3">3k,l</a>). The median peak number of circulating CD19-22.BB.z cells measured by flow cytometry was 36 CAR µl<sup>−1</sup> (IQR = 13–136); by qPCR, it was 1,794 (IQR = 509–4,315) copies of the CD19-22.BB.z transgene per 50 ng of genomic DNA. Peak expansion did not significantly differ between LBCL and B-ALL or dose level (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig12">8a,b</a>). Higher expansion as measured by area under the curve (AUC) was associated with increased CRS and neurotoxicity (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig12">8c,d</a>). Despite a predominance of CD4<sup>+</sup> cells in the manufactured CD19-22.BB.z-CAR products, CD8 CD19-22.BB.z cells demonstrated greater expansion relative to CD4 as measured by both AUC and peak levels (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig12">8e,f</a>) and as seen by a peak CD4:CD8 ratio &lt;1 in most patients (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig12">8g</a>). Analysis of exhaustion markers on CAR<sup>+</sup> cells within the product showed that CD4<sup>+</sup> cells expressed higher levels of CD39 (ref. <sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 34" title="Weber, E. W. et al. Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling. Science 372, eaba1786 (2021)." href="/articles/s41591-021-01436-0#ref-CR34" id="ref-link-section-d45070288e5398">34</a></sup>) and programmed cell death protein 1 (PD-1) (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig12">8h,i</a>), potentially providing a basis for diminished in vivo expansion of CD4<sup>+</sup> compared to CD8<sup>+</sup> CAR T cells.</p><h3 class="c-article__sub-heading" id="Sec11">Antigen expression in patients with progressive disease after CD19-22.BB.z-CAR</h3><p>We next quantified CD19 and CD22 antigen expression at the time of progression after CD19-22.BB.z-CAR. Flow cytometry, as illustrated by patient SA24 (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig4">4a</a>), demonstrated that 5 of 10 patients with B-ALL with progression had negative or low CD19 expression with preserved CD22, using a 90% threshold (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig4">4b</a> and Table <a data-track="click" data-track-label="link" data-track-action="table anchor" href="/articles/s41591-021-01436-0#Tab2">2</a>). Paired pre- and posttherapy antigen quantification in four patients with B-ALL confirmed decreased CD19 expression in three patients with no change in CD22 expression density (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig4">4c</a>). In 14 patients with LBCL biopsied at progression, 3 were CD19<sup>−/lo</sup> (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig13">9a</a>) by IHC. CD22 expression was not required for trial enrollment and pretreatment CD22 expression was heterogenous (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig13">9b</a>); three patients had CD22<sup>−/lo</sup> LBCL and two were undetermined. All 6 patients with a pretreatment CD22 H-score &gt;150 maintained CD22 positivity. Eleven patients with B-ALL or LBCL had quantitative flow cytometry at progression; 6 patients had low CD19 with ≤3,000 molecules per cell (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig4">4d</a>), including 1 patient with LBCL with a CD19 H-score &gt;150. The median CD22 expression in patients with low CD19 was approximately 6,000 molecules per cell. Overall, 4 out of 14 (29%) patients with LBCL were CD19<sup>−/lo</sup> at progression after therapy with CD19-22.BB.z-CAR (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig13">9a</a> and Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig4">4d</a>).</p><div class="c-article-section__figure js-c-reading-companion-figures-item" data-test="figure" data-container-section="figure" id="figure-4" data-title="CD19 negative relapse with preserved CD22 site density after CD19-22.BB.z-CAR and diminished CAR T functionality against CD22."><figure><figcaption><b id="Fig4" class="c-article-section__figure-caption" data-test="figure-caption-text">Fig. 4: CD19 negative relapse with preserved CD22 site density after CD19-22.BB.z-CAR and diminished CAR T functionality against CD22.</b></figcaption><div class="c-article-section__figure-content"><div class="c-article-section__figure-item"><a class="c-article-section__figure-link" data-test="img-link" data-track="click" data-track-label="image" data-track-action="view figure" href="/articles/s41591-021-01436-0/figures/4" rel="nofollow"><picture><source type="image/webp" srcset="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_Fig4_HTML.png?as=webp"><img aria-describedby="Fig4" src="//media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_Fig4_HTML.png" alt="figure 4" loading="lazy" width="685" height="1014"></picture></a></div><div class="c-article-section__figure-description" data-test="bottom-caption" id="figure-4-desc"><p><b>a</b>, Antigen density of patient S24 demonstrating both CD19 and CD22 expression preCD19-22.BB.z (top) with loss of CD19 and preservation of CD22 at progression (bottom, green arrows). <b>b</b>, CD19 and CD22 assessment by conventional flow cytometry in patients with B-ALL pretreatment and postprogression demonstrates CD19 loss with CD22 preservation. <b>c</b>, In B-ALL, 3 of 4 patients with antigen quantification pre- and postCD19-22-CD.BB.z demonstrated loss of CD19 expression associated with preserved CD22 expression. <b>d</b>, CD19 and CD22 antigen density at progression (<i>n</i> = 11 patients) after CD19-22.BB.z, with patient S24 highlighted in green. Six patients had &lt;1,150 CD19 molecules per cell with a median CD22 of approximately 6,000 molecules per cell. Dashed line denotes the cutoff at 3,000 CD19 molecules per cell. <b>e</b>, Schematic of CD19-22.BB.z bispecific CAR, displaying the loop structure. <b>f</b>, Histogram of CD19 and CD22 expression on NALM6 lines tested in <b>g</b>–<b>j</b>. <b>g</b>, ICS heatmap representing the secretion or expression of CD69, CD107a, TNF-α, IFN-γ and IL-2 from CD19-22.BB.z infusion products (<i>n</i> = 11 individual products) stimulated with the NALM6 tumors lines from <b>f</b>. The heatmap shows greater activation and secretion of cytokines with stimulation with N6-CD19 and N6-CD19/22 lines versus N6-CD22 stimulation. <b>h</b>, Schematic of bispecific CD19-22.BB.z versus monospecific CD22.BB.z. <b>i</b>, ICS stimulation of CD19-22.BB.z (<i>n</i> = 11) versus monospecific CD22.BB.z (<i>n</i> = 5) CAR products against the CD22<sup>high</sup> cell line shows increased cytokine secretion of IL-2 and TNF-α through the monospecific CAR22.BB.z (two-tailed <i>t</i>-test). <b>j</b>, Using the single-cell IsoPlexis platform, stimulation of clinical products (<i>n</i> = 7 individual products) with N6-CD19 showed a higher PSI compared to N6-CD22. The CD22 scFV on the bispecific CAR had lower PSI compared to the monospecific CAR22.BB.z (<i>n</i> = 4 individual products) when stimulated with N6-CD22 (Mann–Whitney <i>U</i>-test).</p><p><a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01436-0#MOESM6">Source data</a></p></div></div><div class="u-text-right u-hide-print"><a class="c-article__pill-button" data-test="article-link" data-track="click" data-track-label="button" data-track-action="view figure" href="/articles/s41591-021-01436-0/figures/4" data-track-dest="link:Figure4 Full size image" aria-label="Full size image figure 4" rel="nofollow"><span>Full size image</span><svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-chevron-right-small"></use></svg></a></div></figure></div><h3 class="c-article__sub-heading" id="Sec12">CD19-22.BB.z-CAR T secretes less cytokine when stimulated through the CD22 scFv</h3><p>The pattern of CD19<sup>−/lo</sup> relapse with CD22 preservation suggested that T cells expressing the CD19-22.BB.z-CAR exert significant immune pressure against CD19 but not against CD22. In vitro models demonstrated that CD19-22.BB.z-CAR was active against CD19/CD22<sup>+</sup> cell lines (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig14">10a</a>). To address this, we compared the relative potency of the signal delivered via the CD19 scFv versus the CD22 scFv within the CD19-22.BB.z-CAR (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig4">4e</a>) using single-cell assays. Using samples from 11 manufactured cell products, we measured the intracellular cytokine secretion (ICS) of CD19-22.BB.z-CAR T cells after coculture with double-positive NALM6 (N6-CD19/22, approximately 20,000 CD19 molecules per cell and approximately 50,000 CD22 molecules per cell), NALM6 where CD22 had undergone knockout via CRISPR–Cas9 (N6-CD19, approximately 20,000 CD19 molecules per cell, 0 CD22 molecules per cell), NALM6 where CD19 had undergone knockout via CRISPR–Cas9 (N6-CD22, approximately 40,000 CD22 molecules per cell, 0 CD19 molecules per cell) or NALM6 with both CD19 and CD22 genetically deleted (N6-double knockout) (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig4">4f</a>). These site densities were higher than those seen in patient samples<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 21" title="Majzner, R. G. et al. Tuning the antigen density requirement for CAR T-cell activity. Cancer Discov. 10, 702–723 (2020)." href="/articles/s41591-021-01436-0#ref-CR21" id="ref-link-section-d45070288e5566">21</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 28" title="Tedder, T. F., Poe, J. C. &amp; Haas, K. M. CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction. Adv. Immunol. 88, 1–50 (2005)." href="/articles/s41591-021-01436-0#ref-CR28" id="ref-link-section-d45070288e5569">28</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 35" title="Yu, H. et al. Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma. Am. J. Hematol. 92, E11–E13 (2017)." href="/articles/s41591-021-01436-0#ref-CR35" id="ref-link-section-d45070288e5572">35</a></sup> and have been associated with high levels of cytokine secretion in in vitro models<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 21" title="Majzner, R. G. et al. Tuning the antigen density requirement for CAR T-cell activity. Cancer Discov. 10, 702–723 (2020)." href="/articles/s41591-021-01436-0#ref-CR21" id="ref-link-section-d45070288e5576">21</a></sup>.</p><p>Using ICS, CD19-22.BB.z-CAR manufactured products appeared activated as measured by CD69 expression after coculture with N6-CD19 and less activated with N6-CD22 (<i>P</i> &lt; 0.0001). Higher expression with N6-CD19 compared with N6-CD22 was seen with CD107 (<i>P</i> &lt; 0.0001), tumor necrosis factor-α (TNFα) (<i>P</i> &lt; 0.0001), interleukin-2 (IL-2) (<i>P</i> &lt; 0.0001) and interferon-γ (IFN-γ) (<i>P</i> &lt; 0.0001) (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig4">4g</a>).</p><p>Decreased PSI and ICS resulting from CD22 as opposed to CD19 stimulation suggested decreased potency of the CD22 scFV. We next compared the activity of the CD22 scFv of CD19-22.BB.z-CAR against the identical scFV in a monospecific CD22.BB.z-CAR (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig4">4h</a>)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 22" title="Fry, T. J. et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat. Med. 24, 20–28 (2018)." href="/articles/s41591-021-01436-0#ref-CR22" id="ref-link-section-d45070288e5608">22</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 31" title="Shah, N. N. et al. CD4/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial. J. Clin. Oncol. 38, 1938–1950 (2020)." href="/articles/s41591-021-01436-0#ref-CR31" id="ref-link-section-d45070288e5611">31</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 36" title="Baird, J. H. et al. CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR-refractory large B-cell lymphoma. Blood 137, 2321–2325 (2021)." href="/articles/s41591-021-01436-0#ref-CR36" id="ref-link-section-d45070288e5614">36</a></sup>. We tested good manufacturing practice (GMP)-manufactured CD22.BB.z-CAR T cell products (<i>n</i> = 5) from patients with relapsed/refractory LBCL or B-ALL enrolled on an ongoing clinical trial (<a href="https://clinicaltrials.gov/ct2/show/NCT04088890">NCT04088890</a>) against N6-double knockout and N6-CD22. The mean fluorescence intensity of monospecific CAR on T cells was higher than that of the bispecific CAR (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig14">10b,c</a>). We found that CD19-22.BB.z-CAR and CD22.BB.z-CAR T cells manifested similar levels of activation as measured by CD69 expression and IFN-γ and CD107 secretion (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig4">4i</a>). However, CD22.BB.z-CAR T cells demonstrated significantly higher levels of TNF-α (<i>P</i> = 0.0063) and IL-2 (<i>P</i> = 0.0002) secretion compared to CD19-22.BB.z-CAR T cells. Similarly, single-cell cytokine secretion using the IsoPlexis platform showed a higher PSI for CD22.BB.z-CAR T cells compared to CD19-22.BB.z-CAR in the presence of N6-CD22 (<i>n</i> = 4; Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig4">4j</a>). Single-cell cytokine secretion was assessed with the 32-plex human panel<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 27" title="Haso, W. et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood 121, 1165–1174 (2013)." href="/articles/s41591-021-01436-0#ref-CR27" id="ref-link-section-d45070288e5647">27</a></sup> after stimulation of CD4 and CD8 CAR<sup>+</sup> cells with the N6-CD19/22, N6-double knockout, N6-CD19 or N6-CD22 N6 lines (<i>n</i> = 7). Overall, CD19 stimulation with N6-CD19 yielded a higher polyfunctional strength index (PSI) testing CD8CAR<sup>+</sup> products (<i>P</i> = 0.04) compared to N6-CD22 stimulation (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig4">4j</a>). Together, these data demonstrate that both CD19 and CD22 scFvs contained within CD19/22.BB.z-CAR can signal in response to target recognition but cytokine levels induced after CD22 scFv ligation in the bispecific CAR are lower compared to CD19 scFv ligation. In contrast, CD22 scFv ligation in the monospecific CAR resulted in higher levels of cytokines than the bispecific CD22 scFV. The reduced potency of the CD22 scFV provides a mechanism for relapse with CD19<sup>−/lo</sup> disease with preserved CD22 expression in the population studied here.</p></div></div></section><section data-title="Discussion"><div class="c-article-section" id="Sec13-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec13">Discussion</h2><div class="c-article-section__content" id="Sec13-content"><p>CD19 loss has been frequently identified after CAR19 in B-ALL across numerous studies incorporating variable scFvs and costimulatory domains<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Hay, K. A. et al. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood 133, 1652–1663 (2019)." href="#ref-CR5" id="ref-link-section-d45070288e5676">5</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439–448 (2018)." href="#ref-CR6" id="ref-link-section-d45070288e5676_1">6</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 7" title="Park, J. H. et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N. Engl. J. Med. 378, 449–459 (2018)." href="/articles/s41591-021-01436-0#ref-CR7" id="ref-link-section-d45070288e5679">7</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 15" title="Orlando, E. J. et al. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat. Med. 24, 1504–1506 (2018)." href="/articles/s41591-021-01436-0#ref-CR15" id="ref-link-section-d45070288e5682">15</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 16" title="Sotillo, E. et al. Convergence of acquired mutations and alternative splicing of CD19 enables Resistance to CART-19 Immunotherapy. Cancer Discov. 5, 1282–1295 (2015)." href="/articles/s41591-021-01436-0#ref-CR16" id="ref-link-section-d45070288e5685">16</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 37" title="Gardner, R. et al. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. Blood 127, 2406–2410 (2016)." href="/articles/s41591-021-01436-0#ref-CR37" id="ref-link-section-d45070288e5688">37</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 38" title="Jacoby, E. et al. CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity. Nat. Commun. 7, 12320 (2016)." href="/articles/s41591-021-01436-0#ref-CR38" id="ref-link-section-d45070288e5691">38</a></sup>. In LBCL, case reports have also described CD19 loss after CAR19<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 35" title="Yu, H. et al. Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma. Am. J. Hematol. 92, E11–E13 (2017)." href="/articles/s41591-021-01436-0#ref-CR35" id="ref-link-section-d45070288e5695">35</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Schuster, S. J. et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N. Engl. J. Med. 377, 2545–2554 (2017)." href="#ref-CR39" id="ref-link-section-d45070288e5698">39</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Shalabi, H. et al. Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma. Haematologica 103, e215–e218 (2018)." href="#ref-CR40" id="ref-link-section-d45070288e5698_1">40</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 41" title="Ali, S. A. et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. Blood 128, 1688–1700 (2016)." href="/articles/s41591-021-01436-0#ref-CR41" id="ref-link-section-d45070288e5701">41</a></sup> but a systematic analysis of CD19 expression after CAR19 in LBCL has not been conducted. In this study, we evaluated CD19 expression in 44 patients with LBCL treated with axi-cel at our institution and found that pretreatment quantitative flow cytometry was more sensitive than conventional IHC in identifying lower antigen levels associated with future progression. Quantitative flow cytometry could serve as a predictive biomarker in characterizing antigen modulation as a mechanism of resistance to CAR therapeutics.</p><p>Several studies have demonstrated the efficacy of simultaneous targeting multiple antigens in preclinical models using a variety of CAR configurations to endow multi-specific antigen recognition<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 22" title="Fry, T. J. et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat. Med. 24, 20–28 (2018)." href="/articles/s41591-021-01436-0#ref-CR22" id="ref-link-section-d45070288e5708">22</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Hegde, M. et al. Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape. J. Clin. Invest. 126, 3036–3052 (2016)." href="#ref-CR42" id="ref-link-section-d45070288e5711">42</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Bielamowicz, K. et al. Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma. Neuro Oncol. 20, 506–518 (2018)." href="#ref-CR43" id="ref-link-section-d45070288e5711_1">43</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Zah, E. et al. Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma. Nat. Commun. 11, 2283 (2020)." href="#ref-CR44" id="ref-link-section-d45070288e5711_2">44</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="He, X. et al. Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia. Blood 135, 713–723 (2020)." href="#ref-CR45" id="ref-link-section-d45070288e5711_3">45</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 46" title="Schmidts, A. et al. Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma. Blood Adv. 3, 3248–3260 (2019)." href="/articles/s41591-021-01436-0#ref-CR46" id="ref-link-section-d45070288e5714">46</a></sup>. Early clinical trial results involving tandem CAR T cells targeting CD19 and CD20 have shown promising results with low reported rates of CD19 loss at the time of progression<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 47" title="Shah, N. N. et al. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nat. Med. 26, 1569–1575 (2020)." href="/articles/s41591-021-01436-0#ref-CR47" id="ref-link-section-d45070288e5718">47</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 48" title="Tong, C. et al. Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma. Blood 136, 1632–1644 (2020)." href="/articles/s41591-021-01436-0#ref-CR48" id="ref-link-section-d45070288e5721">48</a></sup>. The CD19-22.BB.z-CAR used in this trial is a single molecule consisting of two scFvs engineered in a loop orientation<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 22" title="Fry, T. J. et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat. Med. 24, 20–28 (2018)." href="/articles/s41591-021-01436-0#ref-CR22" id="ref-link-section-d45070288e5725">22</a></sup>, which demonstrated activity in vitro and in xenograft models<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 32" title="Qin, H. et al. Preclinical development of bivalent chimeric antigen receptors targeting both CD19 and CD22. Mol. Ther. Oncolytics 11, 127–137 (2018)." href="/articles/s41591-021-01436-0#ref-CR32" id="ref-link-section-d45070288e5729">32</a></sup>. The clinical data presented in this study demonstrated that CD19-22.BB.z-CAR T cells were clinically active in both B-ALL, with 82% achieving an MRD<sup>−</sup> CR, and in LBCL with an ORR of 62%. Toxicity was low: 5 and 11% experienced grade ≥3 CRS or neurotoxicity, respectively. Although we observed relapses with absent or low CD19 expression, a definitive determination of whether these rates are reduced compared to those observed with monospecific CAR19 therapeutics cannot be determined in this single-arm trial given the limited data available regarding antigen<sup>−/lo</sup> relapse and the wide variability in antigen loss reported across studies.</p><p>However, the antigen expression pattern observed at relapse in B-ALL was consistent with CD19-22.BB.z-CAR delivering significant immune pressure on the CD19 antigen, whereas the lack of decrease or loss of CD22 expression suggests more limited immune pressure on the CD22 target. Experience with monospecific CD22-CAR T cells clearly demonstrated resistance associated with CD22<sup>lo</sup> B-ALL, which was not observed in this trial<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 22" title="Fry, T. J. et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat. Med. 24, 20–28 (2018)." href="/articles/s41591-021-01436-0#ref-CR22" id="ref-link-section-d45070288e5743">22</a></sup>. In LBCL, CD22<sup>lo</sup> disease at relapse was seen; however, CD22 expression before therapy was heterogeneous and absent in some. Our data show that CD22 scFv ligation in the bispecific CAR provided less cytokine secretion compared to CD19 scFv. These results suggest cytokine production could be a clinically meaningful product quality attribute to predict CAR potency in vivo and illustrate the challenges of delivering equivalent potency across targets in the context of multi-specific chimeric antigen receptors.</p><p>At present, much of CAR engineering is empiric and multiple approaches to simultaneous targeting of CD19 and CD22 are currently under study<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 32" title="Qin, H. et al. Preclinical development of bivalent chimeric antigen receptors targeting both CD19 and CD22. Mol. Ther. Oncolytics 11, 127–137 (2018)." href="/articles/s41591-021-01436-0#ref-CR32" id="ref-link-section-d45070288e5752">32</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Gardner, R. A. et al. Efficacy of SCRI-CAR19x22 T cell product in B-ALL and persistence of anti-CD22 activity. J. Clin. Oncol. 38, 3035 (2020)." href="#ref-CR49" id="ref-link-section-d45070288e5755">49</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Fousek, K. et al. CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression. Leukemia 35, 75–89 (2021)." href="#ref-CR50" id="ref-link-section-d45070288e5755_1">50</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" title="Dai, H. et al. Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. J. Hematol. Oncol. 13, 30 (2020)." href="#ref-CR51" id="ref-link-section-d45070288e5755_2">51</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 52" title="Amrolia, P. J. et al. Phase I study of AUTO3, a bicistronic chimeric antigen receptor (CAR) T-cell therapy targeting CD19 and CD22, in pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL): Amelia study. Blood 134, 2620 (2019)." href="/articles/s41591-021-01436-0#ref-CR52" id="ref-link-section-d45070288e5758">52</a></sup>. Engineering an optimal monospecific CAR is dependent on numerous factors, including prevention of tonic signaling,<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 53" title="Lynn, R. C. et al. c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature 576, 293–300 (2019)." href="/articles/s41591-021-01436-0#ref-CR53" id="ref-link-section-d45070288e5762">53</a></sup> optimizing hinge length,<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 54" title="Guest, R. D. et al. The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens. J. Immunother. 28, 203–211 (2005)." href="/articles/s41591-021-01436-0#ref-CR54" id="ref-link-section-d45070288e5766">54</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 55" title="Hudecek, M. et al. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin. Cancer Res. 19, 3153–3164 (2013)." href="/articles/s41591-021-01436-0#ref-CR55" id="ref-link-section-d45070288e5769">55</a></sup> hinge/transmembrane domain<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 21" title="Majzner, R. G. et al. Tuning the antigen density requirement for CAR T-cell activity. Cancer Discov. 10, 702–723 (2020)." href="/articles/s41591-021-01436-0#ref-CR21" id="ref-link-section-d45070288e5773">21</a></sup> and optimizing the distance between the target epitope and tumor cell membrane<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 27" title="Haso, W. et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood 121, 1165–1174 (2013)." href="/articles/s41591-021-01436-0#ref-CR27" id="ref-link-section-d45070288e5777">27</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 56" title="Long, A. H., Haso, W. M. &amp; Orentas, R. J. Lessons learned from a highly-active CD22-specific chimeric antigen receptor. Oncoimmunology 2, e23621 (2013)." href="/articles/s41591-021-01436-0#ref-CR56" id="ref-link-section-d45070288e5780">56</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 57" title="Li, D. et al. Persistent polyfunctional chimeric antigen receptor T cells that target glypican 3 eliminate orthotopic hepatocellular carcinomas in mice. Gastroenterology 158, 2250–2265.e20 (2020)." href="/articles/s41591-021-01436-0#ref-CR57" id="ref-link-section-d45070288e5783">57</a></sup>. In human trials, numerous chimeric antigen receptors targeting CD22 have demonstrated that small alterations in structure can result in loss of activity<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 49" title="Gardner, R. A. et al. Efficacy of SCRI-CAR19x22 T cell product in B-ALL and persistence of anti-CD22 activity. J. Clin. Oncol. 38, 3035 (2020)." href="/articles/s41591-021-01436-0#ref-CR49" id="ref-link-section-d45070288e5788">49</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 58" title="Singh, N. et al. Single chain variable fragment linker length regulates CAR biology and T cell efficacy. Blood 134, 247 (2019)." href="/articles/s41591-021-01436-0#ref-CR58" id="ref-link-section-d45070288e5791">58</a></sup>. In the context of a tandem CAR (linked scFvs), optimal engineering also requires engineering an optimal bispecific receptor<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 59" title="Grada, Z. et al. TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy. Mol. Ther. Nucleic Acids 2, e105 (2013)." href="/articles/s41591-021-01436-0#ref-CR59" id="ref-link-section-d45070288e5795">59</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 60" title="Zah, E., Lin, M.-Y., Silva-Benedict, A., Jensen, M. C. &amp; Chen, Y. Y. T cells expressing CD19/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells. Cancer Immunol. Res. 4, 498–508 (2016)." href="/articles/s41591-021-01436-0#ref-CR60" id="ref-link-section-d45070288e5798">60</a></sup>, which may be particularly challenging for the CD22 target. When compared to a monospecific CAR with the same scFV, the CD19-22.BB.z-CAR demonstrated decreased TNF-α and IL-2 secretion. The threshold for CAR T cell IL-2 secretion has previously been shown to be higher than that of IFN-γ<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 20" title="Walker, A. J. et al. Tumor antigen and receptor densities regulate efficacy of a chimeric antigen receptor targeting anaplastic lymphoma kinase. Mol. Ther. 25, 2189–2201 (2017)." href="/articles/s41591-021-01436-0#ref-CR20" id="ref-link-section-d45070288e5802">20</a></sup> and may better discriminate CAR efficacy. Our results suggest that engineering iterations should be guided by careful studies of single-cell CAR polyfunctionality incorporating cytokine production as a critical quality attribute.</p><p>We also observed a significant incidence of CD19<sup>+</sup> relapse, as reported in many previous trials of CAR19 for B-ALL and LBCL<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 61" title="Spiegel, J. Y. et al. Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy. Blood 137, 1832–1835 (2021)." href="/articles/s41591-021-01436-0#ref-CR61" id="ref-link-section-d45070288e5812">61</a></sup>, suggesting that potency toward the CD19 target may also be insufficient in some patients. Improvements in CAR manufacturing could prevent antigen<sup>+</sup> resistance, which likely results from T cell failure. Defined composition of CD4:CD8 CAR cells and preferential administration of T cell subsets, such as T<sub>CM</sub><sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 62" title="Blaeschke, F. et al. Induction of a central memory and stem cell memory phenotype in functionally active CD4+ and CD8+ CAR T cells produced in an automated good manufacturing practice system for the treatment of CD19+ acute lymphoblastic leukemia. Cancer Immunol. Immunother. 67, 1053–1066 (2018)." href="/articles/s41591-021-01436-0#ref-CR62" id="ref-link-section-d45070288e5819">62</a>,<a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 63" title="Xu, Y. et al. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood 123, 3750–3759 (2014)." href="/articles/s41591-021-01436-0#ref-CR63" id="ref-link-section-d45070288e5822">63</a></sup>, have been hypothesized to mediate optimal CAR activity<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 1" title="Turtle, C. J. et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J. Clin. Invest. 126, 2123–2138 (2016)." href="/articles/s41591-021-01436-0#ref-CR1" id="ref-link-section-d45070288e5826">1</a></sup>. We found our manufacturing process selectively enriched for T<sub>CM</sub> and T<sub>SCM</sub> with low T<sub>EMRA</sub> but biased the final product toward CD4 predominance. Furthermore, CD4 cells produced with our process expressed higher levels of CD39 and PD-1, which are associated with exhaustion, suggesting that the manufacturing process may not generate an optimal final product composition. Due to these findings, we paused trial enrollment to modify our manufacturing process to attain a more balanced CD4:CD8 ratio, which may also allow CD4 CAR cells to maintain a less exhausted phenotype.</p><p>In summary, this work provides evidence that antigen<sup>−/lo</sup> escape is a major pathway of resistance after CAR19 therapy for LBCL and quantitative antigen density in LBCL correlates with outcomes after CAR T cell therapy. Using a bispecific CAR capable of simultaneously recognizing CD22 and CD19, we demonstrated safety and impressive clinical activity in B-ALL. The 6-month PFS in LBCL (29%, 95% CI 12–48%) in this trial was similar to tisagenlecleucel<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 64" title="Pasquini, M. C. et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 4, 5414–5424 (2020)." href="/articles/s41591-021-01436-0#ref-CR64" id="ref-link-section-d45070288e5842">64</a></sup>. Therefore, the lymphoma arm was closed in this study with enrollment ongoing in patients with B-ALL. Resistance to the bispecific CAR was associated with CD19<sup>+</sup>CD22<sup>+</sup> relapse, probably reflecting intrinsic limitations of CAR T cells, as well as CD19<sup>−/lo</sup> but CD22<sup>+</sup> relapse, implying inadequate immune pressure on the CD22 target. Our data also illustrate the value of cytokine production as a key product quality attribute for credentialing the potency of CAR T cells. Future work is needed to optimize multi-specific targeting by CAR T cells to improve the efficacy of this class of therapeutics both in B cell malignancies and other solid and liquid cancers.</p></div></div></section><section data-title="Methods"><div class="c-article-section" id="Sec14-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec14">Methods</h2><div class="c-article-section__content" id="Sec14-content"><h3 class="c-article__sub-heading" id="Sec15">Trial design</h3><p>We conducted a single-center phase I clinical trial of CD19-22.BB.z-CAR in adult patients with relapsed/refractory LBCL and B-ALL at Stanford University Medical Center. The study was approved by the internal review board and registered with ClinicalTrials.gov (<a href="https://clinicaltrials.gov/ct2/show/NCT03233854">NCT03233854</a>). A trial-specific safety monitoring committee was chartered for safety and trial conduct; it consisted of internal Stanford and external CAR T expert members. In addition, data monitoring was overseen by Stanford’s institutional Data Safety Monitoring Committee. Informed written consent was provided by all patients in accordance with the Declaration of Helsinki (2013). The full clinical trial protocol is included in the <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01436-0#MOESM1">Supplementary Information</a>. The dose escalation phase enrolled both histologies in a single arm and permitted enrollment on three dose levels using a 3 + 3 design: DL1 of 1 × 10<sup>6</sup> cells kg<sup>−1</sup>; DL2 of 3 × 10<sup>6</sup> cells kg<sup>−1</sup>; and DL3 of 1 × 10<sup>7</sup> cells kg<sup>−1</sup>. Primary outcomes were feasibility of manufacture of CD19-22.BB.z-CAR as well as safety of CD19-22.BB.z-CAR. Feasibility of manufacture was defined as greater than 80% of products meeting the protocol-specified dose. Safety was defined by incidence and severity of DLTs at each of the dose levels tested; the maximal tolerated dose was defined as the dose level immediately below the dose level where incidence of DLTs was &gt;30%. After dose escalation, disease-specific dose expansion cohorts could be enrolled at either the maximum tolerated dose or highest dose level tested. Secondary outcomes included efficacy of CD19-22.BB.z-CAR to induce clinical response at three months for LBCL and one month for B-ALL. A futility analysis was conducted after 15 individuals were enrolled at the recommended phase 2 dose. In LBCL, futility was defined as a ≤33% ORR at the 3-month time point. In B-ALL, futility was defined as a ≤40% ORR at the 1-month time point. Exploratory objectives included the rate of CD19<sup>−</sup> and/or CD22<sup>−</sup> relapse after CD19-22.BB.z-CAR, site density of CD19 and CD22 of malignant cells and expansion and persistence of CD19-22.BB.z-CAR after infusion.</p><h3 class="c-article__sub-heading" id="Sec16">Patient enrollment and eligibility</h3><p>Patients eligible for leukapheresis were ≥18 with LBCL or B-ALL relapsed or refractory after ≥2 lines of therapy. If applicable, previous autologous or allogeneic HCT were considered as a line of therapy. Patients with LBCL must have received an anthracycline and an anti-CD20 monoclonal antibody as part of previous therapy. Transformed indolent lymphomas, including Richter transformation, were eligible. Measurable disease by PET/CT was required. For B-ALL, either morphological disease (including extramedullary disease) or detectable MRD with &lt;5% marrow blasts were acceptable; CNS involvement was allowed. Expression of CD19 on malignant cells was required by either flow cytometry or IHC. Previous anti-CD19-directed therapy, including previous CAR T, was allowed provided &lt;5% of circulating T cells expressed the previous CAR. At least two weeks or five half-lives, whichever was shorter, must have elapsed since any previous systemic therapy at the time of leukapheresis and all previous toxicities must be stable or recovered to grade 1 or lower. Adequate marrow function was required unless cytopenias were felt to be due to underlying leukemia/lymphoma: an absolute neutrophil count ≥750 µl, platelet count ≥50,000 µl and absolute lymphocyte count ≥150 µl. Adequate organ function was defined as creatinine ≥2 mg ml<sup>−1</sup>, serum aspartate aminotransferase or alanine aminotransferase less than ten times the upper limit of normal, total bilirubin ≤1.5 mg dl<sup>−1</sup>, cardiac ejection fraction ≥45%, no clinically significant electrocardiogram findings, no clinically significant pleural effusion and baseline oxygen saturation ≥92% on room air. Exclusion criteria included: history of previous malignancy within 3 years; presence of uncontrolled bacterial, viral or fungal infection or infection requiring intravenous antibiotics; known infection with human immunodeficiency virus, hepatitis B (HBsAg<sup>+</sup>) or hepatitis C (anti-hepatitis C virus<sup>+</sup>); CNS disorder impairing one’s ability to evaluate neurotoxicity; history of autoimmune disease requiring systemic immunosuppression within previous 2 years; history of clinically significant cardiac disease within 12 months of enrollment.</p><p>After leukapheresis, bridging therapy was permitted at the investigator’s discretion. Conditioning chemotherapy, consisting of fludarabine 30 mg m<sup>−2</sup> and cyclophosphamide 500 mg m<sup>−2</sup>, was administered on day −5 through day −3 before infusion. Patients were enrolled to receive CD19-22.BB.z-CAR between 12 September 2017 and 19 November 2019. Data were locked as of 15 June 2020. Dose escalation and production feasibility were determined by consecutive patients irrespective of disease type. After dose escalation, separate LBCL and B-ALL cohorts were expanded to treat 15 patients in each cohort at the recommended phase II dose.</p><h3 class="c-article__sub-heading" id="Sec17">Toxicity assessment</h3><p>In the dose escalation phase, CRS was graded according to the Lee criteria<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 66" title="Lee, D. W. et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124, 188–195 (2014)." href="/articles/s41591-021-01436-0#ref-CR66" id="ref-link-section-d45070288e5925">66</a></sup> and neurotoxicity-graded by the Common Terminology Criteria for Adverse Events v.4.0.3. Patients in the cohort expansion were graded according to the American Society for Transplantation and Cellular Therapy (ASTCT) criteria for CRS and ASTCT immune effector cell-associated neurotoxicity syndrome criteria for neurotoxicity<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 67" title="Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transplant. 25, 625–638 (2019)." href="/articles/s41591-021-01436-0#ref-CR67" id="ref-link-section-d45070288e5929">67</a></sup>. For uniform reporting in the article, patients in the dose escalation group were regraded according to the ASTCT criteria. Adverse events were captured for all treated patients until disease relapse or death.</p><h3 class="c-article__sub-heading" id="Sec18">Response assessment</h3><p>Response for patients with LBCL and patients with B-ALL with extramedullary disease without concurrent bone marrow or CNS involvement was assessed using the Lugano PET/CT criteria<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 67" title="Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transplant. 25, 625–638 (2019)." href="/articles/s41591-021-01436-0#ref-CR67" id="ref-link-section-d45070288e5941">67</a></sup>. For all other patients with B-ALL, CR was defined as &lt;5% bone marrow blasts by morphology. MRD negativity was defined as a bone marrow blast percentage &lt;10<sup>−4</sup> by multiparameter flow cytometry.</p><h3 class="c-article__sub-heading" id="Sec19">Axi-cel patients</h3><p>Consecutive patients with LBCL treated with standard-of-care axi-cel between 27 December 2017 and 9 April 2020 were identified. Patients were consented for collection of clinical data as well as blood and lymph node sampling on a clinical outcomes biorepository protocol. Patients with available tissue samples for IHC and/or quantitative flow cytometry were included in the analysis. The protocol was approved by the Stanford Internal Review Board (no. 43375). Clinical data were obtained retrospectively from the chart review. Treatment response was assessed radiographically according to the Lugano criteria.</p><h3 class="c-article__sub-heading" id="Sec20">CD19-22.BB.z production</h3><p>CD19-22.BB.z products were manufactured in the automated closed-system CliniMACS Prodigy in a 7–11 d manufacturing process. All days provided in this CAR T production section are reflective of the manufacturing schema (Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig6">2</a>). The frozen patient apheresis was washed on the Lovo (Fresenius Kabi) and rested overnight in low-dose IL-2 before loading on the CliniMACS Prodigy. On day 0, the apheresis was enriched for CD4 and CD8 T cells before T cell activation with TransAct (Miltenyi Biotec). On day 1, T cells were transduced with CD19-22.BB.z lentiviral vector (Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig2">2a</a>) at a multiplicity of infection of 40. TransAct was subsequently washed out on either day 3 (new matrix) or day 5 (old matrix), followed by a series of media exchanges. On days 7, 9 or 11, when target dose was achieved, the final product was collected, sampled for quality control testing and cryopreserved. The product release criteria are listed in Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01436-0#MOESM1">1</a>. Iterative improvements to the manufacturing process were implemented to shorten the vein-to-vein time during the course of the trial.</p><h3 class="c-article__sub-heading" id="Sec21">IHC</h3><p>Tissue microarrays were constructed with duplicate 0.6-mm cores of formalin-fixed paraffin-embedded tissue from diagnostic biopsies<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 68" title="Marinelli, R. J. et al. The Stanford Tissue Microarray Database. Nucleic Acids Res. 36, D871–D877 (2008)." href="/articles/s41591-021-01436-0#ref-CR68" id="ref-link-section-d45070288e5981">68</a></sup>. Additional whole-tissue sections were evaluated from cases when available.</p><p>Immunohistochemical studies were performed on 4-mm-thick sections of the formalin-fixed paraffin-embedded tissue in tissue microarray or whole-section form. Automated immunostaining was performed using the Leica BOND-III (Leica Biosystems). Slides were stained with antibodies against CD19 (clone BT51E; prediluted mouse monoclonal antibody; Leica Biosystems) and CD22 (clone FPC1; prediluted mouse monoclonal antibody; Leica Biosystems).</p><p>The intensity of staining (0, negative; 1, weak; 2, moderate; 3, strong) and percentage of tumor cells showing staining (0–100%) were evaluated independently then jointly scored by 2 pathologists (S.Y. and Y.N.). An H-score of 0–300 was generated by multiplying the intensity of positivity by the percentage of tumor cells with staining.</p><h3 class="c-article__sub-heading" id="Sec22">Detection of CD19-22.BB.z cells</h3><p>CD19-22.BB.z cells were detected using the CD19 anti-idiotype antibody developed at the MD Anderson Cancer Center<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 69" title="Jena, B. et al. Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials. PLoS ONE 8, e57838 (2013)." href="/articles/s41591-021-01436-0#ref-CR69" id="ref-link-section-d45070288e5999">69</a></sup>. The CD19 anti-idiotype antibody was conjugated to DyLight 650 (Thermo Fisher Scientific) using an antibody labeling kit and stored at −80 °C for downstream flow cytometry use.</p><h3 class="c-article__sub-heading" id="Sec23">Phenotyping of manufacturing samples at apheresis, enrichment and final product collection</h3><p>This section describes the methods for the phenotyping shown in Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig2">2</a>. All samples were washed in FACS buffer (1× PBS, 2% FCS), stained for a minimum of 30 min at 4 °C before additional washes and running flow cytometry on the MACSQuant Analyzer 10 (Miltenyi Biotec). The MACS Comp bead kit (catalog no. 130-097-900; Miltenyi Biotec) was used for compensation controls. The antibodies used for these experiments are listed in Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01436-0#MOESM1">2</a>.</p><h3 class="c-article__sub-heading" id="Sec24">Flow cytometry for phenotyping and exhaustion profiling</h3><p>All samples were washed in FACS buffer (1× PBS, 3% FCS), stained for a minimum of 30 min at 4 °C before additional washes and running flow cytometry. UltraComp eBeads (catalog no. 01-2222-41; Invitrogen) were used for compensation controls and stained with the respective antibody from the antibody index below. Samples were run on the LSRFortessa X-20 (BD Biosciences) and stained using the antibodies from antibody index shown below.</p><h3 class="c-article__sub-heading" id="Sec25">Exhaustion and T cell subset phenotyping panel</h3><p>This section describes the methods for the intracellular cytokine panel in Figs. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig2">2</a> and <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig4">4</a> and Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig6">2</a>. Samples were stained with a panel backbone (CD3, CD4, CD8, CAR, viability) first. Subsequently, samples were split into two for either phenotyping of T cell subsets (CD45RA, CD45RO, CCR7, CD62L, CD95) or exhaustion markers (CD39, LAG3, PD-1); all samples were prepared and washed as described above. Analysis for this and the previous two sections were performed in FlowJo v10.5.3 (FlowJo LLC).</p><h3 class="c-article__sub-heading" id="Sec26">NALM6 tumor line antigen density check by flow cytometry</h3><p>This section describes the methods used for the intracellular cytokine panel in Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig4">4</a>. All NALM6 lines were divided into two and stained with either CD19 or CD22 antibody and prepared and washed as described above.</p><h3 class="c-article__sub-heading" id="Sec27">Coculture of CD19-22.BB.z/CD22.BB.z product with NALM6 target cells</h3><p>This section describes the methods used for the intracellular cytokine panel in Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig4">4</a>. Clinical CAR T products were thawed and rested overnight before incubation in coculture assays with the NALM6 lines described above. During this 6–7 h coculture at 37 °C, cells were coincubated with monensin (Thermo Fisher Scientific) and CD107a. A phorbol myristate acetate/ionomycin (Sigma-Aldrich) condition was included as a positive control, along with no monensin, no CD107a or no tumor cells as negative controls. After coculture, cells were washed with FACS buffer and resuspended in an extracellular antibody cocktail consisting of CD3, CD4, CD8, CD69, CAR, LIVE/DEAD and CD107a and incubated for 30 min at 4 °C. Cells were subsequently washed out with FACS buffer before intracellular cytokine staining using the Fixation/Permeabilization Solution Kit (BD Biosciences). The kit protocol was followed to fix and permeabilize CAR T products, followed by resuspension in an intracellular antibody cocktail consisting of IFN-γ and TNF-α and incubated overnight at 4 °C. Cells were washed the following morning in FACS buffer before proceeding with flow cytometry run on the LSRFortessa X-20. The full panel of antibodies is shown in Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01436-0#MOESM1">3</a>.</p><h3 class="c-article__sub-heading" id="Sec28">Real-time peripheral blood CAR T phenotyping assay</h3><p>A high-dimensional immunophenotyping flow cytometry panel was designed for immune profiling of CAR T and B cells in real time on the LSR II (BD Biosciences) and analyzed in Cytobank. Peripheral blood mononuclear cells (PBMCs) were isolated from fresh whole blood by gradient centrifugation on Ficoll (Ficoll-Paque PLUS; Sigma-Aldrich). Between 2–5 million PBMCs were stained with fixable Live/Dead aqua (Invitrogen) amine-reactive viability. Cells were then preincubated with Fc block (TruStain FcX; BioLegend) for 5 min before staining at room temperature with the panel of antibodies listed in Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01436-0#MOESM1">4</a>. CD19-22.BB.z cells were used as the positive batch control for the daily staining experiments. At least 10<sup>6</sup> cells were acquired unless restricted by the number of cells isolated from 8 ml of whole blood. The assay limit of detection for CAR T cells was calculated as 1 in 10<sup>4</sup> of total acquired PBMCs.</p><h3 class="c-article__sub-heading" id="Sec29">qPCR measurement of in vivo CD19-22.BB.z-CAR expansion</h3><p>DNA was extracted from whole blood (2 × 10<sup>6</sup>–5 × 10<sup>6</sup> PBMCs) using the QIAamp DNA Mini Kit (catalog no. 51306; QIAGEN) at baseline and on days 7, 14, 21, 28, 90 and 180 postCAR infusion. CAR presence was measured by qPCR using the primer and probe sequences provided in Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01436-0#MOESM1">5</a>. For the standard curve, a custom Minigene plasmid (Integrated DNA Technologies) was designed containing a partial CD19-22.BB.z sequence and a partial albumin sequence, which served as a control for normalization. The standard curve contained a tenfold serial dilution of plasmid between 5 × 10<sup>6</sup> and 5 × 10<sup>0</sup> copies. Both plasmid and patient DNA from each time point were run in triplicate, with each reaction containing 5 µl of DNA (50 ng total), 100 nM of forward and reverse albumin primers (or 100 nM of forward and 200 nM reverse CD19-22.BB.z primers), a 150-nM probe suspended in 10 µl of TaqMan Fast Universal PCR Master Mix (2×), No AmpErase UNG or equivalent (Thermo Fisher Scientific) and 5 µl of TE buffer (catalog no. AM9935; Invitrogen). The Bio-Rad CFX96 Touch Real-Time PCR Detection System was used for qPCR with 20 µl per reaction. The quality metrics of all qPCR standard curve results were <i>R</i><sup>2</sup> &gt; 0.99, −3.38 &gt; slope &gt; −3.71 and efficiency &gt;86%.</p><h3 class="c-article__sub-heading" id="Sec30">IsoPlexis for 32-plex cytokines</h3><p>CD19-22.BB.z or CD22.BB.z products were magnetically selected into CD4 or CD8 T cells using microbeads (Miltenyi Biotec). CD4<sup>+</sup> and CD8<sup>+</sup> populations were subsequently cocultured with NALM6-double knockout, NALM6-CD19 or NALM6-CD22 at a 1:2 ratio (T cell:tumor) for 20 h. After incubation and a viability check, tumor cells were depleted from the coculture and the remaining T cells were stained with CD22-Fc-AF647 for CD19-22.BB.z detection. Subsequently, 30,000 viable cells were loaded onto the 32-plex human polyfunctional strength single-cell IsoCode chips (IsoPlexis); duplicate chips were run when sample was available. Chips were loaded into the IsoLight machine for scanning and data were analyzed using the IsoSpeak software v.2.8.0.0 (IsoPlexis). Statistical significance between stimulation conditions for single-cell polyfunctionality, percentage and PSI was done by Mann–Whitney <i>U</i>-test.</p><h3 class="c-article__sub-heading" id="Sec31">Tumor-killing IncuCyte proliferation assay</h3><p>The tumor-killing ability of bispecific CD19-22.BB.z and single CD19 and CD22 CAR T cells was assessed in a coculture assay with either NALM6-wild type, NALM6-CD19 knockoutor NALM6-CD22 knockout at an effector:target ratio of 3:1. CD19-22.BB.z cells, all from the same donor, were grown on the CliniMACS Prodigy and CD19 and CD22 CAR T cells were grown using small-scale plate-based processes. All NALM6 cell lines were green fluorescent protein (GFP)<sup>+</sup>; untransduced T cells were included as a mock condition. Tumor killing was measured as a decrease in GFP overtime using the IncuCyte System (Sartorius) and normalized.</p><h3 class="c-article__sub-heading" id="Sec32">Antigen density assessment</h3><p>Specimens were processed within 24 h of collection (mean ± h), stained using the antibody combination listed in Supplementary Table <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01436-0#MOESM1">6</a> and analyzed on the FACSLyric system (BD Biosciences). The median fluorescence intensities of CD19, CD20 and CD22 were determined under saturating antibody conditions for antigen density measurements; the antibody bound per cell was calculated by calibration with Quantibrite phycoerythrin beads (BD Biosciences) and custom BD Biosciences quantitation beads for allophycocyanin and Brilliant Violet 421 (BD Biosciences) after controlling for the fluorophore to antibody ratio.</p><h3 class="c-article__sub-heading" id="Sec33">Measurement of cell-free tumor DNA</h3><p>Tumor DNA was extracted from archival paraffin-embedded tissue; PCR amplification of the IgH-VDJ, IgH-DJ and Igκ/Igλ regions using universal consensus primers was performed by NGS to determine the tumor clonotype(s) (Adaptive Biotechnologies)<sup><a data-track="click" data-track-action="reference anchor" data-track-label="link" data-test="citation-ref" aria-label="Reference 70" title="Ching, T. et al. Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma. BMC Cancer 20, 612 (2020)." href="/articles/s41591-021-01436-0#ref-CR70" id="ref-link-section-d45070288e6152">70</a></sup>. ctDNA was measured from plasma extracted from blood obtained in EDTA tubes at pre-, 0, 7, 14, 21, 56 and 90 d postCD19-22.BB.z-CAR infusion.</p><h3 class="c-article__sub-heading" id="Sec34">Statistical analysis</h3><p>Descriptive statistics were enumerated by median and IQR for continuous variables and counts and percentages for categorical variables. Fisher’s exact (independent) and McNemar’s (dependent) tests evaluated the association between categorical variables and Spearman correlation was used for the association between two random continuous variables. Between-group comparisons for continuous variables were performed using either a Student’s <i>t</i>-test or Wilcoxon signed-rank test. All tests were two-sided. To associate CD19 antigen density with risk of progression, Firth’s penalized logistic regression was used due to the small sample size. Overall survival was defined as the time from infusion to death from any cause. PFS was defined as the time from infusion to either disease progression or death from any cause. Patients were censored at the time of the last follow-up. Overall survival and PFS were estimated by Kaplan–Meier method. Response rates were summarized along with 95% Clopper–Pearson CIs. Analyses were exploratory and not adjusted for multiple comparisons. The statistical software packages used include R v.3.6.2 and Prism 8 (GraphPad Software). <i>P</i> values generated in Prism 8 did not go below <i>P</i> &lt; 0.0001.</p><h3 class="c-article__sub-heading" id="Sec35">Reporting Summary</h3><p>Further information on research design is available in the <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01436-0#MOESM2">Nature Research Reporting Summary</a> linked to this article.</p></div></div></section>
                    
                </div>
            

            <div class="u-mt-32">
                <section data-title="Data availability"><div class="c-article-section" id="data-availability-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="data-availability">Data availability</h2><div class="c-article-section__content" id="data-availability-content">
              
              <p>All requests for raw and analyzed data will be reviewed by the corresponding author to determine if the request if subject to any intellectual property or confidentiality considerations. Patient-related data not included in the paper were generated as part of clinical trials and may be subject to patient confidentiality. Any data and materials that can be shared will be released via a material transfer agreement. The source data for Figs. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig1">1</a>–<a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig4">4</a> and Extended Data Figs. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig5">1</a>–<a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig11">7</a> are provided with the paper. The CD19-22 bispecific CAR sequence is in the patent application (U.S. Provisional Patent Application no. 62/135442) filed on 19 March 2015, titled Dual Specific Anti-Cd22-Anti-Cd19 Chimeric Antigen Receptors; the amino acid sequence is provided in Supplementary Fig. <a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01436-0#MOESM1">2</a>.</p>
            </div></div></section><div id="MagazineFulltextArticleBodySuffix"><section aria-labelledby="Bib1" data-title="References"><div class="c-article-section" id="Bib1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Bib1">References</h2><div class="c-article-section__content" id="Bib1-content"><div data-container-section="references"><ol class="c-article-references" data-track-component="outbound reference" data-track-context="references section"><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="1."><p class="c-article-references__text" id="ref-CR1">Turtle, C. J. et al. CD19 CAR-T cells of defined CD4<sup>+</sup>:CD8<sup>+</sup> composition in adult B cell ALL patients. <i>J. Clin. Invest.</i> <b>126</b>, 2123–2138 (2016).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1172/JCI85309" data-track-item_id="10.1172/JCI85309" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1172%2FJCI85309" aria-label="Article reference 1" data-doi="10.1172/JCI85309">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27111235" aria-label="PubMed reference 1">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4887159" aria-label="PubMed Central reference 1">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 1" href="http://scholar.google.com/scholar_lookup?&amp;title=CD19%20CAR-T%20cells%20of%20defined%20CD4%2B%3ACD8%2B%20composition%20in%20adult%20B%20cell%20ALL%20patients&amp;journal=J.%20Clin.%20Invest.&amp;doi=10.1172%2FJCI85309&amp;volume=126&amp;pages=2123-2138&amp;publication_year=2016&amp;author=Turtle%2CCJ">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="2."><p class="c-article-references__text" id="ref-CR2">Locke, F. L. et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. <i>Lancet Oncol.</i> <b>20</b>, 31–42 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/S1470-2045(18)30864-7" data-track-item_id="10.1016/S1470-2045(18)30864-7" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2FS1470-2045%2818%2930864-7" aria-label="Article reference 2" data-doi="10.1016/S1470-2045(18)30864-7">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1cXisVSgt7bE" aria-label="CAS reference 2">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30518502" aria-label="PubMed reference 2">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 2" href="http://scholar.google.com/scholar_lookup?&amp;title=Long-term%20safety%20and%20activity%20of%20axicabtagene%20ciloleucel%20in%20refractory%20large%20B-cell%20lymphoma%20%28ZUMA-1%29%3A%20a%20single-arm%2C%20multicentre%2C%20phase%201%E2%80%932%20trial&amp;journal=Lancet%20Oncol.&amp;doi=10.1016%2FS1470-2045%2818%2930864-7&amp;volume=20&amp;pages=31-42&amp;publication_year=2019&amp;author=Locke%2CFL">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="3."><p class="c-article-references__text" id="ref-CR3">Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. <i>N. Engl. J. Med.</i> <b>377</b>, 2531–2544 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1056/NEJMoa1707447" data-track-item_id="10.1056/NEJMoa1707447" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa1707447" aria-label="Article reference 3" data-doi="10.1056/NEJMoa1707447">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1MXhtVGjtbw%3D" aria-label="CAS reference 3">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29226797" aria-label="PubMed reference 3">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5882485" aria-label="PubMed Central reference 3">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 3" href="http://scholar.google.com/scholar_lookup?&amp;title=Axicabtagene%20ciloleucel%20CAR%20T-cell%20therapy%20in%20refractory%20large%20B-cell%20lymphoma&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1707447&amp;volume=377&amp;pages=2531-2544&amp;publication_year=2017&amp;author=Neelapu%2CSS">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="4."><p class="c-article-references__text" id="ref-CR4">Schuster, S. J. et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. <i>N. Engl. J. Med.</i> <b>380</b>, 45–56 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1056/NEJMoa1804980" data-track-item_id="10.1056/NEJMoa1804980" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa1804980" aria-label="Article reference 4" data-doi="10.1056/NEJMoa1804980">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1MXhtFKmtbc%3D" aria-label="CAS reference 4">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30501490" aria-label="PubMed reference 4">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 4" href="http://scholar.google.com/scholar_lookup?&amp;title=Tisagenlecleucel%20in%20adult%20relapsed%20or%20refractory%20diffuse%20large%20B-cell%20lymphoma&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1804980&amp;volume=380&amp;pages=45-56&amp;publication_year=2019&amp;author=Schuster%2CSJ">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="5."><p class="c-article-references__text" id="ref-CR5">Hay, K. A. et al. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. <i>Blood</i> <b>133</b>, 1652–1663 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1182/blood-2018-11-883710" data-track-item_id="10.1182/blood-2018-11-883710" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1182%2Fblood-2018-11-883710" aria-label="Article reference 5" data-doi="10.1182/blood-2018-11-883710">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1MXpslymtbs%3D" aria-label="CAS reference 5">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30728140" aria-label="PubMed reference 5">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6460418" aria-label="PubMed Central reference 5">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 5" href="http://scholar.google.com/scholar_lookup?&amp;title=Factors%20associated%20with%20durable%20EFS%20in%20adult%20B-cell%20ALL%20patients%20achieving%20MRD-negative%20CR%20after%20CD19%20CAR%20T-cell%20therapy&amp;journal=Blood&amp;doi=10.1182%2Fblood-2018-11-883710&amp;volume=133&amp;pages=1652-1663&amp;publication_year=2019&amp;author=Hay%2CKA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="6."><p class="c-article-references__text" id="ref-CR6">Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. <i>N. Engl. J. Med.</i> <b>378</b>, 439–448 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1056/NEJMoa1709866" data-track-item_id="10.1056/NEJMoa1709866" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa1709866" aria-label="Article reference 6" data-doi="10.1056/NEJMoa1709866">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1cXitlylsLw%3D" aria-label="CAS reference 6">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29385370" aria-label="PubMed reference 6">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5996391" aria-label="PubMed Central reference 6">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 6" href="http://scholar.google.com/scholar_lookup?&amp;title=Tisagenlecleucel%20in%20children%20and%20young%20adults%20with%20B-cell%20lymphoblastic%20leukemia&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1709866&amp;volume=378&amp;pages=439-448&amp;publication_year=2018&amp;author=Maude%2CSL">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="7."><p class="c-article-references__text" id="ref-CR7">Park, J. H. et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. <i>N. Engl. J. Med.</i> <b>378</b>, 449–459 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1056/NEJMoa1709919" data-track-item_id="10.1056/NEJMoa1709919" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa1709919" aria-label="Article reference 7" data-doi="10.1056/NEJMoa1709919">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1cXitlylsbY%3D" aria-label="CAS reference 7">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29385376" aria-label="PubMed reference 7">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6637939" aria-label="PubMed Central reference 7">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 7" href="http://scholar.google.com/scholar_lookup?&amp;title=Long-term%20follow-up%20of%20CD19%20CAR%20therapy%20in%20acute%20lymphoblastic%20leukemia&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1709919&amp;volume=378&amp;pages=449-459&amp;publication_year=2018&amp;author=Park%2CJH">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="8."><p class="c-article-references__text" id="ref-CR8">Nastoupil, L. J. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium. <i>J. Clin. Oncol.</i> <b>38</b>, 3119–3128 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1200/JCO.19.02104" data-track-item_id="10.1200/JCO.19.02104" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1200%2FJCO.19.02104" aria-label="Article reference 8" data-doi="10.1200/JCO.19.02104">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32401634" aria-label="PubMed reference 8">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7499611" aria-label="PubMed Central reference 8">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 8" href="http://scholar.google.com/scholar_lookup?&amp;title=Standard-of-care%20axicabtagene%20ciloleucel%20for%20relapsed%20or%20refractory%20large%20B-cell%20lymphoma%3A%20results%20from%20the%20US%20Lymphoma%20CAR%20T%20Consortium&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.19.02104&amp;volume=38&amp;pages=3119-3128&amp;publication_year=2020&amp;author=Nastoupil%2CLJ">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="9."><p class="c-article-references__text" id="ref-CR9">Abramson, J. S. et al. Pivotal safety and efficacy results from Transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed/refractory (R/R) large B cell lymphomas. <i>Blood</i> <b>134</b>, 241 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1182/blood-2019-127508" data-track-item_id="10.1182/blood-2019-127508" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1182%2Fblood-2019-127508" aria-label="Article reference 9" data-doi="10.1182/blood-2019-127508">Article</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 9" href="http://scholar.google.com/scholar_lookup?&amp;title=Pivotal%20safety%20and%20efficacy%20results%20from%20Transcend%20NHL%20001%2C%20a%20multicenter%20phase%201%20study%20of%20lisocabtagene%20maraleucel%20%28liso-cel%29%20in%20relapsed%2Frefractory%20%28R%2FR%29%20large%20B%20cell%20lymphomas&amp;journal=Blood&amp;doi=10.1182%2Fblood-2019-127508&amp;volume=134&amp;publication_year=2019&amp;author=Abramson%2CJS">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="10."><p class="c-article-references__text" id="ref-CR10">Lee, D. W. et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. <i>Lancet</i> <b>385</b>, 517–528 (2015).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/S0140-6736(14)61403-3" data-track-item_id="10.1016/S0140-6736(14)61403-3" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2FS0140-6736%2814%2961403-3" aria-label="Article reference 10" data-doi="10.1016/S0140-6736(14)61403-3">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2cXhslGjtLbM" aria-label="CAS reference 10">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25319501" aria-label="PubMed reference 10">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 10" href="http://scholar.google.com/scholar_lookup?&amp;title=T%20cells%20expressing%20CD19%20chimeric%20antigen%20receptors%20for%20acute%20lymphoblastic%20leukaemia%20in%20children%20and%20young%20adults%3A%20a%20phase%201%20dose-escalation%20trial&amp;journal=Lancet&amp;doi=10.1016%2FS0140-6736%2814%2961403-3&amp;volume=385&amp;pages=517-528&amp;publication_year=2015&amp;author=Lee%2CDW">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="11."><p class="c-article-references__text" id="ref-CR11">Liu, E. et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. <i>N. Engl. J. Med.</i> <b>382</b>, 545–553 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1056/NEJMoa1910607" data-track-item_id="10.1056/NEJMoa1910607" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa1910607" aria-label="Article reference 11" data-doi="10.1056/NEJMoa1910607">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXjtlCgtro%3D" aria-label="CAS reference 11">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32023374" aria-label="PubMed reference 11">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7101242" aria-label="PubMed Central reference 11">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 11" href="http://scholar.google.com/scholar_lookup?&amp;title=Use%20of%20CAR-transduced%20natural%20killer%20cells%20in%20CD19-positive%20lymphoid%20tumors&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1910607&amp;volume=382&amp;pages=545-553&amp;publication_year=2020&amp;author=Liu%2CE">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="12."><p class="c-article-references__text" id="ref-CR12">Majzner, R. G. &amp; Mackall, C. L. Tumor antigen escape from CAR T-cell therapy. <i>Cancer Discov.</i> <b>8</b>, 1219–1226 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/2159-8290.CD-18-0442" data-track-item_id="10.1158/2159-8290.CD-18-0442" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F2159-8290.CD-18-0442" aria-label="Article reference 12" data-doi="10.1158/2159-8290.CD-18-0442">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1MXmt1egu7Y%3D" aria-label="CAS reference 12">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30135176" aria-label="PubMed reference 12">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 12" href="http://scholar.google.com/scholar_lookup?&amp;title=Tumor%20antigen%20escape%20from%20CAR%20T-cell%20therapy&amp;journal=Cancer%20Discov.&amp;doi=10.1158%2F2159-8290.CD-18-0442&amp;volume=8&amp;pages=1219-1226&amp;publication_year=2018&amp;author=Majzner%2CRG&amp;author=Mackall%2CCL">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="13."><p class="c-article-references__text" id="ref-CR13">Bagashev, A. et al. CD19 alterations emerging after CD19-directed immunotherapy cause retention of the misfolded protein in the endoplasmic reticulum. <i>Mol. Cell. Biol.</i> <b>38</b>, e00383-18 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1128/MCB.00383-18" data-track-item_id="10.1128/MCB.00383-18" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1128%2FMCB.00383-18" aria-label="Article reference 13" data-doi="10.1128/MCB.00383-18">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30104252" aria-label="PubMed reference 13">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189457" aria-label="PubMed Central reference 13">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 13" href="http://scholar.google.com/scholar_lookup?&amp;title=CD19%20alterations%20emerging%20after%20CD19-directed%20immunotherapy%20cause%20retention%20of%20the%20misfolded%20protein%20in%20the%20endoplasmic%20reticulum&amp;journal=Mol.%20Cell.%20Biol.&amp;doi=10.1128%2FMCB.00383-18&amp;volume=38&amp;publication_year=2018&amp;author=Bagashev%2CA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="14."><p class="c-article-references__text" id="ref-CR14">Asnani, M. et al. Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19. <i>Leukemia</i> <b>34</b>, 1202–1207 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/s41375-019-0580-z" data-track-item_id="10.1038/s41375-019-0580-z" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41375-019-0580-z" aria-label="Article reference 14" data-doi="10.1038/s41375-019-0580-z">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31591467" aria-label="PubMed reference 14">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 14" href="http://scholar.google.com/scholar_lookup?&amp;title=Retention%20of%20CD19%20intron%202%20contributes%20to%20CART-19%20resistance%20in%20leukemias%20with%20subclonal%20frameshift%20mutations%20in%20CD19&amp;journal=Leukemia&amp;doi=10.1038%2Fs41375-019-0580-z&amp;volume=34&amp;pages=1202-1207&amp;publication_year=2020&amp;author=Asnani%2CM">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="15."><p class="c-article-references__text" id="ref-CR15">Orlando, E. J. et al. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. <i>Nat. Med.</i> <b>24</b>, 1504–1506 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/s41591-018-0146-z" data-track-item_id="10.1038/s41591-018-0146-z" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41591-018-0146-z" aria-label="Article reference 15" data-doi="10.1038/s41591-018-0146-z">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1cXhvVeqs7nE" aria-label="CAS reference 15">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30275569" aria-label="PubMed reference 15">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 15" href="http://scholar.google.com/scholar_lookup?&amp;title=Genetic%20mechanisms%20of%20target%20antigen%20loss%20in%20CAR19%20therapy%20of%20acute%20lymphoblastic%20leukemia&amp;journal=Nat.%20Med.&amp;doi=10.1038%2Fs41591-018-0146-z&amp;volume=24&amp;pages=1504-1506&amp;publication_year=2018&amp;author=Orlando%2CEJ">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="16."><p class="c-article-references__text" id="ref-CR16">Sotillo, E. et al. Convergence of acquired mutations and alternative splicing of CD19 enables Resistance to CART-19 Immunotherapy. <i>Cancer Discov.</i> <b>5</b>, 1282–1295 (2015).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/2159-8290.CD-15-1020" data-track-item_id="10.1158/2159-8290.CD-15-1020" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F2159-8290.CD-15-1020" aria-label="Article reference 16" data-doi="10.1158/2159-8290.CD-15-1020">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2MXhvF2ltb%2FE" aria-label="CAS reference 16">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26516065" aria-label="PubMed reference 16">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4670800" aria-label="PubMed Central reference 16">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 16" href="http://scholar.google.com/scholar_lookup?&amp;title=Convergence%20of%20acquired%20mutations%20and%20alternative%20splicing%20of%20CD19%20enables%20Resistance%20to%20CART-19%20Immunotherapy&amp;journal=Cancer%20Discov.&amp;doi=10.1158%2F2159-8290.CD-15-1020&amp;volume=5&amp;pages=1282-1295&amp;publication_year=2015&amp;author=Sotillo%2CE">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="17."><p class="c-article-references__text" id="ref-CR17">Majzner, R. G. et al. CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors. <i>Clin. Cancer Res.</i> <b>25</b>, 2560–2574 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/1078-0432.CCR-18-0432" data-track-item_id="10.1158/1078-0432.CCR-18-0432" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F1078-0432.CCR-18-0432" aria-label="Article reference 17" data-doi="10.1158/1078-0432.CCR-18-0432">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXhsVeisr3J" aria-label="CAS reference 17">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30655315" aria-label="PubMed reference 17">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8456711" aria-label="PubMed Central reference 17">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 17" href="http://scholar.google.com/scholar_lookup?&amp;title=CAR%20T%20cells%20targeting%20B7-H3%2C%20a%20pan-cancer%20antigen%2C%20demonstrate%20potent%20preclinical%20activity%20against%20pediatric%20solid%20tumors%20and%20brain%20tumors&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-18-0432&amp;volume=25&amp;pages=2560-2574&amp;publication_year=2019&amp;author=Majzner%2CRG">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="18."><p class="c-article-references__text" id="ref-CR18">Watanabe, K. et al. Target antigen density governs the efficacy of anti-CD20-CD28-CD3 ζ chimeric antigen receptor-modified effector CD8<sup>+</sup> T cells. <i>J. Immunol.</i> <b>194</b>, 911–920 (2015).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.4049/jimmunol.1402346" data-track-item_id="10.4049/jimmunol.1402346" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.4049%2Fjimmunol.1402346" aria-label="Article reference 18" data-doi="10.4049/jimmunol.1402346">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2MXhtVCgsLc%3D" aria-label="CAS reference 18">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25520398" aria-label="PubMed reference 18">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 18" href="http://scholar.google.com/scholar_lookup?&amp;title=Target%20antigen%20density%20governs%20the%20efficacy%20of%20anti-CD20-CD28-CD3%20%CE%B6%20chimeric%20antigen%20receptor-modified%20effector%20CD8%2B%20T%20cells&amp;journal=J.%20Immunol.&amp;doi=10.4049%2Fjimmunol.1402346&amp;volume=194&amp;pages=911-920&amp;publication_year=2015&amp;author=Watanabe%2CK">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="19."><p class="c-article-references__text" id="ref-CR19">Hombach, A. A. et al. Superior therapeutic index in lymphoma therapy: CD30<sup>+</sup> CD34<sup>+</sup> hematopoietic stem cells resist a chimeric antigen receptor T-cell attack. <i>Mol. Ther.</i> <b>24</b>, 1423–1434 (2016).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/mt.2016.82" data-track-item_id="10.1038/mt.2016.82" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fmt.2016.82" aria-label="Article reference 19" data-doi="10.1038/mt.2016.82">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC28XhtVOnsrfN" aria-label="CAS reference 19">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27112062" aria-label="PubMed reference 19">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5023391" aria-label="PubMed Central reference 19">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 19" href="http://scholar.google.com/scholar_lookup?&amp;title=Superior%20therapeutic%20index%20in%20lymphoma%20therapy%3A%20CD30%2B%20CD34%2B%20hematopoietic%20stem%20cells%20resist%20a%20chimeric%20antigen%20receptor%20T-cell%20attack&amp;journal=Mol.%20Ther.&amp;doi=10.1038%2Fmt.2016.82&amp;volume=24&amp;pages=1423-1434&amp;publication_year=2016&amp;author=Hombach%2CAA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="20."><p class="c-article-references__text" id="ref-CR20">Walker, A. J. et al. Tumor antigen and receptor densities regulate efficacy of a chimeric antigen receptor targeting anaplastic lymphoma kinase. <i>Mol. Ther.</i> <b>25</b>, 2189–2201 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.ymthe.2017.06.008" data-track-item_id="10.1016/j.ymthe.2017.06.008" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.ymthe.2017.06.008" aria-label="Article reference 20" data-doi="10.1016/j.ymthe.2017.06.008">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2sXhsVKlsbrE" aria-label="CAS reference 20">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28676342" aria-label="PubMed reference 20">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589087" aria-label="PubMed Central reference 20">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 20" href="http://scholar.google.com/scholar_lookup?&amp;title=Tumor%20antigen%20and%20receptor%20densities%20regulate%20efficacy%20of%20a%20chimeric%20antigen%20receptor%20targeting%20anaplastic%20lymphoma%20kinase&amp;journal=Mol.%20Ther.&amp;doi=10.1016%2Fj.ymthe.2017.06.008&amp;volume=25&amp;pages=2189-2201&amp;publication_year=2017&amp;author=Walker%2CAJ">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="21."><p class="c-article-references__text" id="ref-CR21">Majzner, R. G. et al. Tuning the antigen density requirement for CAR T-cell activity. <i>Cancer Discov.</i> <b>10</b>, 702–723 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/2159-8290.CD-19-0945" data-track-item_id="10.1158/2159-8290.CD-19-0945" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F2159-8290.CD-19-0945" aria-label="Article reference 21" data-doi="10.1158/2159-8290.CD-19-0945">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXit1antbjL" aria-label="CAS reference 21">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32193224" aria-label="PubMed reference 21">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7939454" aria-label="PubMed Central reference 21">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 21" href="http://scholar.google.com/scholar_lookup?&amp;title=Tuning%20the%20antigen%20density%20requirement%20for%20CAR%20T-cell%20activity&amp;journal=Cancer%20Discov.&amp;doi=10.1158%2F2159-8290.CD-19-0945&amp;volume=10&amp;pages=702-723&amp;publication_year=2020&amp;author=Majzner%2CRG">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="22."><p class="c-article-references__text" id="ref-CR22">Fry, T. J. et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. <i>Nat. Med.</i> <b>24</b>, 20–28 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/nm.4441" data-track-item_id="10.1038/nm.4441" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fnm.4441" aria-label="Article reference 22" data-doi="10.1038/nm.4441">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2sXhvVaksrjM" aria-label="CAS reference 22">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29155426" aria-label="PubMed reference 22">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 22" href="http://scholar.google.com/scholar_lookup?&amp;title=CD22-targeted%20CAR%20T%20cells%20induce%20remission%20in%20B-ALL%20that%20is%20naive%20or%20resistant%20to%20CD19-targeted%20CAR%20immunotherapy&amp;journal=Nat.%20Med.&amp;doi=10.1038%2Fnm.4441&amp;volume=24&amp;pages=20-28&amp;publication_year=2018&amp;author=Fry%2CTJ">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="23."><p class="c-article-references__text" id="ref-CR23">Cohen, A. D. et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. <i>J. Clin. Invest.</i> <b>129</b>, 2210–2221 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1172/JCI126397" data-track-item_id="10.1172/JCI126397" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1172%2FJCI126397" aria-label="Article reference 23" data-doi="10.1172/JCI126397">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30896447" aria-label="PubMed reference 23">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6546468" aria-label="PubMed Central reference 23">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 23" href="http://scholar.google.com/scholar_lookup?&amp;title=B%20cell%20maturation%20antigen-specific%20CAR%20T%20cells%20are%20clinically%20active%20in%20multiple%20myeloma&amp;journal=J.%20Clin.%20Invest.&amp;doi=10.1172%2FJCI126397&amp;volume=129&amp;pages=2210-2221&amp;publication_year=2019&amp;author=Cohen%2CAD">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="24."><p class="c-article-references__text" id="ref-CR24">Oak, J. et al. Target antigen downregulation and other mechanisms of failure after axicabtagene ciloleucel (CAR19) therapy. <i>Blood</i> <b>132</b>, 4656 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1182/blood-2018-99-120206" data-track-item_id="10.1182/blood-2018-99-120206" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1182%2Fblood-2018-99-120206" aria-label="Article reference 24" data-doi="10.1182/blood-2018-99-120206">Article</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 24" href="http://scholar.google.com/scholar_lookup?&amp;title=Target%20antigen%20downregulation%20and%20other%20mechanisms%20of%20failure%20after%20axicabtagene%20ciloleucel%20%28CAR19%29%20therapy&amp;journal=Blood&amp;doi=10.1182%2Fblood-2018-99-120206&amp;volume=132&amp;publication_year=2018&amp;author=Oak%2CJ">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="25."><p class="c-article-references__text" id="ref-CR25">Neelapu, S. S. et al. CD19-loss with preservation of other B cell lineage features in patients with large B cell lymphoma who relapsed post-axi-cel. <i>Blood</i> <b>134</b>, 203 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1182/blood-2019-126218" data-track-item_id="10.1182/blood-2019-126218" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1182%2Fblood-2019-126218" aria-label="Article reference 25" data-doi="10.1182/blood-2019-126218">Article</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 25" href="http://scholar.google.com/scholar_lookup?&amp;title=CD19-loss%20with%20preservation%20of%20other%20B%20cell%20lineage%20features%20in%20patients%20with%20large%20B%20cell%20lymphoma%20who%20relapsed%20post-axi-cel&amp;journal=Blood&amp;doi=10.1182%2Fblood-2019-126218&amp;volume=134&amp;publication_year=2019&amp;author=Neelapu%2CSS">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="26."><p class="c-article-references__text" id="ref-CR26">Shah, N. N. et al. Characterization of CD22 expression in acute lymphoblastic leukemia. <i>Pediatr. Blood Cancer</i> <b>62</b>, 964–969 (2015).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1002/pbc.25410" data-track-item_id="10.1002/pbc.25410" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1002%2Fpbc.25410" aria-label="Article reference 26" data-doi="10.1002/pbc.25410">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2MXms1GhtL0%3D" aria-label="CAS reference 26">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25728039" aria-label="PubMed reference 26">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4405453" aria-label="PubMed Central reference 26">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 26" href="http://scholar.google.com/scholar_lookup?&amp;title=Characterization%20of%20CD22%20expression%20in%20acute%20lymphoblastic%20leukemia&amp;journal=Pediatr.%20Blood%20Cancer&amp;doi=10.1002%2Fpbc.25410&amp;volume=62&amp;pages=964-969&amp;publication_year=2015&amp;author=Shah%2CNN">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="27."><p class="c-article-references__text" id="ref-CR27">Haso, W. et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. <i>Blood</i> <b>121</b>, 1165–1174 (2013).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1182/blood-2012-06-438002" data-track-item_id="10.1182/blood-2012-06-438002" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1182%2Fblood-2012-06-438002" aria-label="Article reference 27" data-doi="10.1182/blood-2012-06-438002">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC3sXjt1WhsLw%3D" aria-label="CAS reference 27">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23243285" aria-label="PubMed reference 27">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3575759" aria-label="PubMed Central reference 27">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 27" href="http://scholar.google.com/scholar_lookup?&amp;title=Anti-CD22-chimeric%20antigen%20receptors%20targeting%20B-cell%20precursor%20acute%20lymphoblastic%20leukemia&amp;journal=Blood&amp;doi=10.1182%2Fblood-2012-06-438002&amp;volume=121&amp;pages=1165-1174&amp;publication_year=2013&amp;author=Haso%2CW">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="28."><p class="c-article-references__text" id="ref-CR28">Tedder, T. F., Poe, J. C. &amp; Haas, K. M. CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction. <i>Adv. Immunol.</i> <b>88</b>, 1–50 (2005).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/S0065-2776(05)88001-0" data-track-item_id="10.1016/S0065-2776(05)88001-0" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2FS0065-2776%2805%2988001-0" aria-label="Article reference 28" data-doi="10.1016/S0065-2776(05)88001-0">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD1cXhs12lsL8%3D" aria-label="CAS reference 28">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=16227086" aria-label="PubMed reference 28">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 28" href="http://scholar.google.com/scholar_lookup?&amp;title=CD22%3A%20a%20multifunctional%20receptor%20that%20regulates%20B%20lymphocyte%20survival%20and%20signal%20transduction&amp;journal=Adv.%20Immunol.&amp;doi=10.1016%2FS0065-2776%2805%2988001-0&amp;volume=88&amp;pages=1-50&amp;publication_year=2005&amp;author=Tedder%2CTF&amp;author=Poe%2CJC&amp;author=Haas%2CKM">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="29."><p class="c-article-references__text" id="ref-CR29">Raponi, S. et al. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. <i>Leuk. Lymphoma</i> <b>52</b>, 1098–1107 (2011).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.3109/10428194.2011.559668" data-track-item_id="10.3109/10428194.2011.559668" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.3109%2F10428194.2011.559668" aria-label="Article reference 29" data-doi="10.3109/10428194.2011.559668">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC3MXmtl2msLY%3D" aria-label="CAS reference 29">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21348573" aria-label="PubMed reference 29">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 29" href="http://scholar.google.com/scholar_lookup?&amp;title=Flow%20cytometric%20study%20of%20potential%20target%20antigens%20%28CD19%2C%20CD20%2C%20CD22%2C%20CD33%29%20for%20antibody-based%20immunotherapy%20in%20acute%20lymphoblastic%20leukemia%3A%20analysis%20of%20552%20cases&amp;journal=Leuk.%20Lymphoma&amp;doi=10.3109%2F10428194.2011.559668&amp;volume=52&amp;pages=1098-1107&amp;publication_year=2011&amp;author=Raponi%2CS">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="30."><p class="c-article-references__text" id="ref-CR30">Olejniczak, S. H., Stewart, C. C., Donohue, K. &amp; Czuczman, M. S. A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry. <i>Immunol. Invest.</i> <b>35</b>, 93–114 (2006).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1080/08820130500496878" data-track-item_id="10.1080/08820130500496878" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1080%2F08820130500496878" aria-label="Article reference 30" data-doi="10.1080/08820130500496878">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD28XisVarurw%3D" aria-label="CAS reference 30">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=16531332" aria-label="PubMed reference 30">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 30" href="http://scholar.google.com/scholar_lookup?&amp;title=A%20quantitative%20exploration%20of%20surface%20antigen%20expression%20in%20common%20B-cell%20malignancies%20using%20flow%20cytometry&amp;journal=Immunol.%20Invest.&amp;doi=10.1080%2F08820130500496878&amp;volume=35&amp;pages=93-114&amp;publication_year=2006&amp;author=Olejniczak%2CSH&amp;author=Stewart%2CCC&amp;author=Donohue%2CK&amp;author=Czuczman%2CMS">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="31."><p class="c-article-references__text" id="ref-CR31">Shah, N. N. et al. CD4/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial. <i>J. Clin. Oncol.</i> <b>38</b>, 1938–1950 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1200/JCO.19.03279" data-track-item_id="10.1200/JCO.19.03279" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1200%2FJCO.19.03279" aria-label="Article reference 31" data-doi="10.1200/JCO.19.03279">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXhvFantbrN" aria-label="CAS reference 31">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32286905" aria-label="PubMed reference 31">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280047" aria-label="PubMed Central reference 31">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 31" href="http://scholar.google.com/scholar_lookup?&amp;title=CD4%2FCD8%20T-cell%20selection%20affects%20chimeric%20antigen%20receptor%20%28CAR%29%20T-cell%20potency%20and%20toxicity%3A%20updated%20results%20from%20a%20phase%20I%20anti-CD22%20CAR%20T-cell%20trial&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.19.03279&amp;volume=38&amp;pages=1938-1950&amp;publication_year=2020&amp;author=Shah%2CNN">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="32."><p class="c-article-references__text" id="ref-CR32">Qin, H. et al. Preclinical development of bivalent chimeric antigen receptors targeting both CD19 and CD22. <i>Mol. Ther. Oncolytics</i> <b>11</b>, 127–137 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.omto.2018.10.006" data-track-item_id="10.1016/j.omto.2018.10.006" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.omto.2018.10.006" aria-label="Article reference 32" data-doi="10.1016/j.omto.2018.10.006">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1cXisFKqsrzL" aria-label="CAS reference 32">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30581986" aria-label="PubMed reference 32">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6300726" aria-label="PubMed Central reference 32">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 32" href="http://scholar.google.com/scholar_lookup?&amp;title=Preclinical%20development%20of%20bivalent%20chimeric%20antigen%20receptors%20targeting%20both%20CD19%20and%20CD22&amp;journal=Mol.%20Ther.%20Oncolytics&amp;doi=10.1016%2Fj.omto.2018.10.006&amp;volume=11&amp;pages=127-137&amp;publication_year=2018&amp;author=Qin%2CH">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="33."><p class="c-article-references__text" id="ref-CR33">Frank, M. J. et al. Optimizing circulating tumor DNA based assessments in patients with large B-cell lymphoma undergoing axicabtagene ciloleucel. <i>J. Clin. Oncol</i>. <a href="https://doi.org/10.1200/JCO.21.00377" data-track="click_references" data-track-action="external reference" data-track-value="external reference" data-track-label="10.1200/JCO.21.00377">https://doi.org/10.1200/JCO.21.00377</a> (2021).</p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="34."><p class="c-article-references__text" id="ref-CR34">Weber, E. W. et al. Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling. <i>Science</i> <b>372</b>, eaba1786 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1126/science.aba1786" data-track-item_id="10.1126/science.aba1786" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1126%2Fscience.aba1786" aria-label="Article reference 34" data-doi="10.1126/science.aba1786">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXotFGlur0%3D" aria-label="CAS reference 34">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33795428" aria-label="PubMed reference 34">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8049103" aria-label="PubMed Central reference 34">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 34" href="http://scholar.google.com/scholar_lookup?&amp;title=Transient%20rest%20restores%20functionality%20in%20exhausted%20CAR-T%20cells%20through%20epigenetic%20remodeling&amp;journal=Science&amp;doi=10.1126%2Fscience.aba1786&amp;volume=372&amp;publication_year=2021&amp;author=Weber%2CEW">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="35."><p class="c-article-references__text" id="ref-CR35">Yu, H. et al. Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma. <i>Am. J. Hematol.</i> <b>92</b>, E11–E13 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1002/ajh.24594" data-track-item_id="10.1002/ajh.24594" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1002%2Fajh.24594" aria-label="Article reference 35" data-doi="10.1002/ajh.24594">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC28XitFens7zO" aria-label="CAS reference 35">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27779774" aria-label="PubMed reference 35">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 35" href="http://scholar.google.com/scholar_lookup?&amp;title=Repeated%20loss%20of%20target%20surface%20antigen%20after%20immunotherapy%20in%20primary%20mediastinal%20large%20B%20cell%20lymphoma&amp;journal=Am.%20J.%20Hematol.&amp;doi=10.1002%2Fajh.24594&amp;volume=92&amp;pages=E11-E13&amp;publication_year=2017&amp;author=Yu%2CH">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="36."><p class="c-article-references__text" id="ref-CR36">Baird, J. H. et al. CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR-refractory large B-cell lymphoma. <i>Blood</i> <b>137</b>, 2321–2325 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1182/blood.2020009432" data-track-item_id="10.1182/blood.2020009432" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1182%2Fblood.2020009432" aria-label="Article reference 36" data-doi="10.1182/blood.2020009432">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXhtVeisb3L" aria-label="CAS reference 36">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33512414" aria-label="PubMed reference 36">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085484" aria-label="PubMed Central reference 36">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 36" href="http://scholar.google.com/scholar_lookup?&amp;title=CD22-directed%20CAR%20T-cell%20therapy%20induces%20complete%20remissions%20in%20CD19-directed%20CAR-refractory%20large%20B-cell%20lymphoma&amp;journal=Blood&amp;doi=10.1182%2Fblood.2020009432&amp;volume=137&amp;pages=2321-2325&amp;publication_year=2021&amp;author=Baird%2CJH">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="37."><p class="c-article-references__text" id="ref-CR37">Gardner, R. et al. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. <i>Blood</i> <b>127</b>, 2406–2410 (2016).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1182/blood-2015-08-665547" data-track-item_id="10.1182/blood-2015-08-665547" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1182%2Fblood-2015-08-665547" aria-label="Article reference 37" data-doi="10.1182/blood-2015-08-665547">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC28Xhs1ent7vN" aria-label="CAS reference 37">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26907630" aria-label="PubMed reference 37">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4874221" aria-label="PubMed Central reference 37">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 37" href="http://scholar.google.com/scholar_lookup?&amp;title=Acquisition%20of%20a%20CD19-negative%20myeloid%20phenotype%20allows%20immune%20escape%20of%20MLL-rearranged%20B-ALL%20from%20CD19%20CAR-T-cell%20therapy&amp;journal=Blood&amp;doi=10.1182%2Fblood-2015-08-665547&amp;volume=127&amp;pages=2406-2410&amp;publication_year=2016&amp;author=Gardner%2CR">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="38."><p class="c-article-references__text" id="ref-CR38">Jacoby, E. et al. CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity. <i>Nat. Commun.</i> <b>7</b>, 12320 (2016).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/ncomms12320" data-track-item_id="10.1038/ncomms12320" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fncomms12320" aria-label="Article reference 38" data-doi="10.1038/ncomms12320">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC28Xht12nsL3F" aria-label="CAS reference 38">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27460500" aria-label="PubMed reference 38">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4974466" aria-label="PubMed Central reference 38">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 38" href="http://scholar.google.com/scholar_lookup?&amp;title=CD19%20CAR%20immune%20pressure%20induces%20B-precursor%20acute%20lymphoblastic%20leukaemia%20lineage%20switch%20exposing%20inherent%20leukaemic%20plasticity&amp;journal=Nat.%20Commun.&amp;doi=10.1038%2Fncomms12320&amp;volume=7&amp;publication_year=2016&amp;author=Jacoby%2CE">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="39."><p class="c-article-references__text" id="ref-CR39">Schuster, S. J. et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. <i>N. Engl. J. Med.</i> <b>377</b>, 2545–2554 (2017).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1056/NEJMoa1708566" data-track-item_id="10.1056/NEJMoa1708566" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1056%2FNEJMoa1708566" aria-label="Article reference 39" data-doi="10.1056/NEJMoa1708566">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1MXhtVGjtbs%3D" aria-label="CAS reference 39">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29226764" aria-label="PubMed reference 39">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5788566" aria-label="PubMed Central reference 39">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 39" href="http://scholar.google.com/scholar_lookup?&amp;title=Chimeric%20antigen%20receptor%20T%20cells%20in%20refractory%20B-cell%20lymphomas&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1708566&amp;volume=377&amp;pages=2545-2554&amp;publication_year=2017&amp;author=Schuster%2CSJ">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="40."><p class="c-article-references__text" id="ref-CR40">Shalabi, H. et al. Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma. <i>Haematologica</i> <b>103</b>, e215–e218 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.3324/haematol.2017.183459" data-track-item_id="10.3324/haematol.2017.183459" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.3324%2Fhaematol.2017.183459" aria-label="Article reference 40" data-doi="10.3324/haematol.2017.183459">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1MXhsFCnt70%3D" aria-label="CAS reference 40">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29419431" aria-label="PubMed reference 40">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927974" aria-label="PubMed Central reference 40">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 40" href="http://scholar.google.com/scholar_lookup?&amp;title=Sequential%20loss%20of%20tumor%20surface%20antigens%20following%20chimeric%20antigen%20receptor%20T-cell%20therapies%20in%20diffuse%20large%20B-cell%20lymphoma&amp;journal=Haematologica&amp;doi=10.3324%2Fhaematol.2017.183459&amp;volume=103&amp;pages=e215-e218&amp;publication_year=2018&amp;author=Shalabi%2CH">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="41."><p class="c-article-references__text" id="ref-CR41">Ali, S. A. et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. <i>Blood</i> <b>128</b>, 1688–1700 (2016).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1182/blood-2016-04-711903" data-track-item_id="10.1182/blood-2016-04-711903" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1182%2Fblood-2016-04-711903" aria-label="Article reference 41" data-doi="10.1182/blood-2016-04-711903">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2sXhtlSitrk%3D" aria-label="CAS reference 41">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27412889" aria-label="PubMed reference 41">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5043125" aria-label="PubMed Central reference 41">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 41" href="http://scholar.google.com/scholar_lookup?&amp;title=T%20cells%20expressing%20an%20anti-B-cell%20maturation%20antigen%20chimeric%20antigen%20receptor%20cause%20remissions%20of%20multiple%20myeloma&amp;journal=Blood&amp;doi=10.1182%2Fblood-2016-04-711903&amp;volume=128&amp;pages=1688-1700&amp;publication_year=2016&amp;author=Ali%2CSA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="42."><p class="c-article-references__text" id="ref-CR42">Hegde, M. et al. Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape. <i>J. Clin. Invest.</i> <b>126</b>, 3036–3052 (2016).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1172/JCI83416" data-track-item_id="10.1172/JCI83416" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1172%2FJCI83416" aria-label="Article reference 42" data-doi="10.1172/JCI83416">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27427982" aria-label="PubMed reference 42">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966331" aria-label="PubMed Central reference 42">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 42" href="http://scholar.google.com/scholar_lookup?&amp;title=Tandem%20CAR%20T%20cells%20targeting%20HER2%20and%20IL13R%CE%B12%20mitigate%20tumor%20antigen%20escape&amp;journal=J.%20Clin.%20Invest.&amp;doi=10.1172%2FJCI83416&amp;volume=126&amp;pages=3036-3052&amp;publication_year=2016&amp;author=Hegde%2CM">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="43."><p class="c-article-references__text" id="ref-CR43">Bielamowicz, K. et al. Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma. <i>Neuro Oncol.</i> <b>20</b>, 506–518 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1093/neuonc/nox182" data-track-item_id="10.1093/neuonc/nox182" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1093%2Fneuonc%2Fnox182" aria-label="Article reference 43" data-doi="10.1093/neuonc/nox182">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1MXps1Ogtb8%3D" aria-label="CAS reference 43">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29016929" aria-label="PubMed reference 43">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 43" href="http://scholar.google.com/scholar_lookup?&amp;title=Trivalent%20CAR%20T%20cells%20overcome%20interpatient%20antigenic%20variability%20in%20glioblastoma&amp;journal=Neuro%20Oncol.&amp;doi=10.1093%2Fneuonc%2Fnox182&amp;volume=20&amp;pages=506-518&amp;publication_year=2018&amp;author=Bielamowicz%2CK">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="44."><p class="c-article-references__text" id="ref-CR44">Zah, E. et al. Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma. <i>Nat. Commun.</i> <b>11</b>, 2283 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/s41467-020-16160-5" data-track-item_id="10.1038/s41467-020-16160-5" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41467-020-16160-5" aria-label="Article reference 44" data-doi="10.1038/s41467-020-16160-5">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXptVertLo%3D" aria-label="CAS reference 44">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32385241" aria-label="PubMed reference 44">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7210316" aria-label="PubMed Central reference 44">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 44" href="http://scholar.google.com/scholar_lookup?&amp;title=Systematically%20optimized%20BCMA%2FCS1%20bispecific%20CAR-T%20cells%20robustly%20control%20heterogeneous%20multiple%20myeloma&amp;journal=Nat.%20Commun.&amp;doi=10.1038%2Fs41467-020-16160-5&amp;volume=11&amp;publication_year=2020&amp;author=Zah%2CE">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="45."><p class="c-article-references__text" id="ref-CR45">He, X. et al. Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia. <i>Blood</i> <b>135</b>, 713–723 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1182/blood.2019002779" data-track-item_id="10.1182/blood.2019002779" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1182%2Fblood.2019002779" aria-label="Article reference 45" data-doi="10.1182/blood.2019002779">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31951650" aria-label="PubMed reference 45">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7059518" aria-label="PubMed Central reference 45">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 45" href="http://scholar.google.com/scholar_lookup?&amp;title=Bispecific%20and%20split%20CAR%20T%20cells%20targeting%20CD13%20and%20TIM3%20eradicate%20acute%20myeloid%20leukemia&amp;journal=Blood&amp;doi=10.1182%2Fblood.2019002779&amp;volume=135&amp;pages=713-723&amp;publication_year=2020&amp;author=He%2CX">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="46."><p class="c-article-references__text" id="ref-CR46">Schmidts, A. et al. Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma. <i>Blood Adv.</i> <b>3</b>, 3248–3260 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1182/bloodadvances.2019000703" data-track-item_id="10.1182/bloodadvances.2019000703" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1182%2Fbloodadvances.2019000703" aria-label="Article reference 46" data-doi="10.1182/bloodadvances.2019000703">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31698455" aria-label="PubMed reference 46">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6855119" aria-label="PubMed Central reference 46">PubMed Central</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXitVGhsbfK" aria-label="CAS reference 46">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 46" href="http://scholar.google.com/scholar_lookup?&amp;title=Rational%20design%20of%20a%20trimeric%20APRIL-based%20CAR-binding%20domain%20enables%20efficient%20targeting%20of%20multiple%20myeloma&amp;journal=Blood%20Adv.&amp;doi=10.1182%2Fbloodadvances.2019000703&amp;volume=3&amp;pages=3248-3260&amp;publication_year=2019&amp;author=Schmidts%2CA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="47."><p class="c-article-references__text" id="ref-CR47">Shah, N. N. et al. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. <i>Nat. Med.</i> <b>26</b>, 1569–1575 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/s41591-020-1081-3" data-track-item_id="10.1038/s41591-020-1081-3" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41591-020-1081-3" aria-label="Article reference 47" data-doi="10.1038/s41591-020-1081-3">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXhvF2jtLfF" aria-label="CAS reference 47">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33020647" aria-label="PubMed reference 47">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 47" href="http://scholar.google.com/scholar_lookup?&amp;title=Bispecific%20anti-CD20%2C%20anti-CD19%20CAR%20T%20cells%20for%20relapsed%20B%20cell%20malignancies%3A%20a%20phase%201%20dose%20escalation%20and%20expansion%20trial&amp;journal=Nat.%20Med.&amp;doi=10.1038%2Fs41591-020-1081-3&amp;volume=26&amp;pages=1569-1575&amp;publication_year=2020&amp;author=Shah%2CNN">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="48."><p class="c-article-references__text" id="ref-CR48">Tong, C. et al. Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma. <i>Blood</i> <b>136</b>, 1632–1644 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32556247" aria-label="PubMed reference 48">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7596761" aria-label="PubMed Central reference 48">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 48" href="http://scholar.google.com/scholar_lookup?&amp;title=Optimized%20tandem%20CD19%2FCD20%20CAR-engineered%20T%20cells%20in%20refractory%2Frelapsed%20B-cell%20lymphoma&amp;journal=Blood&amp;volume=136&amp;pages=1632-1644&amp;publication_year=2020&amp;author=Tong%2CC">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="49."><p class="c-article-references__text" id="ref-CR49">Gardner, R. A. et al. Efficacy of SCRI-CAR19x22 T cell product in B-ALL and persistence of anti-CD22 activity. <i>J. Clin. Oncol.</i> <b>38</b>, 3035 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1200/JCO.2020.38.15_suppl.3035" data-track-item_id="10.1200/JCO.2020.38.15_suppl.3035" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1200%2FJCO.2020.38.15_suppl.3035" aria-label="Article reference 49" data-doi="10.1200/JCO.2020.38.15_suppl.3035">Article</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 49" href="http://scholar.google.com/scholar_lookup?&amp;title=Efficacy%20of%20SCRI-CAR19x22%20T%20cell%20product%20in%20B-ALL%20and%20persistence%20of%20anti-CD22%20activity&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.2020.38.15_suppl.3035&amp;volume=38&amp;publication_year=2020&amp;author=Gardner%2CRA">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="50."><p class="c-article-references__text" id="ref-CR50">Fousek, K. et al. CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression. <i>Leukemia</i> <b>35</b>, 75–89 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/s41375-020-0792-2" data-track-item_id="10.1038/s41375-020-0792-2" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41375-020-0792-2" aria-label="Article reference 50" data-doi="10.1038/s41375-020-0792-2">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXlvFOlsLc%3D" aria-label="CAS reference 50">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32205861" aria-label="PubMed reference 50">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 50" href="http://scholar.google.com/scholar_lookup?&amp;title=CAR%20T-cells%20that%20target%20acute%20B-lineage%20leukemia%20irrespective%20of%20CD19%20expression&amp;journal=Leukemia&amp;doi=10.1038%2Fs41375-020-0792-2&amp;volume=35&amp;pages=75-89&amp;publication_year=2021&amp;author=Fousek%2CK">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="51."><p class="c-article-references__text" id="ref-CR51">Dai, H. et al. Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. <i>J. Hematol. Oncol.</i> <b>13</b>, 30 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="noopener" data-track-label="10.1186/s13045-020-00856-8" data-track-item_id="10.1186/s13045-020-00856-8" data-track-value="article reference" data-track-action="article reference" href="https://link.springer.com/doi/10.1186/s13045-020-00856-8" aria-label="Article reference 51" data-doi="10.1186/s13045-020-00856-8">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32245502" aria-label="PubMed reference 51">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7126394" aria-label="PubMed Central reference 51">PubMed Central</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXmsVers7Y%3D" aria-label="CAS reference 51">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 51" href="http://scholar.google.com/scholar_lookup?&amp;title=Bispecific%20CAR-T%20cells%20targeting%20both%20CD19%20and%20CD22%20for%20therapy%20of%20adults%20with%20relapsed%20or%20refractory%20B%20cell%20acute%20lymphoblastic%20leukemia&amp;journal=J.%20Hematol.%20Oncol.&amp;doi=10.1186%2Fs13045-020-00856-8&amp;volume=13&amp;publication_year=2020&amp;author=Dai%2CH">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="52."><p class="c-article-references__text" id="ref-CR52">Amrolia, P. J. et al. Phase I study of AUTO3, a bicistronic chimeric antigen receptor (CAR) T-cell therapy targeting CD19 and CD22, in pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL): Amelia study. <i>Blood</i> <b>134</b>, 2620 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1182/blood-2019-123424" data-track-item_id="10.1182/blood-2019-123424" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1182%2Fblood-2019-123424" aria-label="Article reference 52" data-doi="10.1182/blood-2019-123424">Article</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 52" href="http://scholar.google.com/scholar_lookup?&amp;title=Phase%20I%20study%20of%20AUTO3%2C%20a%20bicistronic%20chimeric%20antigen%20receptor%20%28CAR%29%20T-cell%20therapy%20targeting%20CD19%20and%20CD22%2C%20in%20pediatric%20patients%20with%20relapsed%2Frefractory%20B-cell%20acute%20lymphoblastic%20leukemia%20%28r%2Fr%20B-ALL%29%3A%20Amelia%20study&amp;journal=Blood&amp;doi=10.1182%2Fblood-2019-123424&amp;volume=134&amp;publication_year=2019&amp;author=Amrolia%2CPJ">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="53."><p class="c-article-references__text" id="ref-CR53">Lynn, R. C. et al. c-Jun overexpression in CAR T cells induces exhaustion resistance. <i>Nature</i> <b>576</b>, 293–300 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/s41586-019-1805-z" data-track-item_id="10.1038/s41586-019-1805-z" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fs41586-019-1805-z" aria-label="Article reference 53" data-doi="10.1038/s41586-019-1805-z">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1MXitlWku7rF" aria-label="CAS reference 53">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31802004" aria-label="PubMed reference 53">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6944329" aria-label="PubMed Central reference 53">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 53" href="http://scholar.google.com/scholar_lookup?&amp;title=c-Jun%20overexpression%20in%20CAR%20T%20cells%20induces%20exhaustion%20resistance&amp;journal=Nature&amp;doi=10.1038%2Fs41586-019-1805-z&amp;volume=576&amp;pages=293-300&amp;publication_year=2019&amp;author=Lynn%2CRC">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="54."><p class="c-article-references__text" id="ref-CR54">Guest, R. D. et al. The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens. <i>J. Immunother.</i> <b>28</b>, 203–211 (2005).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1097/01.cji.0000161397.96582.59" data-track-item_id="10.1097/01.cji.0000161397.96582.59" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1097%2F01.cji.0000161397.96582.59" aria-label="Article reference 54" data-doi="10.1097/01.cji.0000161397.96582.59">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD2MXjtlKlurc%3D" aria-label="CAS reference 54">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=15838376" aria-label="PubMed reference 54">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 54" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20role%20of%20extracellular%20spacer%20regions%20in%20the%20optimal%20design%20of%20chimeric%20immune%20receptors%3A%20evaluation%20of%20four%20different%20scFvs%20and%20antigens&amp;journal=J.%20Immunother.&amp;doi=10.1097%2F01.cji.0000161397.96582.59&amp;volume=28&amp;pages=203-211&amp;publication_year=2005&amp;author=Guest%2CRD">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="55."><p class="c-article-references__text" id="ref-CR55">Hudecek, M. et al. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. <i>Clin. Cancer Res.</i> <b>19</b>, 3153–3164 (2013).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/1078-0432.CCR-13-0330" data-track-item_id="10.1158/1078-0432.CCR-13-0330" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F1078-0432.CCR-13-0330" aria-label="Article reference 55" data-doi="10.1158/1078-0432.CCR-13-0330">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC3sXpsVyns78%3D" aria-label="CAS reference 55">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23620405" aria-label="PubMed reference 55">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3804130" aria-label="PubMed Central reference 55">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 55" href="http://scholar.google.com/scholar_lookup?&amp;title=Receptor%20affinity%20and%20extracellular%20domain%20modifications%20affect%20tumor%20recognition%20by%20ROR1-specific%20chimeric%20antigen%20receptor%20T%20cells&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-13-0330&amp;volume=19&amp;pages=3153-3164&amp;publication_year=2013&amp;author=Hudecek%2CM">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="56."><p class="c-article-references__text" id="ref-CR56">Long, A. H., Haso, W. M. &amp; Orentas, R. J. Lessons learned from a highly-active CD22-specific chimeric antigen receptor. <i>Oncoimmunology</i> <b>2</b>, e23621 (2013).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.4161/onci.23621" data-track-item_id="10.4161/onci.23621" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.4161%2Fonci.23621" aria-label="Article reference 56" data-doi="10.4161/onci.23621">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23734316" aria-label="PubMed reference 56">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654586" aria-label="PubMed Central reference 56">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 56" href="http://scholar.google.com/scholar_lookup?&amp;title=Lessons%20learned%20from%20a%20highly-active%20CD22-specific%20chimeric%20antigen%20receptor&amp;journal=Oncoimmunology&amp;doi=10.4161%2Fonci.23621&amp;volume=2&amp;publication_year=2013&amp;author=Long%2CAH&amp;author=Haso%2CWM&amp;author=Orentas%2CRJ">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="57."><p class="c-article-references__text" id="ref-CR57">Li, D. et al. Persistent polyfunctional chimeric antigen receptor T cells that target glypican 3 eliminate orthotopic hepatocellular carcinomas in mice. <i>Gastroenterology</i> <b>158</b>, 2250–2265.e20 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1053/j.gastro.2020.02.011" data-track-item_id="10.1053/j.gastro.2020.02.011" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1053%2Fj.gastro.2020.02.011" aria-label="Article reference 57" data-doi="10.1053/j.gastro.2020.02.011">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXhtV2jtrfK" aria-label="CAS reference 57">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32060001" aria-label="PubMed reference 57">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 57" href="http://scholar.google.com/scholar_lookup?&amp;title=Persistent%20polyfunctional%20chimeric%20antigen%20receptor%20T%20cells%20that%20target%20glypican%203%20eliminate%20orthotopic%20hepatocellular%20carcinomas%20in%20mice&amp;journal=Gastroenterology&amp;doi=10.1053%2Fj.gastro.2020.02.011&amp;volume=158&amp;pages=2250-2265.e20&amp;publication_year=2020&amp;author=Li%2CD">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="58."><p class="c-article-references__text" id="ref-CR58">Singh, N. et al. Single chain variable fragment linker length regulates CAR biology and T cell efficacy. <i>Blood</i> <b>134</b>, 247 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1182/blood-2019-131024" data-track-item_id="10.1182/blood-2019-131024" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1182%2Fblood-2019-131024" aria-label="Article reference 58" data-doi="10.1182/blood-2019-131024">Article</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 58" href="http://scholar.google.com/scholar_lookup?&amp;title=Single%20chain%20variable%20fragment%20linker%20length%20regulates%20CAR%20biology%20and%20T%20cell%20efficacy&amp;journal=Blood&amp;doi=10.1182%2Fblood-2019-131024&amp;volume=134&amp;publication_year=2019&amp;author=Singh%2CN">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="59."><p class="c-article-references__text" id="ref-CR59">Grada, Z. et al. TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy. <i>Mol. Ther. Nucleic Acids</i> <b>2</b>, e105 (2013).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1038/mtna.2013.32" data-track-item_id="10.1038/mtna.2013.32" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1038%2Fmtna.2013.32" aria-label="Article reference 59" data-doi="10.1038/mtna.2013.32">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23839099" aria-label="PubMed reference 59">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3731887" aria-label="PubMed Central reference 59">PubMed Central</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC3sXht1elsb3I" aria-label="CAS reference 59">CAS</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 59" href="http://scholar.google.com/scholar_lookup?&amp;title=TanCAR%3A%20a%20novel%20bispecific%20chimeric%20antigen%20receptor%20for%20cancer%20immunotherapy&amp;journal=Mol.%20Ther.%20Nucleic%20Acids&amp;doi=10.1038%2Fmtna.2013.32&amp;volume=2&amp;publication_year=2013&amp;author=Grada%2CZ">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="60."><p class="c-article-references__text" id="ref-CR60">Zah, E., Lin, M.-Y., Silva-Benedict, A., Jensen, M. C. &amp; Chen, Y. Y. T cells expressing CD19/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells. <i>Cancer Immunol. Res.</i> <b>4</b>, 498–508 (2016).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1158/2326-6066.CIR-15-0231" data-track-item_id="10.1158/2326-6066.CIR-15-0231" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1158%2F2326-6066.CIR-15-0231" aria-label="Article reference 60" data-doi="10.1158/2326-6066.CIR-15-0231">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC28XptVersb8%3D" aria-label="CAS reference 60">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27059623" aria-label="PubMed reference 60">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4933590" aria-label="PubMed Central reference 60">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 60" href="http://scholar.google.com/scholar_lookup?&amp;title=T%20cells%20expressing%20CD19%2FCD20%20bispecific%20chimeric%20antigen%20receptors%20prevent%20antigen%20escape%20by%20malignant%20B%20cells&amp;journal=Cancer%20Immunol.%20Res.&amp;doi=10.1158%2F2326-6066.CIR-15-0231&amp;volume=4&amp;pages=498-508&amp;publication_year=2016&amp;author=Zah%2CE&amp;author=Lin%2CM-Y&amp;author=Silva-Benedict%2CA&amp;author=Jensen%2CMC&amp;author=Chen%2CYY">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="61."><p class="c-article-references__text" id="ref-CR61">Spiegel, J. Y. et al. Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy. <i>Blood</i> <b>137</b>, 1832–1835 (2021).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3MXotFansbw%3D" aria-label="CAS reference 61">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33156925" aria-label="PubMed reference 61">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555382" aria-label="PubMed Central reference 61">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 61" href="http://scholar.google.com/scholar_lookup?&amp;title=Outcomes%20of%20patients%20with%20large%20B-cell%20lymphoma%20progressing%20after%20axicabtagene%20ciloleucel%20therapy&amp;journal=Blood&amp;volume=137&amp;pages=1832-1835&amp;publication_year=2021&amp;author=Spiegel%2CJY">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="62."><p class="c-article-references__text" id="ref-CR62">Blaeschke, F. et al. Induction of a central memory and stem cell memory phenotype in functionally active CD4<sup>+</sup> and CD8<sup>+</sup> CAR T cells produced in an automated good manufacturing practice system for the treatment of CD19<sup>+</sup> acute lymphoblastic leukemia. <i>Cancer Immunol. Immunother.</i> <b>67</b>, 1053–1066 (2018).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="noopener" data-track-label="10.1007/s00262-018-2155-7" data-track-item_id="10.1007/s00262-018-2155-7" data-track-value="article reference" data-track-action="article reference" href="https://link.springer.com/doi/10.1007/s00262-018-2155-7" aria-label="Article reference 62" data-doi="10.1007/s00262-018-2155-7">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1cXmslKktrg%3D" aria-label="CAS reference 62">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29605883" aria-label="PubMed reference 62">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 62" href="http://scholar.google.com/scholar_lookup?&amp;title=Induction%20of%20a%20central%20memory%20and%20stem%20cell%20memory%20phenotype%20in%20functionally%20active%20CD4%2B%20and%20CD8%2B%20CAR%20T%20cells%20produced%20in%20an%20automated%20good%20manufacturing%20practice%20system%20for%20the%20treatment%20of%20CD19%2B%20acute%20lymphoblastic%20leukemia&amp;journal=Cancer%20Immunol.%20Immunother.&amp;doi=10.1007%2Fs00262-018-2155-7&amp;volume=67&amp;pages=1053-1066&amp;publication_year=2018&amp;author=Blaeschke%2CF">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="63."><p class="c-article-references__text" id="ref-CR63">Xu, Y. et al. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. <i>Blood</i> <b>123</b>, 3750–3759 (2014).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1182/blood-2014-01-552174" data-track-item_id="10.1182/blood-2014-01-552174" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1182%2Fblood-2014-01-552174" aria-label="Article reference 63" data-doi="10.1182/blood-2014-01-552174">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2cXhtVeltb3O" aria-label="CAS reference 63">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=24782509" aria-label="PubMed reference 63">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4055922" aria-label="PubMed Central reference 63">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 63" href="http://scholar.google.com/scholar_lookup?&amp;title=Closely%20related%20T-memory%20stem%20cells%20correlate%20with%20in%20vivo%20expansion%20of%20CAR.CD19-T%20cells%20and%20are%20preserved%20by%20IL-7%20and%20IL-15&amp;journal=Blood&amp;doi=10.1182%2Fblood-2014-01-552174&amp;volume=123&amp;pages=3750-3759&amp;publication_year=2014&amp;author=Xu%2CY">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="64."><p class="c-article-references__text" id="ref-CR64">Pasquini, M. C. et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. <i>Blood Adv.</i> <b>4</b>, 5414–5424 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1182/bloodadvances.2020003092" data-track-item_id="10.1182/bloodadvances.2020003092" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1182%2Fbloodadvances.2020003092" aria-label="Article reference 64" data-doi="10.1182/bloodadvances.2020003092">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXis12ksL3N" aria-label="CAS reference 64">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33147337" aria-label="PubMed reference 64">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7656920" aria-label="PubMed Central reference 64">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 64" href="http://scholar.google.com/scholar_lookup?&amp;title=Real-world%20evidence%20of%20tisagenlecleucel%20for%20pediatric%20acute%20lymphoblastic%20leukemia%20and%20non-Hodgkin%20lymphoma&amp;journal=Blood%20Adv.&amp;doi=10.1182%2Fbloodadvances.2020003092&amp;volume=4&amp;pages=5414-5424&amp;publication_year=2020&amp;author=Pasquini%2CMC">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="65."><p class="c-article-references__text" id="ref-CR65">Cheson, B. D. et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. <i>J. Clin. Oncol.</i> <b>32</b>, 3059–3067 (2014).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1200/JCO.2013.54.8800" data-track-item_id="10.1200/JCO.2013.54.8800" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1200%2FJCO.2013.54.8800" aria-label="Article reference 65" data-doi="10.1200/JCO.2013.54.8800">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25113753" aria-label="PubMed reference 65">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979083" aria-label="PubMed Central reference 65">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 65" href="http://scholar.google.com/scholar_lookup?&amp;title=Recommendations%20for%20initial%20evaluation%2C%20staging%2C%20and%20response%20assessment%20of%20Hodgkin%20and%20non-Hodgkin%20lymphoma%3A%20the%20Lugano%20classification&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.2013.54.8800&amp;volume=32&amp;pages=3059-3067&amp;publication_year=2014&amp;author=Cheson%2CBD">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="66."><p class="c-article-references__text" id="ref-CR66">Lee, D. W. et al. Current concepts in the diagnosis and management of cytokine release syndrome. <i>Blood</i> <b>124</b>, 188–195 (2014).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1182/blood-2014-05-552729" data-track-item_id="10.1182/blood-2014-05-552729" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1182%2Fblood-2014-05-552729" aria-label="Article reference 66" data-doi="10.1182/blood-2014-05-552729">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC2cXht1WktbrM" aria-label="CAS reference 66">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=24876563" aria-label="PubMed reference 66">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4093680" aria-label="PubMed Central reference 66">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 66" href="http://scholar.google.com/scholar_lookup?&amp;title=Current%20concepts%20in%20the%20diagnosis%20and%20management%20of%20cytokine%20release%20syndrome&amp;journal=Blood&amp;doi=10.1182%2Fblood-2014-05-552729&amp;volume=124&amp;pages=188-195&amp;publication_year=2014&amp;author=Lee%2CDW">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="67."><p class="c-article-references__text" id="ref-CR67">Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. <i>Biol. Blood Marrow Transplant.</i> <b>25</b>, 625–638 (2019).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1016/j.bbmt.2018.12.758" data-track-item_id="10.1016/j.bbmt.2018.12.758" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1016%2Fj.bbmt.2018.12.758" aria-label="Article reference 67" data-doi="10.1016/j.bbmt.2018.12.758">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC1MXhs1aksbw%3D" aria-label="CAS reference 67">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30592986" aria-label="PubMed reference 67">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 67" href="http://scholar.google.com/scholar_lookup?&amp;title=ASTCT%20consensus%20grading%20for%20cytokine%20release%20syndrome%20and%20neurologic%20toxicity%20associated%20with%20immune%20effector%20cells&amp;journal=Biol.%20Blood%20Marrow%20Transplant.&amp;doi=10.1016%2Fj.bbmt.2018.12.758&amp;volume=25&amp;pages=625-638&amp;publication_year=2019&amp;author=Lee%2CDW">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="68."><p class="c-article-references__text" id="ref-CR68">Marinelli, R. J. et al. The Stanford Tissue Microarray Database. <i>Nucleic Acids Res.</i> <b>36</b>, D871–D877 (2008).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1093/nar/gkm861" data-track-item_id="10.1093/nar/gkm861" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1093%2Fnar%2Fgkm861" aria-label="Article reference 68" data-doi="10.1093/nar/gkm861">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BD1cXhtVWit78%3D" aria-label="CAS reference 68">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=17989087" aria-label="PubMed reference 68">PubMed</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 68" href="http://scholar.google.com/scholar_lookup?&amp;title=The%20Stanford%20Tissue%20Microarray%20Database&amp;journal=Nucleic%20Acids%20Res.&amp;doi=10.1093%2Fnar%2Fgkm861&amp;volume=36&amp;pages=D871-D877&amp;publication_year=2008&amp;author=Marinelli%2CRJ">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="69."><p class="c-article-references__text" id="ref-CR69">Jena, B. et al. Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials. <i>PLoS ONE</i> <b>8</b>, e57838 (2013).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="nofollow noopener" data-track-label="10.1371/journal.pone.0057838" data-track-item_id="10.1371/journal.pone.0057838" data-track-value="article reference" data-track-action="article reference" href="https://doi.org/10.1371%2Fjournal.pone.0057838" aria-label="Article reference 69" data-doi="10.1371/journal.pone.0057838">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BC3sXkt1WhtLk%3D" aria-label="CAS reference 69">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23469246" aria-label="PubMed reference 69">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3585808" aria-label="PubMed Central reference 69">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 69" href="http://scholar.google.com/scholar_lookup?&amp;title=Chimeric%20antigen%20receptor%20%28CAR%29-specific%20monoclonal%20antibody%20to%20detect%20CD19-specific%20T%20cells%20in%20clinical%20trials&amp;journal=PLoS%20ONE&amp;doi=10.1371%2Fjournal.pone.0057838&amp;volume=8&amp;publication_year=2013&amp;author=Jena%2CB">
                    Google Scholar</a>&nbsp;
                </p></li><li class="c-article-references__item js-c-reading-companion-references-item" data-counter="70."><p class="c-article-references__text" id="ref-CR70">Ching, T. et al. Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma. <i>BMC Cancer</i> <b>20</b>, 612 (2020).</p><p class="c-article-references__links u-hide-print"><a data-track="click_references" rel="noopener" data-track-label="10.1186/s12885-020-07077-9" data-track-item_id="10.1186/s12885-020-07077-9" data-track-value="article reference" data-track-action="article reference" href="https://link.springer.com/doi/10.1186/s12885-020-07077-9" aria-label="Article reference 70" data-doi="10.1186/s12885-020-07077-9">Article</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="cas reference" data-track-action="cas reference" href="/articles/cas-redirect/1:CAS:528:DC%2BB3cXhtlKgt73E" aria-label="CAS reference 70">CAS</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed reference" data-track-action="pubmed reference" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32605647" aria-label="PubMed reference 70">PubMed</a>&nbsp;
    <a data-track="click_references" rel="nofollow noopener" data-track-label="link" data-track-item_id="link" data-track-value="pubmed central reference" data-track-action="pubmed central reference" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325652" aria-label="PubMed Central reference 70">PubMed Central</a>&nbsp;
    <a data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link" rel="nofollow noopener" aria-label="Google Scholar reference 70" href="http://scholar.google.com/scholar_lookup?&amp;title=Analytical%20evaluation%20of%20the%20clonoSEQ%20Assay%20for%20establishing%20measurable%20%28minimal%29%20residual%20disease%20in%20acute%20lymphoblastic%20leukemia%2C%20chronic%20lymphocytic%20leukemia%2C%20and%20multiple%20myeloma&amp;journal=BMC%20Cancer&amp;doi=10.1186%2Fs12885-020-07077-9&amp;volume=20&amp;publication_year=2020&amp;author=Ching%2CT">
                    Google Scholar</a>&nbsp;
                </p></li></ol><p class="c-article-references__download u-hide-print"><a data-track="click" data-track-action="download citation references" data-track-label="link" rel="nofollow" href="https://citation-needed.springer.com/v2/references/10.1038/s41591-021-01436-0?format=refman&amp;flavour=references">Download references<svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-download-medium"></use></svg></a></p></div></div></div></section></div><section data-title="Acknowledgements"><div class="c-article-section" id="Ack1-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Ack1">Acknowledgements</h2><div class="c-article-section__content" id="Ack1-content"><p>This work was supported by the California Institute for Regenerative Medicine (award no. CLIN2-10846 to C.L.M., principal investigator) and from the National Cancer Institute (grant no. 5P30CA124435 to C.L.M., grant no. U54 CA232568-01 to C.L.M and grant no. 2P01CA049605-29A1 to C.L.M. and D.M.). C.L.M. is a member of the Parker Institute for Cancer Immunotherapy, which supports the Stanford University Cancer Immunotherapy Program. The work was also supported by the Virginia and D.K. Ludwig Fund for Cancer Research (C.L.M.). This work received testing support from the National Gene Vector Biorepository, which is funded by the National Heart, Lung, and Blood Institute, National Institutes of Health (NIH), contract no. 75N92019D00018. J.Y.S. received support from a 2019–2020 American Society of Hematology Research Training Award for Fellows. K.L.D. is supported by the Maternal and Child Health Research Institute as the Anne T. and Robert M. Bass Endowed Faculty Scholar in Pediatric Cancer and Blood Diseases. R.G.M. is the Taube Distinguished Scholar for Pediatric Immunotherapy at Stanford University School of Medicine. We thank our contract manufacturing organizations: the Laboratory of Cell and Gene Medicine, Stanford University and Miltenyi Biotec. We thank Adaptive Biotechnologies for their collaboration in measuring cell-free MRD and Becton Dickinson for assistance in developing the antigen quantitation assays. We thank IsoPlexis for their collaboration in performing the single-cell cytokine analysis on manufactured CAR T products in Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig4">4j</a>. Figs. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig2">2</a> and <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig4">4</a> and Extended Data Fig. <a data-track="click" data-track-label="link" data-track-action="figure anchor" href="/articles/s41591-021-01436-0#Fig5">1</a> were created using BioRender.com.</p></div></div></section><section aria-labelledby="author-information" data-title="Author information"><div class="c-article-section" id="author-information-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="author-information">Author information</h2><div class="c-article-section__content" id="author-information-content"><span class="c-article-author-information__subtitle u-visually-hidden" id="author-notes">Author notes</span><ol class="c-article-author-information__list"><li class="c-article-author-information__item" id="nAff12"><p class="c-article-author-information__authors-list">Rachel Lynn</p><p class="js-present-address">Present address: Lyell Immunopharma, San Francisco, CA, USA</p></li><li class="c-article-author-information__item" id="na1"><p>These authors contributed equally; Jay Y. Spiegel, Shabnum Patel, Lori Muffly.</p></li><li class="c-article-author-information__item" id="na2"><p>These authors jointly supervised this work: Steven Feldman, Crystal Mackall, David B. Miklos.</p></li></ol><h3 class="c-article__sub-heading" id="affiliations">Authors and Affiliations</h3><ol class="c-article-author-affiliation__list"><li id="Aff1"><p class="c-article-author-affiliation__address">Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University School of Medicine, Stanford, CA, USA</p><p class="c-article-author-affiliation__authors-list">Jay Y. Spiegel,&nbsp;Lori Muffly,&nbsp;John H. Baird,&nbsp;Matthew J. Frank,&nbsp;Parveen Shiraz,&nbsp;Juliana Craig,&nbsp;Maria Iglesias,&nbsp;Sally Arai,&nbsp;Laura Johnston,&nbsp;Robert Lowsky,&nbsp;Everett Meyer,&nbsp;Robert S. Negrin,&nbsp;Andrew R. Rezvani,&nbsp;Surbhi Sidana,&nbsp;Judith Shizuru,&nbsp;Wen-Kai Weng&nbsp;&amp;&nbsp;David B. Miklos</p></li><li id="Aff2"><p class="c-article-author-affiliation__address">Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA</p><p class="c-article-author-affiliation__authors-list">Shabnum Patel,&nbsp;Lori Muffly,&nbsp;Bita Sahaf,&nbsp;Harshini Chinnasamy,&nbsp;Zach Ehlinger,&nbsp;Warren Reynolds,&nbsp;Rachel Lynn,&nbsp;Nikolaos Gkitsas,&nbsp;Robbie G. Majzner,&nbsp;Liora Schultz,&nbsp;Sneha Ramakrishna,&nbsp;Kara L. Davis,&nbsp;Katherine A. Kong,&nbsp;Steven Feldman,&nbsp;Crystal L. Mackall&nbsp;&amp;&nbsp;David B. Miklos</p></li><li id="Aff3"><p class="c-article-author-affiliation__address">Division of Hematology/Oncology, Loyola University Medical Center, Chicago, IL, USA</p><p class="c-article-author-affiliation__authors-list">Nasheed M. Hossain</p></li><li id="Aff4"><p class="c-article-author-affiliation__address">Department of Clinical Pathology, Stanford University School of Medicine, Stanford, CA, USA</p><p class="c-article-author-affiliation__authors-list">Jean Oak,&nbsp;Sheren Younes,&nbsp;Yasodha Natkunam,&nbsp;Michael G. Ozawa&nbsp;&amp;&nbsp;Eric Yang</p></li><li id="Aff5"><p class="c-article-author-affiliation__address">Department of Biomedical Data Science, Stanford University School of Medicine, Stanford, CA, USA</p><p class="c-article-author-affiliation__authors-list">John Tamaresis</p></li><li id="Aff6"><p class="c-article-author-affiliation__address">Department of Pediatrics–Hematology/Oncology, Stanford University School of Medicine, Stanford, CA, USA</p><p class="c-article-author-affiliation__authors-list">Maria Caterina Rotiroti,&nbsp;Robbie G. Majzner,&nbsp;Liora Schultz,&nbsp;Sneha Ramakrishna,&nbsp;Kara L. Davis&nbsp;&amp;&nbsp;Crystal L. Mackall</p></li><li id="Aff7"><p class="c-article-author-affiliation__address">Adaptive Biotechnologies, Seattle, WA, USA</p><p class="c-article-author-affiliation__authors-list">Chelsea Mullins,&nbsp;Allison Jacob&nbsp;&amp;&nbsp;Ilan Kirsch</p></li><li id="Aff8"><p class="c-article-author-affiliation__address">IsoPlexis, Brantford, CT, USA</p><p class="c-article-author-affiliation__authors-list">Magali Bazzano,&nbsp;Jing Zhou&nbsp;&amp;&nbsp;Sean Mackay</p></li><li id="Aff9"><p class="c-article-author-affiliation__address">BD Biosciences, San Jose, CA, USA</p><p class="c-article-author-affiliation__authors-list">Scott J. Bornheimer</p></li><li id="Aff10"><p class="c-article-author-affiliation__address">Pediatric Oncology Branch Center for Cancer Research, National Institutes of Health, Bethesda, MD, USA</p><p class="c-article-author-affiliation__authors-list">Liora Schultz,&nbsp;Nirali N. Shah,&nbsp;Haiying Qin&nbsp;&amp;&nbsp;Terry Fry</p></li><li id="Aff11"><p class="c-article-author-affiliation__address">Department of Pediatrics–Hematology/Oncology, University of Colorado Anschutz and Children’s Hospital Colorado, Denver, CO, USA</p><p class="c-article-author-affiliation__authors-list">Terry Fry</p></li></ol><div class="u-js-hide u-hide-print" data-test="author-info"><span class="c-article__sub-heading">Authors</span><ol class="c-article-authors-search u-list-reset"><li id="auth-Jay_Y_-Spiegel-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Jay Y. Spiegel</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Jay%20Y.%20Spiegel" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Jay%20Y.%20Spiegel" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Jay%20Y.%20Spiegel%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Shabnum-Patel-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Shabnum Patel</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Shabnum%20Patel" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Shabnum%20Patel" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Shabnum%20Patel%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Lori-Muffly-Aff1-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Lori Muffly</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Lori%20Muffly" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Lori%20Muffly" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Lori%20Muffly%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Nasheed_M_-Hossain-Aff3"><span class="c-article-authors-search__title u-h3 js-search-name">Nasheed M. Hossain</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Nasheed%20M.%20Hossain" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Nasheed%20M.%20Hossain" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Nasheed%20M.%20Hossain%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Jean-Oak-Aff4"><span class="c-article-authors-search__title u-h3 js-search-name">Jean Oak</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Jean%20Oak" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Jean%20Oak" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Jean%20Oak%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-John_H_-Baird-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">John H. Baird</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=John%20H.%20Baird" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=John%20H.%20Baird" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22John%20H.%20Baird%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Matthew_J_-Frank-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Matthew J. Frank</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Matthew%20J.%20Frank" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Matthew%20J.%20Frank" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Matthew%20J.%20Frank%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Parveen-Shiraz-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Parveen Shiraz</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Parveen%20Shiraz" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Parveen%20Shiraz" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Parveen%20Shiraz%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Bita-Sahaf-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Bita Sahaf</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Bita%20Sahaf" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Bita%20Sahaf" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Bita%20Sahaf%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Juliana-Craig-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Juliana Craig</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Juliana%20Craig" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Juliana%20Craig" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Juliana%20Craig%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Maria-Iglesias-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Maria Iglesias</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Maria%20Iglesias" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Maria%20Iglesias" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Maria%20Iglesias%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Sheren-Younes-Aff4"><span class="c-article-authors-search__title u-h3 js-search-name">Sheren Younes</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Sheren%20Younes" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Sheren%20Younes" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Sheren%20Younes%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Yasodha-Natkunam-Aff4"><span class="c-article-authors-search__title u-h3 js-search-name">Yasodha Natkunam</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Yasodha%20Natkunam" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Yasodha%20Natkunam" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Yasodha%20Natkunam%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Michael_G_-Ozawa-Aff4"><span class="c-article-authors-search__title u-h3 js-search-name">Michael G. Ozawa</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Michael%20G.%20Ozawa" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Michael%20G.%20Ozawa" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Michael%20G.%20Ozawa%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Eric-Yang-Aff4"><span class="c-article-authors-search__title u-h3 js-search-name">Eric Yang</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Eric%20Yang" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Eric%20Yang" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Eric%20Yang%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-John-Tamaresis-Aff5"><span class="c-article-authors-search__title u-h3 js-search-name">John Tamaresis</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=John%20Tamaresis" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=John%20Tamaresis" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22John%20Tamaresis%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Harshini-Chinnasamy-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Harshini Chinnasamy</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Harshini%20Chinnasamy" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Harshini%20Chinnasamy" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Harshini%20Chinnasamy%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Zach-Ehlinger-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Zach Ehlinger</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Zach%20Ehlinger" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Zach%20Ehlinger" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Zach%20Ehlinger%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Warren-Reynolds-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Warren Reynolds</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Warren%20Reynolds" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Warren%20Reynolds" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Warren%20Reynolds%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Rachel-Lynn-Aff2-Aff12"><span class="c-article-authors-search__title u-h3 js-search-name">Rachel Lynn</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Rachel%20Lynn" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Rachel%20Lynn" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Rachel%20Lynn%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Maria_Caterina-Rotiroti-Aff6"><span class="c-article-authors-search__title u-h3 js-search-name">Maria Caterina Rotiroti</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Maria%20Caterina%20Rotiroti" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Maria%20Caterina%20Rotiroti" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Maria%20Caterina%20Rotiroti%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Nikolaos-Gkitsas-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Nikolaos Gkitsas</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Nikolaos%20Gkitsas" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Nikolaos%20Gkitsas" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Nikolaos%20Gkitsas%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Sally-Arai-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Sally Arai</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Sally%20Arai" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Sally%20Arai" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Sally%20Arai%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Laura-Johnston-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Laura Johnston</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Laura%20Johnston" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Laura%20Johnston" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Laura%20Johnston%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Robert-Lowsky-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Robert Lowsky</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Robert%20Lowsky" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Robert%20Lowsky" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Robert%20Lowsky%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Robbie_G_-Majzner-Aff2-Aff6"><span class="c-article-authors-search__title u-h3 js-search-name">Robbie G. Majzner</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Robbie%20G.%20Majzner" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Robbie%20G.%20Majzner" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Robbie%20G.%20Majzner%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Everett-Meyer-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Everett Meyer</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Everett%20Meyer" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Everett%20Meyer" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Everett%20Meyer%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Robert_S_-Negrin-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Robert S. Negrin</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Robert%20S.%20Negrin" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Robert%20S.%20Negrin" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Robert%20S.%20Negrin%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Andrew_R_-Rezvani-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Andrew R. Rezvani</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Andrew%20R.%20Rezvani" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Andrew%20R.%20Rezvani" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Andrew%20R.%20Rezvani%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Surbhi-Sidana-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Surbhi Sidana</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Surbhi%20Sidana" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Surbhi%20Sidana" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Surbhi%20Sidana%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Judith-Shizuru-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Judith Shizuru</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Judith%20Shizuru" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Judith%20Shizuru" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Judith%20Shizuru%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Wen_Kai-Weng-Aff1"><span class="c-article-authors-search__title u-h3 js-search-name">Wen-Kai Weng</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Wen-Kai%20Weng" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Wen-Kai%20Weng" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Wen-Kai%20Weng%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Chelsea-Mullins-Aff7"><span class="c-article-authors-search__title u-h3 js-search-name">Chelsea Mullins</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Chelsea%20Mullins" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Chelsea%20Mullins" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Chelsea%20Mullins%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Allison-Jacob-Aff7"><span class="c-article-authors-search__title u-h3 js-search-name">Allison Jacob</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Allison%20Jacob" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Allison%20Jacob" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Allison%20Jacob%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Ilan-Kirsch-Aff7"><span class="c-article-authors-search__title u-h3 js-search-name">Ilan Kirsch</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Ilan%20Kirsch" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Ilan%20Kirsch" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Ilan%20Kirsch%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Magali-Bazzano-Aff8"><span class="c-article-authors-search__title u-h3 js-search-name">Magali Bazzano</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Magali%20Bazzano" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Magali%20Bazzano" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Magali%20Bazzano%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Jing-Zhou-Aff8"><span class="c-article-authors-search__title u-h3 js-search-name">Jing Zhou</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Jing%20Zhou" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Jing%20Zhou" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Jing%20Zhou%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Sean-Mackay-Aff8"><span class="c-article-authors-search__title u-h3 js-search-name">Sean Mackay</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Sean%20Mackay" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Sean%20Mackay" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Sean%20Mackay%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Scott_J_-Bornheimer-Aff9"><span class="c-article-authors-search__title u-h3 js-search-name">Scott J. Bornheimer</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Scott%20J.%20Bornheimer" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Scott%20J.%20Bornheimer" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Scott%20J.%20Bornheimer%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Liora-Schultz-Aff2-Aff6-Aff10"><span class="c-article-authors-search__title u-h3 js-search-name">Liora Schultz</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Liora%20Schultz" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Liora%20Schultz" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Liora%20Schultz%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Sneha-Ramakrishna-Aff2-Aff6"><span class="c-article-authors-search__title u-h3 js-search-name">Sneha Ramakrishna</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Sneha%20Ramakrishna" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Sneha%20Ramakrishna" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Sneha%20Ramakrishna%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Kara_L_-Davis-Aff2-Aff6"><span class="c-article-authors-search__title u-h3 js-search-name">Kara L. Davis</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Kara%20L.%20Davis" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Kara%20L.%20Davis" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Kara%20L.%20Davis%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Katherine_A_-Kong-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Katherine A. Kong</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Katherine%20A.%20Kong" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Katherine%20A.%20Kong" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Katherine%20A.%20Kong%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Nirali_N_-Shah-Aff10"><span class="c-article-authors-search__title u-h3 js-search-name">Nirali N. Shah</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Nirali%20N.%20Shah" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Nirali%20N.%20Shah" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Nirali%20N.%20Shah%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Haiying-Qin-Aff10"><span class="c-article-authors-search__title u-h3 js-search-name">Haiying Qin</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Haiying%20Qin" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Haiying%20Qin" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Haiying%20Qin%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Terry-Fry-Aff10-Aff11"><span class="c-article-authors-search__title u-h3 js-search-name">Terry Fry</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Terry%20Fry" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Terry%20Fry" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Terry%20Fry%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Steven-Feldman-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">Steven Feldman</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Steven%20Feldman" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Steven%20Feldman" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Steven%20Feldman%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-Crystal_L_-Mackall-Aff2-Aff6"><span class="c-article-authors-search__title u-h3 js-search-name">Crystal L. Mackall</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=Crystal%20L.%20Mackall" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=Crystal%20L.%20Mackall" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22Crystal%20L.%20Mackall%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li><li id="auth-David_B_-Miklos-Aff1-Aff2"><span class="c-article-authors-search__title u-h3 js-search-name">David B. Miklos</span><div class="c-article-authors-search__list"><div class="c-article-authors-search__item c-article-authors-search__list-item--left"><a href="/search?author=David%20B.%20Miklos" class="c-article-button" data-track="click" data-track-action="author link - publication" data-track-label="link" rel="nofollow">View author publications</a></div><div class="c-article-authors-search__item c-article-authors-search__list-item--right"><p class="search-in-title-js c-article-authors-search__text"><span class="c-article-authors-search__links-text">You can also search for this author in</span><span class="c-article-identifiers"><a class="c-article-identifiers__item" href="https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&amp;term=David%20B.%20Miklos" data-track="click" data-track-action="author link - pubmed" data-track-label="link" rel="nofollow">PubMed</a><span class="u-hide">&nbsp;</span><a class="c-article-identifiers__item" href="https://scholar.google.co.uk/scholar?as_q=&amp;num=10&amp;btnG=Search+Scholar&amp;as_epq=&amp;as_oq=&amp;as_eq=&amp;as_occt=any&amp;as_sauthors=%22David%20B.%20Miklos%22&amp;as_publication=&amp;as_ylo=&amp;as_yhi=&amp;as_allsubj=all&amp;hl=en" data-track="click" data-track-action="author link - scholar" data-track-label="link" rel="nofollow">Google Scholar</a></span></p></div></div></li></ol></div><h3 class="c-article__sub-heading" id="contributions">Contributions</h3><p>C.L.M. and D.B.M. conceived and designed the study. D.B.M., S.F., J.Y.S., S.P., L.M., J.H.B., N.M.H., J.O., B.S., J.C., M.I., S.Y., M.G.O., E.Y., Z.E., W.R., R. Lynn and H.C. collected and assembled the data. C.L.M., D.B.M., S.F., J.Y.S., S.P., L.M., J.H.B., M.F., B.S., S.Y., Y.N., J.T., I.K., C.M. and A.J. analyzed and interpreted the data. C.L.M., D.B.M., S.F., J.Y.S., S.P., L.M., J.H.B., N.M.H., J.O., M.F., P.S., B.S., R.G.M., S.A., L.J., R. Lowsky, E.M., R.S.N., A.R.R., S.S., J.S., W.K.W., L.S., S.R., K.L.D., K.A.K., N.N.S., H.Q. and T.F. wrote the manuscript.</p><h3 class="c-article__sub-heading" id="corresponding-author">Corresponding authors</h3><p id="corresponding-author-list">Correspondence to
                <a id="corresp-c1" href="mailto:cmackall@stanford.edu">Crystal L. Mackall</a> or <a id="corresp-c2" href="mailto:dmiklos@stanford.edu">David B. Miklos</a>.</p></div></div></section><section data-title="Ethics declarations"><div class="c-article-section" id="ethics-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="ethics">Ethics declarations</h2><div class="c-article-section__content" id="ethics-content">
              
                <h3 class="c-article__sub-heading" id="FPar3">Competing interests</h3>
                <p>C.L.M. is an inventor on a patent application for CD19/22-CAR T cells and holds several patent applications in the area of CAR T cell immunotherapy. C.L.M. is a founder of, holds equity in and receives consulting fees from Lyell Immunopharma and Syncopation Life Sciences. She has also received consulting fees from NeoImmune Tech, Nektar Therapeutics, Immatics, GlaxoSmithKline and Apricity Health and royalties from Juno Therapeutics for the CD22-CAR. She holds equity in Vor Biopharma and Apricity Health. D.B.M. has consulted for Kite-Gilead, Juno Therapeutics-Celgene-Bristol Myers Squibb, Novartis and Adaptive Biotechnologies. He has received research for Kite-Gilead and Adaptive Biotechnologies. S.F. has consulted for Lonza PerMed, Gradalis, Obsidian and Samsara Biocapital. L.M. has consulted for Amgen, Pfizer and Kite-Gilead. She has received research funding from Adaptive Biotechnologies, Astellas Pharma, Servier and Baxalta. S.P. has consulted for Cellares. R.S.N. has consulted for Kuur Therapeutics, who are developing CAR invariant NKT cells, and CoImmune, who are developing CAR cytokine-induced killer cells. A.R.R. has received research support from Pharmacyclics and performed a one-time ad hoc scientific advisory board role for Nohla and Koledio. He is a medical expert witness for the U.S. Department of Justice; his brother works for Johnson &amp; Johnson. H.Q. is an inventor on a patent application for CD19/22-CAR T cells and holds several patent applications in the area of CAR T cell immunotherapy. She has also received royalties from Lentigen via the NIH for the thymic stromal lymphopoietin receptor-CARs. I.K., C.M. and A.J. are full-time employees and shareholders of Adaptive Biotechnologies. R.G.M. holds several patent applications in the area of CAR T cell immunotherapy and is a consultant for Lyell Immunopharma, Xyphos Biosciences, GammaDelta Therapeutics, Zai Lab and Aptorum Group. The other authors declare no conflicts of interest.</p>
              
            </div></div></section><section data-title="Additional information"><div class="c-article-section" id="additional-information-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="additional-information">Additional information</h2><div class="c-article-section__content" id="additional-information-content"><p><b>Peer review information</b> <i>Nature Medicine</i> thanks Katayoun Rezvani, Saar Gill and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Saheli Sadanand was the primary editor on this article and managed its editorial process and peer review in collaboration with the rest of the editorial team.</p><p><b>Publisher’s note</b> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></div></div></section><section data-title="Extended data"><div class="c-article-section" id="Sec37-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec37">Extended data</h2><div class="c-article-section__content" id="Sec37-content"><div data-test="supplementary-info"><div id="figshareContainer" class="c-article-figshare-container" data-test="figshare-container"></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig5"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 1 model-based prediction of rel" href="/articles/s41591-021-01436-0/figures/5" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_Fig5_ESM.jpg">Extended Data Fig. 1 Model-based prediction of relapse after axi-cel.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Estimated risk of relapse for a given pre-treatment CD19 antigen density based on a fitted penalized logistic regression model.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig6"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 2 evaluation of pre-axi-cel ant" href="/articles/s41591-021-01436-0/figures/6" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_Fig6_ESM.jpg">Extended Data Fig. 2 Evaluation of pre-axi-cel antigen density.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>CD19 IHC H-score and antigen density by quantitative flow cytometry in 15 patients prior to axi-cel. Spearman correlation for these values shown in 1G.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig7"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 3 consort diagram." href="/articles/s41591-021-01436-0/figures/7" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_Fig7_ESM.jpg">Extended Data Fig. 3 CONSORT Diagram.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Consort diagram of CD19-22-CD8.BB.z clinical trial.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig8"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 4 cd19/22 car t manufacturing f" href="/articles/s41591-021-01436-0/figures/8" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_Fig8_ESM.jpg">Extended Data Fig. 4 CD19/22 CAR T manufacturing flowchart and product breakdown by culture days, manufacturing matrix, dose level, and disease.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p><b>a</b>, Manufacturing schematic detailing difference in timing of TransAct washout between the Old and New Matrix. <b>b</b>, Table of Infusion Product Characteristics, categorized by the number of culture days. <b>c</b>, Table of Infusion Product Characteristics, categorized by disease cohort. <b>d</b>, Significant difference in product expansion between the old and new matrix at harvest (p &lt; 0.0001, t-test, two tailed). Box plot center line corresponds to the median; hinges correspond to the 25<sup>th</sup> and 75<sup>th</sup> percentiles with the whiskers signifying minimum and maximum values <b>e</b>, No significant difference in vector copy number based on manufacturing matrix. <b>f</b>,<b>g</b>, Significant decreases in CD39+ (p = 0.012, t-test, two-tailed) and PD1+ (p = 0.0003, t-test, two-tailed) CAR T cells manufactured using the new matrix versus the old matrix. <b>h</b>, Significant increases in CD39+ and PD1+ and a significant decrease in CD57+ expression on CD3+ cells from CD4/8 enriched to final CAR T product (p &lt; 0.0001, t-test, two-tailed; for all 3 tests). No difference in LAG3 expression.</p><p><a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01436-0#MOESM1">Source data</a></p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig9"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 5 adverse events summary." href="/articles/s41591-021-01436-0/figures/9" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_Fig9_ESM.jpg">Extended Data Fig. 5 Adverse events summary.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Adverse events with a Grade≥3 incidence rate of 5% or higher were included. CAR specific toxicities were included regardless of incidence.</p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig10"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 6 lbcl disease monitoring by ct" href="/articles/s41591-021-01436-0/figures/10" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_Fig10_ESM.jpg">Extended Data Fig. 6 LBCL disease monitoring by ctDNA.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Patients with baseline tumor sample were assessed for a dominant clone to allow for disease tracking by cell free tumor DNA in the peripheral blood. Measurements were performed at pre-specified timepoints from pre-infusion to the time of disease progression.</p><p><a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01436-0#MOESM1">Source data</a></p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig11"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 7 b-all disease monitoring by c" href="/articles/s41591-021-01436-0/figures/11" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_Fig11_ESM.jpg">Extended Data Fig. 7 B-ALL disease monitoring by ClonoSeq.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Patients with baseline tumor sample were assessed for a dominant clone to allow for disease tracking by cell free tumor DNA in the peripheral blood. Measurements were performed at pre-specified timepoints from pre-infusion to the time of disease progression.</p><p><a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01436-0#MOESM1">Source data</a></p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig12"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 8 in vivo car-t cell expansion " href="/articles/s41591-021-01436-0/figures/12" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_Fig12_ESM.jpg">Extended Data Fig. 8 In vivo CAR-T cell expansion is CD8 predominant and relates to exhaustion phenotype of CAR-T products.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p><b>a</b>,<b>b</b> Peak CD19-22.BBZ cells as measured by flow cytometry compared by (<b>a</b>) disease type and (<b>b</b>) dose level. No significant difference observed. <b>c</b>,<b>d</b>. CD19-22.BB.z AUC was measured by the trapezoidal method from infusion until Day 60 post infusion.Grades 2-4 (<b>d</b>) CRS (p = 0.04) and (<b>c</b>) neurotoxicity (p = 0.03) associated with higher CD19-22.BBZ AUC. Comparisons by Wilcoxon rank sum. <b>e</b>, Area under the curve calculated by trapezoidal integration of CD4 and CD8 CD19-22.BB.z cells from infusion to 2 months post infusion. The AUC for CD8 was greater than that of CD4 (p = 1.2 × 10<sup>−5</sup>) <b>f</b>, Peak expansion of CD4 and CD8 CD19-22.BB.z-CAR T cells measured by flow cytometry. Peak CD8 CD19-22.BB.z-CAR was greater than that of CD4 (p = 6.0 × 10<sup>−</sup><sup>6</sup>). Comparison in <b>e</b> and <b>f</b> performed by paired Wilcoxon signed rank test. <b>g</b>, Change in the CD4:CD8 ratio from CD19-22.BB.z infusion product to peak expansion, shows the outgrowth of CD4 cells during manufacturing is not seen in the patients at time of peak CAR expansion, where CD8 CAR T+ cells are more abundant. N = 38 patients for a-g. <b>h</b>,<b>i</b> Significantly higher percentage of CD4 CAR T cells in the infusion product express CD39 (p = 5.2 × 10<sup>−8</sup>) and PD-1 (p = 1.2 × 10<sup>−</sup><sup>10</sup>) compared to CD8 CAR-T cells (Wilcoxon signed rank) (n = 34 patients). Gating on CD3+ CAR+ cells. Box plot center line corresponds to the median; hinges correspond to the 25<sup>th</sup> and 75<sup>th</sup> percentiles with the whiskers extending to the smallest or largest value at most 1.5 x IQR from the hinge. All tests were two-sided and not adjusted for multiple comparisons.</p><p><a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01436-0#MOESM1">Source data</a></p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig13"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 9 site density change after cd1" href="/articles/s41591-021-01436-0/figures/13" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_Fig13_ESM.jpg">Extended Data Fig. 9 Site density change after CD19-22.BB.z.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p><b>a</b>, Waterfall plot of assessment of CD19 for patients with LBCL by IHC H-score pre-CD19-22.BB.z and post progression. Cutoff for CD19 positivity was 150. <b>b</b>, Waterfall plot of assessment of CD22 in patients with LBCL by IHC H-score pre-CD19-22-CD8.BB.z and post progression (n = 11 patients for a-b). Cutoff for CD22 positivity was 150.</p><p><a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01436-0#MOESM1">Source data</a></p></div></div><div class="c-article-supplementary__item js-c-reading-companion-figures-item" data-test="supp-item" id="Fig14"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="extended data fig. 10 functional assessment of cd1" href="/articles/s41591-021-01436-0/figures/14" data-supp-info-image="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_Fig14_ESM.jpg">Extended Data Fig. 10 Functional assessment of CD19-22 scFvs by Incucyte and comparison of MFI, transduction efficiency and VCN of CD19-22.BB.z-CAR and CD22-BB.z.CAR.</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p><b>a</b>, Incucyte shows tumor killing after co-culture with CD19-22, CD19, CD22, or Mock T cells, is mediated successfully through either the CD19 scFv or CD22 scFv (n = 1 donor, technical triplicates) <b>b</b>, Mean fluorescence intensity measured via a fluorescently tagged CD22 molecule.<b>c</b>, CAR transduction efficiency and vector copy number. For b-c, n = 5 CD22-BB.z products, 11 CD19-22.BB.z.</p><p><a data-track="click" data-track-label="link" data-track-action="supplementary material anchor" href="/articles/s41591-021-01436-0#MOESM1">Source data</a></p></div></div></div></div></div></section><section data-title="Supplementary information"><div class="c-article-section" id="Sec38-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec38">Supplementary information</h2><div class="c-article-section__content" id="Sec38-content"><div data-test="supplementary-info"><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM1"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="supplementary information" href="https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_MOESM1_ESM.pdf" data-supp-info-image="">Supplementary Information</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Supplementary Tables 1–6, Supplementary Figs. 1–4 and CD19-22.BB.z Trial Protocol.</p></div></div><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM2"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="reporting summary" href="https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_MOESM2_ESM.pdf" data-supp-info-image="">Reporting Summary</a></h3></div></div></div></div></section><section data-title="Source data"><div class="c-article-section" id="Sec39-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="Sec39">Source data</h2><div class="c-article-section__content" id="Sec39-content"><div data-test="supplementary-info"><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM3"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="source data fig. 1" href="https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_MOESM3_ESM.xlsx" data-supp-info-image="">Source Data Fig. 1</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Statistical source data.</p></div></div><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM4"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="source data fig. 2" href="https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_MOESM4_ESM.xlsx" data-supp-info-image="">Source Data Fig. 2</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Statistical source data.</p></div></div><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM5"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="source data fig. 3" href="https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_MOESM5_ESM.xlsx" data-supp-info-image="">Source Data Fig. 3</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Statistical source data.</p></div></div><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM6"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="source data fig. 4" href="https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_MOESM6_ESM.xlsx" data-supp-info-image="">Source Data Fig. 4</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Statistical source data.</p></div></div><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM7"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="source data extended data fig. 4" href="https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_MOESM7_ESM.xlsx" data-supp-info-image="">Source Data Extended Data Fig. 4</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Statistical source data.</p></div></div><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM8"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="source data extended data fig. 6" href="https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_MOESM8_ESM.xlsx" data-supp-info-image="">Source Data Extended Data Fig. 6</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Statistical source data.</p></div></div><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM9"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="source data extended data fig. 7" href="https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_MOESM9_ESM.xlsx" data-supp-info-image="">Source Data Extended Data Fig. 7</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Statistical source data.</p></div></div><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM10"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="source data extended data fig. 8" href="https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_MOESM10_ESM.xlsx" data-supp-info-image="">Source Data Extended Data Fig. 8</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Statistical source data.</p></div></div><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM11"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="source data extended data fig. 9" href="https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_MOESM11_ESM.xlsx" data-supp-info-image="">Source Data Extended Data Fig. 9</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Statistical source data.</p></div></div><div class="c-article-supplementary__item" data-test="supp-item" id="MOESM12"><h3 class="c-article-supplementary__title u-h3"><a class="print-link" data-track="click" data-track-action="view supplementary info" data-test="supp-info-link" data-track-label="source data extended data fig. 10" href="https://static-content.springer.com/esm/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_MOESM12_ESM.xlsx" data-supp-info-image="">Source Data Extended Data Fig. 10</a></h3><div class="c-article-supplementary__description" data-component="thumbnail-container"><p>Statistical source data.</p></div></div></div></div></div></section><section data-title="Rights and permissions"><div class="c-article-section" id="rightslink-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="rightslink">Rights and permissions</h2><div class="c-article-section__content" id="rightslink-content">
                <p><b>Open Access</b>  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <a href="http://creativecommons.org/licenses/by/4.0/" rel="license">http://creativecommons.org/licenses/by/4.0/</a>.</p>
              <p class="c-article-rights"><a data-track="click" data-track-action="view rights and permissions" data-track-label="link" href="https://s100.copyright.com/AppDispatchServlet?title=CAR%20T%20cells%20with%20dual%20targeting%20of%20CD19%20and%20CD22%20in%20adult%20patients%20with%20recurrent%20or%20refractory%20B%20cell%20malignancies%3A%20a%20phase%201%20trial&amp;author=Jay%20Y.%20Spiegel%20et%20al&amp;contentID=10.1038%2Fs41591-021-01436-0&amp;copyright=The%20Author%28s%29&amp;publication=1078-8956&amp;publicationDate=2021-07-26&amp;publisherName=SpringerNature&amp;orderBeanReset=true&amp;oa=CC%20BY">Reprints and permissions</a></p></div></div></section><section aria-labelledby="article-info" data-title="About this article"><div class="c-article-section" id="article-info-section"><h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="article-info">About this article</h2><div class="c-article-section__content" id="article-info-content"><div class="c-bibliographic-information"><div class="u-hide-print c-bibliographic-information__column c-bibliographic-information__column--border"><a data-crossmark="10.1038/s41591-021-01436-0" target="_blank" rel="noopener" href="https://crossmark.crossref.org/dialog/?doi=10.1038/s41591-021-01436-0" data-track="click" data-track-action="Click Crossmark" data-track-label="link" data-test="crossmark"><img loading="lazy" width="57" height="81" alt="Check for updates. Verify currency and authenticity via CrossMark" src="data:image/svg+xml;base64,<svg height="81" width="57" xmlns="http://www.w3.org/2000/svg"><g fill="none" fill-rule="evenodd"><path d="m17.35 35.45 21.3-14.2v-17.03h-21.3" fill="#989898"/><path d="m38.65 35.45-21.3-14.2v-17.03h21.3" fill="#747474"/><path d="m28 .5c-12.98 0-23.5 10.52-23.5 23.5s10.52 23.5 23.5 23.5 23.5-10.52 23.5-23.5c0-6.23-2.48-12.21-6.88-16.62-4.41-4.4-10.39-6.88-16.62-6.88zm0 41.25c-9.8 0-17.75-7.95-17.75-17.75s7.95-17.75 17.75-17.75 17.75 7.95 17.75 17.75c0 4.71-1.87 9.22-5.2 12.55s-7.84 5.2-12.55 5.2z" fill="#535353"/><path d="m41 36c-5.81 6.23-15.23 7.45-22.43 2.9-7.21-4.55-10.16-13.57-7.03-21.5l-4.92-3.11c-4.95 10.7-1.19 23.42 8.78 29.71 9.97 6.3 23.07 4.22 30.6-4.86z" fill="#9c9c9c"/><path d="m.2 58.45c0-.75.11-1.42.33-2.01s.52-1.09.91-1.5c.38-.41.83-.73 1.34-.94.51-.22 1.06-.32 1.65-.32.56 0 1.06.11 1.51.35.44.23.81.5 1.1.81l-.91 1.01c-.24-.24-.49-.42-.75-.56-.27-.13-.58-.2-.93-.2-.39 0-.73.08-1.05.23-.31.16-.58.37-.81.66-.23.28-.41.63-.53 1.04-.13.41-.19.88-.19 1.39 0 1.04.23 1.86.68 2.46.45.59 1.06.88 1.84.88.41 0 .77-.07 1.07-.23s.59-.39.85-.68l.91 1c-.38.43-.8.76-1.28.99-.47.22-1 .34-1.58.34-.59 0-1.13-.1-1.64-.31-.5-.2-.94-.51-1.31-.91-.38-.4-.67-.9-.88-1.48-.22-.59-.33-1.26-.33-2.02zm8.4-5.33h1.61v2.54l-.05 1.33c.29-.27.61-.51.96-.72s.76-.31 1.24-.31c.73 0 1.27.23 1.61.71.33.47.5 1.14.5 2.02v4.31h-1.61v-4.1c0-.57-.08-.97-.25-1.21-.17-.23-.45-.35-.83-.35-.3 0-.56.08-.79.22-.23.15-.49.36-.78.64v4.8h-1.61zm7.37 6.45c0-.56.09-1.06.26-1.51.18-.45.42-.83.71-1.14.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.36c.07.62.29 1.1.65 1.44.36.33.82.5 1.38.5.29 0 .57-.04.83-.13s.51-.21.76-.37l.55 1.01c-.33.21-.69.39-1.09.53-.41.14-.83.21-1.26.21-.48 0-.92-.08-1.34-.25-.41-.16-.76-.4-1.07-.7-.31-.31-.55-.69-.72-1.13-.18-.44-.26-.95-.26-1.52zm4.6-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.07.45-.31.29-.5.73-.58 1.3zm2.5.62c0-.57.09-1.08.28-1.53.18-.44.43-.82.75-1.13s.69-.54 1.1-.71c.42-.16.85-.24 1.31-.24.45 0 .84.08 1.17.23s.61.34.85.57l-.77 1.02c-.19-.16-.38-.28-.56-.37-.19-.09-.39-.14-.61-.14-.56 0-1.01.21-1.35.63-.35.41-.52.97-.52 1.67 0 .69.17 1.24.51 1.66.34.41.78.62 1.32.62.28 0 .54-.06.78-.17.24-.12.45-.26.64-.42l.67 1.03c-.33.29-.69.51-1.08.65-.39.15-.78.23-1.18.23-.46 0-.9-.08-1.31-.24-.4-.16-.75-.39-1.05-.7s-.53-.69-.7-1.13c-.17-.45-.25-.96-.25-1.53zm6.91-6.45h1.58v6.17h.05l2.54-3.16h1.77l-2.35 2.8 2.59 4.07h-1.75l-1.77-2.98-1.08 1.23v1.75h-1.58zm13.69 1.27c-.25-.11-.5-.17-.75-.17-.58 0-.87.39-.87 1.16v.75h1.34v1.27h-1.34v5.6h-1.61v-5.6h-.92v-1.2l.92-.07v-.72c0-.35.04-.68.13-.98.08-.31.21-.57.4-.79s.42-.39.71-.51c.28-.12.63-.18 1.04-.18.24 0 .48.02.69.07.22.05.41.1.57.17zm.48 5.18c0-.57.09-1.08.27-1.53.17-.44.41-.82.72-1.13.3-.31.65-.54 1.04-.71.39-.16.8-.24 1.23-.24s.84.08 1.24.24c.4.17.74.4 1.04.71s.54.69.72 1.13c.19.45.28.96.28 1.53s-.09 1.08-.28 1.53c-.18.44-.42.82-.72 1.13s-.64.54-1.04.7-.81.24-1.24.24-.84-.08-1.23-.24-.74-.39-1.04-.7c-.31-.31-.55-.69-.72-1.13-.18-.45-.27-.96-.27-1.53zm1.65 0c0 .69.14 1.24.43 1.66.28.41.68.62 1.18.62.51 0 .9-.21 1.19-.62.29-.42.44-.97.44-1.66 0-.7-.15-1.26-.44-1.67-.29-.42-.68-.63-1.19-.63-.5 0-.9.21-1.18.63-.29.41-.43.97-.43 1.67zm6.48-3.44h1.33l.12 1.21h.05c.24-.44.54-.79.88-1.02.35-.24.7-.36 1.07-.36.32 0 .59.05.78.14l-.28 1.4-.33-.09c-.11-.01-.23-.02-.38-.02-.27 0-.56.1-.86.31s-.55.58-.77 1.1v4.2h-1.61zm-47.87 15h1.61v4.1c0 .57.08.97.25 1.2.17.24.44.35.81.35.3 0 .57-.07.8-.22.22-.15.47-.39.73-.73v-4.7h1.61v6.87h-1.32l-.12-1.01h-.04c-.3.36-.63.64-.98.86-.35.21-.76.32-1.24.32-.73 0-1.27-.24-1.61-.71-.33-.47-.5-1.14-.5-2.02zm9.46 7.43v2.16h-1.61v-9.59h1.33l.12.72h.05c.29-.24.61-.45.97-.63.35-.17.72-.26 1.1-.26.43 0 .81.08 1.15.24.33.17.61.4.84.71.24.31.41.68.53 1.11.13.42.19.91.19 1.44 0 .59-.09 1.11-.25 1.57-.16.47-.38.85-.65 1.16-.27.32-.58.56-.94.73-.35.16-.72.25-1.1.25-.3 0-.6-.07-.9-.2s-.59-.31-.87-.56zm0-2.3c.26.22.5.37.73.45.24.09.46.13.66.13.46 0 .84-.2 1.15-.6.31-.39.46-.98.46-1.77 0-.69-.12-1.22-.35-1.61-.23-.38-.61-.57-1.13-.57-.49 0-.99.26-1.52.77zm5.87-1.69c0-.56.08-1.06.25-1.51.16-.45.37-.83.65-1.14.27-.3.58-.54.93-.71s.71-.25 1.08-.25c.39 0 .73.07 1 .2.27.14.54.32.81.55l-.06-1.1v-2.49h1.61v9.88h-1.33l-.11-.74h-.06c-.25.25-.54.46-.88.64-.33.18-.69.27-1.06.27-.87 0-1.56-.32-2.07-.95s-.76-1.51-.76-2.65zm1.67-.01c0 .74.13 1.31.4 1.7.26.38.65.58 1.15.58.51 0 .99-.26 1.44-.77v-3.21c-.24-.21-.48-.36-.7-.45-.23-.08-.46-.12-.7-.12-.45 0-.82.19-1.13.59-.31.39-.46.95-.46 1.68zm6.35 1.59c0-.73.32-1.3.97-1.71.64-.4 1.67-.68 3.08-.84 0-.17-.02-.34-.07-.51-.05-.16-.12-.3-.22-.43s-.22-.22-.38-.3c-.15-.06-.34-.1-.58-.1-.34 0-.68.07-1 .2s-.63.29-.93.47l-.59-1.08c.39-.24.81-.45 1.28-.63.47-.17.99-.26 1.54-.26.86 0 1.51.25 1.93.76s.63 1.25.63 2.21v4.07h-1.32l-.12-.76h-.05c-.3.27-.63.48-.98.66s-.73.27-1.14.27c-.61 0-1.1-.19-1.48-.56-.38-.36-.57-.85-.57-1.46zm1.57-.12c0 .3.09.53.27.67.19.14.42.21.71.21.28 0 .54-.07.77-.2s.48-.31.73-.56v-1.54c-.47.06-.86.13-1.18.23-.31.09-.57.19-.76.31s-.33.25-.41.4c-.09.15-.13.31-.13.48zm6.29-3.63h-.98v-1.2l1.06-.07.2-1.88h1.34v1.88h1.75v1.27h-1.75v3.28c0 .8.32 1.2.97 1.2.12 0 .24-.01.37-.04.12-.03.24-.07.34-.11l.28 1.19c-.19.06-.4.12-.64.17-.23.05-.49.08-.76.08-.4 0-.74-.06-1.02-.18-.27-.13-.49-.3-.67-.52-.17-.21-.3-.48-.37-.78-.08-.3-.12-.64-.12-1.01zm4.36 2.17c0-.56.09-1.06.27-1.51s.41-.83.71-1.14c.29-.3.63-.54 1.01-.71.39-.17.78-.25 1.18-.25.47 0 .88.08 1.23.24.36.16.65.38.89.67s.42.63.54 1.03c.12.41.18.84.18 1.32 0 .32-.02.57-.07.76h-4.37c.08.62.29 1.1.65 1.44.36.33.82.5 1.38.5.3 0 .58-.04.84-.13.25-.09.51-.21.76-.37l.54 1.01c-.32.21-.69.39-1.09.53s-.82.21-1.26.21c-.47 0-.92-.08-1.33-.25-.41-.16-.77-.4-1.08-.7-.3-.31-.54-.69-.72-1.13-.17-.44-.26-.95-.26-1.52zm4.61-.62c0-.55-.11-.98-.34-1.28-.23-.31-.58-.47-1.06-.47-.41 0-.77.15-1.08.45-.31.29-.5.73-.57 1.3zm3.01 2.23c.31.24.61.43.92.57.3.13.63.2.98.2.38 0 .65-.08.83-.23s.27-.35.27-.6c0-.14-.05-.26-.13-.37-.08-.1-.2-.2-.34-.28-.14-.09-.29-.16-.47-.23l-.53-.22c-.23-.09-.46-.18-.69-.3-.23-.11-.44-.24-.62-.4s-.33-.35-.45-.55c-.12-.21-.18-.46-.18-.75 0-.61.23-1.1.68-1.49.44-.38 1.06-.57 1.83-.57.48 0 .91.08 1.29.25s.71.36.99.57l-.74.98c-.24-.17-.49-.32-.73-.42-.25-.11-.51-.16-.78-.16-.35 0-.6.07-.76.21-.17.15-.25.33-.25.54 0 .14.04.26.12.36s.18.18.31.26c.14.07.29.14.46.21l.54.19c.23.09.47.18.7.29s.44.24.64.4c.19.16.34.35.46.58.11.23.17.5.17.82 0 .3-.06.58-.17.83-.12.26-.29.48-.51.68-.23.19-.51.34-.84.45-.34.11-.72.17-1.15.17-.48 0-.95-.09-1.41-.27-.46-.19-.86-.41-1.2-.68z" fill="#535353"/></g></svg>"></a></div><div class="c-bibliographic-information__column"><h3 class="c-article__sub-heading" id="citeas">Cite this article</h3><p class="c-bibliographic-information__citation">Spiegel, J.Y., Patel, S., Muffly, L. <i>et al.</i> CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial.
                    <i>Nat Med</i> <b>27</b>, 1419–1431 (2021). https://doi.org/10.1038/s41591-021-01436-0</p><p class="c-bibliographic-information__download-citation u-hide-print"><a data-test="citation-link" data-track="click" data-track-action="download article citation" data-track-label="link" data-track-external="" rel="nofollow" href="https://citation-needed.springer.com/v2/references/10.1038/s41591-021-01436-0?format=refman&amp;flavour=citation">Download citation<svg width="16" height="16" focusable="false" role="img" aria-hidden="true" class="u-icon"><use xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="#icon-eds-i-download-medium"></use></svg></a></p><ul class="c-bibliographic-information__list" data-test="publication-history"><li class="c-bibliographic-information__list-item"><p>Received<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2020-09-29">29 September 2020</time></span></p></li><li class="c-bibliographic-information__list-item"><p>Accepted<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2021-06-09">09 June 2021</time></span></p></li><li class="c-bibliographic-information__list-item"><p>Published<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2021-07-26">26 July 2021</time></span></p></li><li class="c-bibliographic-information__list-item"><p>Issue Date<span class="u-hide">: </span><span class="c-bibliographic-information__value"><time datetime="2021-08">August 2021</time></span></p></li><li class="c-bibliographic-information__list-item c-bibliographic-information__list-item--full-width"><p><abbr title="Digital Object Identifier">DOI</abbr><span class="u-hide">: </span><span class="c-bibliographic-information__value">https://doi.org/10.1038/s41591-021-01436-0</span></p></li></ul><div data-component="share-box"><div class="c-article-share-box u-display-block"><h3 class="c-article__sub-heading">Share this article</h3><p class="c-article-share-box__description">Anyone you share the following link with will be able to read this content:</p><button class="js-get-share-url c-article-share-box__button" type="button" id="get-share-url" data-track="click" data-track-label="button" data-track-external="" data-track-action="get shareable link">Get shareable link</button><div class="js-no-share-url-container u-display-none" hidden=""><p class="js-c-article-share-box__no-sharelink-info c-article-share-box__no-sharelink-info">Sorry, a shareable link is not currently available for this article.</p></div><div class="js-share-url-container u-display-none" hidden=""><p class="js-share-url c-article-share-box__only-read-input" id="share-url" data-track="click" data-track-label="button" data-track-action="select share url"></p><button class="js-copy-share-url c-article-share-box__button--link-like" type="button" id="copy-share-url" data-track="click" data-track-label="button" data-track-action="copy share url" data-track-external="">Copy to clipboard</button></div><p class="js-c-article-share-box__additional-info c-article-share-box__additional-info">
                            Provided by the Springer Nature SharedIt content-sharing initiative
                        </p></div></div><div data-component="article-info-list">
        <h3 class="c-article__sub-heading">Subjects</h3>
        <ul class="c-article-subject-list">
            <li class="c-article-subject-list__subject"><a href="/subjects/acute-lymphocytic-leukaemia" data-track="click" data-track-action="view subject" data-track-label="link">Acute lymphocytic leukaemia</a></li><li class="c-article-subject-list__subject"><a href="/subjects/cancer-immunotherapy" data-track="click" data-track-action="view subject" data-track-label="link">Cancer immunotherapy</a></li><li class="c-article-subject-list__subject"><a href="/subjects/lymphoma" data-track="click" data-track-action="view subject" data-track-label="link">Lymphoma</a></li><li class="c-article-subject-list__subject"><a href="/subjects/phase-i-trials" data-track="click" data-track-action="view subject" data-track-label="link">Phase I trials</a></li>
        </ul>
    </div></div></div></div></div></section>
            </div>

            
        <section>
            <div class="c-article-section js-article-section" id="further-reading-section" data-test="further-reading-section">
                <h2 class="c-article-section__title js-section-title js-c-reading-companion-sections-item" id="further-reading">This article is cited by</h2>
                <div class="c-article-section__content js-collapsible-section" id="further-reading-content">
                    <ul class="c-article-further-reading__list" id="further-reading-list">
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title" data-test="article-title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article" data-track-label="link:CAR-NK cells with dual targeting of PD-L1 and MICA/B in lung cancer tumor models" href="https://doi.org/10.1186/s12885-025-13780-2">
                                        CAR-NK cells with dual targeting of PD-L1 and MICA/B in lung cancer tumor models
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="app-author-list app-author-list--compact app-author-list--truncated u-sans-serif u-mb-4 u-mt-auto">
                                        <li>Lingtong Zhi</li><li>Zikang Zhang</li><li>Wuling Zhu</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>BMC Cancer</i> (2025)</p>
                            </li>
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title" data-test="article-title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article" data-track-label="link:Strategies to overcome tumour relapse caused by antigen escape after CAR T therapy" href="https://doi.org/10.1186/s12943-025-02334-6">
                                        Strategies to overcome tumour relapse caused by antigen escape after CAR T therapy
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="app-author-list app-author-list--compact u-sans-serif u-mb-4 u-mt-auto">
                                        <li>Yufei Lu</li><li>Fu Zhao</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>Molecular Cancer</i> (2025)</p>
                            </li>
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title" data-test="article-title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article" data-track-label="link:Immunotherapy in chronic lymphocytic leukemia: advances and challenges" href="https://doi.org/10.1186/s40164-025-00644-5">
                                        Immunotherapy in chronic lymphocytic leukemia: advances and challenges
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="app-author-list app-author-list--compact app-author-list--truncated u-sans-serif u-mb-4 u-mt-auto">
                                        <li>Pan Gao</li><li>Yang Zhang</li><li>Ya Zhang</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>Experimental Hematology &amp; Oncology</i> (2025)</p>
                            </li>
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title" data-test="article-title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article" data-track-label="link:Beyond the blood: expanding CAR T cell therapy to solid tumors" href="https://doi.org/10.1038/s41587-024-02446-2">
                                        Beyond the blood: expanding CAR T cell therapy to solid tumors
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="app-author-list app-author-list--compact u-sans-serif u-mb-4 u-mt-auto">
                                        <li>Ugur Uslu</li><li>Carl H. June</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>Nature Biotechnology</i> (2025)</p>
                            </li>
                        
                            <li class="c-article-further-reading__item js-ref-item">
                            
                                <h3 class="c-article-further-reading__title" data-test="article-title">
                                    <a class="print-link" data-track="click" data-track-action="view further reading article" data-track-label="link:Design of sensitive monospecific and bispecific synthetic chimeric T cell receptors for cancer therapy" href="https://doi.org/10.1038/s43018-025-00927-0">
                                        Design of sensitive monospecific and bispecific synthetic chimeric T cell receptors for cancer therapy
                                    </a>
                                </h3>
                            
                                
                                    <ul data-test="author-list" class="app-author-list app-author-list--compact app-author-list--truncated u-sans-serif u-mb-4 u-mt-auto">
                                        <li>Sylvain Simon</li><li>Grace Bugos</li><li>Stanley R. Riddell</li>
                                    </ul>
                                
                                <p class="c-article-further-reading__journal-title"><i>Nature Cancer</i> (2025)</p>
                            </li>
                        
                    </ul>
                </div>
            </div>
        </section>
    

        </div>
</article>
</main>

<aside class="c-article-extras u-hide-print" aria-label="Article navigation" data-component-reading-companion="" data-container-type="reading-companion" data-track-component="reading companion">
    <div class="js-context-bar-sticky-point-desktop" data-track-context="reading companion">
        

        
            
                
                    
    
        <div class="c-pdf-download u-clear-both js-pdf-download">
            <a href="/articles/s41591-021-01436-0.pdf" class="u-button u-button--full-width u-button--primary u-justify-content-space-between c-pdf-download__link" data-article-pdf="true" data-readcube-pdf-url="true" data-test="download-pdf" data-draft-ignore="true" data-track="content_download" data-track-type="article pdf download" data-track-action="download pdf" data-track-label="link" data-track-external="" download="">
                <span class="c-pdf-download__text">Download PDF</span>
                <svg aria-hidden="true" focusable="false" width="16" height="16" class="u-icon"><use xlink:href="#icon-download"></use></svg>
            </a>
        </div>
    

                
            
        
    </div>

    
        
    

    
    

    <div class="c-reading-companion">
        <div class="c-reading-companion__sticky" data-component="reading-companion-sticky" data-test="reading-companion-sticky" style="top: 40px;">
            <ul class="c-reading-companion__tabs" role="tablist"><li role="presentation"><button data-tab-target="sections" role="tab" id="tab-sections" aria-controls="tabpanel-sections" aria-selected="true" class="c-reading-companion__tab c-reading-companion__tab--active" data-track="click" data-track-action="sections tab" data-track-label="tab">Sections</button></li><li role="presentation"><button data-tab-target="figures" role="tab" id="tab-figures" aria-controls="tabpanel-figures" aria-selected="false" tabindex="-1" class="c-reading-companion__tab" data-track="click" data-track-action="figures tab" data-track-label="tab">Figures</button></li><li role="presentation"><button data-tab-target="references" role="tab" id="tab-references" aria-controls="tabpanel-references" aria-selected="false" tabindex="-1" class="c-reading-companion__tab" data-track="click" data-track-action="references tab" data-track-label="tab">References</button></li></ul><div class="c-reading-companion__panel c-reading-companion__sections c-reading-companion__panel--active" id="tabpanel-sections" aria-labelledby="tab-sections" role="tabpanel"><div class="c-reading-companion__scroll-pane" style="max-height: none;"><ul class="c-reading-companion__sections-list"><li id="rc-sec-Abs1" class="c-reading-companion__section-item"><a href="#Abs1" data-track="click" data-track-action="section anchor" data-track-label="link:Abstract">Abstract</a></li><li id="rc-sec-Sec1" class="c-reading-companion__section-item"><a href="#Sec1" data-track="click" data-track-action="section anchor" data-track-label="link:Main">Main</a></li><li id="rc-sec-Sec2" class="c-reading-companion__section-item"><a href="#Sec2" data-track="click" data-track-action="section anchor" data-track-label="link:Results">Results</a></li><li id="rc-sec-Sec13" class="c-reading-companion__section-item"><a href="#Sec13" data-track="click" data-track-action="section anchor" data-track-label="link:Discussion">Discussion</a></li><li id="rc-sec-Sec14" class="c-reading-companion__section-item"><a href="#Sec14" data-track="click" data-track-action="section anchor" data-track-label="link:Methods">Methods</a></li><li id="rc-sec-data-availability" class="c-reading-companion__section-item"><a href="#data-availability" data-track="click" data-track-action="section anchor" data-track-label="link:Data availability">Data availability</a></li><li id="rc-sec-Bib1" class="c-reading-companion__section-item"><a href="#Bib1" data-track="click" data-track-action="section anchor" data-track-label="link:References">References</a></li><li id="rc-sec-Ack1" class="c-reading-companion__section-item"><a href="#Ack1" data-track="click" data-track-action="section anchor" data-track-label="link:Acknowledgements">Acknowledgements</a></li><li id="rc-sec-author-information" class="c-reading-companion__section-item"><a href="#author-information" data-track="click" data-track-action="section anchor" data-track-label="link:Author information">Author information</a></li><li id="rc-sec-ethics" class="c-reading-companion__section-item"><a href="#ethics" data-track="click" data-track-action="section anchor" data-track-label="link:Ethics declarations">Ethics declarations</a></li><li id="rc-sec-additional-information" class="c-reading-companion__section-item"><a href="#additional-information" data-track="click" data-track-action="section anchor" data-track-label="link:Additional information">Additional information</a></li><li id="rc-sec-Sec37" class="c-reading-companion__section-item"><a href="#Sec37" data-track="click" data-track-action="section anchor" data-track-label="link:Extended data">Extended data</a></li><li id="rc-sec-Sec38" class="c-reading-companion__section-item"><a href="#Sec38" data-track="click" data-track-action="section anchor" data-track-label="link:Supplementary information">Supplementary information</a></li><li id="rc-sec-Sec39" class="c-reading-companion__section-item"><a href="#Sec39" data-track="click" data-track-action="section anchor" data-track-label="link:Source data">Source data</a></li><li id="rc-sec-rightslink" class="c-reading-companion__section-item"><a href="#rightslink" data-track="click" data-track-action="section anchor" data-track-label="link:Rights and permissions">Rights and permissions</a></li><li id="rc-sec-article-info" class="c-reading-companion__section-item"><a href="#article-info" data-track="click" data-track-action="section anchor" data-track-label="link:About this article">About this article</a></li><li id="rc-sec-further-reading" class="c-reading-companion__section-item"><a href="#further-reading" data-track="click" data-track-action="section anchor" data-track-label="link:This article is cited by">This article is cited by</a></li></ul></div>
                <div class="u-lazy-ad-wrapper u-mt-16 u-show" data-component-mpu="" style="display: none !important;">
                    <div class="c-ad c-ad--300x250">
                        <div class="c-ad__inner">
                            <p class="c-ad__label">Advertisement</p>
                            
    <div id="div-gpt-ad-right-2" class="div-gpt-ad advert medium-rectangle js-ad text-center hide-print grade-c-hide" data-ad-type="right" data-test="right-ad" data-pa11y-ignore="" data-gpt="" data-gpt-unitpath="/285/medicine.nature.com/article" data-gpt-sizes="300x250" data-gpt-targeting="type=article;pos=right;artid=s41591-021-01436-0;doi=10.1038/s41591-021-01436-0;subjmeta=1059,109,1541,1940,1990,2125,2325,2779,283,291,308,631,67,692,699;kwrd=Acute+lymphocytic+leukaemia,Cancer+immunotherapy,Lymphoma,Phase+I+trials">
        <noscript>
            <a href="//pubads.g.doubleclick.net/gampad/jump?iu=/285/medicine.nature.com/article&amp;sz=300x250&amp;c=-1468701408&amp;t=pos%3Dright%26type%3Darticle%26artid%3Ds41591-021-01436-0%26doi%3D10.1038/s41591-021-01436-0%26subjmeta%3D1059,109,1541,1940,1990,2125,2325,2779,283,291,308,631,67,692,699%26kwrd%3DAcute+lymphocytic+leukaemia,Cancer+immunotherapy,Lymphoma,Phase+I+trials">
                <img data-test="gpt-advert-fallback-img"
                     src="//pubads.g.doubleclick.net/gampad/ad?iu=/285/medicine.nature.com/article&amp;sz=300x250&amp;c=-1468701408&amp;t=pos%3Dright%26type%3Darticle%26artid%3Ds41591-021-01436-0%26doi%3D10.1038/s41591-021-01436-0%26subjmeta%3D1059,109,1541,1940,1990,2125,2325,2779,283,291,308,631,67,692,699%26kwrd%3DAcute+lymphocytic+leukaemia,Cancer+immunotherapy,Lymphoma,Phase+I+trials"
                     alt="Advertisement"
                     width="300"
                     height="250"></a>
        </noscript>
    </div>

                        </div>
                    </div>
                </div>
            </div>
            <div class="c-reading-companion__panel c-reading-companion__figures c-reading-companion__panel--full-width" id="tabpanel-figures" aria-labelledby="tab-figures" role="tabpanel"><div class="c-reading-companion__scroll-pane"><ul class="c-reading-companion__figures-list"><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig1">Fig. 1: IHC demonstrates CD19<sup>−/lo</sup> disease postaxi-cel and quantitative flow cytometry of LBCL preaxi-cel therapy is associated with disease progression.</b></figcaption><picture><source data-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_Fig1_HTML.png?"><img data-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_Fig1_HTML.png" alt="figure 1" aria-describedby="rc-Fig1"></picture><p class="c-reading-companion__figure-links"><a href="#Fig1" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-021-01436-0/figures/1" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig2">Fig. 2: Characterization of CAR products throughout the manufacturing process reveals compositional and phenotypic changes.</b></figcaption><picture><source data-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_Fig2_HTML.png?"><img data-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_Fig2_HTML.png" alt="figure 2" aria-describedby="rc-Fig2"></picture><p class="c-reading-companion__figure-links"><a href="#Fig2" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-021-01436-0/figures/2" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig3">Fig. 3: CD19-22.BB.z-CAR is active in both LBCL and B-ALL.</b></figcaption><picture><source data-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_Fig3_HTML.png?"><img data-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_Fig3_HTML.png" alt="figure 3" aria-describedby="rc-Fig3"></picture><p class="c-reading-companion__figure-links"><a href="#Fig3" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-021-01436-0/figures/3" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig4">Fig. 4: CD19 negative relapse with preserved CD22 site density after CD19-22.BB.z-CAR and diminished CAR T functionality against CD22.</b></figcaption><picture><source data-srcset="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_Fig4_HTML.png?"><img data-src="https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_Fig4_HTML.png" alt="figure 4" aria-describedby="rc-Fig4"></picture><p class="c-reading-companion__figure-links"><a href="#Fig4" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-021-01436-0/figures/4" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig5">Extended Data Fig. 1 Model-based prediction of relapse after axi-cel.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_Fig5_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_Fig5_ESM.jpg" alt="extended data figure 5" aria-describedby="rc-Fig5"></picture><p class="c-reading-companion__figure-links"><a href="#Fig5" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-021-01436-0/figures/5" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig6">Extended Data Fig. 2 Evaluation of pre-axi-cel antigen density.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_Fig6_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_Fig6_ESM.jpg" alt="extended data figure 6" aria-describedby="rc-Fig6"></picture><p class="c-reading-companion__figure-links"><a href="#Fig6" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-021-01436-0/figures/6" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig7">Extended Data Fig. 3 CONSORT Diagram.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_Fig7_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_Fig7_ESM.jpg" alt="extended data figure 7" aria-describedby="rc-Fig7"></picture><p class="c-reading-companion__figure-links"><a href="#Fig7" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-021-01436-0/figures/7" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig8">Extended Data Fig. 4 CD19/22 CAR T manufacturing flowchart and product breakdown by culture days, manufacturing matrix, dose level, and disease.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_Fig8_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_Fig8_ESM.jpg" alt="extended data figure 8" aria-describedby="rc-Fig8"></picture><p class="c-reading-companion__figure-links"><a href="#Fig8" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-021-01436-0/figures/8" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig9">Extended Data Fig. 5 Adverse events summary.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_Fig9_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_Fig9_ESM.jpg" alt="extended data figure 9" aria-describedby="rc-Fig9"></picture><p class="c-reading-companion__figure-links"><a href="#Fig9" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-021-01436-0/figures/9" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig10">Extended Data Fig. 6 LBCL disease monitoring by ctDNA.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_Fig10_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_Fig10_ESM.jpg" alt="extended data figure 10" aria-describedby="rc-Fig10"></picture><p class="c-reading-companion__figure-links"><a href="#Fig10" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-021-01436-0/figures/10" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig11">Extended Data Fig. 7 B-ALL disease monitoring by ClonoSeq.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_Fig11_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_Fig11_ESM.jpg" alt="extended data figure 11" aria-describedby="rc-Fig11"></picture><p class="c-reading-companion__figure-links"><a href="#Fig11" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-021-01436-0/figures/11" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig12">Extended Data Fig. 8 In vivo CAR-T cell expansion is CD8 predominant and relates to exhaustion phenotype of CAR-T products.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_Fig12_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_Fig12_ESM.jpg" alt="extended data figure 12" aria-describedby="rc-Fig12"></picture><p class="c-reading-companion__figure-links"><a href="#Fig12" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-021-01436-0/figures/12" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig13">Extended Data Fig. 9 Site density change after CD19-22.BB.z.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_Fig13_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_Fig13_ESM.jpg" alt="extended data figure 13" aria-describedby="rc-Fig13"></picture><p class="c-reading-companion__figure-links"><a href="#Fig13" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-021-01436-0/figures/13" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li><li class="c-reading-companion__figure-item"><figure><figcaption><b class="c-reading-companion__figure-title u-h4" id="rc-Fig14">Extended Data Fig. 10 Functional assessment of CD19-22 scFvs by Incucyte and comparison of MFI, transduction efficiency and VCN of CD19-22.BB.z-CAR and CD22-BB.z.CAR.</b></figcaption><picture><source data-srcset="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_Fig14_ESM.jpg?"><img data-src="//media.springernature.com/lw685/springer-static/esm/art%3A10.1038%2Fs41591-021-01436-0/MediaObjects/41591_2021_1436_Fig14_ESM.jpg" alt="extended data figure 14" aria-describedby="rc-Fig14"></picture><p class="c-reading-companion__figure-links"><a href="#Fig14" data-track="click" data-track-action="figure anchor" data-track-label="link">View in article</a><a href="https://www.nature.com/articles/s41591-021-01436-0/figures/14" class="c-reading-companion__figure-full-link" data-track="click" data-track-action="view figure" data-track-label="link" rel="nofollow">Full size image<svg width="16" height="16" class="u-icon"><use href="#icon-chevron-right"></use></svg></a></p></figure></li></ul></div></div>
            <div class="c-reading-companion__panel c-reading-companion__references c-reading-companion__panel--full-width" id="tabpanel-references" aria-labelledby="tab-references" role="tabpanel"><div class="c-reading-companion__scroll-pane"><ol class="c-reading-companion__references-list c-reading-companion__references-list--numeric" data-track-context="article references sidebar"><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR1">Turtle, C. J. et al. CD19 CAR-T cells of defined CD4<sup>+</sup>:CD8<sup>+</sup> composition in adult B cell ALL patients. <i>J. Clin. Invest.</i> <b>126</b>, 2123–2138 (2016).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1172%2FJCI85309" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1172/JCI85309" data-track-item_id="10.1172/JCI85309">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27111235" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4887159" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=CD19%20CAR-T%20cells%20of%20defined%20CD4%2B%3ACD8%2B%20composition%20in%20adult%20B%20cell%20ALL%20patients&amp;journal=J.%20Clin.%20Invest.&amp;doi=10.1172%2FJCI85309&amp;volume=126&amp;pages=2123-2138&amp;publication_year=2016&amp;author=Turtle%2CCJ" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR2">Locke, F. L. et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. <i>Lancet Oncol.</i> <b>20</b>, 31–42 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2FS1470-2045%2818%2930864-7" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/S1470-2045(18)30864-7" data-track-item_id="10.1016/S1470-2045(18)30864-7">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXisVSgt7bE" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30518502" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Long-term%20safety%20and%20activity%20of%20axicabtagene%20ciloleucel%20in%20refractory%20large%20B-cell%20lymphoma%20%28ZUMA-1%29%3A%20a%20single-arm%2C%20multicentre%2C%20phase%201%E2%80%932%20trial&amp;journal=Lancet%20Oncol.&amp;doi=10.1016%2FS1470-2045%2818%2930864-7&amp;volume=20&amp;pages=31-42&amp;publication_year=2019&amp;author=Locke%2CFL" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR3">Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. <i>N. Engl. J. Med.</i> <b>377</b>, 2531–2544 (2017).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1056%2FNEJMoa1707447" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1056/NEJMoa1707447" data-track-item_id="10.1056/NEJMoa1707447">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXhtVGjtbw%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29226797" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5882485" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Axicabtagene%20ciloleucel%20CAR%20T-cell%20therapy%20in%20refractory%20large%20B-cell%20lymphoma&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1707447&amp;volume=377&amp;pages=2531-2544&amp;publication_year=2017&amp;author=Neelapu%2CSS" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR4">Schuster, S. J. et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. <i>N. Engl. J. Med.</i> <b>380</b>, 45–56 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1056%2FNEJMoa1804980" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1056/NEJMoa1804980" data-track-item_id="10.1056/NEJMoa1804980">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXhtFKmtbc%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30501490" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Tisagenlecleucel%20in%20adult%20relapsed%20or%20refractory%20diffuse%20large%20B-cell%20lymphoma&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1804980&amp;volume=380&amp;pages=45-56&amp;publication_year=2019&amp;author=Schuster%2CSJ" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR5">Hay, K. A. et al. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. <i>Blood</i> <b>133</b>, 1652–1663 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1182%2Fblood-2018-11-883710" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1182/blood-2018-11-883710" data-track-item_id="10.1182/blood-2018-11-883710">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXpslymtbs%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30728140" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6460418" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Factors%20associated%20with%20durable%20EFS%20in%20adult%20B-cell%20ALL%20patients%20achieving%20MRD-negative%20CR%20after%20CD19%20CAR%20T-cell%20therapy&amp;journal=Blood&amp;doi=10.1182%2Fblood-2018-11-883710&amp;volume=133&amp;pages=1652-1663&amp;publication_year=2019&amp;author=Hay%2CKA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR6">Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. <i>N. Engl. J. Med.</i> <b>378</b>, 439–448 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1056%2FNEJMoa1709866" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1056/NEJMoa1709866" data-track-item_id="10.1056/NEJMoa1709866">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXitlylsLw%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29385370" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5996391" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Tisagenlecleucel%20in%20children%20and%20young%20adults%20with%20B-cell%20lymphoblastic%20leukemia&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1709866&amp;volume=378&amp;pages=439-448&amp;publication_year=2018&amp;author=Maude%2CSL" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR7">Park, J. H. et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. <i>N. Engl. J. Med.</i> <b>378</b>, 449–459 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1056%2FNEJMoa1709919" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1056/NEJMoa1709919" data-track-item_id="10.1056/NEJMoa1709919">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXitlylsbY%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29385376" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6637939" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Long-term%20follow-up%20of%20CD19%20CAR%20therapy%20in%20acute%20lymphoblastic%20leukemia&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1709919&amp;volume=378&amp;pages=449-459&amp;publication_year=2018&amp;author=Park%2CJH" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR8">Nastoupil, L. J. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium. <i>J. Clin. Oncol.</i> <b>38</b>, 3119–3128 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1200%2FJCO.19.02104" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1200/JCO.19.02104" data-track-item_id="10.1200/JCO.19.02104">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32401634" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7499611" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Standard-of-care%20axicabtagene%20ciloleucel%20for%20relapsed%20or%20refractory%20large%20B-cell%20lymphoma%3A%20results%20from%20the%20US%20Lymphoma%20CAR%20T%20Consortium&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.19.02104&amp;volume=38&amp;pages=3119-3128&amp;publication_year=2020&amp;author=Nastoupil%2CLJ" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR9">Abramson, J. S. et al. Pivotal safety and efficacy results from Transcend NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed/refractory (R/R) large B cell lymphomas. <i>Blood</i> <b>134</b>, 241 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1182%2Fblood-2019-127508" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1182/blood-2019-127508" data-track-item_id="10.1182/blood-2019-127508">Article</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Pivotal%20safety%20and%20efficacy%20results%20from%20Transcend%20NHL%20001%2C%20a%20multicenter%20phase%201%20study%20of%20lisocabtagene%20maraleucel%20%28liso-cel%29%20in%20relapsed%2Frefractory%20%28R%2FR%29%20large%20B%20cell%20lymphomas&amp;journal=Blood&amp;doi=10.1182%2Fblood-2019-127508&amp;volume=134&amp;publication_year=2019&amp;author=Abramson%2CJS" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR10">Lee, D. W. et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. <i>Lancet</i> <b>385</b>, 517–528 (2015).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2FS0140-6736%2814%2961403-3" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/S0140-6736(14)61403-3" data-track-item_id="10.1016/S0140-6736(14)61403-3">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2cXhslGjtLbM" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25319501" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=T%20cells%20expressing%20CD19%20chimeric%20antigen%20receptors%20for%20acute%20lymphoblastic%20leukaemia%20in%20children%20and%20young%20adults%3A%20a%20phase%201%20dose-escalation%20trial&amp;journal=Lancet&amp;doi=10.1016%2FS0140-6736%2814%2961403-3&amp;volume=385&amp;pages=517-528&amp;publication_year=2015&amp;author=Lee%2CDW" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR11">Liu, E. et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. <i>N. Engl. J. Med.</i> <b>382</b>, 545–553 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1056%2FNEJMoa1910607" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1056/NEJMoa1910607" data-track-item_id="10.1056/NEJMoa1910607">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXjtlCgtro%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32023374" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7101242" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Use%20of%20CAR-transduced%20natural%20killer%20cells%20in%20CD19-positive%20lymphoid%20tumors&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1910607&amp;volume=382&amp;pages=545-553&amp;publication_year=2020&amp;author=Liu%2CE" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR12">Majzner, R. G. &amp; Mackall, C. L. Tumor antigen escape from CAR T-cell therapy. <i>Cancer Discov.</i> <b>8</b>, 1219–1226 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F2159-8290.CD-18-0442" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/2159-8290.CD-18-0442" data-track-item_id="10.1158/2159-8290.CD-18-0442">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXmt1egu7Y%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30135176" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Tumor%20antigen%20escape%20from%20CAR%20T-cell%20therapy&amp;journal=Cancer%20Discov.&amp;doi=10.1158%2F2159-8290.CD-18-0442&amp;volume=8&amp;pages=1219-1226&amp;publication_year=2018&amp;author=Majzner%2CRG&amp;author=Mackall%2CCL" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR13">Bagashev, A. et al. CD19 alterations emerging after CD19-directed immunotherapy cause retention of the misfolded protein in the endoplasmic reticulum. <i>Mol. Cell. Biol.</i> <b>38</b>, e00383-18 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1128%2FMCB.00383-18" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1128/MCB.00383-18" data-track-item_id="10.1128/MCB.00383-18">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30104252" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189457" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=CD19%20alterations%20emerging%20after%20CD19-directed%20immunotherapy%20cause%20retention%20of%20the%20misfolded%20protein%20in%20the%20endoplasmic%20reticulum&amp;journal=Mol.%20Cell.%20Biol.&amp;doi=10.1128%2FMCB.00383-18&amp;volume=38&amp;publication_year=2018&amp;author=Bagashev%2CA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR14">Asnani, M. et al. Retention of CD19 intron 2 contributes to CART-19 resistance in leukemias with subclonal frameshift mutations in CD19. <i>Leukemia</i> <b>34</b>, 1202–1207 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fs41375-019-0580-z" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/s41375-019-0580-z" data-track-item_id="10.1038/s41375-019-0580-z">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31591467" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Retention%20of%20CD19%20intron%202%20contributes%20to%20CART-19%20resistance%20in%20leukemias%20with%20subclonal%20frameshift%20mutations%20in%20CD19&amp;journal=Leukemia&amp;doi=10.1038%2Fs41375-019-0580-z&amp;volume=34&amp;pages=1202-1207&amp;publication_year=2020&amp;author=Asnani%2CM" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR15">Orlando, E. J. et al. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. <i>Nat. Med.</i> <b>24</b>, 1504–1506 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fs41591-018-0146-z" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/s41591-018-0146-z" data-track-item_id="10.1038/s41591-018-0146-z">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXhvVeqs7nE" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30275569" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Genetic%20mechanisms%20of%20target%20antigen%20loss%20in%20CAR19%20therapy%20of%20acute%20lymphoblastic%20leukemia&amp;journal=Nat.%20Med.&amp;doi=10.1038%2Fs41591-018-0146-z&amp;volume=24&amp;pages=1504-1506&amp;publication_year=2018&amp;author=Orlando%2CEJ" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR16">Sotillo, E. et al. Convergence of acquired mutations and alternative splicing of CD19 enables Resistance to CART-19 Immunotherapy. <i>Cancer Discov.</i> <b>5</b>, 1282–1295 (2015).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F2159-8290.CD-15-1020" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/2159-8290.CD-15-1020" data-track-item_id="10.1158/2159-8290.CD-15-1020">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2MXhvF2ltb%2FE" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26516065" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4670800" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Convergence%20of%20acquired%20mutations%20and%20alternative%20splicing%20of%20CD19%20enables%20Resistance%20to%20CART-19%20Immunotherapy&amp;journal=Cancer%20Discov.&amp;doi=10.1158%2F2159-8290.CD-15-1020&amp;volume=5&amp;pages=1282-1295&amp;publication_year=2015&amp;author=Sotillo%2CE" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR17">Majzner, R. G. et al. CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors. <i>Clin. Cancer Res.</i> <b>25</b>, 2560–2574 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F1078-0432.CCR-18-0432" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/1078-0432.CCR-18-0432" data-track-item_id="10.1158/1078-0432.CCR-18-0432">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXhsVeisr3J" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30655315" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8456711" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=CAR%20T%20cells%20targeting%20B7-H3%2C%20a%20pan-cancer%20antigen%2C%20demonstrate%20potent%20preclinical%20activity%20against%20pediatric%20solid%20tumors%20and%20brain%20tumors&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-18-0432&amp;volume=25&amp;pages=2560-2574&amp;publication_year=2019&amp;author=Majzner%2CRG" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR18">Watanabe, K. et al. Target antigen density governs the efficacy of anti-CD20-CD28-CD3 ζ chimeric antigen receptor-modified effector CD8<sup>+</sup> T cells. <i>J. Immunol.</i> <b>194</b>, 911–920 (2015).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.4049%2Fjimmunol.1402346" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.4049/jimmunol.1402346" data-track-item_id="10.4049/jimmunol.1402346">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2MXhtVCgsLc%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25520398" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Target%20antigen%20density%20governs%20the%20efficacy%20of%20anti-CD20-CD28-CD3%20%CE%B6%20chimeric%20antigen%20receptor-modified%20effector%20CD8%2B%20T%20cells&amp;journal=J.%20Immunol.&amp;doi=10.4049%2Fjimmunol.1402346&amp;volume=194&amp;pages=911-920&amp;publication_year=2015&amp;author=Watanabe%2CK" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR19">Hombach, A. A. et al. Superior therapeutic index in lymphoma therapy: CD30<sup>+</sup> CD34<sup>+</sup> hematopoietic stem cells resist a chimeric antigen receptor T-cell attack. <i>Mol. Ther.</i> <b>24</b>, 1423–1434 (2016).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fmt.2016.82" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/mt.2016.82" data-track-item_id="10.1038/mt.2016.82">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC28XhtVOnsrfN" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27112062" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5023391" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Superior%20therapeutic%20index%20in%20lymphoma%20therapy%3A%20CD30%2B%20CD34%2B%20hematopoietic%20stem%20cells%20resist%20a%20chimeric%20antigen%20receptor%20T-cell%20attack&amp;journal=Mol.%20Ther.&amp;doi=10.1038%2Fmt.2016.82&amp;volume=24&amp;pages=1423-1434&amp;publication_year=2016&amp;author=Hombach%2CAA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR20">Walker, A. J. et al. Tumor antigen and receptor densities regulate efficacy of a chimeric antigen receptor targeting anaplastic lymphoma kinase. <i>Mol. Ther.</i> <b>25</b>, 2189–2201 (2017).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.ymthe.2017.06.008" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.ymthe.2017.06.008" data-track-item_id="10.1016/j.ymthe.2017.06.008">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXhsVKlsbrE" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=28676342" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589087" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Tumor%20antigen%20and%20receptor%20densities%20regulate%20efficacy%20of%20a%20chimeric%20antigen%20receptor%20targeting%20anaplastic%20lymphoma%20kinase&amp;journal=Mol.%20Ther.&amp;doi=10.1016%2Fj.ymthe.2017.06.008&amp;volume=25&amp;pages=2189-2201&amp;publication_year=2017&amp;author=Walker%2CAJ" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR21">Majzner, R. G. et al. Tuning the antigen density requirement for CAR T-cell activity. <i>Cancer Discov.</i> <b>10</b>, 702–723 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F2159-8290.CD-19-0945" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/2159-8290.CD-19-0945" data-track-item_id="10.1158/2159-8290.CD-19-0945">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXit1antbjL" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32193224" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7939454" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Tuning%20the%20antigen%20density%20requirement%20for%20CAR%20T-cell%20activity&amp;journal=Cancer%20Discov.&amp;doi=10.1158%2F2159-8290.CD-19-0945&amp;volume=10&amp;pages=702-723&amp;publication_year=2020&amp;author=Majzner%2CRG" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR22">Fry, T. J. et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. <i>Nat. Med.</i> <b>24</b>, 20–28 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fnm.4441" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/nm.4441" data-track-item_id="10.1038/nm.4441">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXhvVaksrjM" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29155426" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=CD22-targeted%20CAR%20T%20cells%20induce%20remission%20in%20B-ALL%20that%20is%20naive%20or%20resistant%20to%20CD19-targeted%20CAR%20immunotherapy&amp;journal=Nat.%20Med.&amp;doi=10.1038%2Fnm.4441&amp;volume=24&amp;pages=20-28&amp;publication_year=2018&amp;author=Fry%2CTJ" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR23">Cohen, A. D. et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. <i>J. Clin. Invest.</i> <b>129</b>, 2210–2221 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1172%2FJCI126397" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1172/JCI126397" data-track-item_id="10.1172/JCI126397">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30896447" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6546468" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=B%20cell%20maturation%20antigen-specific%20CAR%20T%20cells%20are%20clinically%20active%20in%20multiple%20myeloma&amp;journal=J.%20Clin.%20Invest.&amp;doi=10.1172%2FJCI126397&amp;volume=129&amp;pages=2210-2221&amp;publication_year=2019&amp;author=Cohen%2CAD" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR24">Oak, J. et al. Target antigen downregulation and other mechanisms of failure after axicabtagene ciloleucel (CAR19) therapy. <i>Blood</i> <b>132</b>, 4656 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1182%2Fblood-2018-99-120206" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1182/blood-2018-99-120206" data-track-item_id="10.1182/blood-2018-99-120206">Article</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Target%20antigen%20downregulation%20and%20other%20mechanisms%20of%20failure%20after%20axicabtagene%20ciloleucel%20%28CAR19%29%20therapy&amp;journal=Blood&amp;doi=10.1182%2Fblood-2018-99-120206&amp;volume=132&amp;publication_year=2018&amp;author=Oak%2CJ" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR25">Neelapu, S. S. et al. CD19-loss with preservation of other B cell lineage features in patients with large B cell lymphoma who relapsed post-axi-cel. <i>Blood</i> <b>134</b>, 203 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1182%2Fblood-2019-126218" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1182/blood-2019-126218" data-track-item_id="10.1182/blood-2019-126218">Article</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=CD19-loss%20with%20preservation%20of%20other%20B%20cell%20lineage%20features%20in%20patients%20with%20large%20B%20cell%20lymphoma%20who%20relapsed%20post-axi-cel&amp;journal=Blood&amp;doi=10.1182%2Fblood-2019-126218&amp;volume=134&amp;publication_year=2019&amp;author=Neelapu%2CSS" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR26">Shah, N. N. et al. Characterization of CD22 expression in acute lymphoblastic leukemia. <i>Pediatr. Blood Cancer</i> <b>62</b>, 964–969 (2015).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1002%2Fpbc.25410" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1002/pbc.25410" data-track-item_id="10.1002/pbc.25410">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2MXms1GhtL0%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25728039" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4405453" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Characterization%20of%20CD22%20expression%20in%20acute%20lymphoblastic%20leukemia&amp;journal=Pediatr.%20Blood%20Cancer&amp;doi=10.1002%2Fpbc.25410&amp;volume=62&amp;pages=964-969&amp;publication_year=2015&amp;author=Shah%2CNN" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR27">Haso, W. et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. <i>Blood</i> <b>121</b>, 1165–1174 (2013).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1182%2Fblood-2012-06-438002" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1182/blood-2012-06-438002" data-track-item_id="10.1182/blood-2012-06-438002">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3sXjt1WhsLw%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23243285" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3575759" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Anti-CD22-chimeric%20antigen%20receptors%20targeting%20B-cell%20precursor%20acute%20lymphoblastic%20leukemia&amp;journal=Blood&amp;doi=10.1182%2Fblood-2012-06-438002&amp;volume=121&amp;pages=1165-1174&amp;publication_year=2013&amp;author=Haso%2CW" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR28">Tedder, T. F., Poe, J. C. &amp; Haas, K. M. CD22: a multifunctional receptor that regulates B lymphocyte survival and signal transduction. <i>Adv. Immunol.</i> <b>88</b>, 1–50 (2005).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2FS0065-2776%2805%2988001-0" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/S0065-2776(05)88001-0" data-track-item_id="10.1016/S0065-2776(05)88001-0">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD1cXhs12lsL8%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=16227086" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=CD22%3A%20a%20multifunctional%20receptor%20that%20regulates%20B%20lymphocyte%20survival%20and%20signal%20transduction&amp;journal=Adv.%20Immunol.&amp;doi=10.1016%2FS0065-2776%2805%2988001-0&amp;volume=88&amp;pages=1-50&amp;publication_year=2005&amp;author=Tedder%2CTF&amp;author=Poe%2CJC&amp;author=Haas%2CKM" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR29">Raponi, S. et al. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. <i>Leuk. Lymphoma</i> <b>52</b>, 1098–1107 (2011).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.3109%2F10428194.2011.559668" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.3109/10428194.2011.559668" data-track-item_id="10.3109/10428194.2011.559668">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3MXmtl2msLY%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=21348573" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Flow%20cytometric%20study%20of%20potential%20target%20antigens%20%28CD19%2C%20CD20%2C%20CD22%2C%20CD33%29%20for%20antibody-based%20immunotherapy%20in%20acute%20lymphoblastic%20leukemia%3A%20analysis%20of%20552%20cases&amp;journal=Leuk.%20Lymphoma&amp;doi=10.3109%2F10428194.2011.559668&amp;volume=52&amp;pages=1098-1107&amp;publication_year=2011&amp;author=Raponi%2CS" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR30">Olejniczak, S. H., Stewart, C. C., Donohue, K. &amp; Czuczman, M. S. A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry. <i>Immunol. Invest.</i> <b>35</b>, 93–114 (2006).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1080%2F08820130500496878" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1080/08820130500496878" data-track-item_id="10.1080/08820130500496878">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD28XisVarurw%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=16531332" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=A%20quantitative%20exploration%20of%20surface%20antigen%20expression%20in%20common%20B-cell%20malignancies%20using%20flow%20cytometry&amp;journal=Immunol.%20Invest.&amp;doi=10.1080%2F08820130500496878&amp;volume=35&amp;pages=93-114&amp;publication_year=2006&amp;author=Olejniczak%2CSH&amp;author=Stewart%2CCC&amp;author=Donohue%2CK&amp;author=Czuczman%2CMS" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR31">Shah, N. N. et al. CD4/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial. <i>J. Clin. Oncol.</i> <b>38</b>, 1938–1950 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1200%2FJCO.19.03279" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1200/JCO.19.03279" data-track-item_id="10.1200/JCO.19.03279">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXhvFantbrN" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32286905" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280047" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=CD4%2FCD8%20T-cell%20selection%20affects%20chimeric%20antigen%20receptor%20%28CAR%29%20T-cell%20potency%20and%20toxicity%3A%20updated%20results%20from%20a%20phase%20I%20anti-CD22%20CAR%20T-cell%20trial&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.19.03279&amp;volume=38&amp;pages=1938-1950&amp;publication_year=2020&amp;author=Shah%2CNN" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR32">Qin, H. et al. Preclinical development of bivalent chimeric antigen receptors targeting both CD19 and CD22. <i>Mol. Ther. Oncolytics</i> <b>11</b>, 127–137 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.omto.2018.10.006" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.omto.2018.10.006" data-track-item_id="10.1016/j.omto.2018.10.006">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXisFKqsrzL" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30581986" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6300726" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Preclinical%20development%20of%20bivalent%20chimeric%20antigen%20receptors%20targeting%20both%20CD19%20and%20CD22&amp;journal=Mol.%20Ther.%20Oncolytics&amp;doi=10.1016%2Fj.omto.2018.10.006&amp;volume=11&amp;pages=127-137&amp;publication_year=2018&amp;author=Qin%2CH" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR33">Frank, M. J. et al. Optimizing circulating tumor DNA based assessments in patients with large B-cell lymphoma undergoing axicabtagene ciloleucel. <i>J. Clin. Oncol</i>. <a href="https://doi.org/10.1200/JCO.21.00377" data-track="click_references" data-track-action="external reference" data-track-value="external reference" data-track-label="10.1200/JCO.21.00377">https://doi.org/10.1200/JCO.21.00377</a> (2021).</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR34">Weber, E. W. et al. Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling. <i>Science</i> <b>372</b>, eaba1786 (2021).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1126%2Fscience.aba1786" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1126/science.aba1786" data-track-item_id="10.1126/science.aba1786">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXotFGlur0%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33795428" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8049103" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Transient%20rest%20restores%20functionality%20in%20exhausted%20CAR-T%20cells%20through%20epigenetic%20remodeling&amp;journal=Science&amp;doi=10.1126%2Fscience.aba1786&amp;volume=372&amp;publication_year=2021&amp;author=Weber%2CEW" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR35">Yu, H. et al. Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma. <i>Am. J. Hematol.</i> <b>92</b>, E11–E13 (2017).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1002%2Fajh.24594" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1002/ajh.24594" data-track-item_id="10.1002/ajh.24594">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC28XitFens7zO" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27779774" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Repeated%20loss%20of%20target%20surface%20antigen%20after%20immunotherapy%20in%20primary%20mediastinal%20large%20B%20cell%20lymphoma&amp;journal=Am.%20J.%20Hematol.&amp;doi=10.1002%2Fajh.24594&amp;volume=92&amp;pages=E11-E13&amp;publication_year=2017&amp;author=Yu%2CH" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR36">Baird, J. H. et al. CD22-directed CAR T-cell therapy induces complete remissions in CD19-directed CAR-refractory large B-cell lymphoma. <i>Blood</i> <b>137</b>, 2321–2325 (2021).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1182%2Fblood.2020009432" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1182/blood.2020009432" data-track-item_id="10.1182/blood.2020009432">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXhtVeisb3L" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33512414" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8085484" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=CD22-directed%20CAR%20T-cell%20therapy%20induces%20complete%20remissions%20in%20CD19-directed%20CAR-refractory%20large%20B-cell%20lymphoma&amp;journal=Blood&amp;doi=10.1182%2Fblood.2020009432&amp;volume=137&amp;pages=2321-2325&amp;publication_year=2021&amp;author=Baird%2CJH" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR37">Gardner, R. et al. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy. <i>Blood</i> <b>127</b>, 2406–2410 (2016).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1182%2Fblood-2015-08-665547" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1182/blood-2015-08-665547" data-track-item_id="10.1182/blood-2015-08-665547">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC28Xhs1ent7vN" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=26907630" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4874221" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Acquisition%20of%20a%20CD19-negative%20myeloid%20phenotype%20allows%20immune%20escape%20of%20MLL-rearranged%20B-ALL%20from%20CD19%20CAR-T-cell%20therapy&amp;journal=Blood&amp;doi=10.1182%2Fblood-2015-08-665547&amp;volume=127&amp;pages=2406-2410&amp;publication_year=2016&amp;author=Gardner%2CR" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR38">Jacoby, E. et al. CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity. <i>Nat. Commun.</i> <b>7</b>, 12320 (2016).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fncomms12320" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/ncomms12320" data-track-item_id="10.1038/ncomms12320">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC28Xht12nsL3F" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27460500" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4974466" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=CD19%20CAR%20immune%20pressure%20induces%20B-precursor%20acute%20lymphoblastic%20leukaemia%20lineage%20switch%20exposing%20inherent%20leukaemic%20plasticity&amp;journal=Nat.%20Commun.&amp;doi=10.1038%2Fncomms12320&amp;volume=7&amp;publication_year=2016&amp;author=Jacoby%2CE" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR39">Schuster, S. J. et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. <i>N. Engl. J. Med.</i> <b>377</b>, 2545–2554 (2017).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1056%2FNEJMoa1708566" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1056/NEJMoa1708566" data-track-item_id="10.1056/NEJMoa1708566">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXhtVGjtbs%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29226764" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5788566" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Chimeric%20antigen%20receptor%20T%20cells%20in%20refractory%20B-cell%20lymphomas&amp;journal=N.%20Engl.%20J.%20Med.&amp;doi=10.1056%2FNEJMoa1708566&amp;volume=377&amp;pages=2545-2554&amp;publication_year=2017&amp;author=Schuster%2CSJ" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR40">Shalabi, H. et al. Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma. <i>Haematologica</i> <b>103</b>, e215–e218 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.3324%2Fhaematol.2017.183459" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.3324/haematol.2017.183459" data-track-item_id="10.3324/haematol.2017.183459">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXhsFCnt70%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29419431" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5927974" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Sequential%20loss%20of%20tumor%20surface%20antigens%20following%20chimeric%20antigen%20receptor%20T-cell%20therapies%20in%20diffuse%20large%20B-cell%20lymphoma&amp;journal=Haematologica&amp;doi=10.3324%2Fhaematol.2017.183459&amp;volume=103&amp;pages=e215-e218&amp;publication_year=2018&amp;author=Shalabi%2CH" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR41">Ali, S. A. et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma. <i>Blood</i> <b>128</b>, 1688–1700 (2016).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1182%2Fblood-2016-04-711903" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1182/blood-2016-04-711903" data-track-item_id="10.1182/blood-2016-04-711903">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2sXhtlSitrk%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27412889" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5043125" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=T%20cells%20expressing%20an%20anti-B-cell%20maturation%20antigen%20chimeric%20antigen%20receptor%20cause%20remissions%20of%20multiple%20myeloma&amp;journal=Blood&amp;doi=10.1182%2Fblood-2016-04-711903&amp;volume=128&amp;pages=1688-1700&amp;publication_year=2016&amp;author=Ali%2CSA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR42">Hegde, M. et al. Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape. <i>J. Clin. Invest.</i> <b>126</b>, 3036–3052 (2016).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1172%2FJCI83416" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1172/JCI83416" data-track-item_id="10.1172/JCI83416">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27427982" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4966331" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Tandem%20CAR%20T%20cells%20targeting%20HER2%20and%20IL13R%CE%B12%20mitigate%20tumor%20antigen%20escape&amp;journal=J.%20Clin.%20Invest.&amp;doi=10.1172%2FJCI83416&amp;volume=126&amp;pages=3036-3052&amp;publication_year=2016&amp;author=Hegde%2CM" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR43">Bielamowicz, K. et al. Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma. <i>Neuro Oncol.</i> <b>20</b>, 506–518 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1093%2Fneuonc%2Fnox182" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1093/neuonc/nox182" data-track-item_id="10.1093/neuonc/nox182">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXps1Ogtb8%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29016929" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Trivalent%20CAR%20T%20cells%20overcome%20interpatient%20antigenic%20variability%20in%20glioblastoma&amp;journal=Neuro%20Oncol.&amp;doi=10.1093%2Fneuonc%2Fnox182&amp;volume=20&amp;pages=506-518&amp;publication_year=2018&amp;author=Bielamowicz%2CK" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR44">Zah, E. et al. Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma. <i>Nat. Commun.</i> <b>11</b>, 2283 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fs41467-020-16160-5" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/s41467-020-16160-5" data-track-item_id="10.1038/s41467-020-16160-5">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXptVertLo%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32385241" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7210316" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Systematically%20optimized%20BCMA%2FCS1%20bispecific%20CAR-T%20cells%20robustly%20control%20heterogeneous%20multiple%20myeloma&amp;journal=Nat.%20Commun.&amp;doi=10.1038%2Fs41467-020-16160-5&amp;volume=11&amp;publication_year=2020&amp;author=Zah%2CE" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR45">He, X. et al. Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia. <i>Blood</i> <b>135</b>, 713–723 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1182%2Fblood.2019002779" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1182/blood.2019002779" data-track-item_id="10.1182/blood.2019002779">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31951650" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7059518" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Bispecific%20and%20split%20CAR%20T%20cells%20targeting%20CD13%20and%20TIM3%20eradicate%20acute%20myeloid%20leukemia&amp;journal=Blood&amp;doi=10.1182%2Fblood.2019002779&amp;volume=135&amp;pages=713-723&amp;publication_year=2020&amp;author=He%2CX" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR46">Schmidts, A. et al. Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma. <i>Blood Adv.</i> <b>3</b>, 3248–3260 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1182%2Fbloodadvances.2019000703" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1182/bloodadvances.2019000703" data-track-item_id="10.1182/bloodadvances.2019000703">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31698455" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6855119" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXitVGhsbfK" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Rational%20design%20of%20a%20trimeric%20APRIL-based%20CAR-binding%20domain%20enables%20efficient%20targeting%20of%20multiple%20myeloma&amp;journal=Blood%20Adv.&amp;doi=10.1182%2Fbloodadvances.2019000703&amp;volume=3&amp;pages=3248-3260&amp;publication_year=2019&amp;author=Schmidts%2CA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR47">Shah, N. N. et al. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. <i>Nat. Med.</i> <b>26</b>, 1569–1575 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fs41591-020-1081-3" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/s41591-020-1081-3" data-track-item_id="10.1038/s41591-020-1081-3">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXhvF2jtLfF" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33020647" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Bispecific%20anti-CD20%2C%20anti-CD19%20CAR%20T%20cells%20for%20relapsed%20B%20cell%20malignancies%3A%20a%20phase%201%20dose%20escalation%20and%20expansion%20trial&amp;journal=Nat.%20Med.&amp;doi=10.1038%2Fs41591-020-1081-3&amp;volume=26&amp;pages=1569-1575&amp;publication_year=2020&amp;author=Shah%2CNN" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR48">Tong, C. et al. Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma. <i>Blood</i> <b>136</b>, 1632–1644 (2020).</p><p class="c-reading-companion__reference-links"><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32556247" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7596761" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Optimized%20tandem%20CD19%2FCD20%20CAR-engineered%20T%20cells%20in%20refractory%2Frelapsed%20B-cell%20lymphoma&amp;journal=Blood&amp;volume=136&amp;pages=1632-1644&amp;publication_year=2020&amp;author=Tong%2CC" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR49">Gardner, R. A. et al. Efficacy of SCRI-CAR19x22 T cell product in B-ALL and persistence of anti-CD22 activity. <i>J. Clin. Oncol.</i> <b>38</b>, 3035 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1200%2FJCO.2020.38.15_suppl.3035" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1200/JCO.2020.38.15_suppl.3035" data-track-item_id="10.1200/JCO.2020.38.15_suppl.3035">Article</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Efficacy%20of%20SCRI-CAR19x22%20T%20cell%20product%20in%20B-ALL%20and%20persistence%20of%20anti-CD22%20activity&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.2020.38.15_suppl.3035&amp;volume=38&amp;publication_year=2020&amp;author=Gardner%2CRA" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR50">Fousek, K. et al. CAR T-cells that target acute B-lineage leukemia irrespective of CD19 expression. <i>Leukemia</i> <b>35</b>, 75–89 (2021).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fs41375-020-0792-2" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/s41375-020-0792-2" data-track-item_id="10.1038/s41375-020-0792-2">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXlvFOlsLc%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32205861" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=CAR%20T-cells%20that%20target%20acute%20B-lineage%20leukemia%20irrespective%20of%20CD19%20expression&amp;journal=Leukemia&amp;doi=10.1038%2Fs41375-020-0792-2&amp;volume=35&amp;pages=75-89&amp;publication_year=2021&amp;author=Fousek%2CK" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR51">Dai, H. et al. Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. <i>J. Hematol. Oncol.</i> <b>13</b>, 30 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://link.springer.com/doi/10.1186/s13045-020-00856-8" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1186/s13045-020-00856-8" data-track-item_id="10.1186/s13045-020-00856-8">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32245502" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7126394" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXmsVers7Y%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Bispecific%20CAR-T%20cells%20targeting%20both%20CD19%20and%20CD22%20for%20therapy%20of%20adults%20with%20relapsed%20or%20refractory%20B%20cell%20acute%20lymphoblastic%20leukemia&amp;journal=J.%20Hematol.%20Oncol.&amp;doi=10.1186%2Fs13045-020-00856-8&amp;volume=13&amp;publication_year=2020&amp;author=Dai%2CH" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR52">Amrolia, P. J. et al. Phase I study of AUTO3, a bicistronic chimeric antigen receptor (CAR) T-cell therapy targeting CD19 and CD22, in pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL): Amelia study. <i>Blood</i> <b>134</b>, 2620 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1182%2Fblood-2019-123424" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1182/blood-2019-123424" data-track-item_id="10.1182/blood-2019-123424">Article</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Phase%20I%20study%20of%20AUTO3%2C%20a%20bicistronic%20chimeric%20antigen%20receptor%20%28CAR%29%20T-cell%20therapy%20targeting%20CD19%20and%20CD22%2C%20in%20pediatric%20patients%20with%20relapsed%2Frefractory%20B-cell%20acute%20lymphoblastic%20leukemia%20%28r%2Fr%20B-ALL%29%3A%20Amelia%20study&amp;journal=Blood&amp;doi=10.1182%2Fblood-2019-123424&amp;volume=134&amp;publication_year=2019&amp;author=Amrolia%2CPJ" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR53">Lynn, R. C. et al. c-Jun overexpression in CAR T cells induces exhaustion resistance. <i>Nature</i> <b>576</b>, 293–300 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fs41586-019-1805-z" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/s41586-019-1805-z" data-track-item_id="10.1038/s41586-019-1805-z">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXitlWku7rF" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=31802004" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6944329" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=c-Jun%20overexpression%20in%20CAR%20T%20cells%20induces%20exhaustion%20resistance&amp;journal=Nature&amp;doi=10.1038%2Fs41586-019-1805-z&amp;volume=576&amp;pages=293-300&amp;publication_year=2019&amp;author=Lynn%2CRC" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR54">Guest, R. D. et al. The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens. <i>J. Immunother.</i> <b>28</b>, 203–211 (2005).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1097%2F01.cji.0000161397.96582.59" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1097/01.cji.0000161397.96582.59" data-track-item_id="10.1097/01.cji.0000161397.96582.59">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD2MXjtlKlurc%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=15838376" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=The%20role%20of%20extracellular%20spacer%20regions%20in%20the%20optimal%20design%20of%20chimeric%20immune%20receptors%3A%20evaluation%20of%20four%20different%20scFvs%20and%20antigens&amp;journal=J.%20Immunother.&amp;doi=10.1097%2F01.cji.0000161397.96582.59&amp;volume=28&amp;pages=203-211&amp;publication_year=2005&amp;author=Guest%2CRD" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR55">Hudecek, M. et al. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. <i>Clin. Cancer Res.</i> <b>19</b>, 3153–3164 (2013).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F1078-0432.CCR-13-0330" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/1078-0432.CCR-13-0330" data-track-item_id="10.1158/1078-0432.CCR-13-0330">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3sXpsVyns78%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23620405" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3804130" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Receptor%20affinity%20and%20extracellular%20domain%20modifications%20affect%20tumor%20recognition%20by%20ROR1-specific%20chimeric%20antigen%20receptor%20T%20cells&amp;journal=Clin.%20Cancer%20Res.&amp;doi=10.1158%2F1078-0432.CCR-13-0330&amp;volume=19&amp;pages=3153-3164&amp;publication_year=2013&amp;author=Hudecek%2CM" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR56">Long, A. H., Haso, W. M. &amp; Orentas, R. J. Lessons learned from a highly-active CD22-specific chimeric antigen receptor. <i>Oncoimmunology</i> <b>2</b>, e23621 (2013).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.4161%2Fonci.23621" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.4161/onci.23621" data-track-item_id="10.4161/onci.23621">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23734316" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654586" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Lessons%20learned%20from%20a%20highly-active%20CD22-specific%20chimeric%20antigen%20receptor&amp;journal=Oncoimmunology&amp;doi=10.4161%2Fonci.23621&amp;volume=2&amp;publication_year=2013&amp;author=Long%2CAH&amp;author=Haso%2CWM&amp;author=Orentas%2CRJ" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR57">Li, D. et al. Persistent polyfunctional chimeric antigen receptor T cells that target glypican 3 eliminate orthotopic hepatocellular carcinomas in mice. <i>Gastroenterology</i> <b>158</b>, 2250–2265.e20 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1053%2Fj.gastro.2020.02.011" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1053/j.gastro.2020.02.011" data-track-item_id="10.1053/j.gastro.2020.02.011">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXhtV2jtrfK" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32060001" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Persistent%20polyfunctional%20chimeric%20antigen%20receptor%20T%20cells%20that%20target%20glypican%203%20eliminate%20orthotopic%20hepatocellular%20carcinomas%20in%20mice&amp;journal=Gastroenterology&amp;doi=10.1053%2Fj.gastro.2020.02.011&amp;volume=158&amp;pages=2250-2265.e20&amp;publication_year=2020&amp;author=Li%2CD" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR58">Singh, N. et al. Single chain variable fragment linker length regulates CAR biology and T cell efficacy. <i>Blood</i> <b>134</b>, 247 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1182%2Fblood-2019-131024" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1182/blood-2019-131024" data-track-item_id="10.1182/blood-2019-131024">Article</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Single%20chain%20variable%20fragment%20linker%20length%20regulates%20CAR%20biology%20and%20T%20cell%20efficacy&amp;journal=Blood&amp;doi=10.1182%2Fblood-2019-131024&amp;volume=134&amp;publication_year=2019&amp;author=Singh%2CN" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR59">Grada, Z. et al. TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy. <i>Mol. Ther. Nucleic Acids</i> <b>2</b>, e105 (2013).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1038%2Fmtna.2013.32" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1038/mtna.2013.32" data-track-item_id="10.1038/mtna.2013.32">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23839099" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3731887" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3sXht1elsb3I" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=TanCAR%3A%20a%20novel%20bispecific%20chimeric%20antigen%20receptor%20for%20cancer%20immunotherapy&amp;journal=Mol.%20Ther.%20Nucleic%20Acids&amp;doi=10.1038%2Fmtna.2013.32&amp;volume=2&amp;publication_year=2013&amp;author=Grada%2CZ" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR60">Zah, E., Lin, M.-Y., Silva-Benedict, A., Jensen, M. C. &amp; Chen, Y. Y. T cells expressing CD19/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells. <i>Cancer Immunol. Res.</i> <b>4</b>, 498–508 (2016).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1158%2F2326-6066.CIR-15-0231" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1158/2326-6066.CIR-15-0231" data-track-item_id="10.1158/2326-6066.CIR-15-0231">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC28XptVersb8%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=27059623" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4933590" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=T%20cells%20expressing%20CD19%2FCD20%20bispecific%20chimeric%20antigen%20receptors%20prevent%20antigen%20escape%20by%20malignant%20B%20cells&amp;journal=Cancer%20Immunol.%20Res.&amp;doi=10.1158%2F2326-6066.CIR-15-0231&amp;volume=4&amp;pages=498-508&amp;publication_year=2016&amp;author=Zah%2CE&amp;author=Lin%2CM-Y&amp;author=Silva-Benedict%2CA&amp;author=Jensen%2CMC&amp;author=Chen%2CYY" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR61">Spiegel, J. Y. et al. Outcomes of patients with large B-cell lymphoma progressing after axicabtagene ciloleucel therapy. <i>Blood</i> <b>137</b>, 1832–1835 (2021).</p><p class="c-reading-companion__reference-links"><a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXotFansbw%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33156925" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555382" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Outcomes%20of%20patients%20with%20large%20B-cell%20lymphoma%20progressing%20after%20axicabtagene%20ciloleucel%20therapy&amp;journal=Blood&amp;volume=137&amp;pages=1832-1835&amp;publication_year=2021&amp;author=Spiegel%2CJY" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR62">Blaeschke, F. et al. Induction of a central memory and stem cell memory phenotype in functionally active CD4<sup>+</sup> and CD8<sup>+</sup> CAR T cells produced in an automated good manufacturing practice system for the treatment of CD19<sup>+</sup> acute lymphoblastic leukemia. <i>Cancer Immunol. Immunother.</i> <b>67</b>, 1053–1066 (2018).</p><p class="c-reading-companion__reference-links"><a href="https://link.springer.com/doi/10.1007/s00262-018-2155-7" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1007/s00262-018-2155-7" data-track-item_id="10.1007/s00262-018-2155-7">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1cXmslKktrg%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=29605883" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Induction%20of%20a%20central%20memory%20and%20stem%20cell%20memory%20phenotype%20in%20functionally%20active%20CD4%2B%20and%20CD8%2B%20CAR%20T%20cells%20produced%20in%20an%20automated%20good%20manufacturing%20practice%20system%20for%20the%20treatment%20of%20CD19%2B%20acute%20lymphoblastic%20leukemia&amp;journal=Cancer%20Immunol.%20Immunother.&amp;doi=10.1007%2Fs00262-018-2155-7&amp;volume=67&amp;pages=1053-1066&amp;publication_year=2018&amp;author=Blaeschke%2CF" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR63">Xu, Y. et al. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. <i>Blood</i> <b>123</b>, 3750–3759 (2014).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1182%2Fblood-2014-01-552174" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1182/blood-2014-01-552174" data-track-item_id="10.1182/blood-2014-01-552174">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2cXhtVeltb3O" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=24782509" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4055922" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Closely%20related%20T-memory%20stem%20cells%20correlate%20with%20in%20vivo%20expansion%20of%20CAR.CD19-T%20cells%20and%20are%20preserved%20by%20IL-7%20and%20IL-15&amp;journal=Blood&amp;doi=10.1182%2Fblood-2014-01-552174&amp;volume=123&amp;pages=3750-3759&amp;publication_year=2014&amp;author=Xu%2CY" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR64">Pasquini, M. C. et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. <i>Blood Adv.</i> <b>4</b>, 5414–5424 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1182%2Fbloodadvances.2020003092" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1182/bloodadvances.2020003092" data-track-item_id="10.1182/bloodadvances.2020003092">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXis12ksL3N" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=33147337" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7656920" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Real-world%20evidence%20of%20tisagenlecleucel%20for%20pediatric%20acute%20lymphoblastic%20leukemia%20and%20non-Hodgkin%20lymphoma&amp;journal=Blood%20Adv.&amp;doi=10.1182%2Fbloodadvances.2020003092&amp;volume=4&amp;pages=5414-5424&amp;publication_year=2020&amp;author=Pasquini%2CMC" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR65">Cheson, B. D. et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. <i>J. Clin. Oncol.</i> <b>32</b>, 3059–3067 (2014).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1200%2FJCO.2013.54.8800" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1200/JCO.2013.54.8800" data-track-item_id="10.1200/JCO.2013.54.8800">Article</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=25113753" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979083" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Recommendations%20for%20initial%20evaluation%2C%20staging%2C%20and%20response%20assessment%20of%20Hodgkin%20and%20non-Hodgkin%20lymphoma%3A%20the%20Lugano%20classification&amp;journal=J.%20Clin.%20Oncol.&amp;doi=10.1200%2FJCO.2013.54.8800&amp;volume=32&amp;pages=3059-3067&amp;publication_year=2014&amp;author=Cheson%2CBD" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR66">Lee, D. W. et al. Current concepts in the diagnosis and management of cytokine release syndrome. <i>Blood</i> <b>124</b>, 188–195 (2014).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1182%2Fblood-2014-05-552729" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1182/blood-2014-05-552729" data-track-item_id="10.1182/blood-2014-05-552729">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC2cXht1WktbrM" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=24876563" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4093680" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Current%20concepts%20in%20the%20diagnosis%20and%20management%20of%20cytokine%20release%20syndrome&amp;journal=Blood&amp;doi=10.1182%2Fblood-2014-05-552729&amp;volume=124&amp;pages=188-195&amp;publication_year=2014&amp;author=Lee%2CDW" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR67">Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. <i>Biol. Blood Marrow Transplant.</i> <b>25</b>, 625–638 (2019).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1016%2Fj.bbmt.2018.12.758" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1016/j.bbmt.2018.12.758" data-track-item_id="10.1016/j.bbmt.2018.12.758">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXhs1aksbw%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=30592986" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=ASTCT%20consensus%20grading%20for%20cytokine%20release%20syndrome%20and%20neurologic%20toxicity%20associated%20with%20immune%20effector%20cells&amp;journal=Biol.%20Blood%20Marrow%20Transplant.&amp;doi=10.1016%2Fj.bbmt.2018.12.758&amp;volume=25&amp;pages=625-638&amp;publication_year=2019&amp;author=Lee%2CDW" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR68">Marinelli, R. J. et al. The Stanford Tissue Microarray Database. <i>Nucleic Acids Res.</i> <b>36</b>, D871–D877 (2008).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1093%2Fnar%2Fgkm861" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1093/nar/gkm861" data-track-item_id="10.1093/nar/gkm861">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BD1cXhtVWit78%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=17989087" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=The%20Stanford%20Tissue%20Microarray%20Database&amp;journal=Nucleic%20Acids%20Res.&amp;doi=10.1093%2Fnar%2Fgkm861&amp;volume=36&amp;pages=D871-D877&amp;publication_year=2008&amp;author=Marinelli%2CRJ" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR69">Jena, B. et al. Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials. <i>PLoS ONE</i> <b>8</b>, e57838 (2013).</p><p class="c-reading-companion__reference-links"><a href="https://doi.org/10.1371%2Fjournal.pone.0057838" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1371/journal.pone.0057838" data-track-item_id="10.1371/journal.pone.0057838">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC3sXkt1WhtLk%3D" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=23469246" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3585808" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Chimeric%20antigen%20receptor%20%28CAR%29-specific%20monoclonal%20antibody%20to%20detect%20CD19-specific%20T%20cells%20in%20clinical%20trials&amp;journal=PLoS%20ONE&amp;doi=10.1371%2Fjournal.pone.0057838&amp;volume=8&amp;publication_year=2013&amp;author=Jena%2CB" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li><li class="c-reading-companion__reference-item"><p class="c-reading-companion__reference-citation u-font-family-serif" id="rc-ref-CR70">Ching, T. et al. Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma. <i>BMC Cancer</i> <b>20</b>, 612 (2020).</p><p class="c-reading-companion__reference-links"><a href="https://link.springer.com/doi/10.1186/s12885-020-07077-9" data-track="click_references" data-track-action="article reference" data-track-value="article reference" data-track-label="10.1186/s12885-020-07077-9" data-track-item_id="10.1186/s12885-020-07077-9">Article</a>&nbsp;<a href="https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXhtlKgt73E" data-track="click_references" data-track-action="cas reference" data-track-value="cas reference" data-track-label="link" data-track-item_id="link">CAS</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Abstract&amp;list_uids=32605647" data-track="click_references" data-track-action="pubmed reference" data-track-value="pubmed reference" data-track-label="link" data-track-item_id="link">PubMed</a>&nbsp;<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325652" data-track="click_references" data-track-action="pubmed central reference" data-track-value="pubmed central reference" data-track-label="link" data-track-item_id="link">PubMed Central</a>&nbsp;<a href="http://scholar.google.com/scholar_lookup?&amp;title=Analytical%20evaluation%20of%20the%20clonoSEQ%20Assay%20for%20establishing%20measurable%20%28minimal%29%20residual%20disease%20in%20acute%20lymphoblastic%20leukemia%2C%20chronic%20lymphocytic%20leukemia%2C%20and%20multiple%20myeloma&amp;journal=BMC%20Cancer&amp;doi=10.1186%2Fs12885-020-07077-9&amp;volume=20&amp;publication_year=2020&amp;author=Ching%2CT" data-track="click_references" data-track-action="google scholar reference" data-track-value="google scholar reference" data-track-label="link" data-track-item_id="link">
                    Google Scholar</a>&nbsp;</p></li></ol></div></div>
        </div>
    </div>
</aside>
</div>


    
        
    
    
        
            
        

        
            
        
    
    <script>
        window.dataLayer = window.dataLayer || [];
        window.dataLayer.push({
            page: {
                content: {
                    fundingWidget: "true",
                        }
                    }
                });
    </script>




<footer class="composite-layer" itemscope="" itemtype="http://schema.org/Periodical">
        <meta itemprop="publisher" content="Springer Nature">
        

        <div class="u-mt-16 u-mb-16">
    <div class="u-container">
        <div class="u-display-flex u-flex-wrap u-justify-content-space-between">
            

            <div class="c-meta u-ma-0 u-flex-shrink">
                <p class="c-meta__item c-meta__type u-mt-0">
                    <span itemprop="name">
                        Nature Medicine
                    </span>
                    (<i itemprop="alternateName">Nat Med</i>)
                </p>
                
    
        <p class="c-meta__item u-mt-0">
            <abbr title="International Standard Serial Number">ISSN</abbr> <span itemprop="issn">1546-170X</span> (online)
        </p>
    

                
    
        <p class="c-meta__item u-mt-0">
            <abbr title="International Standard Serial Number">ISSN</abbr> <span itemprop="issn">1078-8956</span> (print)
        </p>
    

            </div>
        </div>
    </div>
</div>

    <div class="c-footer">
        <div class="u-hide-print" data-track-component="footer">
    <h2 class="u-visually-hidden">nature.com sitemap</h2>
    <div class="c-footer__container">
        <div class="c-footer__grid c-footer__group--separator">
            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">About Nature Portfolio</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/npg_/company_info/index.html" data-track="click" data-track-action="about us" data-track-label="link">About us</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/npg_/press_room/press_releases.html" data-track="click" data-track-action="press releases" data-track-label="link">Press releases</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://press.nature.com/" data-track="click" data-track-action="press office" data-track-label="link">Press office</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://support.nature.com/support/home" data-track="click" data-track-action="contact us" data-track-label="link">Contact us</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Discover content</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/siteindex" data-track="click" data-track-action="journals a-z" data-track-label="link">Journals A-Z</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/subjects" data-track="click" data-track-action="article by subject" data-track-label="link">Articles by subject</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.protocols.io/" data-track="click" data-track-action="protocols.io" data-track-label="link">protocols.io</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.natureindex.com/" data-track="click" data-track-action="nature index" data-track-label="link">Nature Index</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Publishing policies</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/authors/editorial_policies" data-track="click" data-track-action="Nature portfolio policies" data-track-label="link">Nature portfolio policies</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/nature-research/open-access" data-track="click" data-track-action="open access" data-track-label="link">Open access</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Author &amp; Researcher services</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/reprints" data-track="click" data-track-action="reprints and permissions" data-track-label="link">Reprints &amp; permissions</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.springernature.com/gp/authors/research-data" data-track="click" data-track-action="data research service" data-track-label="link">Research data</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://authorservices.springernature.com/language-editing/" data-track="click" data-track-action="language editing" data-track-label="link">Language editing</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://authorservices.springernature.com/scientific-editing/" data-track="click" data-track-action="scientific editing" data-track-label="link">Scientific editing</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://masterclasses.nature.com/" data-track="click" data-track-action="nature masterclasses" data-track-label="link">Nature Masterclasses</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://solutions.springernature.com/" data-track="click" data-track-action="research solutions" data-track-label="link">Research Solutions</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Libraries &amp; institutions</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.springernature.com/gp/librarians/tools-services" data-track="click" data-track-action="librarian service and tools" data-track-label="link">Librarian service &amp; tools</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.springernature.com/gp/librarians/manage-your-account/librarianportal" data-track="click" data-track-action="librarian portal" data-track-label="link">Librarian portal</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/openresearch/about-open-access/information-for-institutions" data-track="click" data-track-action="open research" data-track-label="link">Open research</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.springernature.com/gp/librarians/recommend-to-your-library" data-track="click" data-track-action="Recommend to library" data-track-label="link">Recommend to library</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Advertising &amp; partnerships</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://partnerships.nature.com/product/digital-advertising/" data-track="click" data-track-action="advertising" data-track-label="link">Advertising</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://partnerships.nature.com/" data-track="click" data-track-action="partnerships and services" data-track-label="link">Partnerships &amp; Services</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://partnerships.nature.com/media-kits/" data-track="click" data-track-action="media kits" data-track-label="link">Media kits</a>
                    </li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://partnerships.nature.com/product/branded-content-native-advertising/" data-track-action="branded content" data-track-label="link">Branded
                        content</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Professional development</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/naturecareers/" data-track="click" data-track-action="nature careers" data-track-label="link">Nature Careers</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://conferences.nature.com" data-track="click" data-track-action="nature conferences" data-track-label="link">Nature<span class="u-visually-hidden"> </span>
                        Conferences</a></li>
                </ul>
            </div>

            <div class="c-footer__group">
                <h3 class="c-footer__heading u-mt-0">Regional websites</h3>
                <ul class="c-footer__list">
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/natafrica" data-track="click" data-track-action="nature africa" data-track-label="link">Nature Africa</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="http://www.naturechina.com" data-track="click" data-track-action="nature china" data-track-label="link">Nature China</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/nindia" data-track="click" data-track-action="nature india" data-track-label="link">Nature India</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/natitaly" data-track="click" data-track-action="nature Italy" data-track-label="link">Nature Italy</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.natureasia.com/ja-jp" data-track="click" data-track-action="nature japan" data-track-label="link">Nature Japan</a></li>
                    <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/nmiddleeast" data-track="click" data-track-action="nature middle east" data-track-label="link">Nature Middle East</a></li>
                </ul>
            </div>

        </div>
    </div>
    <div class="c-footer__container">
        <ul class="c-footer__links">
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/privacy" data-track="click" data-track-action="privacy policy" data-track-label="link">Privacy
                Policy</a></li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/cookies" data-track="click" data-track-action="use of cookies" data-track-label="link">Use
                of cookies</a></li>
            <li class="c-footer__item">
                <button class="optanon-toggle-display c-footer__link" onclick="javascript:;" data-cc-action="preferences" data-track="click" data-track-action="manage cookies" data-track-label="link">Your privacy choices/Manage cookies
                </button>
            </li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/legal-notice" data-track="click" data-track-action="legal notice" data-track-label="link">Legal
                notice</a></li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/accessibility-statement" data-track="click" data-track-action="accessibility statement" data-track-label="link">Accessibility
                statement</a></li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.nature.com/info/terms-and-conditions" data-track="click" data-track-action="terms and conditions" data-track-label="link">Terms &amp; Conditions</a></li>
            <li class="c-footer__item"><a class="c-footer__link" href="https://www.springernature.com/ccpa" data-track="click" data-track-action="california privacy statement" data-track-label="link">Your US state privacy rights</a></li>
            
        </ul>
    </div>
</div>


        <div class="c-footer__container">
    <a href="https://www.springernature.com/" class="c-footer__link">
        <img src="/static/images/logos/sn-logo-white-ea63208b81.svg" alt="Springer Nature" loading="lazy" width="200" height="20">
    </a>
    <p class="c-footer__legal" data-test="copyright">© 2025 Springer Nature Limited</p>
</div>

    </div>
    <div class="u-visually-hidden" aria-hidden="true">
    
    <!--?xml version="1.0" encoding="UTF-8"?--><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink"><defs><path id="a" d="M0 .74h56.72v55.24H0z"></path></defs><symbol id="icon-access" viewBox="0 0 18 18"><path d="m14 8c.5522847 0 1 .44771525 1 1v7h2.5c.2761424 0 .5.2238576.5.5v1.5h-18v-1.5c0-.2761424.22385763-.5.5-.5h2.5v-7c0-.55228475.44771525-1 1-1s1 .44771525 1 1v6.9996556h8v-6.9996556c0-.55228475.4477153-1 1-1zm-8 0 2 1v5l-2 1zm6 0v7l-2-1v-5zm-2.42653766-7.59857636 7.03554716 4.92488299c.4162533.29137735.5174853.86502537.226108 1.28127873-.1721584.24594054-.4534847.39241464-.7536934.39241464h-14.16284822c-.50810197 0-.92-.41189803-.92-.92 0-.30020869.1464741-.58153499.39241464-.75369337l7.03554714-4.92488299c.34432015-.2410241.80260453-.2410241 1.14692468 0zm-.57346234 2.03988748-3.65526982 2.55868888h7.31053962z" fill-rule="evenodd"></path></symbol><symbol id="icon-account" viewBox="0 0 18 18"><path d="m10.2379028 16.9048051c1.3083556-.2032362 2.5118471-.7235183 3.5294683-1.4798399-.8731327-2.5141501-2.0638925-3.935978-3.7673711-4.3188248v-1.27684611c1.1651924-.41183641 2-1.52307546 2-2.82929429 0-1.65685425-1.3431458-3-3-3-1.65685425 0-3 1.34314575-3 3 0 1.30621883.83480763 2.41745788 2 2.82929429v1.27684611c-1.70347856.3828468-2.89423845 1.8046747-3.76737114 4.3188248 1.01762123.7563216 2.22111275 1.2766037 3.52946833 1.4798399.40563808.0629726.81921174.0951949 1.23790281.0951949s.83226473-.0322223 1.2379028-.0951949zm4.3421782-2.1721994c1.4927655-1.4532925 2.419919-3.484675 2.419919-5.7326057 0-4.418278-3.581722-8-8-8s-8 3.581722-8 8c0 2.2479307.92715352 4.2793132 2.41991895 5.7326057.75688473-2.0164459 1.83949951-3.6071894 3.48926591-4.3218837-1.14534283-.70360829-1.90918486-1.96796271-1.90918486-3.410722 0-2.209139 1.790861-4 4-4s4 1.790861 4 4c0 1.44275929-.763842 2.70711371-1.9091849 3.410722 1.6497664.7146943 2.7323812 2.3054378 3.4892659 4.3218837zm-5.580081 3.2673943c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9z" fill-rule="evenodd"></path></symbol><symbol id="icon-alert" viewBox="0 0 18 18"><path d="m4 10h2.5c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-3.08578644l-1.12132034 1.1213203c-.18753638.1875364-.29289322.4418903-.29289322.7071068v.1715729h14v-.1715729c0-.2652165-.1053568-.5195704-.2928932-.7071068l-1.7071068-1.7071067v-3.4142136c0-2.76142375-2.2385763-5-5-5-2.76142375 0-5 2.23857625-5 5zm3 4c0 1.1045695.8954305 2 2 2s2-.8954305 2-2zm-5 0c-.55228475 0-1-.4477153-1-1v-.1715729c0-.530433.21071368-1.0391408.58578644-1.4142135l1.41421356-1.4142136v-3c0-3.3137085 2.6862915-6 6-6s6 2.6862915 6 6v3l1.4142136 1.4142136c.3750727.3750727.5857864.8837805.5857864 1.4142135v.1715729c0 .5522847-.4477153 1-1 1h-4c0 1.6568542-1.3431458 3-3 3-1.65685425 0-3-1.3431458-3-3z" fill-rule="evenodd"></path></symbol><symbol id="icon-arrow-broad" viewBox="0 0 16 16"><path d="m6.10307866 2.97190702v7.69043288l2.44965196-2.44676915c.38776071-.38730439 1.0088052-.39493524 1.38498697-.01919617.38609051.38563612.38643641 1.01053024-.00013864 1.39665039l-4.12239817 4.11754683c-.38616704.3857126-1.01187344.3861062-1.39846576-.0000311l-4.12258206-4.11773056c-.38618426-.38572979-.39254614-1.00476697-.01636437-1.38050605.38609047-.38563611 1.01018509-.38751562 1.4012233.00306241l2.44985644 2.4469734v-8.67638639c0-.54139983.43698413-.98042709.98493125-.98159081l7.89910522-.0043627c.5451687 0 .9871152.44142642.9871152.98595351s-.4419465.98595351-.9871152.98595351z" fill-rule="evenodd" transform="matrix(-1 0 0 -1 14 15)"></path></symbol><symbol id="icon-arrow-down" viewBox="0 0 16 16"><path d="m3.28337502 11.5302405 4.03074001 4.176208c.37758093.3912076.98937525.3916069 1.367372-.0000316l4.03091977-4.1763942c.3775978-.3912252.3838182-1.0190815.0160006-1.4001736-.3775061-.39113013-.9877245-.39303641-1.3700683.003106l-2.39538585 2.4818345v-11.6147896l-.00649339-.11662112c-.055753-.49733869-.46370161-.88337888-.95867408-.88337888-.49497246 0-.90292107.38604019-.95867408.88337888l-.00649338.11662112v11.6147896l-2.39518594-2.4816273c-.37913917-.39282218-.98637524-.40056175-1.35419292-.0194697-.37750607.3911302-.37784433 1.0249269.00013556 1.4165479z" fill-rule="evenodd"></path></symbol><symbol id="icon-arrow-left" viewBox="0 0 16 16"><path d="m4.46975946 3.28337502-4.17620792 4.03074001c-.39120768.37758093-.39160691.98937525.0000316 1.367372l4.1763942 4.03091977c.39122514.3775978 1.01908149.3838182 1.40017357.0160006.39113012-.3775061.3930364-.9877245-.00310603-1.3700683l-2.48183446-2.39538585h11.61478958l.1166211-.00649339c.4973387-.055753.8833789-.46370161.8833789-.95867408 0-.49497246-.3860402-.90292107-.8833789-.95867408l-.1166211-.00649338h-11.61478958l2.4816273-2.39518594c.39282216-.37913917.40056173-.98637524.01946965-1.35419292-.39113012-.37750607-1.02492687-.37784433-1.41654791.00013556z" fill-rule="evenodd"></path></symbol><symbol id="icon-arrow-right" viewBox="0 0 16 16"><path d="m11.5302405 12.716625 4.176208-4.03074003c.3912076-.37758093.3916069-.98937525-.0000316-1.367372l-4.1763942-4.03091981c-.3912252-.37759778-1.0190815-.38381821-1.4001736-.01600053-.39113013.37750607-.39303641.98772445.003106 1.37006824l2.4818345 2.39538588h-11.6147896l-.11662112.00649339c-.49733869.055753-.88337888.46370161-.88337888.95867408 0 .49497246.38604019.90292107.88337888.95867408l.11662112.00649338h11.6147896l-2.4816273 2.39518592c-.39282218.3791392-.40056175.9863753-.0194697 1.3541929.3911302.3775061 1.0249269.3778444 1.4165479-.0001355z" fill-rule="evenodd"></path></symbol><symbol id="icon-arrow-sub" viewBox="0 0 16 16"><path d="m7.89692134 4.97190702v7.69043288l-2.44965196-2.4467692c-.38776071-.38730434-1.0088052-.39493519-1.38498697-.0191961-.38609047.3856361-.38643643 1.0105302.00013864 1.3966504l4.12239817 4.1175468c.38616704.3857126 1.01187344.3861062 1.39846576-.0000311l4.12258202-4.1177306c.3861843-.3857298.3925462-1.0047669.0163644-1.380506-.3860905-.38563612-1.0101851-.38751563-1.4012233.0030624l-2.44985643 2.4469734v-8.67638639c0-.54139983-.43698413-.98042709-.98493125-.98159081l-7.89910525-.0043627c-.54516866 0-.98711517.44142642-.98711517.98595351s.44194651.98595351.98711517.98595351z" fill-rule="evenodd"></path></symbol><symbol id="icon-arrow-up" viewBox="0 0 16 16"><path d="m12.716625 4.46975946-4.03074003-4.17620792c-.37758093-.39120768-.98937525-.39160691-1.367372.0000316l-4.03091981 4.1763942c-.37759778.39122514-.38381821 1.01908149-.01600053 1.40017357.37750607.39113012.98772445.3930364 1.37006824-.00310603l2.39538588-2.48183446v11.61478958l.00649339.1166211c.055753.4973387.46370161.8833789.95867408.8833789.49497246 0 .90292107-.3860402.95867408-.8833789l.00649338-.1166211v-11.61478958l2.39518592 2.4816273c.3791392.39282216.9863753.40056173 1.3541929.01946965.3775061-.39113012.3778444-1.02492687-.0001355-1.41654791z" fill-rule="evenodd"></path></symbol><symbol id="icon-article" viewBox="0 0 18 18"><path d="m13 15v-12.9906311c0-.0073595-.0019884-.0093689.0014977-.0093689l-11.00158888.00087166v13.00506804c0 .5482678.44615281.9940603.99415146.9940603h10.27350412c-.1701701-.2941734-.2675644-.6357129-.2675644-1zm-12 .0059397v-13.00506804c0-.5562408.44704472-1.00087166.99850233-1.00087166h11.00299537c.5510129 0 .9985023.45190985.9985023 1.0093689v2.9906311h3v9.9914698c0 1.1065798-.8927712 2.0085302-1.9940603 2.0085302h-12.01187942c-1.09954652 0-1.99406028-.8927712-1.99406028-1.9940603zm13-9.0059397v9c0 .5522847.4477153 1 1 1s1-.4477153 1-1v-9zm-10-2h7v4h-7zm1 1v2h5v-2zm-1 4h7v1h-7zm0 2h7v1h-7zm0 2h7v1h-7z" fill-rule="evenodd"></path></symbol><symbol id="icon-audio" viewBox="0 0 18 18"><path d="m13.0957477 13.5588459c-.195279.1937043-.5119137.193729-.7072234.0000551-.1953098-.193674-.1953346-.5077061-.0000556-.7014104 1.0251004-1.0168342 1.6108711-2.3905226 1.6108711-3.85745208 0-1.46604976-.5850634-2.83898246-1.6090736-3.85566829-.1951894-.19379323-.1950192-.50782531.0003802-.70141028.1953993-.19358497.512034-.19341614.7072234.00037709 1.2094886 1.20083761 1.901635 2.8250555 1.901635 4.55670148 0 1.73268608-.6929822 3.35779608-1.9037571 4.55880738zm2.1233994 2.1025159c-.195234.193749-.5118687.1938462-.7072235.0002171-.1953548-.1936292-.1954528-.5076613-.0002189-.7014104 1.5832215-1.5711805 2.4881302-3.6939808 2.4881302-5.96012998 0-2.26581266-.9046382-4.3883241-2.487443-5.95944795-.1952117-.19377107-.1950777-.50780316.0002993-.70141031s.5120117-.19347426.7072234.00029682c1.7683321 1.75528196 2.7800854 4.12911258 2.7800854 6.66056144 0 2.53182498-1.0120556 4.90597838-2.7808529 6.66132328zm-14.21898205-3.6854911c-.5523759 0-1.00016505-.4441085-1.00016505-.991944v-3.96777631c0-.54783558.44778915-.99194407 1.00016505-.99194407h2.0003301l5.41965617-3.8393633c.44948677-.31842296 1.07413994-.21516983 1.39520191.23062232.12116339.16823446.18629727.36981184.18629727.57655577v12.01603479c0 .5478356-.44778914.9919441-1.00016505.9919441-.20845738 0-.41170538-.0645985-.58133413-.184766l-5.41965617-3.8393633zm0-.991944h2.32084805l5.68047235 4.0241292v-12.01603479l-5.68047235 4.02412928h-2.32084805z" fill-rule="evenodd"></path></symbol><symbol id="icon-block" viewBox="0 0 24 24"><path d="m0 0h24v24h-24z" fill-rule="evenodd"></path></symbol><symbol id="icon-book" viewBox="0 0 18 18"><path d="m4 13v-11h1v11h11v-11h-13c-.55228475 0-1 .44771525-1 1v10.2675644c.29417337-.1701701.63571286-.2675644 1-.2675644zm12 1h-13c-.55228475 0-1 .4477153-1 1s.44771525 1 1 1h13zm0 3h-13c-1.1045695 0-2-.8954305-2-2v-12c0-1.1045695.8954305-2 2-2h13c.5522847 0 1 .44771525 1 1v14c0 .5522847-.4477153 1-1 1zm-8.5-13h6c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-6c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm1 2h4c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-4c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill-rule="evenodd"></path></symbol><symbol id="icon-broad" viewBox="0 0 24 24"><path d="m9.18274226 7.81v7.7999954l2.48162734-2.4816273c.3928221-.3928221 1.0219731-.4005617 1.4030652-.0194696.3911301.3911301.3914806 1.0249268-.0001404 1.4165479l-4.17620796 4.1762079c-.39120769.3912077-1.02508144.3916069-1.41671995-.0000316l-4.1763942-4.1763942c-.39122514-.3912251-.39767006-1.0190815-.01657798-1.4001736.39113012-.3911301 1.02337106-.3930364 1.41951349.0031061l2.48183446 2.4818344v-8.7999954c0-.54911294.4426881-.99439484.99778758-.99557515l8.00221246-.00442485c.5522847 0 1 .44771525 1 1s-.4477153 1-1 1z" fill-rule="evenodd" transform="matrix(-1 0 0 -1 20.182742 24.805206)"></path></symbol><symbol id="icon-calendar" viewBox="0 0 18 18"><path d="m12.5 0c.2761424 0 .5.21505737.5.49047852v.50952148h2c1.1072288 0 2 .89451376 2 2v12c0 1.1072288-.8945138 2-2 2h-12c-1.1072288 0-2-.8945138-2-2v-12c0-1.1072288.89451376-2 2-2h1v1h-1c-.55393837 0-1 .44579254-1 1v3h14v-3c0-.55393837-.4457925-1-1-1h-2v1.50952148c0 .27088381-.2319336.49047852-.5.49047852-.2761424 0-.5-.21505737-.5-.49047852v-3.01904296c0-.27088381.2319336-.49047852.5-.49047852zm3.5 7h-14v8c0 .5539384.44579254 1 1 1h12c.5539384 0 1-.4457925 1-1zm-11 6v1h-1v-1zm3 0v1h-1v-1zm3 0v1h-1v-1zm-6-2v1h-1v-1zm3 0v1h-1v-1zm6 0v1h-1v-1zm-3 0v1h-1v-1zm-3-2v1h-1v-1zm6 0v1h-1v-1zm-3 0v1h-1v-1zm-5.5-9c.27614237 0 .5.21505737.5.49047852v.50952148h5v1h-5v1.50952148c0 .27088381-.23193359.49047852-.5.49047852-.27614237 0-.5-.21505737-.5-.49047852v-3.01904296c0-.27088381.23193359-.49047852.5-.49047852z" fill-rule="evenodd"></path></symbol><symbol id="icon-cart" viewBox="0 0 18 18"><path d="m5 14c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2-2-.8954305-2-2 .8954305-2 2-2zm10 0c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2-2-.8954305-2-2 .8954305-2 2-2zm-10 1c-.55228475 0-1 .4477153-1 1s.44771525 1 1 1 1-.4477153 1-1-.44771525-1-1-1zm10 0c-.5522847 0-1 .4477153-1 1s.4477153 1 1 1 1-.4477153 1-1-.4477153-1-1-1zm-12.82032249-15c.47691417 0 .88746157.33678127.98070211.80449199l.23823144 1.19501025 13.36277974.00045554c.5522847.00001882.9999659.44774934.9999659 1.00004222 0 .07084994-.0075361.14150708-.022474.2107727l-1.2908094 5.98534344c-.1007861.46742419-.5432548.80388386-1.0571651.80388386h-10.24805106c-.59173366 0-1.07142857.4477153-1.07142857 1 0 .5128358.41361449.9355072.94647737.9932723l.1249512.0067277h10.35933776c.2749512 0 .4979349.2228539.4979349.4978051 0 .2749417-.2227336.4978951-.4976753.4980063l-10.35959736.0041886c-1.18346732 0-2.14285714-.8954305-2.14285714-2 0-.6625717.34520317-1.24989198.87690425-1.61383592l-1.63768102-8.19004794c-.01312273-.06561364-.01950005-.131011-.0196107-.19547395l-1.71961253-.00064219c-.27614237 0-.5-.22385762-.5-.5 0-.27614237.22385763-.5.5-.5zm14.53193359 2.99950224h-13.11300004l1.20580469 6.02530174c.11024034-.0163252.22327998-.02480398.33844139-.02480398h10.27064786z"></path></symbol><symbol id="icon-chevron-less" viewBox="0 0 10 10"><path d="m5.58578644 4-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" fill-rule="evenodd" transform="matrix(0 -1 -1 0 9 9)"></path></symbol><symbol id="icon-chevron-more" viewBox="0 0 10 10"><path d="m5.58578644 6-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4.00000002c-.39052429.3905243-1.02368927.3905243-1.41421356 0s-.39052429-1.02368929 0-1.41421358z" fill-rule="evenodd" transform="matrix(0 1 -1 0 11 1)"></path></symbol><symbol id="icon-chevron-right" viewBox="0 0 10 10"><path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path></symbol><symbol id="icon-circle-fill" viewBox="0 0 16 16"><path d="m8 14c-3.3137085 0-6-2.6862915-6-6s2.6862915-6 6-6 6 2.6862915 6 6-2.6862915 6-6 6z" fill-rule="evenodd"></path></symbol><symbol id="icon-circle" viewBox="0 0 16 16"><path d="m8 12c2.209139 0 4-1.790861 4-4s-1.790861-4-4-4-4 1.790861-4 4 1.790861 4 4 4zm0 2c-3.3137085 0-6-2.6862915-6-6s2.6862915-6 6-6 6 2.6862915 6 6-2.6862915 6-6 6z" fill-rule="evenodd"></path></symbol><symbol id="icon-citation" viewBox="0 0 18 18"><path d="m8.63593473 5.99995183c2.20913897 0 3.99999997 1.79084375 3.99999997 3.99996146 0 1.40730761-.7267788 2.64486871-1.8254829 3.35783281 1.6240224.6764218 2.8754442 2.0093871 3.4610603 3.6412466l-1.0763845.000006c-.5310008-1.2078237-1.5108121-2.1940153-2.7691712-2.7181346l-.79002167-.329052v-1.023992l.63016577-.4089232c.8482885-.5504661 1.3698342-1.4895187 1.3698342-2.51898361 0-1.65683828-1.3431457-2.99996146-2.99999997-2.99996146-1.65685425 0-3 1.34312318-3 2.99996146 0 1.02946491.52154569 1.96851751 1.36983419 2.51898361l.63016581.4089232v1.023992l-.79002171.329052c-1.25835905.5241193-2.23817037 1.5103109-2.76917113 2.7181346l-1.07638453-.000006c.58561612-1.6318595 1.8370379-2.9648248 3.46106024-3.6412466-1.09870405-.7129641-1.82548287-1.9505252-1.82548287-3.35783281 0-2.20911771 1.790861-3.99996146 4-3.99996146zm7.36897597-4.99995183c1.1018574 0 1.9950893.89353404 1.9950893 2.00274083v5.994422c0 1.10608317-.8926228 2.00274087-1.9950893 2.00274087l-3.0049107-.0009037v-1l3.0049107.00091329c.5490631 0 .9950893-.44783123.9950893-1.00275046v-5.994422c0-.55646537-.4450595-1.00275046-.9950893-1.00275046h-14.00982141c-.54906309 0-.99508929.44783123-.99508929 1.00275046v5.9971821c0 .66666024.33333333.99999036 1 .99999036l2-.00091329v1l-2 .0009037c-1 0-2-.99999041-2-1.99998077v-5.9971821c0-1.10608322.8926228-2.00274083 1.99508929-2.00274083zm-8.5049107 2.9999711c.27614237 0 .5.22385547.5.5 0 .2761349-.22385763.5-.5.5h-4c-.27614237 0-.5-.2238651-.5-.5 0-.27614453.22385763-.5.5-.5zm3 0c.2761424 0 .5.22385547.5.5 0 .2761349-.2238576.5-.5.5h-1c-.27614237 0-.5-.2238651-.5-.5 0-.27614453.22385763-.5.5-.5zm4 0c.2761424 0 .5.22385547.5.5 0 .2761349-.2238576.5-.5.5h-2c-.2761424 0-.5-.2238651-.5-.5 0-.27614453.2238576-.5.5-.5z" fill-rule="evenodd"></path></symbol><symbol id="icon-close" viewBox="0 0 16 16"><path d="m2.29679575 12.2772478c-.39658757.3965876-.39438847 1.0328109-.00062148 1.4265779.39651227.3965123 1.03246768.3934888 1.42657791-.0006214l4.27724782-4.27724787 4.2772478 4.27724787c.3965876.3965875 1.0328109.3943884 1.4265779.0006214.3965123-.3965122.3934888-1.0324677-.0006214-1.4265779l-4.27724787-4.2772478 4.27724787-4.27724782c.3965875-.39658757.3943884-1.03281091.0006214-1.42657791-.3965122-.39651226-1.0324677-.39348875-1.4265779.00062148l-4.2772478 4.27724782-4.27724782-4.27724782c-.39658757-.39658757-1.03281091-.39438847-1.42657791-.00062148-.39651226.39651227-.39348875 1.03246768.00062148 1.42657791l4.27724782 4.27724782z" fill-rule="evenodd"></path></symbol><symbol id="icon-collections" viewBox="0 0 18 18"><path d="m15 4c1.1045695 0 2 .8954305 2 2v9c0 1.1045695-.8954305 2-2 2h-8c-1.1045695 0-2-.8954305-2-2h1c0 .5128358.38604019.9355072.88337887.9932723l.11662113.0067277h8c.5128358 0 .9355072-.3860402.9932723-.8833789l.0067277-.1166211v-9c0-.51283584-.3860402-.93550716-.8833789-.99327227l-.1166211-.00672773h-1v-1zm-4-3c1.1045695 0 2 .8954305 2 2v9c0 1.1045695-.8954305 2-2 2h-8c-1.1045695 0-2-.8954305-2-2v-9c0-1.1045695.8954305-2 2-2zm0 1h-8c-.51283584 0-.93550716.38604019-.99327227.88337887l-.00672773.11662113v9c0 .5128358.38604019.9355072.88337887.9932723l.11662113.0067277h8c.5128358 0 .9355072-.3860402.9932723-.8833789l.0067277-.1166211v-9c0-.51283584-.3860402-.93550716-.8833789-.99327227zm-1.5 7c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-5c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm0-2c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-5c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm0-2c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-5c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill-rule="evenodd"></path></symbol><symbol id="icon-compare" viewBox="0 0 18 18"><path d="m12 3c3.3137085 0 6 2.6862915 6 6s-2.6862915 6-6 6c-1.0928452 0-2.11744941-.2921742-2.99996061-.8026704-.88181407.5102749-1.90678042.8026704-3.00003939.8026704-3.3137085 0-6-2.6862915-6-6s2.6862915-6 6-6c1.09325897 0 2.11822532.29239547 3.00096303.80325037.88158756-.51107621 1.90619177-.80325037 2.99903697-.80325037zm-6 1c-2.76142375 0-5 2.23857625-5 5 0 2.7614237 2.23857625 5 5 5 .74397391 0 1.44999672-.162488 2.08451611-.4539116-1.27652344-1.1000812-2.08451611-2.7287264-2.08451611-4.5460884s.80799267-3.44600721 2.08434391-4.5463015c-.63434719-.29121054-1.34037-.4536985-2.08434391-.4536985zm6 0c-.7439739 0-1.4499967.16248796-2.08451611.45391156 1.27652341 1.10008123 2.08451611 2.72872644 2.08451611 4.54608844s-.8079927 3.4460072-2.08434391 4.5463015c.63434721.2912105 1.34037001.4536985 2.08434391.4536985 2.7614237 0 5-2.2385763 5-5 0-2.76142375-2.2385763-5-5-5zm-1.4162763 7.0005324h-3.16744736c.15614659.3572676.35283837.6927622.58425872 1.0006671h1.99892988c.23142036-.3079049.42811216-.6433995.58425876-1.0006671zm.4162763-2.0005324h-4c0 .34288501.0345146.67770871.10025909 1.0011864h3.79948181c.0657445-.32347769.1002591-.65830139.1002591-1.0011864zm-.4158423-1.99953894h-3.16831543c-.13859957.31730812-.24521946.651783-.31578599.99935097h3.79988742c-.0705665-.34756797-.1771864-.68204285-.315786-.99935097zm-1.58295822-1.999926-.08316107.06199199c-.34550042.27081213-.65446126.58611297-.91825862.93727862h2.00044041c-.28418626-.37830727-.6207872-.71499149-.99902072-.99927061z" fill-rule="evenodd"></path></symbol><symbol id="icon-download-file" viewBox="0 0 18 18"><path d="m10.0046024 0c.5497429 0 1.3179837.32258606 1.707238.71184039l4.5763192 4.57631922c.3931386.39313859.7118404 1.16760135.7118404 1.71431368v8.98899651c0 1.1092806-.8945138 2.0085302-1.9940603 2.0085302h-12.01187942c-1.10128908 0-1.99406028-.8926228-1.99406028-1.9950893v-14.00982141c0-1.10185739.88743329-1.99508929 1.99961498-1.99508929zm0 1h-7.00498742c-.55709576 0-.99961498.44271433-.99961498.99508929v14.00982141c0 .5500396.44491393.9950893.99406028.9950893h12.01187942c.5463747 0 .9940603-.4506622.9940603-1.0085302v-8.98899651c0-.28393444-.2150684-.80332809-.4189472-1.0072069l-4.5763192-4.57631922c-.2038461-.20384606-.718603-.41894717-1.0001312-.41894717zm-1.5046024 4c.27614237 0 .5.21637201.5.49209595v6.14827645l1.7462789-1.77990922c.1933927-.1971171.5125222-.19455839.7001689-.0069117.1932998.19329992.1910058.50899492-.0027774.70277812l-2.59089271 2.5908927c-.19483374.1948337-.51177825.1937771-.70556873-.0000133l-2.59099079-2.5909908c-.19484111-.1948411-.19043735-.5151448-.00279066-.70279146.19329987-.19329987.50465175-.19237083.70018565.00692852l1.74638684 1.78001764v-6.14827695c0-.27177709.23193359-.49209595.5-.49209595z" fill-rule="evenodd"></path></symbol><symbol id="icon-download" viewBox="0 0 16 16"><path d="m12.9975267 12.999368c.5467123 0 1.0024733.4478567 1.0024733 1.000316 0 .5563109-.4488226 1.000316-1.0024733 1.000316h-9.99505341c-.54671233 0-1.00247329-.4478567-1.00247329-1.000316 0-.5563109.44882258-1.000316 1.00247329-1.000316zm-4.9975267-11.999368c.55228475 0 1 .44497754 1 .99589209v6.80214418l2.4816273-2.48241149c.3928222-.39294628 1.0219732-.4006883 1.4030652-.01947579.3911302.39125371.3914806 1.02525073-.0001404 1.41699553l-4.17620792 4.17752758c-.39120769.3913313-1.02508144.3917306-1.41671995-.0000316l-4.17639421-4.17771394c-.39122513-.39134876-.39767006-1.01940351-.01657797-1.40061601.39113012-.39125372 1.02337105-.3931606 1.41951349.00310701l2.48183446 2.48261871v-6.80214418c0-.55001601.44386482-.99589209 1-.99589209z" fill-rule="evenodd"></path></symbol><symbol id="icon-editors" viewBox="0 0 18 18"><path d="m8.72592184 2.54588137c-.48811714-.34391207-1.08343326-.54588137-1.72592184-.54588137-1.65685425 0-3 1.34314575-3 3 0 1.02947485.5215457 1.96853646 1.3698342 2.51900785l.6301658.40892721v1.02400182l-.79002171.32905522c-1.93395773.8055207-3.20997829 2.7024791-3.20997829 4.8180274v.9009805h-1v-.9009805c0-2.5479714 1.54557359-4.79153984 3.82548288-5.7411543-1.09870406-.71297106-1.82548288-1.95054399-1.82548288-3.3578652 0-2.209139 1.790861-4 4-4 1.09079823 0 2.07961816.43662103 2.80122451 1.1446278-.37707584.09278571-.7373238.22835063-1.07530267.40125357zm-2.72592184 14.45411863h-1v-.9009805c0-2.5479714 1.54557359-4.7915398 3.82548288-5.7411543-1.09870406-.71297106-1.82548288-1.95054399-1.82548288-3.3578652 0-2.209139 1.790861-4 4-4s4 1.790861 4 4c0 1.40732121-.7267788 2.64489414-1.8254829 3.3578652 2.2799093.9496145 3.8254829 3.1931829 3.8254829 5.7411543v.9009805h-1v-.9009805c0-2.1155483-1.2760206-4.0125067-3.2099783-4.8180274l-.7900217-.3290552v-1.02400184l.6301658-.40892721c.8482885-.55047139 1.3698342-1.489533 1.3698342-2.51900785 0-1.65685425-1.3431458-3-3-3-1.65685425 0-3 1.34314575-3 3 0 1.02947485.5215457 1.96853646 1.3698342 2.51900785l.6301658.40892721v1.02400184l-.79002171.3290552c-1.93395773.8055207-3.20997829 2.7024791-3.20997829 4.8180274z" fill-rule="evenodd"></path></symbol><symbol id="icon-email" viewBox="0 0 18 18"><path d="m16.0049107 2c1.1018574 0 1.9950893.89706013 1.9950893 2.00585866v9.98828264c0 1.1078052-.8926228 2.0058587-1.9950893 2.0058587h-14.00982141c-1.10185739 0-1.99508929-.8970601-1.99508929-2.0058587v-9.98828264c0-1.10780515.8926228-2.00585866 1.99508929-2.00585866zm0 1h-14.00982141c-.54871518 0-.99508929.44887827-.99508929 1.00585866v9.98828264c0 .5572961.44630695 1.0058587.99508929 1.0058587h14.00982141c.5487152 0 .9950893-.4488783.9950893-1.0058587v-9.98828264c0-.55729607-.446307-1.00585866-.9950893-1.00585866zm-.0049107 2.55749512v1.44250488l-7 4-7-4v-1.44250488l7 4z" fill-rule="evenodd"></path></symbol><symbol id="icon-error" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm2.8630343 4.71100931-2.8630343 2.86303426-2.86303426-2.86303426c-.39658757-.39658757-1.03281091-.39438847-1.4265779-.00062147-.39651227.39651226-.39348876 1.03246767.00062147 1.4265779l2.86303426 2.86303426-2.86303426 2.8630343c-.39658757.3965875-.39438847 1.0328109-.00062147 1.4265779.39651226.3965122 1.03246767.3934887 1.4265779-.0006215l2.86303426-2.8630343 2.8630343 2.8630343c.3965875.3965876 1.0328109.3943885 1.4265779.0006215.3965122-.3965123.3934887-1.0324677-.0006215-1.4265779l-2.8630343-2.8630343 2.8630343-2.86303426c.3965876-.39658757.3943885-1.03281091.0006215-1.4265779-.3965123-.39651227-1.0324677-.39348876-1.4265779.00062147z" fill-rule="evenodd"></path></symbol><symbol id="icon-ethics" viewBox="0 0 18 18"><path d="m6.76384967 1.41421356.83301651-.8330165c.77492941-.77492941 2.03133823-.77492941 2.80626762 0l.8330165.8330165c.3750728.37507276.8837806.58578644 1.4142136.58578644h1.3496361c1.1045695 0 2 .8954305 2 2v1.34963611c0 .53043298.2107137 1.03914081.5857864 1.41421356l.8330165.83301651c.7749295.77492941.7749295 2.03133823 0 2.80626762l-.8330165.8330165c-.3750727.3750728-.5857864.8837806-.5857864 1.4142136v1.3496361c0 1.1045695-.8954305 2-2 2h-1.3496361c-.530433 0-1.0391408.2107137-1.4142136.5857864l-.8330165.8330165c-.77492939.7749295-2.03133821.7749295-2.80626762 0l-.83301651-.8330165c-.37507275-.3750727-.88378058-.5857864-1.41421356-.5857864h-1.34963611c-1.1045695 0-2-.8954305-2-2v-1.3496361c0-.530433-.21071368-1.0391408-.58578644-1.4142136l-.8330165-.8330165c-.77492941-.77492939-.77492941-2.03133821 0-2.80626762l.8330165-.83301651c.37507276-.37507275.58578644-.88378058.58578644-1.41421356v-1.34963611c0-1.1045695.8954305-2 2-2h1.34963611c.53043298 0 1.03914081-.21071368 1.41421356-.58578644zm-1.41421356 1.58578644h-1.34963611c-.55228475 0-1 .44771525-1 1v1.34963611c0 .79564947-.31607052 1.55871121-.87867966 2.12132034l-.8330165.83301651c-.38440512.38440512-.38440512 1.00764896 0 1.39205408l.8330165.83301646c.56260914.5626092.87867966 1.3256709.87867966 2.1213204v1.3496361c0 .5522847.44771525 1 1 1h1.34963611c.79564947 0 1.55871121.3160705 2.12132034.8786797l.83301651.8330165c.38440512.3844051 1.00764896.3844051 1.39205408 0l.83301646-.8330165c.5626092-.5626092 1.3256709-.8786797 2.1213204-.8786797h1.3496361c.5522847 0 1-.4477153 1-1v-1.3496361c0-.7956495.3160705-1.5587112.8786797-2.1213204l.8330165-.83301646c.3844051-.38440512.3844051-1.00764896 0-1.39205408l-.8330165-.83301651c-.5626092-.56260913-.8786797-1.32567087-.8786797-2.12132034v-1.34963611c0-.55228475-.4477153-1-1-1h-1.3496361c-.7956495 0-1.5587112-.31607052-2.1213204-.87867966l-.83301646-.8330165c-.38440512-.38440512-1.00764896-.38440512-1.39205408 0l-.83301651.8330165c-.56260913.56260914-1.32567087.87867966-2.12132034.87867966zm3.58698944 11.4960218c-.02081224.002155-.04199226.0030286-.06345763.002542-.98766446-.0223875-1.93408568-.3063547-2.75885125-.8155622-.23496767-.1450683-.30784554-.4531483-.16277726-.688116.14506827-.2349677.45314827-.3078455.68811595-.1627773.67447084.4164161 1.44758575.6483839 2.25617384.6667123.01759529.0003988.03495764.0017019.05204365.0038639.01713363-.0017748.03452416-.0026845.05212715-.0026845 2.4852814 0 4.5-2.0147186 4.5-4.5 0-1.04888973-.3593547-2.04134635-1.0074477-2.83787157-.1742817-.21419731-.1419238-.5291218.0722736-.70340353.2141973-.17428173.5291218-.14192375.7034035.07227357.7919032.97327203 1.2317706 2.18808682 1.2317706 3.46900153 0 3.0375661-2.4624339 5.5-5.5 5.5-.02146768 0-.04261937-.0013529-.06337445-.0039782zm1.57975095-10.78419583c.2654788.07599731.419084.35281842.3430867.61829728-.0759973.26547885-.3528185.419084-.6182973.3430867-.37560116-.10752146-.76586237-.16587951-1.15568824-.17249193-2.5587807-.00064534-4.58547766 2.00216524-4.58547766 4.49928198 0 .62691557.12797645 1.23496.37274865 1.7964426.11035133.2531347-.0053975.5477984-.25853224.6581497-.25313473.1103514-.54779841-.0053975-.65814974-.2585322-.29947131-.6869568-.45606667-1.43097603-.45606667-2.1960601 0-3.05211432 2.47714695-5.50006595 5.59399617-5.49921198.48576182.00815502.96289603.0795037 1.42238033.21103795zm-1.9766658 6.41091303 2.69835-2.94655317c.1788432-.21040373.4943901-.23598862.7047939-.05714545.2104037.17884318.2359886.49439014.0571454.70479387l-3.01637681 3.34277395c-.18039088.1999106-.48669547.2210637-.69285412.0478478l-1.93095347-1.62240047c-.21213845-.17678204-.24080048-.49206439-.06401844-.70420284.17678204-.21213844.49206439-.24080048.70420284-.06401844z" fill-rule="evenodd"></path></symbol><symbol id="icon-expand"><path d="M7.498 11.918a.997.997 0 0 0-.003-1.411.995.995 0 0 0-1.412-.003l-4.102 4.102v-3.51A1 1 0 0 0 .98 10.09.992.992 0 0 0 0 11.092V17c0 .554.448 1.002 1.002 1.002h5.907c.554 0 1.002-.45 1.002-1.003 0-.539-.45-.978-1.006-.978h-3.51zm3.005-5.835a.997.997 0 0 0 .003 1.412.995.995 0 0 0 1.411.003l4.103-4.103v3.51a1 1 0 0 0 1.001 1.006A.992.992 0 0 0 18 6.91V1.002A1 1 0 0 0 17 0h-5.907a1.003 1.003 0 0 0-1.002 1.003c0 .539.45.978 1.006.978h3.51z" fill-rule="evenodd"></path></symbol><symbol id="icon-explore" viewBox="0 0 18 18"><path d="m9 17c4.418278 0 8-3.581722 8-8s-3.581722-8-8-8-8 3.581722-8 8 3.581722 8 8 8zm0 1c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9zm0-2.5c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5c2.969509 0 5.400504-2.3575119 5.497023-5.31714844.0090007-.27599565.2400359-.49243782.5160315-.48343711.2759957.0090007.4924378.2400359.4834371.51603155-.114093 3.4985237-2.9869632 6.284554-6.4964916 6.284554zm-.29090657-12.99359748c.27587424-.01216621.50937715.20161139.52154336.47748563.01216621.27587423-.20161139.50937715-.47748563.52154336-2.93195733.12930094-5.25315116 2.54886451-5.25315116 5.49456849 0 .27614237-.22385763.5-.5.5s-.5-.22385763-.5-.5c0-3.48142406 2.74307146-6.34074398 6.20909343-6.49359748zm1.13784138 8.04763908-1.2004882-1.20048821c-.19526215-.19526215-.19526215-.51184463 0-.70710678s.51184463-.19526215.70710678 0l1.20048821 1.2004882 1.6006509-4.00162734-4.50670359 1.80268144-1.80268144 4.50670359zm4.10281269-6.50378907-2.6692597 6.67314927c-.1016411.2541026-.3029834.4554449-.557086.557086l-6.67314927 2.6692597 2.66925969-6.67314926c.10164107-.25410266.30298336-.45544495.55708602-.55708602z" fill-rule="evenodd"></path></symbol><symbol id="icon-filter" viewBox="0 0 16 16"><path d="m14.9738641 0c.5667192 0 1.0261359.4477136 1.0261359 1 0 .24221858-.0902161.47620768-.2538899.65849851l-5.6938314 6.34147206v5.49997973c0 .3147562-.1520673.6111434-.4104543.7999971l-2.05227171 1.4999945c-.45337535.3313696-1.09655869.2418269-1.4365902-.1999993-.13321514-.1730955-.20522717-.3836284-.20522717-.5999978v-6.99997423l-5.69383133-6.34147206c-.3731872-.41563511-.32996891-1.0473954.09653074-1.41107611.18705584-.15950448.42716133-.2474224.67571519-.2474224zm-5.9218641 8.5h-2.105v6.491l.01238459.0070843.02053271.0015705.01955278-.0070558 2.0532976-1.4990996zm-8.02585008-7.5-.01564945.00240169 5.83249953 6.49759831h2.313l5.836-6.499z"></path></symbol><symbol id="icon-home" viewBox="0 0 18 18"><path d="m9 5-6 6v5h4v-4h4v4h4v-5zm7 6.5857864v4.4142136c0 .5522847-.4477153 1-1 1h-5v-4h-2v4h-5c-.55228475 0-1-.4477153-1-1v-4.4142136c-.25592232 0-.51184464-.097631-.70710678-.2928932l-.58578644-.5857864c-.39052429-.3905243-.39052429-1.02368929 0-1.41421358l8.29289322-8.29289322 8.2928932 8.29289322c.3905243.39052429.3905243 1.02368928 0 1.41421358l-.5857864.5857864c-.1952622.1952622-.4511845.2928932-.7071068.2928932zm-7-9.17157284-7.58578644 7.58578644.58578644.5857864 7-6.99999996 7 6.99999996.5857864-.5857864z" fill-rule="evenodd"></path></symbol><symbol id="icon-image" viewBox="0 0 18 18"><path d="m10.0046024 0c.5497429 0 1.3179837.32258606 1.707238.71184039l4.5763192 4.57631922c.3931386.39313859.7118404 1.16760135.7118404 1.71431368v8.98899651c0 1.1092806-.8945138 2.0085302-1.9940603 2.0085302h-12.01187942c-1.10128908 0-1.99406028-.8926228-1.99406028-1.9950893v-14.00982141c0-1.10185739.88743329-1.99508929 1.99961498-1.99508929zm-3.49645283 10.1752453-3.89407257 6.7495552c.11705545.048464.24538859.0751995.37998328.0751995h10.60290092l-2.4329715-4.2154691-1.57494129 2.7288098zm8.49779013 6.8247547c.5463747 0 .9940603-.4506622.9940603-1.0085302v-8.98899651c0-.28393444-.2150684-.80332809-.4189472-1.0072069l-4.5763192-4.57631922c-.2038461-.20384606-.718603-.41894717-1.0001312-.41894717h-7.00498742c-.55709576 0-.99961498.44271433-.99961498.99508929v13.98991071l4.50814957-7.81026689 3.08089884 5.33809539 1.57494129-2.7288097 3.5875735 6.2159812zm-3.0059397-11c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2-2-.8954305-2-2 .8954305-2 2-2zm0 1c-.5522847 0-1 .44771525-1 1s.4477153 1 1 1 1-.44771525 1-1-.4477153-1-1-1z" fill-rule="evenodd"></path></symbol><symbol id="icon-info" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm0 7h-1.5l-.11662113.00672773c-.49733868.05776511-.88337887.48043643-.88337887.99327227 0 .47338693.32893365.86994729.77070917.97358929l.1126697.01968298.11662113.00672773h.5v3h-.5l-.11662113.0067277c-.42082504.0488782-.76196299.3590206-.85696816.7639815l-.01968298.1126697-.00672773.1166211.00672773.1166211c.04887817.4208251.35902055.761963.76398144.8569682l.1126697.019683.11662113.0067277h3l.1166211-.0067277c.4973387-.0577651.8833789-.4804365.8833789-.9932723 0-.4733869-.3289337-.8699473-.7707092-.9735893l-.1126697-.019683-.1166211-.0067277h-.5v-4l-.00672773-.11662113c-.04887817-.42082504-.35902055-.76196299-.76398144-.85696816l-.1126697-.01968298zm0-3.25c-.69035594 0-1.25.55964406-1.25 1.25s.55964406 1.25 1.25 1.25 1.25-.55964406 1.25-1.25-.55964406-1.25-1.25-1.25z" fill-rule="evenodd"></path></symbol><symbol id="icon-institution" viewBox="0 0 18 18"><path d="m7 16.9998189v-2.0003623h4v2.0003623h2v-3.0005434h-8v3.0005434zm-3-10.00181122h-1.52632364c-.27614237 0-.5-.22389817-.5-.50009056 0-.13995446.05863589-.27350497.16166338-.36820841l1.23156713-1.13206327h-2.36690687v12.00217346h3v-2.0003623h-3v-1.0001811h3v-1.0001811h1v-4.00072448h-1zm10 0v2.00036224h-1v4.00072448h1v1.0001811h3v1.0001811h-3v2.0003623h3v-12.00217346h-2.3695309l1.2315671 1.13206327c.2033191.186892.2166633.50325042.0298051.70660631-.0946863.10304615-.2282126.16169266-.3681417.16169266zm3-3.00054336c.5522847 0 1 .44779634 1 1.00018112v13.00235456h-18v-13.00235456c0-.55238478.44771525-1.00018112 1-1.00018112h3.45499992l4.20535144-3.86558216c.19129876-.17584288.48537447-.17584288.67667324 0l4.2053514 3.86558216zm-4 3.00054336h-8v1.00018112h8zm-2 6.00108672h1v-4.00072448h-1zm-1 0v-4.00072448h-2v4.00072448zm-3 0v-4.00072448h-1v4.00072448zm8-4.00072448c.5522847 0 1 .44779634 1 1.00018112v2.00036226h-2v-2.00036226c0-.55238478.4477153-1.00018112 1-1.00018112zm-12 0c.55228475 0 1 .44779634 1 1.00018112v2.00036226h-2v-2.00036226c0-.55238478.44771525-1.00018112 1-1.00018112zm5.99868798-7.81907007-5.24205601 4.81852671h10.48411203zm.00131202 3.81834559c-.55228475 0-1-.44779634-1-1.00018112s.44771525-1.00018112 1-1.00018112 1 .44779634 1 1.00018112-.44771525 1.00018112-1 1.00018112zm-1 11.00199236v1.0001811h2v-1.0001811z" fill-rule="evenodd"></path></symbol><symbol id="icon-location" viewBox="0 0 18 18"><path d="m9.39521328 16.2688008c.79596342-.7770119 1.59208152-1.6299956 2.33285652-2.5295081 1.4020032-1.7024324 2.4323601-3.3624519 2.9354918-4.871847.2228715-.66861448.3364384-1.29323246.3364384-1.8674457 0-3.3137085-2.6862915-6-6-6-3.36356866 0-6 2.60156856-6 6 0 .57421324.11356691 1.19883122.3364384 1.8674457.50313169 1.5093951 1.53348863 3.1694146 2.93549184 4.871847.74077492.8995125 1.53689309 1.7524962 2.33285648 2.5295081.13694479.1336842.26895677.2602648.39521328.3793207.12625651-.1190559.25826849-.2456365.39521328-.3793207zm-.39521328 1.7311992s-7-6-7-11c0-4 3.13400675-7 7-7 3.8659932 0 7 3.13400675 7 7 0 5-7 11-7 11zm0-8c-1.65685425 0-3-1.34314575-3-3s1.34314575-3 3-3c1.6568542 0 3 1.34314575 3 3s-1.3431458 3-3 3zm0-1c1.1045695 0 2-.8954305 2-2s-.8954305-2-2-2-2 .8954305-2 2 .8954305 2 2 2z" fill-rule="evenodd"></path></symbol><symbol id="icon-minus" viewBox="0 0 16 16"><path d="m2.00087166 7h11.99825664c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-11.99825664c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"></path></symbol><symbol id="icon-newsletter" viewBox="0 0 18 18"><path d="m9 11.8482489 2-1.1428571v-1.7053918h-4v1.7053918zm-3-1.7142857v-2.1339632h6v2.1339632l3-1.71428574v-6.41967746h-12v6.41967746zm10-5.3839632 1.5299989.95624934c.2923814.18273835.4700011.50320827.4700011.8479983v8.44575236c0 1.1045695-.8954305 2-2 2h-14c-1.1045695 0-2-.8954305-2-2v-8.44575236c0-.34479003.1776197-.66525995.47000106-.8479983l1.52999894-.95624934v-2.75c0-.55228475.44771525-1 1-1h12c.5522847 0 1 .44771525 1 1zm0 1.17924764v3.07075236l-7 4-7-4v-3.07075236l-1 .625v8.44575236c0 .5522847.44771525 1 1 1h14c.5522847 0 1-.4477153 1-1v-8.44575236zm-10-1.92924764h6v1h-6zm-1 2h8v1h-8z" fill-rule="evenodd"></path></symbol><symbol id="icon-orcid" viewBox="0 0 18 18"><path d="m9 1c4.418278 0 8 3.581722 8 8s-3.581722 8-8 8-8-3.581722-8-8 3.581722-8 8-8zm-2.90107518 5.2732337h-1.41865256v7.1712107h1.41865256zm4.55867178.02508949h-2.99247027v7.14612121h2.91062487c.7673039 0 1.4476365-.1483432 2.0410182-.445034s1.0511995-.7152915 1.3734671-1.2558144c.3222677-.540523.4833991-1.1603247.4833991-1.85942385 0-.68545815-.1602789-1.30270225-.4808414-1.85175082-.3205625-.54904856-.7707074-.97532211-1.3504481-1.27883343-.5797408-.30351132-1.2413173-.45526471-1.9847495-.45526471zm-.1892674 1.07933542c.7877654 0 1.4143875.22336734 1.8798852.67010873.4654977.44674138.698243 1.05546001.698243 1.82617415 0 .74343221-.2310402 1.34447791-.6931277 1.80315511-.4620874.4586773-1.0750688.6880124-1.8389625.6880124h-1.46810075v-4.98745039zm-5.08652545-3.71099194c-.21825533 0-.410525.08444276-.57681478.25333081-.16628977.16888806-.24943341.36245684-.24943341.58071218 0 .22345188.08314364.41961891.24943341.58850696.16628978.16888806.35855945.25333082.57681478.25333082.233845 0 .43390938-.08314364.60019916-.24943342.16628978-.16628977.24943342-.36375592.24943342-.59240436 0-.233845-.08314364-.43131115-.24943342-.59240437s-.36635416-.24163862-.60019916-.24163862z" fill-rule="evenodd"></path></symbol><symbol id="icon-plus" viewBox="0 0 16 16"><path d="m2.00087166 7h4.99912834v-4.99912834c0-.55276616.44386482-1.00087166 1-1.00087166.55228475 0 1 .44463086 1 1.00087166v4.99912834h4.9991283c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-4.9991283v4.9991283c0 .5527662-.44386482 1.0008717-1 1.0008717-.55228475 0-1-.4446309-1-1.0008717v-4.9991283h-4.99912834c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"></path></symbol><symbol id="icon-print" viewBox="0 0 18 18"><path d="m16.0049107 5h-14.00982141c-.54941618 0-.99508929.4467783-.99508929.99961498v6.00077002c0 .5570958.44271433.999615.99508929.999615h1.00491071v-3h12v3h1.0049107c.5494162 0 .9950893-.4467783.9950893-.999615v-6.00077002c0-.55709576-.4427143-.99961498-.9950893-.99961498zm-2.0049107-1v-2.00208688c0-.54777062-.4519464-.99791312-1.0085302-.99791312h-7.9829396c-.55661731 0-1.0085302.44910695-1.0085302.99791312v2.00208688zm1 10v2.0018986c0 1.103521-.9019504 1.9981014-2.0085302 1.9981014h-7.9829396c-1.1092806 0-2.0085302-.8867064-2.0085302-1.9981014v-2.0018986h-1.00491071c-1.10185739 0-1.99508929-.8874333-1.99508929-1.999615v-6.00077002c0-1.10435686.8926228-1.99961498 1.99508929-1.99961498h1.00491071v-2.00208688c0-1.10341695.90195036-1.99791312 2.0085302-1.99791312h7.9829396c1.1092806 0 2.0085302.89826062 2.0085302 1.99791312v2.00208688h1.0049107c1.1018574 0 1.9950893.88743329 1.9950893 1.99961498v6.00077002c0 1.1043569-.8926228 1.999615-1.9950893 1.999615zm-1-3h-10v5.0018986c0 .5546075.44702548.9981014 1.0085302.9981014h7.9829396c.5565964 0 1.0085302-.4491701 1.0085302-.9981014zm-9 1h8v1h-8zm0 2h5v1h-5zm9-5c-.5522847 0-1-.44771525-1-1s.4477153-1 1-1 1 .44771525 1 1-.4477153 1-1 1z" fill-rule="evenodd"></path></symbol><symbol id="icon-search" viewBox="0 0 22 22"><path d="M21.697 20.261a1.028 1.028 0 01.01 1.448 1.034 1.034 0 01-1.448-.01l-4.267-4.267A9.812 9.811 0 010 9.812a9.812 9.811 0 1117.43 6.182zM9.812 18.222A8.41 8.41 0 109.81 1.403a8.41 8.41 0 000 16.82z" fill-rule="evenodd"></path></symbol><symbol id="icon-social-facebook" viewBox="0 0 24 24"><path d="m6.00368507 20c-1.10660471 0-2.00368507-.8945138-2.00368507-1.9940603v-12.01187942c0-1.10128908.89451376-1.99406028 1.99406028-1.99406028h12.01187942c1.1012891 0 1.9940603.89451376 1.9940603 1.99406028v12.01187942c0 1.1012891-.88679 1.9940603-2.0032184 1.9940603h-2.9570132v-6.1960818h2.0797387l.3114113-2.414723h-2.39115v-1.54164807c0-.69911803.1941355-1.1755439 1.1966615-1.1755439l1.2786739-.00055875v-2.15974763l-.2339477-.02492088c-.3441234-.03134957-.9500153-.07025255-1.6293054-.07025255-1.8435726 0-3.1057323 1.12531866-3.1057323 3.19187953v1.78079225h-2.0850778v2.414723h2.0850778v6.1960818z" fill-rule="evenodd"></path></symbol><symbol id="icon-social-twitter" viewBox="0 0 24 24"><path d="m18.8767135 6.87445248c.7638174-.46908424 1.351611-1.21167363 1.6250764-2.09636345-.7135248.43394112-1.50406.74870123-2.3464594.91677702-.6695189-.73342162-1.6297913-1.19486605-2.6922204-1.19486605-2.0399895 0-3.6933555 1.69603749-3.6933555 3.78628909 0 .29642457.0314329.58673729.0942985.8617704-3.06469922-.15890802-5.78835241-1.66547825-7.60988389-3.9574208-.3174714.56076194-.49978171 1.21167363-.49978171 1.90536824 0 1.31404706.65223085 2.47224203 1.64236444 3.15218497-.60350999-.0198635-1.17401554-.1925232-1.67222562-.47366811v.04583885c0 1.83355406 1.27302891 3.36609966 2.96411421 3.71294696-.31118484.0886217-.63651445.1329326-.97441718.1329326-.2357461 0-.47149219-.0229194-.69466516-.0672303.47149219 1.5065703 1.83253297 2.6036468 3.44975116 2.632678-1.2651707 1.0160946-2.85724264 1.6196394-4.5891906 1.6196394-.29861172 0-.59093688-.0152796-.88011875-.0504227 1.63450624 1.0726291 3.57548241 1.6990934 5.66104951 1.6990934 6.79263079 0 10.50641749-5.7711113 10.50641749-10.7751859l-.0094298-.48894775c.7229547-.53478659 1.3516109-1.20250585 1.8419628-1.96190282-.6632323.30100846-1.3751855.50422736-2.1217148.59590507z" fill-rule="evenodd"></path></symbol><symbol id="icon-social-youtube" viewBox="0 0 24 24"><path d="m10.1415 14.3973208-.0005625-5.19318431 4.863375 2.60554491zm9.963-7.92753362c-.6845625-.73643756-1.4518125-.73990314-1.803375-.7826454-2.518875-.18714178-6.2971875-.18714178-6.2971875-.18714178-.007875 0-3.7861875 0-6.3050625.18714178-.352125.04274226-1.1188125.04620784-1.8039375.7826454-.5394375.56084773-.7149375 1.8344515-.7149375 1.8344515s-.18 1.49597903-.18 2.99138042v1.4024082c0 1.495979.18 2.9913804.18 2.9913804s.1755 1.2736038.7149375 1.8344515c.685125.7364376 1.5845625.7133337 1.9850625.7901542 1.44.1420891 6.12.1859866 6.12.1859866s3.78225-.005776 6.301125-.1929178c.3515625-.0433198 1.1188125-.0467854 1.803375-.783223.5394375-.5608477.7155-1.8344515.7155-1.8344515s.18-1.4954014.18-2.9913804v-1.4024082c0-1.49540139-.18-2.99138042-.18-2.99138042s-.1760625-1.27360377-.7155-1.8344515z" fill-rule="evenodd"></path></symbol><symbol id="icon-subject-medicine" viewBox="0 0 18 18"><path d="m12.5 8h-6.5c-1.65685425 0-3 1.34314575-3 3v1c0 1.6568542 1.34314575 3 3 3h1v-2h-.5c-.82842712 0-1.5-.6715729-1.5-1.5s.67157288-1.5 1.5-1.5h1.5 2 1 2c1.6568542 0 3-1.34314575 3-3v-1c0-1.65685425-1.3431458-3-3-3h-2v2h1.5c.8284271 0 1.5.67157288 1.5 1.5s-.6715729 1.5-1.5 1.5zm-5.5-1v-1h-3.5c-1.38071187 0-2.5-1.11928813-2.5-2.5s1.11928813-2.5 2.5-2.5h1.02786405c.46573528 0 .92507448.10843528 1.34164078.31671843l1.13382424.56691212c.06026365-1.05041141.93116291-1.88363055 1.99667093-1.88363055 1.1045695 0 2 .8954305 2 2h2c2.209139 0 4 1.790861 4 4v1c0 2.209139-1.790861 4-4 4h-2v1h2c1.1045695 0 2 .8954305 2 2s-.8954305 2-2 2h-2c0 1.1045695-.8954305 2-2 2s-2-.8954305-2-2h-1c-2.209139 0-4-1.790861-4-4v-1c0-2.209139 1.790861-4 4-4zm0-2v-2.05652691c-.14564246-.03538148-.28733393-.08714006-.42229124-.15461871l-1.15541752-.57770876c-.27771087-.13885544-.583937-.21114562-.89442719-.21114562h-1.02786405c-.82842712 0-1.5.67157288-1.5 1.5s.67157288 1.5 1.5 1.5zm4 1v1h1.5c.2761424 0 .5-.22385763.5-.5s-.2238576-.5-.5-.5zm-1 1v-5c0-.55228475-.44771525-1-1-1s-1 .44771525-1 1v5zm-2 4v5c0 .5522847.44771525 1 1 1s1-.4477153 1-1v-5zm3 2v2h2c.5522847 0 1-.4477153 1-1s-.4477153-1-1-1zm-4-1v-1h-.5c-.27614237 0-.5.2238576-.5.5s.22385763.5.5.5zm-3.5-9h1c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5z" fill-rule="evenodd"></path></symbol><symbol id="icon-success" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm3.4860198 4.98163161-4.71802968 5.50657859-2.62834168-2.02300024c-.42862421-.36730544-1.06564993-.30775346-1.42283677.13301307-.35718685.44076653-.29927542 1.0958383.12934879 1.46314377l3.40735508 2.7323063c.42215801.3385221 1.03700951.2798252 1.38749189-.1324571l5.38450527-6.33394549c.3613513-.43716226.3096573-1.09278382-.115462-1.46437175-.4251192-.37158792-1.0626796-.31842941-1.4240309.11873285z" fill-rule="evenodd"></path></symbol><symbol id="icon-table" viewBox="0 0 18 18"><path d="m16.0049107 2c1.1018574 0 1.9950893.89706013 1.9950893 2.00585866v9.98828264c0 1.1078052-.8926228 2.0058587-1.9950893 2.0058587l-4.0059107-.001.001.001h-1l-.001-.001h-5l.001.001h-1l-.001-.001-3.00391071.001c-1.10185739 0-1.99508929-.8970601-1.99508929-2.0058587v-9.98828264c0-1.10780515.8926228-2.00585866 1.99508929-2.00585866zm-11.0059107 5h-3.999v6.9941413c0 .5572961.44630695 1.0058587.99508929 1.0058587h3.00391071zm6 0h-5v8h5zm5.0059107-4h-4.0059107v3h5.001v1h-5.001v7.999l4.0059107.001c.5487152 0 .9950893-.4488783.9950893-1.0058587v-9.98828264c0-.55729607-.446307-1.00585866-.9950893-1.00585866zm-12.5049107 9c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm12 0c.2761424 0 .5.2238576.5.5s-.2238576.5-.5.5h-2c-.2761424 0-.5-.2238576-.5-.5s.2238576-.5.5-.5zm-6 0c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-2c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm-6-2c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm12 0c.2761424 0 .5.2238576.5.5s-.2238576.5-.5.5h-2c-.2761424 0-.5-.2238576-.5-.5s.2238576-.5.5-.5zm-6 0c.27614237 0 .5.2238576.5.5s-.22385763.5-.5.5h-2c-.27614237 0-.5-.2238576-.5-.5s.22385763-.5.5-.5zm-6-2c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-1c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm12 0c.2761424 0 .5.22385763.5.5s-.2238576.5-.5.5h-2c-.2761424 0-.5-.22385763-.5-.5s.2238576-.5.5-.5zm-6 0c.27614237 0 .5.22385763.5.5s-.22385763.5-.5.5h-2c-.27614237 0-.5-.22385763-.5-.5s.22385763-.5.5-.5zm1.499-5h-5v3h5zm-6 0h-3.00391071c-.54871518 0-.99508929.44887827-.99508929 1.00585866v1.99414134h3.999z" fill-rule="evenodd"></path></symbol><symbol id="icon-tick-circle" viewBox="0 0 24 24"><path d="m12 2c5.5228475 0 10 4.4771525 10 10s-4.4771525 10-10 10-10-4.4771525-10-10 4.4771525-10 10-10zm0 1c-4.97056275 0-9 4.02943725-9 9 0 4.9705627 4.02943725 9 9 9 4.9705627 0 9-4.0294373 9-9 0-4.97056275-4.0294373-9-9-9zm4.2199868 5.36606669c.3613514-.43716226.9989118-.49032077 1.424031-.11873285s.4768133 1.02720949.115462 1.46437175l-6.093335 6.94397871c-.3622945.4128716-.9897871.4562317-1.4054264.0971157l-3.89719065-3.3672071c-.42862421-.3673054-.48653564-1.0223772-.1293488-1.4631437s.99421256-.5003185 1.42283677-.1330131l3.11097438 2.6987741z" fill-rule="evenodd"></path></symbol><symbol id="icon-tick" viewBox="0 0 16 16"><path d="m6.76799012 9.21106946-3.1109744-2.58349728c-.42862421-.35161617-1.06564993-.29460792-1.42283677.12733148s-.29927541 1.04903009.1293488 1.40064626l3.91576307 3.23873978c.41034319.3393961 1.01467563.2976897 1.37450571-.0948578l6.10568327-6.660841c.3613513-.41848908.3096572-1.04610608-.115462-1.4018218-.4251192-.35571573-1.0626796-.30482786-1.424031.11366122z" fill-rule="evenodd"></path></symbol><symbol id="icon-update" viewBox="0 0 18 18"><path d="m1 13v1c0 .5522847.44771525 1 1 1h14c.5522847 0 1-.4477153 1-1v-1h-1v-10h-14v10zm16-1h1v2c0 1.1045695-.8954305 2-2 2h-14c-1.1045695 0-2-.8954305-2-2v-2h1v-9c0-.55228475.44771525-1 1-1h14c.5522847 0 1 .44771525 1 1zm-1 0v1h-4.5857864l-1 1h-2.82842716l-1-1h-4.58578644v-1h5l1 1h2l1-1zm-13-8h12v7h-12zm1 1v5h10v-5zm1 1h4v1h-4zm0 2h4v1h-4z" fill-rule="evenodd"></path></symbol><symbol id="icon-upload" viewBox="0 0 18 18"><path d="m10.0046024 0c.5497429 0 1.3179837.32258606 1.707238.71184039l4.5763192 4.57631922c.3931386.39313859.7118404 1.16760135.7118404 1.71431368v8.98899651c0 1.1092806-.8945138 2.0085302-1.9940603 2.0085302h-12.01187942c-1.10128908 0-1.99406028-.8926228-1.99406028-1.9950893v-14.00982141c0-1.10185739.88743329-1.99508929 1.99961498-1.99508929zm0 1h-7.00498742c-.55709576 0-.99961498.44271433-.99961498.99508929v14.00982141c0 .5500396.44491393.9950893.99406028.9950893h12.01187942c.5463747 0 .9940603-.4506622.9940603-1.0085302v-8.98899651c0-.28393444-.2150684-.80332809-.4189472-1.0072069l-4.5763192-4.57631922c-.2038461-.20384606-.718603-.41894717-1.0001312-.41894717zm-1.85576936 4.14572769c.19483374-.19483375.51177826-.19377714.70556874.00001334l2.59099082 2.59099079c.1948411.19484112.1904373.51514474.0027906.70279143-.1932998.19329987-.5046517.19237083-.7001856-.00692852l-1.74638687-1.7800176v6.14827687c0 .2717771-.23193359.492096-.5.492096-.27614237 0-.5-.216372-.5-.492096v-6.14827641l-1.74627892 1.77990922c-.1933927.1971171-.51252214.19455839-.70016883.0069117-.19329987-.19329988-.19100584-.50899493.00277731-.70277808z" fill-rule="evenodd"></path></symbol><symbol id="icon-video" viewBox="0 0 18 18"><path d="m16.0049107 2c1.1018574 0 1.9950893.89706013 1.9950893 2.00585866v9.98828264c0 1.1078052-.8926228 2.0058587-1.9950893 2.0058587h-14.00982141c-1.10185739 0-1.99508929-.8970601-1.99508929-2.0058587v-9.98828264c0-1.10780515.8926228-2.00585866 1.99508929-2.00585866zm0 1h-14.00982141c-.54871518 0-.99508929.44887827-.99508929 1.00585866v9.98828264c0 .5572961.44630695 1.0058587.99508929 1.0058587h14.00982141c.5487152 0 .9950893-.4488783.9950893-1.0058587v-9.98828264c0-.55729607-.446307-1.00585866-.9950893-1.00585866zm-8.30912922 2.24944486 4.60460462 2.73982242c.9365543.55726659.9290753 1.46522435 0 2.01804082l-4.60460462 2.7398224c-.93655425.5572666-1.69578148.1645632-1.69578148-.8937585v-5.71016863c0-1.05087579.76670616-1.446575 1.69578148-.89375851zm-.67492769.96085624v5.5750128c0 .2995102-.10753745.2442517.16578928.0847713l4.58452283-2.67497259c.3050619-.17799716.3051624-.21655446 0-.39461026l-4.58452283-2.67497264c-.26630747-.15538481-.16578928-.20699944-.16578928.08477139z" fill-rule="evenodd"></path></symbol><symbol id="icon-warning" viewBox="0 0 18 18"><path d="m9 11.75c.69035594 0 1.25.5596441 1.25 1.25s-.55964406 1.25-1.25 1.25-1.25-.5596441-1.25-1.25.55964406-1.25 1.25-1.25zm.41320045-7.75c.55228475 0 1.00000005.44771525 1.00000005 1l-.0034543.08304548-.3333333 4c-.043191.51829212-.47645714.91695452-.99654578.91695452h-.15973424c-.52008864 0-.95335475-.3986624-.99654576-.91695452l-.33333333-4c-.04586475-.55037702.36312325-1.03372649.91350028-1.07959124l.04148683-.00259031zm-.41320045 14c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9z" fill-rule="evenodd"></path></symbol><symbol id="icon-checklist-banner" viewBox="0 0 56.69 56.69"><path style="fill:none" d="M0 0h56.69v56.69H0z"></path><clipPath id="b"><use xlink:href="#a" style="overflow:visible"></use></clipPath><path d="M21.14 34.46c0-6.77 5.48-12.26 12.24-12.26s12.24 5.49 12.24 12.26-5.48 12.26-12.24 12.26c-6.76-.01-12.24-5.49-12.24-12.26zm19.33 10.66 10.23 9.22s1.21 1.09 2.3-.12l2.09-2.32s1.09-1.21-.12-2.3l-10.23-9.22m-19.29-5.92c0-4.38 3.55-7.94 7.93-7.94s7.93 3.55 7.93 7.94c0 4.38-3.55 7.94-7.93 7.94-4.38-.01-7.93-3.56-7.93-7.94zm17.58 12.99 4.14-4.81" style="clip-path:url(#b);fill:none;stroke:#01324b;stroke-width:2;stroke-linecap:round"></path><path d="M8.26 9.75H28.6M8.26 15.98H28.6m-20.34 6.2h12.5m14.42-5.2V4.86s0-2.93-2.93-2.93H4.13s-2.93 0-2.93 2.93v37.57s0 2.93 2.93 2.93h15.01M8.26 9.75H28.6M8.26 15.98H28.6m-20.34 6.2h12.5" style="clip-path:url(#b);fill:none;stroke:#01324b;stroke-width:2;stroke-linecap:round;stroke-linejoin:round"></path></symbol><symbol id="icon-chevron-down" viewBox="0 0 16 16"><path d="m5.58578644 3-3.29289322-3.29289322c-.39052429-.39052429-.39052429-1.02368927 0-1.41421356s1.02368927-.39052429 1.41421356 0l4 4c.39052429.39052429.39052429 1.02368927 0 1.41421356l-4 4c-.39052429.39052429-1.02368927.39052429-1.41421356 0s-.39052429-1.02368927 0-1.41421356z" fill-rule="evenodd" transform="matrix(0 1 -1 0 11 1)"></path></symbol><symbol id="icon-eds-i-arrow-right-medium" viewBox="0 0 24 24"><path d="m12.728 3.293 7.98 7.99a.996.996 0 0 1 .281.561l.011.157c0 .32-.15.605-.384.788l-7.908 7.918a1 1 0 0 1-1.416-1.414L17.576 13H4a1 1 0 0 1 0-2h13.598l-6.285-6.293a1 1 0 0 1-.082-1.32l.083-.095a1 1 0 0 1 1.414.001Z"></path></symbol><symbol id="icon-eds-i-check-circle-medium" viewBox="0 0 24 24"><path d="M12 1c6.075 0 11 4.925 11 11s-4.925 11-11 11S1 18.075 1 12 5.925 1 12 1Zm0 2a9 9 0 1 0 0 18 9 9 0 0 0 0-18Zm5.125 4.72a1 1 0 0 1 .156 1.405l-6 7.5a1 1 0 0 1-1.421.143l-3-2.5a1 1 0 0 1 1.28-1.536l2.217 1.846 5.362-6.703a1 1 0 0 1 1.406-.156Z"></path></symbol><symbol id="icon-eds-i-chevron-down-medium" viewBox="0 0 16 16"><path d="m2.00087166 7h4.99912834v-4.99912834c0-.55276616.44386482-1.00087166 1-1.00087166.55228475 0 1 .44463086 1 1.00087166v4.99912834h4.9991283c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-4.9991283v4.9991283c0 .5527662-.44386482 1.0008717-1 1.0008717-.55228475 0-1-.4446309-1-1.0008717v-4.9991283h-4.99912834c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"></path></symbol><symbol id="icon-eds-i-chevron-down-small" viewBox="0 0 16 16"><path d="M13.692 5.278a1 1 0 0 1 .03 1.414L9.103 11.51a1.491 1.491 0 0 1-2.188.019L2.278 6.692a1 1 0 0 1 1.444-1.384L8 9.771l4.278-4.463a1 1 0 0 1 1.318-.111l.096.081Z"></path></symbol><symbol id="icon-eds-i-chevron-right-medium" viewBox="0 0 10 10"><path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path></symbol><symbol id="icon-eds-i-chevron-right-small" viewBox="0 0 10 10"><path d="m5.96738168 4.70639573 2.39518594-2.41447274c.37913917-.38219212.98637524-.38972225 1.35419292-.01894278.37750606.38054586.37784436.99719163-.00013556 1.37821513l-4.03074001 4.06319683c-.37758093.38062133-.98937525.38100976-1.367372-.00003075l-4.03091981-4.06337806c-.37759778-.38063832-.38381821-.99150444-.01600053-1.3622839.37750607-.38054587.98772445-.38240057 1.37006824.00302197l2.39538588 2.4146743.96295325.98624457z" fill-rule="evenodd" transform="matrix(0 -1 1 0 0 10)"></path></symbol><symbol id="icon-eds-i-chevron-up-medium" viewBox="0 0 16 16"><path d="m2.00087166 7h11.99825664c.5527662 0 1.0008717.44386482 1.0008717 1 0 .55228475-.4446309 1-1.0008717 1h-11.99825664c-.55276616 0-1.00087166-.44386482-1.00087166-1 0-.55228475.44463086-1 1.00087166-1z" fill-rule="evenodd"></path></symbol><symbol id="icon-eds-i-close-medium" viewBox="0 0 16 16"><path d="m2.29679575 12.2772478c-.39658757.3965876-.39438847 1.0328109-.00062148 1.4265779.39651227.3965123 1.03246768.3934888 1.42657791-.0006214l4.27724782-4.27724787 4.2772478 4.27724787c.3965876.3965875 1.0328109.3943884 1.4265779.0006214.3965123-.3965122.3934888-1.0324677-.0006214-1.4265779l-4.27724787-4.2772478 4.27724787-4.27724782c.3965875-.39658757.3943884-1.03281091.0006214-1.42657791-.3965122-.39651226-1.0324677-.39348875-1.4265779.00062148l-4.2772478 4.27724782-4.27724782-4.27724782c-.39658757-.39658757-1.03281091-.39438847-1.42657791-.00062148-.39651226.39651227-.39348875 1.03246768.00062148 1.42657791l4.27724782 4.27724782z" fill-rule="evenodd"></path></symbol><symbol id="icon-eds-i-copy-link" viewBox="0 0 24 24"><path fill-rule="evenodd" clip-rule="evenodd" d="M19.4594 8.57015C19.0689 8.17963 19.0689 7.54646 19.4594 7.15594L20.2927 6.32261C20.2927 6.32261 20.2927 6.32261 20.2927 6.32261C21.0528 5.56252 21.0528 4.33019 20.2928 3.57014C19.5327 2.81007 18.3004 2.81007 17.5404 3.57014L16.7071 4.40347C16.3165 4.794 15.6834 4.794 15.2928 4.40348C14.9023 4.01296 14.9023 3.3798 15.2928 2.98927L16.1262 2.15594C17.6673 0.614803 20.1659 0.614803 21.707 2.15593C23.2481 3.69705 23.248 6.19569 21.707 7.7368L20.8737 8.57014C20.4831 8.96067 19.85 8.96067 19.4594 8.57015Z"></path><path fill-rule="evenodd" clip-rule="evenodd" d="M18.0944 5.90592C18.4849 6.29643 18.4849 6.9296 18.0944 7.32013L16.4278 8.9868C16.0373 9.37733 15.4041 9.37734 15.0136 8.98682C14.6231 8.59631 14.6231 7.96314 15.0136 7.57261L16.6802 5.90594C17.0707 5.51541 17.7039 5.5154 18.0944 5.90592Z"></path><path fill-rule="evenodd" clip-rule="evenodd" d="M13.5113 6.32243C13.9018 6.71295 13.9018 7.34611 13.5113 7.73664L12.678 8.56997C12.678 8.56997 12.678 8.56997 12.678 8.56997C11.9179 9.33006 11.9179 10.5624 12.6779 11.3224C13.438 12.0825 14.6703 12.0825 15.4303 11.3224L16.2636 10.4891C16.6542 10.0986 17.2873 10.0986 17.6779 10.4891C18.0684 10.8796 18.0684 11.5128 17.6779 11.9033L16.8445 12.7366C15.3034 14.2778 12.8048 14.2778 11.2637 12.7366C9.72262 11.1955 9.72266 8.69689 11.2637 7.15578L12.097 6.32244C12.4876 5.93191 13.1207 5.93191 13.5113 6.32243Z"></path><path d="M8 20V22H19.4619C20.136 22 20.7822 21.7311 21.2582 21.2529C21.7333 20.7757 22 20.1289 22 19.4549V15C22 14.4477 21.5523 14 21 14C20.4477 14 20 14.4477 20 15V19.4549C20 19.6004 19.9426 19.7397 19.8408 19.842C19.7399 19.9433 19.6037 20 19.4619 20H8Z"></path><path d="M4 13H2V19.4619C2 20.136 2.26889 20.7822 2.74705 21.2582C3.22434 21.7333 3.87105 22 4.5451 22H9C9.55228 22 10 21.5523 10 21C10 20.4477 9.55228 20 9 20H4.5451C4.39957 20 4.26028 19.9426 4.15804 19.8408C4.05668 19.7399 4 19.6037 4 19.4619V13Z"></path><path d="M4 13H2V4.53808C2 3.86398 2.26889 3.21777 2.74705 2.74178C3.22434 2.26666 3.87105 2 4.5451 2H9C9.55228 2 10 2.44772 10 3C10 3.55228 9.55228 4 9 4H4.5451C4.39957 4 4.26028 4.05743 4.15804 4.15921C4.05668 4.26011 4 4.39633 4 4.53808V13Z"></path></symbol><symbol id="icon-eds-i-download-medium" viewBox="0 0 16 16"><path d="m12.9975267 12.999368c.5467123 0 1.0024733.4478567 1.0024733 1.000316 0 .5563109-.4488226 1.000316-1.0024733 1.000316h-9.99505341c-.54671233 0-1.00247329-.4478567-1.00247329-1.000316 0-.5563109.44882258-1.000316 1.00247329-1.000316zm-4.9975267-11.999368c.55228475 0 1 .44497754 1 .99589209v6.80214418l2.4816273-2.48241149c.3928222-.39294628 1.0219732-.4006883 1.4030652-.01947579.3911302.39125371.3914806 1.02525073-.0001404 1.41699553l-4.17620792 4.17752758c-.39120769.3913313-1.02508144.3917306-1.41671995-.0000316l-4.17639421-4.17771394c-.39122513-.39134876-.39767006-1.01940351-.01657797-1.40061601.39113012-.39125372 1.02337105-.3931606 1.41951349.00310701l2.48183446 2.48261871v-6.80214418c0-.55001601.44386482-.99589209 1-.99589209z" fill-rule="evenodd"></path></symbol><symbol id="icon-eds-i-info-filled-medium" viewBox="0 0 18 18"><path d="m9 0c4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9zm0 7h-1.5l-.11662113.00672773c-.49733868.05776511-.88337887.48043643-.88337887.99327227 0 .47338693.32893365.86994729.77070917.97358929l.1126697.01968298.11662113.00672773h.5v3h-.5l-.11662113.0067277c-.42082504.0488782-.76196299.3590206-.85696816.7639815l-.01968298.1126697-.00672773.1166211.00672773.1166211c.04887817.4208251.35902055.761963.76398144.8569682l.1126697.019683.11662113.0067277h3l.1166211-.0067277c.4973387-.0577651.8833789-.4804365.8833789-.9932723 0-.4733869-.3289337-.8699473-.7707092-.9735893l-.1126697-.019683-.1166211-.0067277h-.5v-4l-.00672773-.11662113c-.04887817-.42082504-.35902055-.76196299-.76398144-.85696816l-.1126697-.01968298zm0-3.25c-.69035594 0-1.25.55964406-1.25 1.25s.55964406 1.25 1.25 1.25 1.25-.55964406 1.25-1.25-.55964406-1.25-1.25-1.25z" fill-rule="evenodd"></path></symbol><symbol id="icon-eds-i-institution-medium" viewBox="0 0 24 24"><g><path fill-rule="evenodd" clip-rule="evenodd" d="M11.9967 1C11.6364 1 11.279 1.0898 10.961 1.2646C10.9318 1.28061 10.9035 1.29806 10.8761 1.31689L2.79765 6.87C2.46776 7.08001 2.20618 7.38466 2.07836 7.76668C1.94823 8.15561 1.98027 8.55648 2.12665 8.90067C2.42086 9.59246 3.12798 10 3.90107 10H4.99994V16H4.49994C3.11923 16 1.99994 17.1193 1.99994 18.5V19.5C1.99994 20.8807 3.11923 22 4.49994 22H19.4999C20.8807 22 21.9999 20.8807 21.9999 19.5V18.5C21.9999 17.1193 20.8807 16 19.4999 16H18.9999V10H20.0922C20.8653 10 21.5725 9.59252 21.8667 8.90065C22.0131 8.55642 22.0451 8.15553 21.9149 7.7666C21.7871 7.38459 21.5255 7.07997 21.1956 6.86998L13.1172 1.31689C13.0898 1.29806 13.0615 1.28061 13.0324 1.2646C12.7143 1.0898 12.357 1 11.9967 1ZM4.6844 8L11.9472 3.00755C11.9616 3.00295 11.9783 3 11.9967 3C12.015 3 12.0318 3.00295 12.0461 3.00755L19.3089 8H4.6844ZM16.9999 16V10H14.9999V16H16.9999ZM12.9999 16V10H10.9999V16H12.9999ZM8.99994 16V10H6.99994V16H8.99994ZM3.99994 18.5C3.99994 18.2239 4.2238 18 4.49994 18H19.4999C19.7761 18 19.9999 18.2239 19.9999 18.5V19.5C19.9999 19.7761 19.7761 20 19.4999 20H4.49994C4.2238 20 3.99994 19.7761 3.99994 19.5V18.5Z"></path></g></symbol><symbol id="icon-eds-i-mail-medium" viewBox="0 0 24 24"><path d="m19.462 0c1.413 0 2.538 1.184 2.538 2.619v12.762c0 1.435-1.125 2.619-2.538 2.619h-16.924c-1.413 0-2.538-1.184-2.538-2.619v-12.762c0-1.435 1.125-2.619 2.538-2.619zm.538 5.158-7.378 6.258a2.549 2.549 0 0 1 -3.253-.008l-7.369-6.248v10.222c0 .353.253.619.538.619h16.924c.285 0 .538-.266.538-.619zm-.538-3.158h-16.924c-.264 0-.5.228-.534.542l8.65 7.334c.2.165.492.165.684.007l8.656-7.342-.001-.025c-.044-.3-.274-.516-.531-.516z"></path></symbol><symbol id="icon-eds-i-menu-medium" viewBox="0 0 24 24"><path d="M21 4a1 1 0 0 1 0 2H3a1 1 0 1 1 0-2h18Zm-4 7a1 1 0 0 1 0 2H3a1 1 0 0 1 0-2h14Zm4 7a1 1 0 0 1 0 2H3a1 1 0 0 1 0-2h18Z"></path></symbol><symbol id="icon-eds-i-search-medium" viewBox="0 0 24 24"><path d="M11 1c5.523 0 10 4.477 10 10 0 2.4-.846 4.604-2.256 6.328l3.963 3.965a1 1 0 0 1-1.414 1.414l-3.965-3.963A9.959 9.959 0 0 1 11 21C5.477 21 1 16.523 1 11S5.477 1 11 1Zm0 2a8 8 0 1 0 0 16 8 8 0 0 0 0-16Z"></path></symbol><symbol id="icon-eds-i-user-single-medium" viewBox="0 0 24 24"><path d="M12 1a5 5 0 1 1 0 10 5 5 0 0 1 0-10Zm0 2a3 3 0 1 0 0 6 3 3 0 0 0 0-6Zm-.406 9.008a8.965 8.965 0 0 1 6.596 2.494A9.161 9.161 0 0 1 21 21.025V22a1 1 0 0 1-1 1H4a1 1 0 0 1-1-1v-.985c.05-4.825 3.815-8.777 8.594-9.007Zm.39 1.992-.299.006c-3.63.175-6.518 3.127-6.678 6.775L5 21h13.998l-.009-.268a7.157 7.157 0 0 0-1.97-4.573l-.214-.213A6.967 6.967 0 0 0 11.984 14Z"></path></symbol><symbol id="icon-eds-i-warning-filled-medium" viewBox="0 0 18 18"><path d="m9 11.75c.69035594 0 1.25.5596441 1.25 1.25s-.55964406 1.25-1.25 1.25-1.25-.5596441-1.25-1.25.55964406-1.25 1.25-1.25zm.41320045-7.75c.55228475 0 1.00000005.44771525 1.00000005 1l-.0034543.08304548-.3333333 4c-.043191.51829212-.47645714.91695452-.99654578.91695452h-.15973424c-.52008864 0-.95335475-.3986624-.99654576-.91695452l-.33333333-4c-.04586475-.55037702.36312325-1.03372649.91350028-1.07959124l.04148683-.00259031zm-.41320045 14c-4.97056275 0-9-4.0294373-9-9 0-4.97056275 4.02943725-9 9-9 4.9705627 0 9 4.02943725 9 9 0 4.9705627-4.0294373 9-9 9z" fill-rule="evenodd"></path></symbol><symbol id="icon-expand-image" viewBox="0 0 18 18"><path d="m7.49754099 11.9178212c.38955542-.3895554.38761957-1.0207846-.00290473-1.4113089-.39324695-.3932469-1.02238878-.3918247-1.41130883-.0029047l-4.10273549 4.1027355.00055454-3.5103985c.00008852-.5603185-.44832171-1.006032-1.00155062-1.0059446-.53903074.0000852-.97857527.4487442-.97866268 1.0021075l-.00093318 5.9072465c-.00008751.553948.44841131 1.001882 1.00174994 1.0017946l5.906983-.0009331c.5539233-.0000875 1.00197907-.4486389 1.00206646-1.0018679.00008515-.5390307-.45026621-.9784332-1.00588841-.9783454l-3.51010549.0005545zm3.00571741-5.83449376c-.3895554.38955541-.3876196 1.02078454.0029047 1.41130883.393247.39324696 1.0223888.39182478 1.4113089.00290473l4.1027355-4.10273549-.0005546 3.5103985c-.0000885.56031852.4483217 1.006032 1.0015506 1.00594461.5390308-.00008516.9785753-.44874418.9786627-1.00210749l.0009332-5.9072465c.0000875-.553948-.4484113-1.00188204-1.0017499-1.00179463l-5.906983.00093313c-.5539233.00008751-1.0019791.44863892-1.0020665 1.00186784-.0000852.53903074.4502662.97843325 1.0058884.97834547l3.5101055-.00055449z" fill-rule="evenodd"></path></symbol><symbol id="icon-github" viewBox="0 0 100 100"><path fill-rule="evenodd" clip-rule="evenodd" d="M48.854 0C21.839 0 0 22 0 49.217c0 21.756 13.993 40.172 33.405 46.69 2.427.49 3.316-1.059 3.316-2.362 0-1.141-.08-5.052-.08-9.127-13.59 2.934-16.42-5.867-16.42-5.867-2.184-5.704-5.42-7.17-5.42-7.17-4.448-3.015.324-3.015.324-3.015 4.934.326 7.523 5.052 7.523 5.052 4.367 7.496 11.404 5.378 14.235 4.074.404-3.178 1.699-5.378 3.074-6.6-10.839-1.141-22.243-5.378-22.243-24.283 0-5.378 1.94-9.778 5.014-13.2-.485-1.222-2.184-6.275.486-13.038 0 0 4.125-1.304 13.426 5.052a46.97 46.97 0 0 1 12.214-1.63c4.125 0 8.33.571 12.213 1.63 9.302-6.356 13.427-5.052 13.427-5.052 2.67 6.763.97 11.816.485 13.038 3.155 3.422 5.015 7.822 5.015 13.2 0 18.905-11.404 23.06-22.324 24.283 1.78 1.548 3.316 4.481 3.316 9.126 0 6.6-.08 11.897-.08 13.526 0 1.304.89 2.853 3.316 2.364 19.412-6.52 33.405-24.935 33.405-46.691C97.707 22 75.788 0 48.854 0z"></path></symbol><symbol id="icon-springer-arrow-left"><path d="M15 7a1 1 0 000-2H3.385l2.482-2.482a.994.994 0 00.02-1.403 1.001 1.001 0 00-1.417 0L.294 5.292a1.001 1.001 0 000 1.416l4.176 4.177a.991.991 0 001.4.016 1 1 0 00-.003-1.42L3.385 7H15z"></path></symbol><symbol id="icon-springer-arrow-right"><path d="M1 7a1 1 0 010-2h11.615l-2.482-2.482a.994.994 0 01-.02-1.403 1.001 1.001 0 011.417 0l4.176 4.177a1.001 1.001 0 010 1.416l-4.176 4.177a.991.991 0 01-1.4.016 1 1 0 01.003-1.42L12.615 7H1z"></path></symbol><symbol id="icon-submit-open" viewBox="0 0 16 17"><path d="M12 0c1.10457 0 2 .895431 2 2v5c0 .276142-.223858.5-.5.5S13 7.276142 13 7V2c0-.512836-.38604-.935507-.883379-.993272L12 1H6v3c0 1.10457-.89543 2-2 2H1v8c0 .512836.38604.935507.883379.993272L2 15h6.5c.276142 0 .5.223858.5.5s-.223858.5-.5.5H2c-1.104569 0-2-.89543-2-2V5.828427c0-.530433.210714-1.039141.585786-1.414213L4.414214.585786C4.789286.210714 5.297994 0 5.828427 0H12Zm3.41 11.14c.250899.250899.250274.659726 0 .91-.242954.242954-.649606.245216-.9-.01l-1.863671-1.900337.001043 5.869492c0 .356992-.289839.637138-.647372.637138-.347077 0-.647371-.285256-.647371-.637138l-.001043-5.869492L9.5 12.04c-.253166.258042-.649726.260274-.9.01-.242954-.242954-.252269-.657731 0-.91l2.942184-2.951303c.250908-.250909.66127-.252277.91353-.000017L15.41 11.14ZM5 1.413 1.413 5H4c.552285 0 1-.447715 1-1V1.413ZM11 3c.276142 0 .5.223858.5.5s-.223858.5-.5.5H7.5c-.276142 0-.5-.223858-.5-.5s.223858-.5.5-.5H11Zm0 2c.276142 0 .5.223858.5.5s-.223858.5-.5.5H7.5c-.276142 0-.5-.223858-.5-.5s.223858-.5.5-.5H11Z" fill-rule="nonzero"></path></symbol></svg>
</div>
</footer>




    

    

<div class="c-site-messages message u-hide u-hide-print c-site-messages--nature-briefing c-site-messages--nature-briefing-email-variant c-site-messages--nature-briefing-redesign-2020 sans-serif " data-component-id="nature-briefing-banner" data-component-expirydays="30" data-component-trigger-scroll-percentage="15" data-track="in-view" data-track-action="in-view" data-track-category="nature briefing" data-track-label="Briefing banner visible: Flagship">

    
    <div class="c-site-messages__banner-large">

        
<div class="c-site-messages__close-container">
    <button class="c-site-messages__close" data-track="click" data-track-category="nature briefing" data-track-label="Briefing banner dismiss: Flagship">
        <svg width="25px" height="25px" focusable="false" aria-hidden="true" viewBox="0 0 25 25" version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
            <title>Close banner</title>
            <defs></defs>
            <g stroke="none" stroke-width="1" fill="none" fill-rule="evenodd">
                <rect opacity="0" x="0" y="0" width="25" height="25"></rect>
                <path d="M6.29679575,16.2772478 C5.90020818,16.6738354 5.90240728,17.3100587 6.29617427,17.7038257 C6.69268654,18.100338 7.32864195,18.0973145 7.72275218,17.7032043 L12,13.4259564 L16.2772478,17.7032043 C16.6738354,18.0997918 17.3100587,18.0975927 17.7038257,17.7038257 C18.100338,17.3073135 18.0973145,16.671358 17.7032043,16.2772478 L13.4259564,12 L17.7032043,7.72275218 C18.0997918,7.32616461 18.0975927,6.68994127 17.7038257,6.29617427 C17.3073135,5.89966201 16.671358,5.90268552 16.2772478,6.29679575 L12,10.5740436 L7.72275218,6.29679575 C7.32616461,5.90020818 6.68994127,5.90240728 6.29617427,6.29617427 C5.89966201,6.69268654 5.90268552,7.32864195 6.29679575,7.72275218 L10.5740436,12 L6.29679575,16.2772478 Z" fill="#ffffff"></path>
            </g>
        </svg>
        <span class="visually-hidden">Close</span>
    </button>
</div>


        <div class="c-site-messages__form-container">

            <div class="grid grid-12 last">
                <div class="grid grid-4">
                    <img alt="Nature Briefing" src="/static/images/logos/nature-briefing-logo-n150-white-d81c9da3ec.svg" width="250" height="40">
                    <p class="c-site-messages--nature-briefing__strapline extra-tight-line-height">Sign up for the <em>Nature Briefing</em> newsletter — what matters in science, free to your inbox daily.</p>
                </div>
                <div class="grid grid-8 last">
                    <form action="https://www.nature.com/briefing/briefing" method="post" data-location="banner" data-track="signup_nature_briefing_banner" data-track-action="transmit-form" data-track-category="nature briefing" data-track-label="Briefing banner submit: Flagship">
                        <input id="briefing-banner-signup-form-input-track-originReferralPoint" type="hidden" name="track_originReferralPoint" value="MainBriefingBanner">
                        <input id="briefing-banner-signup-form-input-track-formType" type="hidden" name="track_formType" value="DirectEmailBanner">

                        <input type="hidden" value="false" name="gdpr_tick" id="gdpr_tick_banner">
                        <input type="hidden" value="false" name="marketing" id="marketing_input_banner">
                        <input type="hidden" value="false" name="marketing_tick" id="marketing_tick_banner">
                        <input type="hidden" value="MainBriefingBanner" name="brieferEntryPoint" id="brieferEntryPoint_banner">

                        <label class="nature-briefing-banner__email-label" for="emailAddress">Email address</label>

                        <div class="nature-briefing-banner__email-wrapper">
                            <input class="nature-briefing-banner__email-input box-sizing text14" type="email" id="emailAddress" name="emailAddress" value="" placeholder="e.g. jo.smith@university.ac.uk" required="" data-test-element="briefing-emailbanner-email-input">
                            
                            <input type="hidden" value="true" name="N:nature_briefing_daily" id="defaultNewsletter_banner">
                            <button type="submit" class="nature-briefing-banner__submit-button box-sizing text14" data-test-element="briefing-emailbanner-signup-button">Sign up</button>
                        </div>

                        <div class="nature-briefing-banner__checkbox-wrapper grid grid-12 last">
                            <input class="nature-briefing-banner__checkbox-checkbox" id="gdpr-briefing-banner-checkbox" type="checkbox" name="gdpr" value="true" data-test-element="briefing-emailbanner-gdpr-checkbox" required="">
                            <label class="nature-briefing-banner__checkbox-label box-sizing text13 sans-serif block tighten-line-height" for="gdpr-briefing-banner-checkbox">I agree my information will be processed in accordance with the <em>Nature</em> and Springer Nature Limited <a href="https://www.nature.com/info/privacy">Privacy Policy</a>.</label>
                        </div>
                    </form>
                </div>
            </div>

        </div>

    </div>

    
    <div class="c-site-messages__banner-small">

        
<div class="c-site-messages__close-container">
    <button class="c-site-messages__close" data-track="click" data-track-category="nature briefing" data-track-label="Briefing banner dismiss: Flagship">
        <svg width="25px" height="25px" focusable="false" aria-hidden="true" viewBox="0 0 25 25" version="1.1" xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink">
            <title>Close banner</title>
            <defs></defs>
            <g stroke="none" stroke-width="1" fill="none" fill-rule="evenodd">
                <rect opacity="0" x="0" y="0" width="25" height="25"></rect>
                <path d="M6.29679575,16.2772478 C5.90020818,16.6738354 5.90240728,17.3100587 6.29617427,17.7038257 C6.69268654,18.100338 7.32864195,18.0973145 7.72275218,17.7032043 L12,13.4259564 L16.2772478,17.7032043 C16.6738354,18.0997918 17.3100587,18.0975927 17.7038257,17.7038257 C18.100338,17.3073135 18.0973145,16.671358 17.7032043,16.2772478 L13.4259564,12 L17.7032043,7.72275218 C18.0997918,7.32616461 18.0975927,6.68994127 17.7038257,6.29617427 C17.3073135,5.89966201 16.671358,5.90268552 16.2772478,6.29679575 L12,10.5740436 L7.72275218,6.29679575 C7.32616461,5.90020818 6.68994127,5.90240728 6.29617427,6.29617427 C5.89966201,6.69268654 5.90268552,7.32864195 6.29679575,7.72275218 L10.5740436,12 L6.29679575,16.2772478 Z" fill="#ffffff"></path>
            </g>
        </svg>
        <span class="visually-hidden">Close</span>
    </button>
</div>


        <div class="c-site-messages__content text14">
            <span class="c-site-messages--nature-briefing__strapline strong">Get the most important science stories of the day, free in your inbox.</span>
            <a class="nature-briefing__link text14 sans-serif" data-track="click" data-track-category="nature briefing" data-track-label="Small-screen banner CTA to site" data-test-element="briefing-banner-link" target="_blank" rel="noreferrer noopener" href="https://www.nature.com/briefing/signup/?brieferEntryPoint=MainBriefingBanner">Sign up for Nature Briefing
            </a>
        </div>

    </div>

</div>






<noscript>
    <img hidden src="https://verify.nature.com/verify/nature.png" width="0" height="0" style="display: none" alt="">
</noscript>




<script src="//content.readcube.com/ping?doi=10.1038/s41591-021-01436-0&amp;format=js&amp;last_modified=2021-07-26" async=""></script>

<knh-fkredixktcaz></knh-fkredixktcaz><div data-cc-ghost="" style="height: 352px;"></div><script type="text/javascript" id="fetch-contextual-ads-campaign-data" charset="">(function(){var g=function(a){a=new CustomEvent("campaignDataLoaded",{detail:a});document.dispatchEvent(a)},b=google_tag_manager["rm"]["50443292"](18);if(b){var k=1500;b=google_tag_manager["rm"]["50443292"](19);b="link"===b?google_tag_manager["rm"]["50443292"](20):google_tag_manager["rm"]["50443292"](21);var m=function(a,c){var h=!1,l=setTimeout(function(){h=!0;c(null)},k),d=new XMLHttpRequest;d.onload=function(){var e=null,f=[];if(200===d.status){try{e=JSON.parse(d.responseText)}catch(p){e={}}f=e.campaigns||[]}h||(clearTimeout(l),c(f.length?f.join(","):null))};d.open("GET",
"/platform/contextual?doi\x3d"+a);d.send()},n=function(a,c){a&&-1===a.indexOf("not set")?m(a,c):setTimeout(c,1)};n(b,function(a){window.campaignsForContextualAds=a;g(a);window.dataLayer.push({content:{article:{campaignID:a}}})})}else window.campaignsForContextualAds="",g(null)})();</script>
<script type="text/javascript" id="gtm-setup-accessdetailsloaded-handler" charset="">document.addEventListener("accessdetailsloaded",function(a){a=a.detail||{};var b={event:"update-access-details"};a.institutional_business_partner_ids&&a.resolved_by||console.log("BPID data could not be retrieved from /exposed-details");a.logged_in_to_sn_profile||console.log("logged_in_to_sn_profile could not be retrieved from /exposed-details");var c=a.institutional_business_partner_ids&&a.institutional_business_partner_ids.join?a.institutional_business_partner_ids.join(";"):"",d=a.resolved_by&&a.resolved_by.join?
a.resolved_by.join(";"):"",e=a.personal_business_partner_id_found,f=a.logged_in_to_sn_profile,g=a.snid;b.user={};b.user.profile={};b.user.profile.profileInfo={resolvedBy:d||null,bpid:c||null,personal:e||null,logged_in_to_sn_profile:f,snid:g||null};b.session={};b.session.authentication={};b.session.authentication.token=a.token||null;b.session.authentication.legacy={};window.dataLayer.push(b);window.idpUserDataLoaded=!0},!1);window.dataLayer.push({event:"accessdetailsloaded-handler-added"});
window.accessDetailsLoadedHandlerAdded=!0;</script><script type="text/javascript" id="gtm-mediatrust" charset="">var s=document.getElementsByTagName("script")[0],p=document.createElement("script");p.async="async";p.src="https://scripts.webcontentassessor.com/scripts/93dabb8d80079a87fec7bb6f67b807fce90e1688f8957ad7ad152bfd58ea01c2";s.parentNode.insertBefore(p,s);</script><script id="crossmark-script" text="" charset="" type="text/javascript" src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script><script type="text/javascript" id="polyfill-matches" charset="">Element.prototype.matches||(Element.prototype.matches=Element.prototype.matchesSelector||Element.prototype.mozMatchesSelector||Element.prototype.msMatchesSelector||Element.prototype.oMatchesSelector||Element.prototype.webkitMatchesSelector||function(a){a=(this.document||this.ownerDocument).querySelectorAll(a);for(var b=a.length;0<=--b&&a.item(b)!==this;);return-1<b});</script><script type="text/javascript" id="fetch-idp-user-data" charset="">(function(a){if("function"===typeof window.CustomEvent)return!1;var c=function(d,b){b=b||{};var e=document.createEvent("CustomEvent");e.initCustomEvent(d,b.bubbles||!1,b.cancelable||!1,b.detail||a);return e};c.prototype=window.Event.prototype;window.CustomEvent=c})();var parse=function(a,c){try{return 200===a?JSON.parse(c):null}catch(d){return null}},dispatch=function(a){a=new CustomEvent("accessdetailsloaded",{detail:a});document.dispatchEvent(a)},site=google_tag_manager["rm"]["50443292"](59),idpUrl;
switch(site){case "nature":idpUrl=-1<window.location.hostname.indexOf("local-www")||-1<window.location.hostname.indexOf("test-www")?"https://staging-idp.nature.com/exposed-details":"https://idp.nature.com/exposed-details";break;case "link":idpUrl=-1<window.location.hostname.indexOf("link-qa")?"https://staging-idp.springer.com/exposed-details":"https://idp.springer.com/exposed-details";break;case "springer":idpUrl=-1<window.location.hostname.indexOf("local-www")||-1<window.location.hostname.indexOf("test-www")?
"https://staging-idp.springer.com/exposed-details":"https://idp.springer.com/exposed-details"}if(void 0!==idpUrl){var transport=new XMLHttpRequest;transport.open("GET",idpUrl,!0);transport.withCredentials=!0;transport.onreadystatechange=function(){4===transport.readyState&&dispatch(parse(transport.status,transport.responseText))};transport.send()}else dispatch(null);</script><script src="https://verify.nature.com/verify/nature.min.js"></script><script type="text/javascript" id="create-ad-slots" charset="">function createAndLoadAds(){function h(b){"nature"===a&&google_tag_manager["rm"]["50443292"](87)(b);"bmc"!==a&&"springeropen"!==a||google_tag_manager["rm"]["50443292"](99)(b);("link"===a&&"oscar"===google_tag_manager["rm"]["50443292"](100)||"springer"===a||"link"===a&&!0===google_tag_manager["rm"]["50443292"](101))&&google_tag_manager["rm"]["50443292"](126)(b);"link"===a&&"bunsen"===google_tag_manager["rm"]["50443292"](127)&&google_tag_manager["rm"]["50443292"](152)(b);"link"===a&&"Core"===google_tag_manager["rm"]["50443292"](153)&&google_tag_manager["rm"]["50443292"](165)(b)}window.googletag=window.googletag||{cmd:[]};var a=google_tag_manager["rm"]["50443292"](166),e=google_tag_manager["rm"]["50443292"](168);
if(-1===window.location.search.indexOf("hide_ads\x3dtrue"))if(window.adSlots&&0!==Object.keys(window.adSlots).length)console.log("Ads previously loaded. Will not update ad slots until next page load.");else{window.adSlots||(window.adSlots={});window.getAd=function(b,f){for(var c in window.adSlots)if(-1<c.indexOf(b)){if("object"===f)return adSlots[c];if("slot"===f)return adSlots[c].slot}};googletag.cmd.push(function(){googletag.pubads().setPrivacySettings({limitedAds:e});console.log("limitedAds is ",
e);googletag.pubads().setRequestNonPersonalizedAds(google_tag_manager["rm"]["50443292"](170));googletag.pubads().enableSingleRequest();googletag.pubads().disableInitialLoad()});for(var g=document.querySelectorAll("[data-gpt]"),d=0;g[d];++d)h(g[d]);googletag.cmd.push(function(){googletag.enableServices()})}}createAndLoadAds();</script>
</body></html>